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Abstract  
Three drugs were approved for obesity treatment in the UK between 1998 and 2006: orlistat, 
sibutramine, and rimonabant; however the latter two drugs were withdrawn from the market. 
The National Institute for Health and Clinical Excellence guidelines (NICE) issued in 
recommended that anti-obesity drugs were appropriate for obesity management in children and 
adolescents aged ≥ 12 years in certain circumstances. Currently, there is little evidence on drug 
use for obesity treatment in young people in the UK.  
 
From a meta-analysis of RCTs, after 6 months of treatment, orlistat together with behavioural 
therapy reduced body mass index (BMI) by 0.83 mg/m2, with a high number of gastrointestinal 
adverse drug reactions (ADRs). Sibutramine with behavioural therapy reduced BMI by 2.20 
mg/m2. Between 1999 and 2006, the use of anti-obesity drug in primary care increased 15-fold. 
Approximately 45% of orlistat and 25% of sibutramine prescriptions were discontinued after 
one month of treatment. This may indicate that these drugs were not effective or poorly 
tolerated in children.  
 
A meta-analysis of 12 RCTs on metformin has shown a BMI reduction by 0.64 mg/m2 in obese 
young people without diabetes. A cohort study from a paediatric obesity clinic has shown that 
metformin was the most commonly prescribed drug. Metformin together with lifestyle 
intervention was shown a small but statistically significant effect on reducing the BMI standard 
deviation score in girls compared to lifestyle intervention alone after 6 months of treatment.   
 
The questionnaire study shows that over half of GPs who initiated drug prescriptions to obese 
young patients did not consult specialists for advice. Despite NICE guidance, GPs expressed a 
need to have an obesity guidance covers pharmacological and non-pharmacological 
interventions. 
 
As there is increased use of metformin for obesity treatment, in both primary and secondary 
care, clinicians should use the most up-to-date evidence when prescribing metformin for 
treatment in young people.  
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Chapter 1  Introduction  
1.1.Definition of childhood obesity 
Obesity is a common nutritional disorder in young people. Childhood obesity has significantly 
increased over the years, which has caused serious public health concerns worldwide. The 
World Health Organisation (WHO) estimated that nearly 40 million children aged under five 
years were overweight in 2010 (WHO, 2012). According to the WHO, obesity is defined as 
abnormal or excessive fat accumulation that may impair health. It is normally caused by two 
main factors: unhealthy diet (e.g. excess intake of sugars, fats, carbohydrates) and lack of 
physical activity.  
The most commonly used measure of obesity is the body mass index (BMI), which is a fairly 
accurate measure of an individual’s body weight in relation to their height, and is calculated 
as: weight in kilograms divided by the square of height in metres (kg/m2). BMI is an indicator 
to assess weight status in adults as well as in children. In adults, the cut-off points to define 
overweight and obesity are not related to age and sex. However, the weight and height of 
children and teenagers varies continuously with age and differs for boys and girls. BMI in 
children and adolescents can be expressed as a BMI centile; the centile is normally used to 
assess the growth patterns of individual children in relation to an age- and sex-matched 
reference population. These reference populations describe the growth patterns for children at 
different ages and by sex, and have normally been compiled using data from healthy paediatric 
populations (Wright et al., 2002). 
Four growth reference charts have been widely used in the UK: the Tanner-Whitehouse (TW), 
Gairdner-Pearson (GP), Buckler-Tanner (BT) and the UK 1990 (UK 90).  Confusion as to 
which reference chart should be used led the Royal College of Paediatrics and Child Health 
(RCPCH) to persuade the Growth Reference Review Group to provide advice on validity and 
comparability of these reference charts. The review group recommended that the UK 90 was 
the only suitable reference chart to assess weight relative to height (Wright et al., 2002). The 
UK growth chart weight categories and the corresponding centiles are shown in the below 
table:  
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Table 1.1: The UK 90 growth chart reference weight categories 
BMI classification BMI centile range 
Underweight < 2nd centile 
Healthy weight >=2nd to  <85th centile 
Overweight >=85th to  <95th centile 
Obese >=95th centile 
The degree of obesity can also be expressed using BMI standard deviation score (BMI SDS) 
above the mean i.e. BMI at 50th centile for age and sex. BMI SDS is also known as BMI z-
score; the z-score expresses the number of standard deviations away from the population mean. 
The BMI SDS is calculated as:  
BMI SDS = (V-M)/S 
where V is the value of the individual’s body weight and M is the mean of BMI value for age 
in boys and girls. S is the standard deviation (SD) for that mean value (Hall & Cole, 2006). 
BMI SDS can be used to classify the degree of overweight/obesity of a child’s weight status. 
For example, a child having a BMI SDS of 2 or more (2/more SD above mean value) is 
considered obese (Kiess et al., 2004).  
Another concern for BMI measurement in children is defining the cut-off points to define 
overweight and obesity. Adults with a BMI value of 25kg/m2 are defined as overweight and 
those with a BMI of 30 kg/m2 as obese; this definition in the adult population is internationally 
recognised. However, as the BMI measurement varies with age and sex in children the adult 
cut-off points cannot be applied to children and adolescents. Two international references have 
been used to define overweight and obese children: the International Obesity Task Force 
(IOTF) reference (Cole et al., 1995) and the WHO standard (de Onis et al., 2004). The IOTF 
reference is based on data from six countries (Brazil, Great Britain, Hong Kong, the 
Netherlands, Singapore and the USA); a total number of 97,876 boys and 94,851 girls are 
included from birth to 25 years old. The WHO standard is derived from six countries (Brazil, 
Ghana, India, Norway, Oman and the US) with a sample of 26,985 children, aged 18-71 months 
(de Onis et al., 2004). Those children with a BMI greater than the 85th centile of the reference 
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population are considered at risk of being overweight according to the WHO definition, which 
is the same as the UK90 chart.  
In the United States (US), the Center for Disease Control and Prevention (CDC) chart is based 
on height and weight data produced by the US National Center for Health Statistics (NCHS). 
The US age- and sex-specific BMI centile chart for children and adolescents aged 2-20 years 
has been used worldwide. It defines a BMI greater than 95th centile of the US reference 
population as a cut-off point for obesity in children. At present, the WHO recommends the 
NCHS/CDC age- and sex-specific BMI centile chart to determine young people who are 
overweight and obese (Lahti-Koski et al., 2004). However, a national BMI centiles chart 
(Figure 1.1 & Figure 1.2) derived from the UK 1990 growth reference curves is available (Cole 
et al., 1995). Based on this reference, obesity in children in the UK is defined as a BMI ≥98th 
centile. In general, a BMI between the 5th-84th centile is defined as a healthy weight. It has 
been suggested that if the aim is to identify severely obese young people, the cut-off points 
should be set between the 98th or 99.6th centile, as these individuals may be aware of their 
obesity and should be considered candidates for intervention (Hall & Cole, 2006).  
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Figure 1.1: UK childhood BMI centile charts: BMI chart for boys 
 
Reproduced with permission of the Child Growth Foundation (Charity Registration Number 274325) © Child Growth 
Foundation 1997/1 2 Mayfield Avenue, London W4 1PW. 
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Figure 1.2: UK childhood BMI centile charts: BMI chart for girls 
 
Reproduced with permission of the Child Growth Foundation (Charity Registration Number 274325) © Child Growth 
Foundation 1997/1 2 Mayfield Avenue, London W4 1PW.
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Table 1.2 illustrates the different BMI cut-off criteria used to define overweight and obese 
children in these charts. Currently, there is no compelling evidence to show which cut-off point 
should be used to determine normal and abnormal BMI in young people (NICE, 2006; Monasta 
et al., 2011). In addition, many countries have developed their own BMI centile charts and 
selected different cut-off points to define overweight and obesity, further complicating the BMI 
for childhood obesity issue (Hall & Cole, 2006). The discussion on selection of an appropriate 
reference population and cut-off points in BMI centiles in order to define weight status in obese 
young people is on-going (Monasta et al., 2011).   
As discussed, the BMI cut-off point for defining childhood obesity is somewhat unclear at 
present. The different cut-off criteria would affect the number of children screened into 
different obesity categories (Livingstone, 2001), and also affect the advice given in regard to 
obesity treatment (Hall & Cole, 2006). Furthermore, different cut-off criteria make it difficult 
to directly compare the prevalence of overweight and obese children in different countries 
(Livingstone, 2001; Wang & Lobstein, 2006; Monasta et al., 2011). The issue of defining the 
BMI cut-off criteria is beyond the scope of this project, nevertheless the BMI centile charts for 
age is an acceptable tool to assess adiposity in childhood obesity worldwide (Hall & Cole, 
2006). 
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Table 1.2: BMI cut-off points for overweight and obesity definition in children (modified from Poskitt & Edmunds, 2008) 
 Centile    
 Overweight Obesity  Growth standards used Reference 
1990 UK BMI reference 
charts 
>91st  ≥98th  UK Scottish Intercollegiate Guidelines Network (SIGN, 
2010); National Institute for Health and Clinical 
Excellence (NICE, 2006). 
WHO standard  91st  98th  BMI standard based on 26985 
children records from Brazil, 
Ghana, India, Norway, Oman, 
and United States. 
WHO Multicentre Growth Reference Study 
(MGRS) (de Onis et al., 2004) 
IOTF ≥90th and ≤97th   >97th  International comparison: 
children in United Kingdom, 
Hong Kong, Singapore, Brazil, 
the Netherlands, United State. 
Cole et al., (2000) 
CDCb >85th  ≥95th  USA Must & Anderson (2006) 
 
Abbreviation: WHO, World Health Organisation; IOTF: International Obesity Task Force; CDC: Center for Disease Control.
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1.2.Epidemiology of childhood obesity  
The obesity epidemic in young people has increased globally. As mentioned earlier, direct 
comparison of prevalence of childhood obesity between countries is difficult since different 
criteria are used to define obesity and being overweight in young people. Data from national 
and regional studies on the prevalence of overweight and obese children and adolescents have 
been published over the years. Table 1.3 illustrates the global trend of prevalence of overweight 
and obesity in school-aged children (Wang & Lobstein, 2006). It clearly shows that the 
prevalence of overweight and obesity varies between countries; this is mainly due to different 
definitions of overweight and obesity used in studies. From this global trend between the 1970s 
and late 1990s, the prevalence rates of overweight and obese children and adolescents have 
shown a steady increase. 
   
In Europe, it has been estimated that approximately 15 million children and adolescents will 
be overweight and obese by 2010 if obesity continues to increase at the same rate as in the 
1990s (Branca et al., 2007). In 2007, Branca’s team reported that the highest prevalence rates 
of overweight children were in Portugal (aged 7-9, 32%), followed by Spain (aged 2-9, 31%), 
and Italy (aged 6-11, 27%) in both sexes. The lowest rates of overweight prevalence of children 
were Germany (aged 5-6, 13%), Cyprus (aged 2-6, 14%), and Serbia and Montenegro (aged 6-
10, 15%). However, it should be noted that different socioeconomic groups, cultural 
determinants of diet and physical activity may have an impact on the prevalence of obesity in 
these European countries.  
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Table 1.3: Worldwide trends of overweight and obesity prevalence in school-age 
children (reproduced from Wang & Lobstein, 2006) 
Country Date of 
survey 
Criteria of 
definition 
Age (years) Prevalence of 
Obesity (%) 
Prevalence of 
Overweight and 
obesity (%) 
Sample size National or 
local 
survey 
North/South America 
Canada 
 
 
1981;1996 
 
 
IOTF 
 
7-13 
 
Boys: 2.0→10.0 
Girls: 2.0→9.0 
 
Boys: 11.0→33.0 
Girls: 13.0→27.0 
 
1981: 2879 
1996: 6277 
 
N 
Chile 
 
1987;2000 
 
IOTF 6 Boys: 1.8→7.2 
Girls: 2.1→7.5 
Boys: 10.6→18.8 
Girls: 11.6→19.6 
1987: 166,891 
2000:199,444 
N 
United States 
 
1971-1974 
1988-1994 
IOTF 6-18 INA 15.4→25.6 1971-1974: 4472 
1988-1994: 6108 
N 
United States 
 
1971-1974 
1999-2000 
CDC  6-19 6-11y: 4.0→15.3 
12-19y: 6.1→15.5 
INA 1971-1974: INA 
1999-2000: 3298 
N 
Europe  
Czech Republic 
 
 
1991;2000 
 
 
Czech 90th/97th 
centiles chart 
 
7-11 
 
3.0-6.0 
 
10.0-13.0 
 
 
3343 
 
N 
Finland 
 
1977;1999 
 
IOTF 12-18 Boys: 1.1→2.7 
Girls: 0.4→1.4 
Boys: 8.3→19.4 
Girls: 4.5→11.2 
1977:2832 
1997:66,211 
N 
France 
 
1980;1990 
 
 4-17 2.5-3.2 10.0→11.7 1980:6697 
1990:5795 
N 
France (North) 
 
1992;2000 
 
IOTF 5-12 Boys: 1.7→1.3 
Girls: 1.6→4.4 
Boys: 9→10.2 
Girls: 14.1→18.6 
1992: 804 
2000: 601 
L 
Germany  
 
1985;1995 
 
BMI 90th/97th 
centiles chart 
7-14 Boys: 5.3→8.2 
Girls: 4.7→9.9 
Boys: 10.0→16.3 
Girls: 11.7→20.7 
1985: 2002 
1995: 1901 
L 
Greece (Crete) 
 
1982 IOTF 11-13 Boys: 4.2-12.7 Boys: 20.6-39.7 1982:528 
2002:620 
L 
Iceland 
 
1978;1998 
 
IOTF 9 Boys: 1.8→5.8 
Girls: 0.5→4.2 
Boys: 12.4→22.0 
Girls: 11.9→25.5 
1978: 418 
1998: 601 
N 
The Netherlands  
 
1980 
1996-1997 
IOTF 9 Boys: 0.1→1.1 
Girls: 0.5→1.9 
Boys: 3.3→9.0 
Girls: 6.8→13.2 
Approx. 700 N 
Poland 
 
 
1987;1997 
 
Local BMI 
85th/95th 
centiles chart 
14 8.4→9.7 23.8→22.1 1987: 3165 
1997: 1014 
L 
Spain  
 
 
 
 
 
1985;1995 
 
IOTF 6-7  
13-14  
Children 
Boys: 6.5→14.2 
Girls: 10.0→17.7 
Adolescents 
Boys: 3.1→6.0 
Girls: 1.1→1.5 
Children 
Boys: 21→34 
Girls: 25→36 
Adolescents 
Boys: 13→21 
Girls: 16→21 
  
 Sweden  
 
1986;2001 
 
ITOF 6-13 1.2→4.8 11.5→23.1 1986: 507 (aged 6-11) 
2001: 1115 (aged 6-13) 
L 
 United Kingdom 
 
 
1984;2002 
 
ITOF 4-11 Boys: 1.7→5.4 
Girls: 2.6→7.8 
Boys: 9.0→20.7 
Girls: 13.5→27.4 
1984: 5874 (aged 4-11) 
2002: 9982 (aged 2-10) 
N 
 Northern Ireland 
 
Australia 
Australia 
1990;2000 
 
 
1985;1995 
ITOF 
 
 
ITOF 
12 
 
 
7-15 
Boys: 4.0→4.7 
Girls: 1.6→4.7 
 
Boys:1.4→4.7 
Boys: 16.0→19.5 
Girls: 15.9→26.3 
 
Boys:10.7→20.0 
1990: 509 
2000: 1047 
 
1985:8492 
N 
 
 
N 
  
 
 
 
  Girls: 1.2→5.5 
 
Girls: 11.8→21.5 
 
1995:2962  
 28 
 
Continued.  
Asia 
China, mainland  
 
 
 
1991:1997 
 
 
ITOF 
 
6-18 
 
INA 
 
All: 6.4→7.7 
Urban: 7.7→12.4 
Rural: 5.9→6.4 
 
1991: 3014 
1997: 2688 
 
N 
 
China, mainland 
 
 
 
 
 
 
1985:2000 
 
 
China BMI 
 
7-22 
 
Urban 
Boys: 1.1→10.4 
Girls: 0.2→2.3 
Rural  
Boys: 0.04→1.5 
Girls: 0.06→0.9 
 
Urban  
Boys: 1.3→14.8 
Girls: 1.7→8.3 
Rural  
Boys: 0.5→5.8 
Girls: 1.7→4.7 
 
1985: 4,71,115 
2000: 2,66,431 
 
N 
 
Taiwan 
 
 
 
1980-1982 
1994-1996 
 
≥110% local 
and ≥ 120 
BMI reference 
 
12-15 
 
Boys: 12.4→16.4 
Girls: 10.1→11.1 
 
Boys: 25.4→28.0 
Girls: 21.4→21.3 
 
1980-1982: 1980 
1994-1996: 1366 
 
N 
 
Japan  
 
 
 
1976-1980 
1996-2000 
 
≥ 120 local 
BMI reference 
 
6-14 
 
Boys: 6.1→11.1 
Girls: 7.1→10.2 
 
 
INA 
 
1976-1980: 
15,677 
1996-2000: 6079 
 
N 
 
Japan  
 
 
 
1976-1980 
1996-2000 
 
IOTF 
 
6-14 
 
Boys: 1.5→3.8 
Girls: 1.2→2.9 
 
Boys: 10.7→20.0 
Girls: 10.1→17.2 
 
 
1976-1980: 
15,677 
1996-2000: 6079 
 
N 
 
Singapore 
 
 
 
1975:1993 
 
 
≥ 120 local 
BMI reference 
 
6-16 
 
Boys: 1.6→15.2 
Girls: 1.1→12.9 
 
INA 
 
INA 
 
N 
Abbreviation: INA: Information not available, N: national; L: Local ITOF: the IOTF age- and sex-specific BMI cut-off points that correspond to a BMI of 
25mg/m2 and 30mg/m2 at age 18.  
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In the UK, data from the National Study of Health and Growth (NSHG) has shown that the 
prevalence of obesity increased from 0.6% in 1984 to 1.7% in 1994 in boys and from 1.3% to 
2.6% in girls. The number of children defined as overweight also increased, for boys from 
5.4% to 9.0% and for girls from 9.3% to 13.5% (Chinn & Rona, 2001). The report of a recent 
survey, the Health Survey of England (HSE) in 2008, found that the prevalence of obesity 
among boys aged 2-15 years, increased from 11.1% in 1995 to 16.8% in 2008, and the increase 
for girls in this age range was from 12.2% to 15.2%. However, there was a significant decrease 
in obesity between 2005 and 2008. The prevalence of obesity in boys decreased from 18.5% 
in 2005 to 16.8% in 2008 and from 18.8% to 15.2% in girls. It has been suggested that HSE 
should continue monitoring whether the overall trend in childhood obesity is decreasing or 
continuing to increase gradually (HSE, 2008). The most recent reports from HSE and the UK 
National Child Measurement programme have shown that the prevalence of childhood obesity 
has apparently plateaued (HSE, 2014; the UK National Child Measurement programme, 2014).  
 
Current estimates have also shown that the prevalence of obesity in young people has levelled 
off in some countries. In Switzerland, a national survey included children aged 6-13 years and 
used US CDC cut-off points to define underweight, overweight, and obesity in the years 2002 
(2,431 children) and 2007 (2,222 children). In 2002, the prevalence of being overweight in 
boys and girls was 12.5% and 13.2%, respectively. However in 2007, the prevalence of being 
overweight was significantly lower, 11.5% in boys and 10.0% in girls. Prevalence of obesity 
also decreased in both genders between 2002 and 2007 (Aeberli et al., 2010). In France, overall 
prevalence of being overweight (including obesity) using the IOTF in children aged 7-9 years 
was 18.1% in 2000  with a decrease to 15.8% in 2007 (Salanave et al., 2009). The authors 
stated that the stabilised trend may be due to the introduction of a National Nutrition and Health 
Program (PNNS) in 2001.  
 
A German study analysed the CrescNet database, consisting of 462,241 patients aged 4 to 16 
years from 321 paediatricians, to investigate the prevalence of overweight and obesity between 
1999 and 2008. Prevalence of overweight and obesity increased between 1999 and 2003, but 
the trend declined significantly between 2004 and 2008 (Bluher et al., 2011). Data from 
monitoring overweight and obese children assessed at school enrolment examinations (SEE), 
also in Germany, were analysed. The SEE is an annual compulsory programme in Germany in 
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which the weight and height of all children are measured at school enrolment. In December 
2008, data were retrieved from 721,364 children aged 6 years in 16 federal states. The German 
reference cut-off points were used to define overweight (BMI >90th centile) and obesity (BMI 
>97th centile). Prevalence of overweight and obesity had decreased from 3% to 1.8% between 
2004 and 2008 (Moss et al., 2012).  
 
In Greece, data were analysed from 11 annual national school-based health surveys from 1997 
to 2007. Height and weight were measured for 651,582 children aged 8-9 years, using IOTF 
BMI cut-off points to define underweight, normal weight, overweight and obesity. Prevalence 
of obesity significantly increased from 7.2% in 1997 to 11.3% in 2004 in girls. A similar 
increasing trend was also observed in boys from 8.1% to 12.3% during this period. However, 
the trend began to level in both genders from 2004 onwards (Tambalis et al., 2010). A 
systematic review and meta-analysis were undertaken to investigate the prevalence of 
childhood overweight and obesity in Australia. A total of 41 studies were included, which 
involved 264,905 children aged 2 to 18 years. The estimated prevalence of overweight and 
obesity in boys increased from 10.2% to 21.6% and from 11.6% to 24.3% in girls, between 
1985 and 1996. However, the estimated prevalence has recently plateaued, with only a slight 
increase to 23.7% in boys and 24.8% in girls in 2008 (Olds et al., 2010).  
 
A recent US study analysed 15,271 children and adolescents (from birth to 19 years) from the 
National Health and Nutrition Examination Survey (NHANES) to investigate the prevalence 
of obesity between 1999 and 2010. The CDC 2000 BMI-for-age growth chart was used to 
define overweight (BMI≥85th centile and <95th centile) and obesity (BMI≥ 95th centile). 
Overall, there was no change in obesity prevalence between 2007-2008 and 2009-2010 (Ogden 
et al., 2012). The explanations for this recent levelling in the trend  of increasing obesity 
prevalence could be due to the increasing recognition by health professionals, schools, 
community programmes, and policy interventions or media coverage (Aeberli et al., 2010; 
Salanave et al., 2009; Tambalis et al., 2009; Olds et al., 2010; Moss et al., 2012). At present, 
there is no evidence to show which interventions accounted for this change in the trend. Further 
research is needed to understand why this increasing trend has levelled off in children and 
young people. Despite the apparent plateau in the prevalence of obesity, there is still growing 
concern that childhood obesity may lead to obesity related complications such as type 2 
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diabetes and/or, hypertension. These complications will subsequently contribute to the 
economic burden of treating these patients when they reach adulthood (Lobstein & Jackson-
Leach, 2006; Branca et al., 2007). A brief review on obesity-related complications in children 
and adolescents is given in the following section. 
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1.3.Complications of childhood obesity  
It has been suggested that overweight children are more likely to become obese adults (Loke, 
2002). There is strong evidence that childhood obesity is a risk factor for several medical 
complications, which may lead to life-threatening conditions in adulthood (Wabitsch, 2000; 
Ebbeling et al., 2002; Ludwig, 2007; Wall, 2010) (Figure 1.3). A long-term study of 276,835 
Danish school children (aged 7-13 years) which investigated the association between 
childhood obesity and coronary heart disease (CHD) in adulthood (aged 25 years or older), 
found that a higher BMI in childhood was associated with an increased risk of CHD in 
adulthood (Baker et al., 2007). It has been recently suggested that the prevalence of CHD will 
increase from 5 to 16% by the year 2035, which is attributable to the increased obesity in 
adolescents currently (Bibbins-Domingo et al., 2007). This association between childhood 
obesity and cardiovascular risk may increase premature mortality (Franks et al., 2010).  
 
                                Figure 1.3: Medical complications of childhood obesity
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Childhood obesity is strongly associated with other chronic conditions including metabolic 
syndrome, hypertension, type 2 diabetes, and a range of psychosocial dysfunctions.  The 
association between type 2 diabetes and obesity in young people is another challenging issue 
in public health. The incidence rate of type 2 diabetes has significantly increased in children 
(Pinhas-Hamiel et al., 1996; Scott et al., 1997; Haines et al., 2007). A study by Fagot-
Campagna et al., (2000) found that type 2 diabetes was more common than type 1 diabetes 
among 45% of newly diagnosed diabetic Indian adolescents aged 15-19 years in the US, during 
the years 1976-1976, and also during 1987-1996. In the UK, the prevalence of type 2 diabetes 
in adolescents dramatically increased from 0.006 per 1000 children in 1998 to 0.05 per 1000 
children in 2005; the prevalence increased with age especially among adolescents aged 12-18 
years (Hsia et al., 2009). There is strong evidence that the rise of type 2 diabetes in young 
people is mainly due to increasing levels of obesity in young people (Ebbelling et al., 2002; 
Han et al., 2010).  
 
The obstructive sleep apnoea syndrome is another serious condition amongst obese young 
people (Loke, 2002). This syndrome is the result of excessive fat in the neck which 
consequently causes partial obstruction of the upper airway during sleep. During the past few 
years, this syndrome has become widely recognised as a serious obesity related condition in 
children (Tauman & Gozal 2006). The poor quality of sleep at night will consequently result 
in morning headache and daytime sleepiness and it also affects their daily functioning (e.g. 
learning and school performing) (Gozal, 1998). Psychological problems are also common in 
overweight and obese young people. Obese children and adolescents may encounter 
discrimination at an early age. Viner et al., (2006) reported that approximately 13% of obese 
adolescents suffered from psychological distress in the UK. A Canadian study included 5,749 
boys and girls aged 11 to 16 years to investigate the association between bullying behaviours 
(physical, verbal, relational and sexual harassment) with overweight and obesity status 
(Janssen et al., 2004). Their findings have shown that overweight and/or obese boys and girls 
were likely to have verbal, physical and relational bullying compared with their normal weight 
peers. A recent systematic review which examined the association between obesity and 
depression using data from published prospective cohort studies found that obesity increased 
the risk of depression (Luppino et al., 2010).  
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There is economic burden for covering the treatment of obesity-related complications in young 
people. A US study examined the economic cost of treating obesity-related conditions in young 
people aged 6-17 years during 1979 and 1999 (Wang & Dietz, 2002). Their results have shown 
that hospital costs for treating obesity-related complications increased from $35 million during 
1979-1981 to $127 million during 1997-1999, increasing more than threefold during a twenty-
year period. Due to the current obesity epidemic in children and adolescents, there will be a 
significant increase in physical, psychological, and economic consequences in the near future. 
These obesity-related complications mean urgent action needs to be taken by healthcare 
professionals to improve the quality of life of overweight and/or obese children and 
adolescents.  
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1.4.Management of childhood obesity  
It has been recommended that the successful management of obesity should be through lifestyle 
changes including diet modification and increased physical activity (Iughetti et al., 2011). 
Since obesity may cause other medical conditions such as psychosocial problems and increased 
risk of mortality, it is recommended that multidisciplinary interventions are appropriate for 
childhood obesity management (Epstein, 2001). It has been suggested that the 
multidisciplinary team may include the GP, practice nurse, health visitor, school nurse and 
other professionals such as a dietician, and psychologist (Gibson et al., no date). Multi-
component intervention for childhood obesity is also recommended by UK national guidelines 
(NICE, 2006; SIGN, 2010). The multi-component intervention includes diet (e.g. decreased fat 
intake, increased fruit and vegetable intake), increased physical activity, behaviour 
interventions (e.g. goal setting, rewards for reaching goals), and family involvement (NICE, 
2006).  
 
A systematic review examined 37 RCT trials on effectiveness of dietary intervention in obese 
young people (aged <18 years) from 1975 to 2003 (Collins et al., 2006). However, the authors 
concluded that due to poor study design, it was difficult to assess the effectiveness of dietary 
intervention in obese young people. Collins and colleagues (2007) conducted another 
systematic review to investigate the optimal dietetic treatment for overweight and/or obese 
young people (aged <18 years). Studies which evaluated the effectiveness of nutrition or 
dietary interventions for treating obesity were all included. They included all types of study 
designs: RCTs, longitudinal studies, cohort (retrospective and prospective), or case-control 
studies. In addition, government reports from the UK, US, and Australia were included in the 
review. A total of 116 studies were identified between 1975 and 2003 in the final review, of 
which 49 (42%) studies were of RCT design. However, as the dietary outcomes of included 
studies were rarely reported, the authors stated that there was an urgent need to have well-
designed studies to address the efficacy and effectiveness of dietary interventions in children 
and adolescent. At present, there is no evidence to suggest which particular dietary intervention 
is more effective for weight management in young people.  
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In 2004, a national report from the Department of Health in the UK suggested that the general 
population of children and adolescents should have at least 60 minutes of moderate intensity 
physical activity each day (DoH, 2004a). The NICE guidelines on obesity management (NICE 
2006) also recommended that an increase of physical activity levels or a decrease of inactivity 
should be included in a multi-component interventions programme.  
 
Behavioural intervention is part of a multi-component interventions programme. The NICE 
guideline (2006) suggested that a behavioural intervention must include: stimulus control, self-
monitoring, goal setting, rewards for reaching goals, and problem solving. In Scotland, there 
was a RCT study that investigated behavioural intervention for obesity in children in the UK 
(Hughes et al., 2008). This study was conducted at the Royal Hospitals for Sick Children in 
Glasgow and Edinburgh, Scotland. A total of 134 overweight children (BMI ≥98th centile 
according to British 1990 reference data) aged 5-11 years were included. Children were 
randomly assigned to either the behaviour programme (intervention group) or standard care 
(control group). Behaviour intervention included modifying diet, changes in physical activity, 
and behavioural change techniques (e.g. to enhance the child’s motivation, goal getting, self-
monitoring, use of rewards) as well as standard care in the intervention group. Children in the 
control group received normal dietetic care. The findings showed that the behaviour 
programme had modest benefits on physical activity, sedentary behaviour, and quality of life 
(QoL). However, there was no significant difference between the intervention and control 
groups on BMI SDS, and weight over 12 months of treatment. For children who complied well 
with treatment, their weight gain was significantly lower in the intervention group compared 
with the control group, from baseline to 6 months. Another recent multicomponent, 
community-based childhood obesity intervention (Mind, Exercise, Nutrition, Do it (MEND) 
Program) RCT was conducted to investigate the effectiveness of a 6-month intervention. This 
program also engaged with families in the process of weight management. The interventions 
consisted of nutrition sessions (e.g. nutrition education, healthy eating advice), behaviour 
change sessions (to teach parents and children to apply behaviour techniques e.g. goal setting, 
stimulus control), and exercise sessions (included 1 hour of exercise). A total of 116 obese 
children (BMI ≥ 98th centile according to British 1990 reference data) were included and 
randomly assigned to intervention. The following outcomes were assessed at baseline and at 6 
months: waist circumference, BMI, body composition, physical activity level, sedentary 
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activities, cardiovascular fitness, and self-esteem. All children were followed up 12 months 
from baseline. Children in the intervention group had a statistically significant reduction in 
waist circumference z-score and BMI z-score compared to control group at 6 months. In 
addition to significant improvements in adiposity, the intervention also improved 
cardiovascular health and psychological well-being (Scher et al., 2010). In most contemporary 
RCTs of lifestyle interventions for childhood obesity treatment, there is at least one parent or 
carer involved in the treatment programme, with the aim of changing the whole family’s 
lifestyle (SIGN, 2010). For example, the recommendation from 2006 NICE guideline for diet 
intervention should be multi-component, including dietary modification, targeted advice, 
family involvement and goal setting.  
 
In general, overweight young people can be managed in the community by a primary care 
team. However, patients should be referred to specialists in secondary care for further 
assessment if they are extremely obese individuals with severe obesity-related co-morbidities 
(NICE, 2006). Figure 1.4 shows the childhood obesity management pathway in primary care 
and secondary care within the National Health System (NHS) (NICE 2006).  The 2010 SIGN 
guidelines adopted the advice from the US Expert Committee of criteria for referral to a 
hospital general paediatric clinic for obese and/or overweight children and young people. The 
recommendations from SIGN guidelines are given below:  
 
1) Children who may have serious obesity-related morbidity that requires weight loss (e.g. 
benign intracranial hypertension, sleep apnoea, obesity hypoventilation syndrome, 
orthopaedic problems and psychological morbidity). 
2) Children with a suspected underlying medical (e.g. endocrine) cause of obesity 
including all children aged 24 months of age who are severely obese (BMI ≥ 99.6th 
centile). 
 
Recently, the Obesity Services for Children and Adolescents (OSCA) network released 
guidance on assessing childhood obesity in secondary care (Viner et al., 2012). The OSCA 
guidance provided more clear and detailed criteria for patient referral to secondary care 
compared to the NICE and SIGN guidelines. The OSCA criteria for patient referral to 
secondary care are given below:  
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1) There is a possibility of secondary obesity 
 Short stature for genetic potential/poor growth 
 Dysmorphisms 
 Learning difficulties 
2) A likelihood of co-morbidity:  
 Hypertension 
 Symptoms of sleep apnoea 
 Acanthosis nigricans 
 Evidence of polycystic ovary syndrome (PCOS) 
 Psychological morbidities 
 Child safeguarding concerns 
 Biochemical evidence of impaired glucose tolerance: dyslipidaemia, liver 
dysfunction 
 Family history in close relatives: type 2 diabetes before 40 years or 
cardiovascular disease before 60 years 
 
In the NHS clinical pathway for childhood obesity management, drug treatment and surgery 
should be initiated by specialists in secondary care. Drug treatment is not recommended in 
children younger than 12 years old, except for children with life-threatening co-morbidities. 
Drug treatment for obese and/or overweight children and adolescents is discussed in the next 
section. To date, there is much evidence to support efficacy of bariatric surgery in obese young 
people but less on safety issue (Michalsky et al., 2014). It is not recommended as the first line 
choice of intervention in overweight young people. National guidelines recommend that 
bariatric surgery is only used for those who have a BMI ≥35mg/m2 with serious obesity related 
co-morbidities, or BMI ≥40mg/m2 with minor co-morbidities of obesity, the same guidelines 
as for adults (NICE, 2006; SIGN, 2010). 
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Figure 1.4: The UK clinical care pathway for children and young people with 
overweight and obesity (NICE 2006) 
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1.5.Pharmacological treatment in childhood obesity 
As discussed earlier, pharmacological treatment should not be viewed in isolation in childhood 
obesity management in clinical practice. Pharmacological treatment is considered to be an 
appropriate approach for paediatric patients with BMI ≥30kg/m2 with no obesity related risk 
factors and patients with BMI ≥27mg/m2 with obesity-related complications, along with 
lifestyle modification (e.g. diet, exercise) (Ioannides-Demos et al., 2005). In general, the 
potential pharmacological agents for obesity treatment broadly fall into four categories: 1) 
drugs that stimulate anorexigenic signals (e.g. agonists of 5-HT receptors), 2) drugs that inhibit 
orexigenic signals (e.g. somatostatin analogues), 3) gastrointestinal peptides (e.g. 
oxyntomodulin analogues), 4) drugs that increase energy expenditure (e.g. growth hormone 
receptor agonist) (Isidro & Cordido, 2010).  
 
Ideally, an anti-obesity drug should decrease appetite, increase energy expenditure, and/or 
modulate insulin production with no serious adverse reactions and achieve a 5% loss of initial 
body weight as required by the FDA and a 10% weight loss required by the EMA (Elangbam, 
2009; Heal et al., 2009). Unfortunately, over the past decades, several anti-obesity drugs have 
been reported to be associated with serious adverse reactions, and as a result most anti-obesity 
drugs have been withdrawn from international market. A review of previously withdrawn anti-
obesity drugs, those currently still on the market, and drugs in the late-stage of clinical 
development is presented in Table 1.4. In 2000, phentermine was withdrawn after the Europe-
wide review of the risk and benefits of anorectic agents/appetite suppressants. In December 
2002, the MHRA (medicines) is reinstating the relevant marketing authorisations for 
phentermine in the European Union. 
(http://www.investorvillage.com/smbd.asp?mb=633&mn=37850&pt=msg&mid=12071773). 
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Table 1.4: Anti-obesity drugs withdrawn from the market, on the market, and in late-stage clinical development (adapted from 
Elangbam 2009; Heal et al., 2009; Heal et al., 2012) 
Drug Trade name Year of approval Mechanism of action United States European Union 
Phentermine Lonamin®, Duromine® 1959 NE, and DA reuptake inhibitor Marketed Withdrawn 2000 and reinstated 
2002 
Diethylpropion Tenuate®, Apisate® 1959 in US 
 
NE and DA reuptake inhibitor Marketed Withdrawn 2000 
Fenfluramine Ponderax®, Pondimin® 1973 in US  
 
5-HT releaser and reuptake 
inhibitor 
Withdrawn 1997 Withdrawn 1997 
Dexfenfluramine Redux® 1996 5-HT releaser and reuptake 
inhibitor 
Withdrawn 1997 Withdrawn 1997 
Orlistat  Xenical® 1998 Lipase inhibitor  Marketed Marketed 
Rimonabant  Acomplia® 2006 Cannabinoid CB1 antagonist Not approved Withdrawn 2008 
Sibutramine  Meridia®, Reductil® 1997 in US 
2000 in Europe 
NA and 5-HT reuptake inhibitor Withdrawn 2010 Withdrawn 2010 
Topiramate/phentermine Qnexa® 2012 NA and DA releasing agent Pre-registration* Pre-registration 
Bupropion/naltrexone Contrave® NA DA reuptake inhibitor/opioid 
antagonist) 
2014 Phase 3 
Lorcaserin (APD356) Lorqess® Approved in US 5-HT2c agonist  Marketed† Phase 3 
Zonisamide/bupropion Empatic® NA DA reuptake inhibitor  Phase 2 Phase 2 
Abbreviations: CB1, cannabinoid receptor type1; 5-HT2c, 5-hydroxytryptamine (serotonin) receptor 2C; NE, noradrenaline; DA, dopamine; NA, not available.  
*FDA Advisory Committee recommends approval of Qnexa® for obesity treatment in adult on 22nd February 2012. † FDA Advisory Committee recommends approval  
of Lorqess® for obesity treatment in adult in June 2012.        
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These drugs presented in Table 1.4 were originally licensed only for use in adults. In the mid-
1990s, fenfluramine and dexfenfluramine (serotonin agonist) were both withdrawn due to 
pulmonary hypertension (Hutchinson & Ryder, 2007). In 2006, rimonabant was approved by 
the European Medicines Agency (EMA) for obesity treatment. It has been reported that UK, 
Germany, and France were the highest consumers of rimonabant worldwide (MHRA, 2008). 
However, due to the increasing numbers of reports of psychiatric adverse reactions amongst 
patients taking rimonabant, the EMA recommended the suspension of marketing authorisation 
of rimonabant in Europe. In the US, the FDA did not approve rimonabant for obesity treatment 
due to safety concerns on anxiety, and depression (Heal et al., 2012). In 2010, sibutramine was 
withdrawn from both the US and European markets as the data from clinical trials indicated an 
increased risk of cardiovascular disease (e.g. heart attack and stroke) in adults (James et al., 
2010).  
 
Following the withdrawal of rimonabant and sibutramine, there is currently only one drug, 
orlistat (Xenical®), an inhibitor of gastric and pancreatic lipases, approved for the treatment of 
obesity in Europe. In the US, in addition to orlistat, there are two centrally acting drugs 
approved for short-term obesity treatment (≤12 weeks), phentermine and diethylpropion. Of 
these centrally acting drugs, phentermine is the most frequently prescribed anti-obesity drug 
in adults (Hutchinson & Ryder, 2007).  In 2010, there were three drugs in the pre-registration 
phase: Qnexa®, Contrave®, and Lorqess®. All these drugs are centrally acting agents. On 22nd 
February 2012, the FDA’s advisory Committee approved Qnexa® for obesity treatment in 
adults. However, Qnexa® is still at the pre-registration phase and has not been approved by the 
EMA for obesity treatment at present. In addition to Qnexa®, the FDA approved another drug 
for obesity treatment in adults: Lorcaserin (Lorqess®). A review by Chan et al., (2012) 
investigated the efficacy of lorcaserin for obesity treatment from 3 published RCTs in adults 
aged 18-65 years. The result from the meta-analysis has shown that lorcaserin treatment 
reduced body weight by 3.23 kg and a reduction of BMI by 1.16 kg/m2 compared to placebo 
after one year of treatment in adults. However, there is currently no evidence of lorcaserin for 
obesity treatment in children and adolescents. In 2014, Bupropion/naltrexone (Contrave®) was 
approved by FDA for obesity treatment in adults. In the same year, FDA also approved 
liraglutide (Saxenda®) as a treatment option for chronic weight management for adults with 
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BMI ≥ 30 kg/m2 or adults with BMI of 27 kg/m2 who have at least one weight-related condition 
such as hypertension, type 2 diabetes or high cholesterol (dyslipidaemia) (FDA 2014). 
 
At the time of commencement of this thesis, there were two FDA approved anti-obesity drugs 
for use in adolescents: orlistat for patients aged ≥ 12 (approved in 1999) and sibutramine for 
patients aged ≥ 16 years (approved in 1997) in the US (Barlow, 2007). According to the 
Summary of Product Characteristics (SPC), anti-obesity drugs (orlistat, sibutramine) are not 
approved for use in patients aged less than 18 years in the UK (Orlistat SPC 2012; Sibutramine 
SPC 2011). Also, the EMA has not approved any anti-obesity drugs for use in children and 
adolescents in Europe (Karres et al., 2011).   However, the UK national guidelines (NICE, 
2006; SIGN, 2010) recommended that pharmacological intervention (orlistat, sibutramine) can 
be considered for adolescents and for children younger than 12 years with life-threatening co-
morbidities. Table 1.5 shows the 2006 NICE recommendations for use of anti-obesity drugs 
(orlistat, sibutramine) in children and adolescents. For children aged 12 years or older, drug 
treatment is only recommended if physical co-morbidities (e.g. orthopaedic problems or sleep 
apnoea) or severe psychological co-morbidities are present. Although lifestyle and behavioural 
modifications, diet, and exercise are recommended as first line treatment for weight loss, there 
is still a need for pharmacological intervention as adjunctive therapy in real life (Karres et al., 
2011). Given the short-term beneficial effects of the available drugs in adults, and the lack of 
long-term randomised controlled-trial trial (RCT) data on efficacy and safety data in paediatric 
populations at present, weight loss expectations from anti-obesity drugs need to be viewed 
realistically.  
 
In 2006, the Committee for Medicinal Products for Human Use (CHMP) of the EMA gave 
guidance on the development of weight control products (double-blind randomised controlled 
trial) for use in adults. In 2008, the CHMP outlined an addendum to give guidance on 
development of weight control products for paediatric populations (EMA, 2008). In general, 
clinical trials with anti-obesity drugs should be at least 1 year in duration (long-term) in both 
adults and young people. It also recommended that the observation phase after discontinuation 
of drug therapy should last at least 6 months. Table 1.6 presents the CHMP of EMA guidance 
on the development of new anti-obesity drugs in adults and paediatric population (EMA 2007).  
At the commencement of research for this thesis in 2007, three anti-obesity drugs were 
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approved for obesity treatment in adults in UK clinical practice: orlistat, rimonabant, and 
sibutramine. Their prescribing patterns are described in Chapter 4. The details of individual 
anti-obesity drugs, their classes, pharmacology and indications of use will be given in the 
following sections.  
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Table 1.5: National Institute for Health and Clinical Excellence criteria for use of 
orlistat and sibutramine in children and adolescents (2006)* 
 Drug treatment is not generally recommended for children younger than 12 years 
 In children younger than 12 years, drug treatment may be used only in exceptional circumstances, 
if severe life-threatening co-morbidities (such as sleep apnoea or raised intracranial pressure) are 
presented. Prescribing should be started and monitored only in specialist paediatric settings 
 In children aged ≥12 years, treatment with orlistat or sibutramine is recommended only if physical 
co-morbidities (such as orthopaedic problems or sleep apnoea) or severe psychological co-
morbidities are present. Treatment should be started in a specialist paediatric setting, by 
multidisciplinary teams with experience of prescribing in this age group 
 Orlistat or sibutramine should be prescribed for obesity in children only by a multidisciplinary team 
with expertise in: 
-drug monitoring  
             -psychological support 
             -behavioural interventions 
             -interventions to increase physical activity 
             -interventions to improve diet 
 Orlistat and sibutramine should be prescribed for young people only if the prescriber is willing to 
submit data to the proposed national registry on the use of these drugs in young people 
 After drug treatment has been started in specialist care, it may be continued in primary care if local 
circumstance and/or licensing allow 
 If orlistat or sibutramine is prescribed for children, a 6- to 12-month trial is recommended, with 
regular review to assess effectiveness, adverse effects and adherence 
*21st January 2010, the European Medicines Agency (EMA) announced the withdrawn of sibutramine due to the cardiovascular 
risks outweigh its benefits.  
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Table 1.6: The Committee for Medicinal Products for Human Use (CHMP) guidance on 
the development of weight control product in adult and paediatric population  
Adult 
 Primary endpoints for efficacy assessment: 10% of weight loss from baseline weight  
 The secondary efficacy variables include quality of life parameters, biochemical parameters of lipid  and 
glucose metabolism, blood pressure, cardiac function, and sleep apnoea episodes 
 Selection of patients: 
    -patients with BMI ≥30mg/m2 
    -patients with secondary effects of obesity (such as hypertension, hyperlipidaemia, diabetes, or    
cardiovascular disease) should be considered for inclusion if their BMI > 27mg/m2 
 Patients should all be given similar instruction on diet, and behaviour modification*  
 Drug interactions on anti-hypertensives and oral hypoglycaemic agents should be investigated 
 It is required that treatment effects to be documented for at least one year. If a trial is designed to 
demonstrate the effect of weight loss on morbidity and mortality it would require a longer prospective 
study 
 
Paediatric population (children and adolescents) 
 Two age categories to define paediatric population 
   -Younger children: age 6 to 10 years (or puberty) for girls and 6 to 12 years (or puberty) for boys 
   -Adolescents: age 10  (or puberty)to 18  for girls and 12(or puberty) to 18 years for boys 
 Primary endpoints for efficacy assessment: a change of BMI SDS 
 Secondary endpoints for efficacy assessment:  improved glucose control,  improved lipid profile, better 
mental health and/or quality of life, reduced use of adjunct medications etc. 
 It is not recommended that children aged 2 to 6 years receive pharmacological intervention, only lifestyle 
modification  
 Surgical intervention is normally restricted to adults 
 Selection of patients: 
   -Patients with BMI≥ 25mg/m2 (overweight), or patients with BMI ≥30mg/m2 (obesity) 
   -Patients with secondary causes of childhood obesity such as mental retardation, chromosomal problems 
or syndromic obesity (e.g. Prader-Willi syndrome) should be excluded from the trial; separate trials are 
needed for children with secondary causes of obesity 
   -Patients who have undergone any surgical intervention for obesity management should be excluded  
from the trial 
 It is recommended that separate trials for younger children (6 years to puberty) versus adolescent 
children (puberty to 18 years) are carried out 
 The treatment phase should last at least 1 year 
 Safety data should be collected for at least one year 
Abbreviations; BMI, body mass index; BMI SDS, body mass index standard deviation score. *Behaviour modification such 
as goal setting or use of rewards.  
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1.5.1.Orlistat 
Orlistat is a hydrated derivative of endogenous lipstatin produced by Streptomyces toxytricini 
(McNeely & Benfield, 1998). It is a synthetic gastrointestinal lipase inhibitor which prevents 
the absorption of dietary fat by approximately 30%. It binds to pancreatic lipase and increases 
faecal fat excretion (Figure 1.5) (Ioannides-Demos et al., 2005; Padwal & Majumdar, 2007; 
Elangbam, 2009).  Orlistat’s mechanism of action is to decrease the absorption of ingested fat 
which decreases caloric absorption and consequently leads to weight loss. As orlistat increases 
fat excretion, the most frequent adverse drug reactions are gastrointestinal such as oily spotting 
and faecal urgency. It is recommended that patients should take a daily multivitamin 
supplement as orlistat may decrease the absorption of fat-soluble vitamins (vitamins A, D, E, 
and K) (Padwal & Majumdar 2007).  
 
Figure 1.5: Schematic illustration of mechanism of action of orlistat (reproduced with 
permission from Elangbam 2009) 
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Orlistat was approved for obesity treatment in adults by the FDA in US and by the EMA in 
Europe in 1998. Table 1.7 shows detailed information about orlistat.  
 
Table 1.7: Detailed information and licensed indications of Orlistat 
Name  Orlistat  
Structural Formula  
 
Manufacturer  Roche, GlaxoSmithKline (GSK) 
Mechanism  Blocks fat absorption in the gut 
Year of license  1999 
Formulation  Xenical® 120mg capsules (Roche) 
Alli® 60mg capsules (GSK) 
Alli® 27mg chewable tables (GSK) 
Dose  Adults: over 18 years, 120mg (up to maximal 360mg daily) 
 
Indications from SPC Adults: in conjunction with a mildly hypocaloric diet for obese 
patients with a body mass index (BMI) ≥ 30 kg/m2 or overweight 
patients with BMI >28 kg/m2 with associated risk factors. 
Children: there is no relevant indication for use of Xenical® in 
children. To use in children over 12 years, it should be initiated by 
specialist only [unlicensed use] 
Indications from BNF-C Initiated by specialist  
Children aged 12-18 years: 120 mg once daily; continue treatment 
beyond 12 weeks only under specialist recommendation.  
Vitamin supplementation (especially of vitamin D) may be 
considered if there is a concern about deficiency of fat-soluble 
vitamins. 
Adverse drug reactions  Gastrointestinal adverse reactions (e.g. oily spotting, faecal 
urgency).  
Abbreviations: SPC, Summary Product Characteristics; BNF-C, British National Formulary for Children.  
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Although orlistat when licensed in 1999, was not initially licensed for use in children and 
adolescents, the FDA approved it for obese young people aged ≥ 12 in the US in 2003 (FDA, 
2003). In the UK, orlistat is approved at a dose of 120 mg three times daily with meals for 
obesity treatment in adults aged over 18 years. As discussed (Table 1.5), in 2006 NICE 
recommended that orlistat may be prescribed for children aged 12 and under with life-
threatening co-morbidities. According to BNF-C (2011), orlistat can only be initiated by a 
specialist if patients are aged 12-18 years and should be closely monitored if treatment 
continues for more than 12 weeks. There is limited evidence on the efficacy and tolerability of 
orlistat in young people since most clinical trials excluded patients younger than 18 years old 
(Ioannides-Demos et al., 2006). At the beginning of the study period in 1999, the effect of 
orlistat in children had not been studied (SPC 1999). Therefore, orlistat is not approved for use 
in obese/overweight children in the UK at present.  
 
In 2006, the FDA approved orlistat as an over-the-counter (OTC) product at a lower dose of 
60mg in US (Alli®, GlaxoSmithKline) (FDA, 2007). Subsequently, the EMA granted approval 
to GSK to sell 60mg and 27mg of orlistat (Alli®) as over-the-counter (OTC) products 
throughout Europe in 2007 (EMA, 2007). Despite the new formulation, Alli® is only licensed 
for obesity treatment in adults; the safety and efficacy of use in children aged under 18 years, 
has not been established (Orlistat SPC 2012).  
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1.5.2.Sibutramine 
Sibutramine is a centrally acting appetite suppressant which was originally developed as an 
antidepressant.  It acts by inhibiting the re-uptake of norephinephrine and serotonin (5 
hydroxytryptamine; 5-HT) in the central nervous system which leads to a sense of satiety. 
Sibutramine also has a moderate effect on energy expenditure by stimulating thermogenesis, 
these effects are essential to anti-obesity actions (McNeely & Goa, 1998; Finer, 2002). 
Sibutramine was initially approved by the FDA for long-term (1 year) weight loss in adults in 
1997 and in Europe in 2000. Detailed information on sibutramine is presented in Table 1.8. 
 
Table 1.8: Detailed information and licensed indications of Sibutramine* 
Name  Sibutramine  
Structural Formula 
 
Manufacturer  Abbott Laboratories 
Mechanism  To inhibit the re-uptake of serotonin and noradrenaline from 
hypothalamic neurones. A centrally acting appetite suppressant.  
Year of license  2000 
Formulation  Reductil®: 10mg capsule  
Dose Initially 10mg daily in the morning, increased if weight loss less than 
2kg after 4 weeks to 15mg daily. Period for treatment 1 year.  
Indications from SPC Adults: obese patients with a body mass index (BMI) ≥ 30 kg/m2 
(and no associated co-morbidity) or patients with BMI >27 kg/m2 
with associated risk factors such as type 2 diabetes or 
hypercholesterolaemia.  
It is not licensed for use longer than 1 year. 
Children and adolescents under 18 years and elderly over 65 years 
not recommended.  
Indications from BNF-C BNF-C (2009): sibutramine may be chosen for patients who cannot 
control their eating.  
BNF-C (2012): No information for sibutramine use in children  
Adverse drug reactions  Constipation, anorexia, dry mouth, insomnia, tachycardia, 
palpitation, arrhythmias, hypertension; rarely blurred vision.  
Abbreviations: SPC, Summary Product Characteristics; BNF-C, British National Formulary for Children. *information from 
SPC were recommended before the withdrawal of sibutramine in 2010.  
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In the US, the FDA approved sibutramine for use in patients aged ≥16 years (Barlow, 2007). 
Although NICE guidelines (2006) suggested that sibutramine could be used for children aged 
≥12 years with life-threatening co-morbidities, this drug was not licensed for use in children 
and adolescents for obesity treatment in the UK. In January 2010, the EMA recommended 
withdrawal of sibutramine from all markets in the European Union (EU). The decision was 
based on data from the SCOUT trial (Sibutramine Cardiovascular Outcome Trial) funded by 
the manufacturer, Abbott Laboratories.  
 
The SCOUT trial was a multi-centre, double-blind, placebo-controlled randomised trial to 
investigate the risk of developing cardiovascular events in overweight/obese patients aged ≥55 
years. Unlike other clinical trials, patients with high risk conditions (e.g. pre-existing 
cardiovascular diseases were eligible for the SCOUT trial (James, 2005). A total of 9,804 
patients were included, of which 4,906 patients received sibutramine and 4,898 received 
placebo. The primary outcomes were to investigate the first occurrence of nonfatal myocardial 
infarction, nonfatal stroke, and resuscitation after a cardiac arrest, or cardiovascular death in 
both the sibutramine group and the placebo group. Despite the sibutramine group losing more 
weight than the placebo group, the risk of a primary outcome event  was significantly increased 
(16%) in the sibutramine group compared with the placebo group, with overall incidences of 
11.4% and 10.0% in the two groups, respectively (James et al., 2010). Following a review of 
this trial, the EMA concluded that the benefits of sibutramine did not outweigh its risks and 
that it should be suspended in Europe (EMA, 2010). Since the withdrawal of sibutramine, there 
is only one anti-obesity drug (orlistat) approved for the management of weight loss in obese or 
overweight adults in Europe.  
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1.5.3. Rimonabant 
Rimonabant is a selective endocannabinoid receptor blocker, acting to inhibit the action of 
central and peripheral cannabinoid (CB)-1 receptors (Figure 1.6). Rimonabant modulates 
several peripheral signals such as ghrelin, leptin (peptides affect food intake when given 
peripherally) in rodents, which improve lipid and glucose metabolism and regulate food intake 
and energy balance (Boyd & Fremming, 2005; Henness et al., 2006). The most commonly 
reported adverse drug reactions are nausea, dizziness, diarrhoea and insomnia (Henness et al., 
2006). Rimonabant was initially developed to treat obesity and smoking-cessation.  However, 
development for smoking-cessation was discontinued in the US (Padwal & Majumdar, 2007). 
It was approved for anti-obesity treatment by the EMA in the EU in 2006 but the FDA did not 
grant approval for use in the US.  
 
Figure 1.6: Rimonabant potential anti-obesity actions, metabolic and major side effects 
(adapted from Padwal & Majumdar 2007) 
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The Rimonabant in Obesity (RIO) programme included four phase III double-blind 
randomised controlled trials: RIO-North America (Pi-Sunyer et al., 2006), RIO-Europe (Van 
Gaal et al., 2005), RIO-Diabetes (Scheen et al., 2006), and RIO-Lipids (Despres et al., 2005) 
which were conducted to compare the efficacy of rimonabant 5mg or 20mg daily with placebo, 
in 6,635 overweight and/or obese patients. Table 1.9 presents the weight change from baseline 
after 1 year (12 months) treatment in the four RIO studies. It appears there was minimal 
efficacy on weight reduction with 5mg dose of rimonabant compared with the results of the 
20mg dose in the four studies. The RIO-North America study also included the results of a 
second year of follow-up of patients who received rimonabant treatment in the first 1 year and 
were re-randomised to either placebo or continued to receive rimonabant (Pi-Sunyer et al., 
2006).  In the RIO-Diabetes trial, HbA1c levels improved significantly compared to placebo 
rimonabant (Scheen et al., 2006). In the RIO-Europe and RIO-North America studies, LDL 
cholesterol and blood pressure either did not change or were slightly reduced in rimonabant-
treated patients (Pi-Sunyer et al., 2006; Van Gaal et al., 2005).  
 
In the RIO programme, patients who withdrew from the study due to side effects, most reported 
mood disorders. However, the majority of the patients did not withdraw due to side effects. 
Also, patients who received 20 mg rimonabant were reported to have had more adverse 
reactions of nausea, vomiting, diarrhoea, headache, dizziness, and anxiety than the lower dose 
group and the placebo group. The authors stated that in the RIO-Diabetes trial, no serious 
adverse events linked to psychiatric disorders were recorded in rimonabant-treated patients. 
However, patients with severe mental illness were not included in the RIO programme, so their 
estimates of psychiatric adverse reactions associated with rimonabant treatment maybe 
conservative.   
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Table 1.9: One year results from four Rimonabant in Obesity (RIO) programme (Van Gaal et al., 2005; Despres et al., 2005; Pi-
Sunyer et al., 2006; Scheen et al., 2006) 
Study Study population*  Study period Study design  Weight (kg) change from baseline† 
    
Placebo 5mg 
P value 
(5mg rimonabant vs placebo) 
20mg 
P value 
(20mg rimonabant vs 
placebo) 
RIO-North 
America§ 
3,045 overweight or obese 
patients in North America 
(US, and Canada)   
August 2001-
April 2004 
Rimonabant 20mg daily 
(n=1222)  vs placebo (n=607) 
Rimonabant 5mg daily 
(n=1216) vs placebo (n=607) 
NA -1.3  <0.001 -4.7 <0.001 
RIO-Europe 1507 overweight or obese 
patients in Europe 
October 2001- 
June 2004 
Rimonabant 20mg daily 
(n=599) vs placebo (n=305) 
Rimonabant 5mg daily (n=603) 
vs placebo (n=305) 
-3.6 -4.8  0.042 -8.6 <0.001 
RIO-Lipids‡ 1036 overweight or obese 
patients with untreated 
dyslipidaemia and without 
diabetes. Patients were from 
67 centres in 8 countries 
September 
2001-November 
2003 
Rimonabant 20mg daily 
(n=346) vs placebo (n=342) 
Rimonabant 5mg daily (n=345) 
vs placebo (n=342) 
-1.5 -3.1 <0.001 -6.9 <0.001 
RIO-Diabetes 1047 overweight or obese 
patients with type 2 diabetes. 
Patients were from 159 
centres in 11 countries 
(Europe, North America, and 
South America) 
October 2001-
May 2004 
Rimonabant 20mg daily 
(n=339) vs placebo (n=348) 
Rimonabant 5mg daily (n=358) 
vs placebo (n=348) 
-1.4 -2.3 0.01 -5.3 <0.0001 
Abbreviation: NA, not available. *Study population: obese was defined as patients with body mass index (BMI) ≥30kg/m2 and overweight as patients with BMI >27kg/m2. ‡RIO-Lipids study included patients with 
BMI from 27 to 40 kg/m2. §RIO-North America: results were reported from placebo-subtracted changes from baseline body weight. †Weight change from baseline was taken from 1 year results; intention-to-treat 
(ITT) approached was used and last-observation-carried-forward method was applied for missing data. 
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Table 1.10 presents detailed information on rimonabant. Rimonabant was not approved for use 
in young people aged <18 years (Rimonabant SPC 2008). In October 2008, the EMA’s CHMP 
decided to withdraw rimonabant from the EU as post-marketing data and new data from on-
going clinical trials had shown that serious psychiatric disorders were reported at a higher 
frequency than at the time of the initial assessment (EMA, 2008).  
 
Table 1.10: Detailed information and licensed indications of Rimonabant* 
Name  Rimonabant 
Structural Formula 
 
Manufacturer  Sanofi-Aventis 
Mechanism  Cannabinoid receptor-1 blocker 
Year of license  2006 
Formulation  Acomplia®: 20mg tablet  
Dose Adult over 18 years: 20mg daily  
Indications from SPC Adults: obese patients with a body mass index (BMI) ≥ 30 kg/m2 or 
patients with BMI > 27 kg/m2 in the presence of other risk factors 
such as type 2 diabetes or dyslipidaemia.  
Indications from BNF-C BNF-C: No information for rimonabant use in children 
Adverse drug reactions  Depression: patients and carers should be informed of the risk of 
depression and advised to stop treatment and seek medical attention 
if symptoms occur. 
Nausea, vomiting, diarrhoea, dry mouth, anorexia, depression, 
anxiety, nervousness, sleep disorders 
Abbreviations: SPC, Summary Product Characteristics; BNF-C, British National Formulary for Children. *information from 
SPC were recommended before the withdrawn of rimonabant in 2008.  
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1.5.4.New drugs potentially for obesity treatment  
 
As discussed (see Table 1.4.), there are FDA-approved appetite suppressants for short-term 
obesity treatment in adults in the US such as diethylpropion and phentermine. These drugs are 
structurally related to amphetamines and pose a risk of addiction (Bray, 2007). These appetite 
suppressants are not approved for obesity treatment in Europe.  In addition to the development 
of new drug therapies (e.g. topiramate/phentermine,  bupropion/naltrexone, lorcaserin) for 
obesity treatment, there are several marketed drugs that have been considered for weight loss, 
including selective serotonin reuptake inhibitors (SSRIs) e.g. fluoxetine), antiepileptic drugs 
(e.g. topiramate, zonisamide), and the anti-diabetic drug (metformin). Despite the lack of long-
term RCTs’ data to support their use for obesity treatment, these drugs have been prescribed 
to obese patients in clinical practice (Ioannides-Demos et al., 2005; Bray, 2007; Wald & Uli, 
2009). Of these drugs, metformin is considered the best drug for weight loss for patients with 
type 2 diabetes (Hundal & Inzucchi, 2003).  
 
Studies have shown that metformin is also effective as an anti-obesity drug, aiding moderate 
weight loss in obese paediatric patients, and is commonly prescribed by doctors in clinics 
(Clarson et al., 2009; Wald & Uli 2009; Wilson et al., 2010; Rogovik et al., 2010). A 
systematic review that investigated five randomized controlled trials (RCTs) in children and 
adolescents aged ≤ 19 years without diabetes, showed that metformin significantly reduced 
BMI by 1.41 kg/m2 (95%CI 0.83 to 2.02) over 6 months treatment (Park et al., 2009). Although 
metformin has shown a moderate effect on weight loss in children and adolescents in the short-
term, there is a lack of long-term efficacy and safety studies to demonstrate its benefit on 
weight reduction in young people. Furthermore, metformin is only licensed for the treatment 
of type 2 diabetes in adults and children over the age of 10. Its use for obesity treatment has 
not been approved for either adults or children in the UK nor in other parts of Europe.  
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1.6.Summary  
The treatment of obesity in young people presents a substantial challenge for health care 
professionals. The childhood obesity epidemic is currently one of the foremost health priorities 
in the UK. Despite limited evidence on the use of anti-obesity drugs in children and 
adolescents, these drugs are being prescribed in clinical practice. Therefore, there is a need to 
understand not only the efficacy and safety of these drugs but also their utilisation and 
prescribing patterns in obese young people. Investigation of the appropriateness of prescribing 
and the outcomes of pharmacological treatment in obese young people would enable clinicians 
to identify gaps between the evidence and clinical practice.  
 
1.7.Scope of the thesis  
The epidemic of childhood obesity is one of the common health problems affecting children in 
the UK. Obesity and its related conditions (e.g. diabetes, cardiovascular diseases) in childhood 
can persist in some patients into adolescence and adulthood. Obesity can be treated using 
various modes of therapy from lifestyle modification, behaviour support, or psychological 
intervention to the use of anti-obesity drugs.   Despite comprehensive national guidance on 
obesity management for children and adolescents in primary care (NICE 2006; SIGN, 2010) 
and secondary care (OSCA, 2012), studies reporting the use of anti-obesity drugs have been 
conducted in other countries with no information on their use in the UK. Data from other 
countries may not be extrapolated to UK practice due to differences in approaches to obesity 
treatment and the health care systems of various countries.  Information on anti-obesity drug 
use in young people is therefore essential to establish patterns of prescribing in UK clinical 
practice.  
 
In January 2011, the Paediatric Research in Obesity Multi-model Intervention and Service 
Evaluation (PROMISE) programme was launched. This programme compromises five studies 
and aims to improve the care and experiences of obese children and adolescents in the UK. 
PROMISE is led by Professor Russell Viner at University College London (UCL) Institute of 
Child Health (ICH) with funding from the National Institute of Health Research (NIHR). The 
studies of this thesis were conducted in collaboration with the PROMISE programme in 
particular, pharmacological interventions for obesity treatment.  
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Chapter 3 of this thesis describes the systematic review conducted to investigate the efficacy 
and adverse drug reactions from published randomised controlled trials regarding the use of 
anti-obesity drugs in children and adolescents. The statistical technique of meta-analysis, was 
employed to determine the pooled estimated treatment effects of these drugs. This information 
provided an understanding of the treatment effects of these drugs on weight reduction and 
reported adverse reactions in young people (Viner et al., 2010). 
 
Chapter 4 discusses the pharmacoepidemiological methods used to investigate anti-obesity 
drug prescribing in children and adolescents in primary care clinical databases: the General 
Practice Research Database (GPRD), and IMS Disease Analyzer (IMS DA). Initially in section 
4.1, the prescribing trends of anti-obesity drugs were investigated and treatment duration of 
these drugs was also examined (Viner et al., 2009). Due to the withdrawal of rimonabant and 
sibutramine, the use of metformin for obesity treatment may increase its popularity. Therefore, 
section 4.2 of Chapter 4 provides detailed information on metformin utilisation and prescribing 
trends in young people (Hsia et al., 2012).  
 
Chapter 5 describes patterns of prescribing in the primary care setting. As suggested in the 
NICE guideline anti-obesity drug use should be initiated by a specialist in secondary care. 
There is currently no data on drug prescribing for obesity treatment from secondary care in the 
UK. In Chapter 5, a systematic review and meta-analysis was undertaken to investigate 
metformin efficacy on weight loss in non-diabetic obese children and adolescents from RCTs. 
Following this systematic review and meta-analysis, a prospective cohort study was conducted 
to investigate drug use for obesity treatment in young people at a regional secondary care 
sector, is reported. Initially, drug prescribing patterns for obesity treatment were investigated. 
This information was useful for understanding the prescribing practice for obesity treatment in 
secondary care. A study was subsequently conducted to assess the effect of metformin 
treatment on weight reduction (BMI, BMI SDS, weight) in this study population at six months 
of treatment.  
 
To date, there is very little research to assess pharmacological intervention in childhood obesity 
management in primary care and secondary settings in the UK. It is difficult to extrapolate 
clinicians’ experiences toward anti-obesity prescribing to obese young people from previous 
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studies which were conducted outside UK.  A national questionnaire survey was conducted to 
evaluate clinicians’ experiences and their attitudes in prescribing anti-obesity drug to obese 
children and adolescents in primary care and secondary care in the UK.  
 
Chapter 2 describes the aims and objectives of this thesis in more detail.  
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Chapter 2  Aim and Objectives  
The overall aim of this thesis was to investigate anti-obesity drug prescribing in children and 
adolescents in both primary care and secondary care in the UK. Rimonabant and sibutramine 
were withdrawn from the market in 2008 and 2010, respectively, after the start of the work for 
this thesis. Therefore, data on the prescribing patterns of these drugs have been included in this 
thesis. To achieve this aim, three main research questions were proposed:  
 
1) What is the evidence in the literature from RCTs concerning the efficacy and adverse 
drug reactions of anti-obesity drugs used in children and adolescents? 
2) How are anti-obesity drug prescribed for children and adolescents in primary care in 
the UK?  
3) What are the anti-obesity drug prescribing patterns for young people in secondary care 
in the UK?  
 
To answer these questions, the following research projects were undertaken.  
  
2.1.Systematic review and meta-analysis of RCTs of anti-obesity drugs in children and 
adolescents (Chapter 3)   
In 2006, the recommendations from the National Institute for Health and Clinical Excellence 
(NICE) guidance on anti-obesity drug use in young people were based on a small number of 
randomised controlled trials (RCTs). There is a need for current evidence to support anti-
obesity drug use in children and adolescents.  
 
2.1.1.Aim 
To systematically evaluate information from randomised controlled trials for anti-obesity drug 
use in young people.  
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2.1.2.Objective 
To conduct a systematic review and meta-analysis of randomised controlled trials to investigate 
the efficacy and safety of anti-obesity drugs (orlistat, sibutramine, rimonabant) used in children 
and adolescents aged between 0 and 18 years.  
 
2.2.Anti-obesity drug prescribing patterns to young people in primary care in the UK 
(Chapter 4) 
The epidemic of childhood obesity is well-documented in the UK and globally. However, prior 
to 2007 there were few data on the use of anti-obesity drugs (orlistat, sibutramine, rimonabant) 
in young people in primary care in the UK. Two drug utilisation studies were conducted to 
investigate anti-obesity drug prescribing patterns in children and adolescents in UK primary 
care. In the UK, general practitioners (GPs) manage their patients’ medical records 
electronically. These electronic records are a valuable source of data for medical research. Due 
to the withdrawal of rimonabant in 2008 and sibutramine in 2010, the popularity of the use of 
metformin for obesity treatment in clinical practice, may have increased. Therefore, the 
prescribing trend for metformin and the indications for its use in primary care were also 
examined. 
 
2.2.1.Aims 
1) To investigate anti-obesity drug (orlistat, sibutramine, rimonabant) prescribing 
patterns and duration of use in children and adolescents aged 18 or younger in general 
practices in the UK.  
2) To examine the prescribing trend and indications for metformin prescribing to young 
people in general practices.  
2.2.2.Objectives 
1) To investigate annual, age- and sex-specific trends in prescribing anti-obesity drugs 
(orlistat, sibutramine, rimonabant) in children and adolescents aged 0-18 years between 
January 1999 and December 2006. 
2) To determine the duration of anti-obesity drug use in children and adolescents using 
Kaplan-Meier survival analysis.  
3) To investigate annual, age- and sex-specific metformin prescribing trends in children 
and adolescents between January 2000 and December 2010.  
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4) To examine indications for metformin prescribing in children and adolescents in 
general practices.  
2.3.Anti-obesity drug prescribing patterns to obese young people in the secondary care 
(Chapter 5) 
Due to the withdrawal of sibutramine in January 2010, currently orlistat is the only drug 
recommended by NICE guideline for obesity treatment. Several potential marketed drugs have 
been used for obesity treatment in clinical practice in the UK (Chapter 1, section 5). Of these 
metformin is suggested as the best drug of choice, because obese patients are likely to have 
metabolic syndromes. To date, there is limited evidence on the effect of metformin treatment 
on weight loss in obese young people either from RCTs or from clinical practice. A systematic 
review and meta-analysis of published RCTs was undertaken to investigate the efficacy of 
metformin treatment on weight loss in this population. Following this review a prospective 
cohort study was conducted in a paediatric weight management clinic at University College 
London Hospital (UCLH). Data were collected from January 2007 to December 2010 to 
investigate anti-obesity drug prescribing patterns. Subsequently an observational cohort study 
was conducted to determine the effect of metformin treatment on weight loss in patients who 
received this drug for obesity treatment in this paediatric clinic.   
 
2.3.1.Aims 
1) To investigate the efficacy of metformin treatment on weight loss in obese young 
people from RCTs.  
2) To investigate pharmacological interventions in obese young people at University 
College London Hospital (UCLH) paediatric weight management clinic.  
2.3.2.Objectives 
1) To conduct a systematic review and meta-analysis to investigate metformin efficacy 
from published RCTs in non-diabetic children and adolescents aged 0-18 years.  
2) To describe anti-obesity drug prescribing patterns for patients aged 10-18 years 
attending a weight management clinic at UCLH, between January 2007 and December 
2010.  
3) To determine the effect of metformin treatment on weight loss at 6 months of 
treatment for patients attending a weight management clinic at UCLH aged 10-18years.  
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2.4.Anti-obesity drug prescribing patterns to young people in primary care and 
secondary care: a national questionnaire survey study (Chapter 6)  
Several studies have been carried out to assess health practitioners’ behaviour towards 
childhood obesity management in clinical practice. These studies primarily evaluated 
practitioners’ attitudes toward childhood obesity management in general. None of these studies 
specifically evaluated practitioners’ experiences in pharmacological intervention to manage 
childhood obesity in their clinical practice. Furthermore most of these studies were conducted 
outside the UK. To date, there has been very little research to evaluate health practitioners’ 
attitudes and experiences on prescribing anti-obesity drugs to obese children and adolescents 
across different clinical settings in the UK. A questionnaire survey was conducted to assess 
clinicians’ attitudes and experiences on prescribing anti-obesity drug to young people for 
obesity treatment in primary care.  
 
2.4.1.Aims and objectives:  
The aim of this study was to survey clinicians about their anti-obesity drug prescribing practice 
to obese young people in their clinical practice via questionnaires. There were four specific 
objectives:  
1) To investigate GP experiences on prescribing anti-obesity drugs to  young people 
2) To investigate  GP knowledge and skills on prescribing anti-obesity drugs 
3) To investigate the reasons for discontinuing anti-obesity drug treatment. 
4)  To identify key elements for future prescribing guidance or intervention to support 
prescribing of anti-obesity drugs to young people in both primary care and secondary 
care. 
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Chapter 3  Systematic review and meta-analysis of randomised controlled 
trials on anti-obesity drugs 
3.1.Introduction  
As discussed earlier, there has been an increase of childhood obesity worldwide during past 
decades. Although attention has focused mainly on lifestyle modification interventions, a role 
for the use of anti-obesity drugs in the treatment of children and adolescents has been identified 
(Freemark, 2007). Detailed information on anti-obesity drugs have been described previously 
(Chapter 1.5). However, the NICE recommendation of prescribing anti-obesity drug for 
children and adolescents was based on a limited evidence base, with a small number of 
randomised controlled trials for each drug. There is a need for current evidence to support the 
use of these drugs in young people (Freemark, 2007).  
 
Two systematic reviews were identified on obesity treatment in children and adolescents 
(McGovern et al., 2008; Oude et al., 2009). McGovern et al. (2008) conducted a systematic 
review on randomised trials of nonsurgical interventions (diet, physical activity, and 
pharmacological agents) in overweight children and adolescents aged 2-18 years to investigate 
the efficacy of obesity treatment. These authors reported on the overall efficacy of three 
pharmacological interventions (orlistat, sibutramine, metformin) regardless of the different 
length of follow-up of the studies. The pooled estimate from the meta-analysis in the review 
showed that orlistat reduced BMI by 0.7 kg/m2 (95% CI 0.3 to 1.2) and the reduction of BMI 
for sibutramine treatment was 2.4 kg/m2 (95% CI 1.8 to 3.1). Use of metformin showed a small 
non-significant BMI reduction of 0.17 kg/m2 (95% CI -0.62 to 0.28). A Cochrane review by 
Oude et al. (2009) investigated lifestyle interventions (diet, physical activity and/or 
behavioural therapy interventions), drug therapy (orlistat, sibutramine, metformin, 
rimonabant) and surgical interventions in obese children aged less than 18 years. In this 
Cochrane review, the authors included drug trials that had at least up to 3 months drug therapy 
and 6 months follow up period. In these two reviews, of pharmacotherapy use in paediatric 
populations, adverse drug reactions (ADRs) associated with the anti-obesity drug treatment 
were not investigated. Therefore, a systematic review and meta-analysis of randomized 
controlled trials investigating the efficacy and safety of the use of anti-obesity drugs in children 
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and adolescents was conducted. In this systematic review, three anti-obesity drugs approved at 
the time in the UK were included: orlistat, sibutramine, and rimonabant.  
3.2.Aim and objective 
The overall aim of this review was to evaluate the efficacy and safety of anti-obesity drugs 
used in children and adolescents. This was achieved by conducting a systematic review and 
meta-analysis of randomised controlled trials of anti-obesity drugs. Specific objectives 
included:  
1) To assess the efficacy of anti-obesity drugs (orlistat, sibutramine, rimonabant) used 
in children and adolescents aged between 0 to 18 years.  
2) To evaluate adverse drug reactions (ADRs) related to anti-obesity drug treatment in 
children and adolescents aged between 0 to 18 years.  
3.3.Systematic review of randomised controlled trials 
There has been an increasing amount of scientific information about health care. In order to 
integrate this large amount of information into practice, published studies need to be reviewed 
and the evidence for a specific topic summarised for health care professionals (Egger et al., 
2001). Traditionally, reviews of medical literature summarise the studies and examine the 
heterogeneity of them, and then report them descriptively in the form of “narrative review” 
(Petticrew, 2003). Although narrative review has been widely used in medical research, it has 
been criticised for its high risk of selection bias. In addition, studies may use a variety of 
methods and this may often lead to contradictory findings in a narrative review (Cook et al., 
1997). To ensure the results of the literature review are less biased, systematic review and 
meta-analysis have gained popularity amongst health care professionals in recent years.  
 
Systematic reviews use explicit methods to search evidence and to summarise the literature 
systematically. Systematic reviews are defined as “scientific investigations in themselves, with 
pre-planned methods and an assembly of original studies as their subjects. They synthesise the 
results of multiple primary investigations by using strategies that limit bias and random error” 
(Mulrow, 1987; Cook et al., 1995).  A systematic review may, or may not, include a meta-
analysis (Egger et al., 2001). Meta-analysis is a statistical method of summarising data from 
individual studies and produces a pooled estimate of intervention effect (Egger et al., 2001). A 
detailed discussion of meta-analysis is presented in the subsequent section.  
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The term systematic review was first used by Archie Cochrane, a British physician and 
epidemiologist, known for his influential book, Effectiveness and Efficiency: Random 
Reflections on Health Services, published in 1972. Cochrane identified a lack of access for 
people who wanted to have reliable evidence in health care. He also stressed the importance of 
collating evidence from RCTs as these can provide more reliable information than evidence 
from other sources. Although his ideas have received enormous support, applying his approach 
in research has been very slow (Chalmers, 1993; Chalmers et al., 2002). Systematic reviews 
were not widely used until the 1990s. In 1992, in response to Cochrane’s call for “systematic, 
up-to-date reviews of all relevant RCTs of health care”, the first Cochrane centre was 
established in Oxford to support the National Health Service (NHS) (Chalmers, 1993). The 
following year, the Cochrane Collaboration was set up to provide healthcare professionals, 
policy makers and patients with well-documented evidence through systematic reviews of the 
effect of health care interventions. In addition, the Cochrane Collaboration is able to provide 
evidence at international level (http://www.cochrane.org/).  
 
Cook and colleagues (1997) tabulated the differences between systematic reviews and 
traditional narrative reviews (Table 3.1). A systematic review is generally driven by a specific 
research question. A well-formulated research question can help reviewers to make decisions 
about which studies are relevant and should be included and which are not relevant and 
therefore should be excluded, during the review process (Greenhalgh, 1997).  
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Table 3.1: Summary of the differences between narrative reviews and systematic 
reviews (adapted from Cook et al., 1997) 
Feature  Narrative review Systematic review 
Question  Often broad in scope  Often a focused clinical question 
Sources and search Not usually specified, potentially 
biased 
Comprehensive sources and 
explicit search strategy  
Selection  Not usually specified, potentially 
biased 
Criterion-based selection, 
uniformly applied  
Appraisal  Variable  Rigorous critical appraisal   
Synthesis  Often a qualitative summary Quantitative summary  
Inference  Sometimes evidence-based Usually evidence-based 
A quantitative summary which includes a statistical synthesis is a meta-analysis.  
 
Traditional narrative review is often conducted to cover a broad range of issues related to a 
specific topic (Cook et al., 1997). The advantage of a narrative review is that it provides a 
broad perspective on a specific topic and it may also be useful for background reading. 
However, a narrative review does not normally describe how reviewers selected and assessed 
the studies during the review process. The absence of explicit methods may cause 
methodological flaws, and may bias the reviewers’ conclusion and could result in inappropriate 
recommendations (Murlow, 1987; Akobeng, 2005). As narrative reviews are not conducted via 
a pre-planned method it is sometimes difficult to replicate the findings (Feldstein, 2005; Egger 
et al., 2001). In addition, it can be difficult to identify important information required for 
guiding improvements to treatment, from narrative reviews which sometimes will cause a 
delay in implementing changes (Greenhalgh, 1997). The Cochrane Collaboration logo is a 
striking example to demonstrate the unnecessary delay in implementing new therapy. Detailed 
explanation of the Cochrane Collaboration logo is discussed in the next section (see section 
3.5). However when conducting systematic reviews, all existing published literature should be 
examined and analysed in a structured way which assists rational decision making for 
clinicians, researchers, and policy makers. Systematic reviews have now often replaced 
traditional narrative reviews in medical research.  
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As a result of the success of the Cochrane Collaboration programme, the number of published 
systematic reviews has increased substantially in the past decade, it has now become an 
important part of epidemiological research (Mulrow, 1994; Blettner et al., 1999; Egger et al., 
2001). Systematic reviews have been classified as similar to observational studies by utilising 
available evidence for research (Egger et al., 2001). To conduct a high quality scientific, 
systematic review, comprehensive steps must be followed which are outlined in Table 3.2.  
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Table 3.2: Steps for conducting systematic review with or without meta-analysis 
(Egger et al., 2001) 
1. Formulate review question 
2. Define inclusion and exclusion criteria 
 Participants 
 Interventions and comparisons 
 Outcomes 
 Study designs and methodological quality 
3. Locate studies 
Develop search strategy considering the following sources:  
 The Cochrane Controlled Trials Register (CCTR) 
 Electronic databases and trials registers not covered by CCTR 
 Checking of reference lists 
 Hand searching of key journals 
 Personal communication with experts in the field  
4. Select studies 
 Have eligibility checked by more than one observer 
 Develop strategy to resolve disagreements 
 Keep log of excluded studies, with reasons for exclusions 
5. Assess study quality  
 Consider assessment by more than one observer 
 Use simple checklists rather than quality scales 
 Always assess concealment of treatment allocation, blinding and handling of 
patient attrition 
 Consider blinding of observers to authors, institutions and journals 
6. Extract data  
 Design and pilot data extraction form 
 Consider data extraction by more than one observer  
 Consider blinding of observers to authors, institutions and journals 
7. Analyse and present results*  
 Tabulate results from individuals studies  
 Examine forest plot 
 Explore possible sources of heterogeneity 
 Consider meta-analysis of all trials or subgroups of trials 
 Perform sensitivity analyses 
 Make list of excluded studies available to interested readers 
8. Interpret results 
 Consider limitations, including publication and related biases 
 Consider strength of evidence 
 Consider applicability  
 Consider numbers-needed-to-treat to benefit / harm 
 Consider economic implications 
 Consider implications for future research  
*This step describes when systematic review and meta-analysis are conducted in the review.  
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Data sources that could be searched for relevant articles also need to be considered before a 
systematic review is undertaken. Greenhalgh (1997) provided a list of possible data sources 
that could be included in a systematic review (Table 3.3). It is also recommended that the 
references from identified articles are searched, which may not have been included in the initial 
search. If data are not available in published RCT studies, review authors should consider 
contacting study authors for information (Higgins & Green, 2009).   
                    
Table 3.3: Data sources for systematic reviews (Greenhalgh, 1997) 
 
1 MEDLINE database  
2 Cochrane controlled clinical trials register 
3 Other medical and paramedical databases (e.g. PsycINFO) 
4 Foreign language literature 
5 Grey literature (e.g. thesis, internal reports, non-peer reviewed journal, 
pharmaceutical industry files) 
6 References (and references of references, etc.) listed in primary source 
7 Other unpublished sources known to experts in the field (e.g. personal 
communication) 
8 Raw data from published trials (e.g. personal communication) 
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3.4.Meta-analysis of randomised controlled trials 
The term meta-analysis was first introduced by Glass in 1976 to emphasise the need for better 
summary of research results. Glass defined meta-analysis as “the statistical analysis of a large 
collection of analysis results from individual studies for the purpose of integration of the 
findings” (Glass, 1976). There are two types of meta-analysis: meta-analysis of randomised 
controlled trials and meta-analysis of epidemiological studies such as observational studies 
(Egger et al., 2001). Meta-analysis of observational studies is beyond the scope of this thesis, 
so there is no further discussion of these techniques and issues.  
 
Meta-analysis is a powerful statistical tool; by bringing together samples from individual 
studies the sample size is increased as well as the precision of the estimates of intervention 
effects (Sutton et al., 2000). As discussed, meta-analysis is a part of the systematic review 
process but it may not be necessary to include it. The Cochrane Statistical Methods Group 
provides several reasons for not including a meta-analysis in a review; these are listed below 
(Higgins & Green, 2009):   
 
1. If studies are clinically diverse then a meta-analysis may be meaningless, and genuine 
differences in effects may be obscured. Furthermore, it is important not to combine 
outcomes that are too diverse. Decisions concerning what should and should not be 
combined are inevitably subjective, and are not amenable to statistical solutions but 
require discussion and clinical judgement. 
2. If bias is present in each (or some) of the individual studies, meta-analysis will simply 
compound the errors, and produce wrong results that may be interpreted as having 
more credibility.  
3. Meta-analysis in the presence of serious publication and/or reporting biases are likely 
to produce an inappropriate summary.  
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In general, there is a two-stage process of conducting meta-analysis. The first stage of meta-
analysis is to calculate the effect size; such as the treatment effect between two interventions, 
with 95% confidence intervals (CI) for each of the individual studies, the ‘effect 
measurement(s)’ used depend on the outcome data available. There are two types of effect: 
dichotomous data (binary) and continuous data (Sutton et al., 2000; Akobeng, 2005; Higgins 
& Green, 2009). The three most commonly used effect measurements for dichotomous 
outcomes data are: 1) risk ratio (RR) (also called relative risk); 2) the odds ratio (OR); 3) the 
risk difference (RD). Risk is the number of patients with an event (outcome) divided by the 
total number of patients. Odds describe the ratio of the probability that an event (outcome) 
occurred to the probability that it did not occur (Higgins & Green, 2009). For continuous data, 
the most commonly used calculation in meta-analysis for effect measurement, is mean 
difference (MD). The MD is a summary statistic to measure the difference between the mean 
value in the two groups (experimental group and control group) in a clinical trial (Higgins & 
Green, 2009).  
 
The second stage of meta-analysis is to estimate a summary (pooled) of the treatment effect. 
The treatment effect is calculated as a weighted average of the intervention effects estimated 
in each individual study (Sutton et al., 2000; Higgins & Green, 2009). The graph used to 
display the results of the weighted results in meta-analysis is called a “forest plot”. The first 
forest plot of a meta-analysis was produced by Lewis and Ellis in 1982. In general, the smaller 
studies will produce less precise estimate with wider confidence intervals (Lewis & Clarke, 
2001). There are two approaches that can be used to investigate overall treatment effect; fixed 
effect model and random effect model. The fixed effect model assumes that treatment effect 
sizes are the same in all studies. This approach can only reflect overall treatment variations 
within trials, not between trials. In contrast to the fixed model, the random effect model 
assumes treatment effect sizes are different and that variations exist within and between studies 
(Sutton et al., 2000).  Therefore, the random effect model is favoured over the fixed model in 
routine use.  
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It is essential to assess the consistency of effects across studies in meta-analysis, as there maybe 
variability amongst studies. The variability in meta-analysis is called “heterogeneity”. Several 
causes of heterogeneity have been suggested; 1) due to chance, 2) the scale used to measure 
the treatment effect, 3) patient-level covariates which can be further investigated if individual 
patient data are available, 4) characteristics of study design, and 5) unexplainable (if none of 
the above account for it) (Sutton et al., 2000). It is important to examine to what extent the 
results of studies are consistent. Therefore, it is common to test for heterogeneity to investigate 
the consistency of findings when combining studies (Higgins & Green, 2009).  
 
The usual measurement of heterogeneity in meta-analysis is Cochrane’s Q. The Cochrane’s Q 
is the chi-square statistic test, which is calculated as the weighted sum of square differences 
between individual study effects and pooled effects across studies (Higgins et al., 2003). 
Another measurement to test heterogeneity is I2 value to quantify inconsistency across studies. 
I2 value is calculated as: (Q-df)/Q x 100%, where df is degrees of freedom (Higgins, 2003). 
The Cochrane review group has suggested a rough guideline to interpret I2 value as below 
(Higgins & Green, 2009):  
 
 0% to 40%: might not be important; 
 30% to 60%: may represent moderate heterogeneity; 
 50% to 90%: may represent substantial heterogeneity; 
 75% to 100%: considerable heterogeneity.  
 
If I2 value greater than 30%, the P value from chi-square test and/or confidence interval for I2 
value are also indicators to show the extent of heterogeneity. A commonly used approach to 
quantity the magnitude of variance between studies in a random-effect model is to measure 
tau-square (τ2 or Tau2). The value of τ2 takes into account the variance both within studies and 
between studies.  
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As mentioned, the Cochrane Collaboration logo is an example to demonstrate the advantage 
of conducting systematic review and meta-analysis. The Cochrane Collaboration logo is a 
representation of a systematic review of data from 7 RCTs conducted between 1972 and 1982 
(Figure 3.1).  
 
Figure 3.1: Cochrane Collaboration logo (reproduced with permission 
from Cochrane Library) 
 
       
 
 
 
 
    
    
 
The review was performed to investigate corticosteroids given to women expected to give birth 
prematurely. The graphical test in the middle of the logo is called a “forest plot”. Each 
horizontal line represents the result of an individual trial, and the length of line represents the 
confidence intervals (the wider the line, the more uncertain the result). The vertical line 
indicates the position around which the horizontal lines would cluster if the treatments 
compared in the trials had similar effects. The diamond at the bottom is the combined results 
(pooled estimated treatment effect). If the position of diamond is on the left of the vertical line, 
this indicates that the treatment in the trials is beneficial (Cochrane website: 
http://www.cochrane.org/about-us/history/our-logo).  
 
The results from this systematic review showed that there was about a 30-50% reduction of 
death for the babies born to women who had received corticosteroids (Chalmers, 1993). 
Unfortunately, this review was not performed until 1989. If these RCTs had been 
systematically reviewed earlier, the benefit of corticosteroid therapy would have been 
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recognised as early as the 1980s, and it may have saved many premature babies’ lives. There 
are similar examples to show the inadequacy of traditional narrative reviews resulting in delays 
in adopting beneficial therapy (Feldstein, 2005).  
  
Despite the obvious advantages of systematic review and meta-analysis, there are potential 
problems that need to be addressed. The findings from a systematic review only be as reliable 
only as the included studies’ quality. To combine poorly-performed studies may sometimes 
produce misleading results. Moher and colleagues (1998) randomly selected 11 meta-analyses 
which included 127 RCTs on interventions for digestive diseases, mental health, pregnancy 
and childbirth. They found a statistically significant 30-50% exaggeration of treatment efficacy 
when lower quality studies were included. The similar finding was reported by Schulz et al., 
(1995), they examined 33 meta-analyses that involved 250 clinical trials from the Cochrane 
Pregnancy and Childbirth Database. Studies with inadequate allocation concealment 
overestimated the treatment efficacy by 30-40% compared to studies that had adequate 
allocation concealment. It is essential to assess the methodological quality in the review 
process as poor-quality studies may produce results that are biased and imprecise.  
 
Another potential problem for systematic reviews is publication bias. The publication bias has 
been long recognised in medical research (Chalmers, 1993). Studies with positive results are 
more likely to be published therefore these studies are more easily identified for a systematic 
review. To include only published studies is likely to overestimate the intervention efficacy 
consequently this may lead to a biased estimate of treatment effect (Sutton et al., 2000; Egger 
et al., 2001). The statistical method that has been developed to minimise publication bias is the 
test for funnel plot asymmetry. This test is used to examine whether the association between 
the estimated treatment effect and the study size (e.g. standard error of treatment effect) is 
greater than might be expected to occur by chance (Higgins & Green, 2009). The Cochrane 
Collaboration suggested that a funnel plot asymmetry test can only be conducted if there are at 
least 10 studies included in the meta-analysis. This is because the power will be too low to 
detect the bias when a small number of studies are included.  There have been several initiatives 
to improve the methodological quality of reporting systematic reviews and meta-analysis 
(Egger et al., 2001). In 1996, the QUOROM (QUality Of Reporting Of Meta-analysis) 
statement was developed and published in 1999. The QUOROM statement was developed by 
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a group of epidemiologists, clinicians, statisticians, and researchers who are interested in meta-
analyses and who conducted meta-analyses in the UK and North America (Moher et al., 1999). 
The QUOROM statement was mainly developed for reporting meta-analysis of RCTs. The 
statement included a checklist and a flow diagram. The checklist is organised into 21 headings 
and subheadings, and provides review authors with a standard way to present their reports. The 
flow diagram gives information about the number of RCTs identified, included, excluded, and 
the reasons for their exclusion. The QUOROM statement checklist is presented in Table 3.4 
and the QUOROM flowchart in Figure 3.2. 
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Table 3.4: QUOROM statement checklist: the quality of reports for meta-analysis of 
randomised controlled trials (adapted from Moher et al., 1999) 
 
Heading Subheading Descriptor 
Title  Identify the report as a meta-analysis (or systematic review) of RCTs 
Abstract  Use a structured format 
  Describe: 
 Objective The clinical question explicitly 
 Data Source The databases (i.e. list) and other information sources 
 Review methods The selection criteria (i.e. population, intervention, outcome, and study 
design); methods for validity assessment, data abstraction, and study 
characteristics, and quantitative data synthesis in sufficient detail to permit 
replication 
 Results Characteristics of the RCTs included and excluded; qualitative and 
quantitative findings (i.e. point estimates and confidence intervals); and 
subgroup analyses 
 Conclusion The main results 
Introduction  The explicit clinical problem, biological rational for the intervention, and 
rationale for review 
Methods   
 Searching  The information sources, in detail (e.g. databases, registers, personal files, 
expert information, hand-searching), and any restrictions (years considered, 
publication status, language of publication).  
 Section  The inclusion and exclusion criteria (defining population, intervention, 
principal outcomes, and study design) 
 Validity assessment The criteria and process used (e.g. masked conditions, quality assessment, 
and their findings) 
 Data abstraction The process or processes used (e.g. completed independently, in duplicate) 
 Study characteristics The type of study design, participants’ characteristics, details of intervention, 
outcome definitions, and how clinical heterogeneity was assessed. 
 Quantitative data 
synthesis 
The principal measures of effect (e.g. relative risk), method of combining 
results (statistical testing and confidence intervals), handling of missing data; 
how statistical heterogeneity was assessment; a rationale for any a-priori 
sensitivity and subgroup analyses; and any assessment of publication bias.  
Results Trial flow Provide a meta-analysis profile summarising trial flow (see figure) 
 Study characteristics Present descriptive data for each trial (e.g. age, sample size, intervention, 
dose, duration, follow-up period) 
 Quantitative data 
synthesis 
Report agreement on the selection and validity assessment; present simple 
summary results (for each treatment group in each trial, for each primary 
outcome): present data needed to calculate effect sizes and confidence 
intervals in intention-to-treat analyses (e.g. 2x2 tables of counts, means and 
SDs, proportions) 
Discussion  Summarise key findings; discuss clinical inferences based on internal and 
external validity; interpret the results in the light of the totality of available 
evidence; describe potential biases in the review process (e.g. publication 
bias); and suggest a future research  agenda  
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Figure 3.2: The QUOROM statement flow diagram: improving the quality of reports of 
meta-analysis of randomised controlled trials (adapted from Moher et al., 1999) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant RCTs identified and screened for 
retrieval (n=….) 
RCTs excluded, with reasons 
(n=….) 
RCTs retrieved for more detailed evaluation (n=….) 
RCTs excluded, with reasons 
(n=…..) 
Potentially appropriate RCTs to be included in the 
meta-analysis (n=….) 
RCTs excluded from meta-
analysis, with reasons (n=…..) 
RCTs included in meta-analysis (n=….) 
RCTs withdrawn, by outcome, 
with reasons (n=…..) 
RCTs with usable information, by outcomes (n=….) 
 79 
 
The QUOROM statement is a useful guideline to help researchers to undertake systematic 
reviews and meta-analysis, in particular for RCT studies however, there is an increasing use of 
systematic reviews to summarise evidence from other types of research (e.g. observational 
studies). In 2005, a group of 29 review authors, methodologists and clinicians developed the 
PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analysis) statement 
(Liberati et al., 2009). PRISMA, which is an evolution of the QUOROM guideline, consists of 
a 27-item checklist for the reporting of meta-analyses, covering title, abstract, methods, results, 
discussion and funding. Together with a four-phase flow diagram to guide researchers through 
the different stages of systematic reviews in different phases. The advantage of the PRISMA 
statement is that it can also be used to report systematic reviews and meta-analysis for studies 
other than RCTs. As this project commenced prior to the publication of the PRISMA statement, 
the QUOROM statement was used in this systematic review.  
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3.5.Methods 
3.5.1.Inclusion and exclusion criteria  
All randomised placebo-controlled clinical trials (RCTs) investigating the efficacy and safety 
of the three anti-obesity drugs, orlistat, sibutramine, rimonabant, in children and adolescents 
aged under 19 years were included. All clinical trials included, needed to provide at least 6 
months data as it is more important to evaluate the longer term effects of treatment. Quasi-
randomised, open label crossover trials, open labelled non-blinded randomised trials, and 
studies published only in abstract form were excluded from the review. Since a range of 
definitions of childhood obesity exist, any trials which used an established definition of 
overweight or obesity (BMI ≥85th, 95th or 98th percentile; BMI > International Obesity 
Taskforce definition) were included in this review.   
 
3.5.2.Outcome measures  
To be included in this review, studies had to have reported a change in the body mass index 
(BMI) as the primary outcome measure or to have presented a baseline and a post-treatment 
measurement, as these data can be used to calculate a change in BMI from baseline, if not 
reported within the study. The secondary outcome measures were adverse drug reactions 
(ADRs) related to anti-obesity drug treatment.   
 
3.5.3.Search methods for identification of studies 
The following databases were searched from January 1996 to January 2008 for clinical trials 
investigating anti-obesity drugs and body weight reduction in children and adolescents aged 
under 19: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials 
(CENTRAL). Additionally, a number of trial register websites were searched for corroborative 
evidence: the metaRegister of Controlled Trials (www.controlled-trials.com), WHO clinical 
trial register (http://www.who.int/ctrp/en/), and the government Clinical trials register 
(http://www.clinicaltrials.gov/). Search strategies and search terms for individual electronic 
databases are presented in Appendix 1 (MEDLINE), Appendix 2 (EMBASE), and Appendix 
3 (CENTRAL). A further hand search was also carried out to examine the reference lists of the 
identified studies. Studies were not excluded on the basis of language.  
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3.5.4.Data Extraction and Quality Assessment  
The electronic database searches were performed by two reviewers; Yingfen Hsia, and Tania 
Tomsic- currently a clinical pharmacist at General Hospital Novo Mesto in Slovenia. The 
electronic searches of all databases were performed independently. Once the searches had been 
completed, the two reviewers screened all the included abstracts separately. This initial review 
was to check whether these studies met the eligibility criteria. If studies clearly did not meet 
the inclusion criteria they were rejected on initial review. The full text of studies marked for 
potential inclusion were then obtained electronically or in paper copy, and assessed again for 
inclusion in the review. Any disagreement between the two reviewers, over which papers 
should be included, was resolved by discussion with Professor Russell Viner1 to reach 
consensus. The included studies, deemed to meet the inclusion criteria, were then appraised by 
both reviewers.  
 
A standardised form was used to record all the details of the papers reviewed (Egger et al., 
2001). The standard form included study design, blinding status, trial duration, mean age of 
participants, gender, and numbers of participants in the treatment and placebo groups, 
interventions, and the assessment of intention-to-treat (ITT). The QUORUM (Quality of 
Reporting of Meta-analyses) guideline was used for reporting the review (Moher, 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
1 Professor Russell Viner is a consultant and director of Adolescent Medicine, University of College London Hospital and 
Great Ormond Street Hospital.  
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3.6.Statistical Analysis 
The primary outcome was expressed as a change in raw BMI (kg/m2) rather than in BMI 
standard deviation score (SDS), as use of BMI SDS masks significant loss of body mass in the 
very obese during adolescence. We calculated weighted mean differences for continuous 
outcomes (e.g. BMI) and risk differences for dichotomous outcomes, at the end of the study 
follow-up period. A random effects model was used for the meta-analysis of this review.  
 
The primary outcome analysis (BMI) was based upon intention to treat data from the 
completion of the randomised trial, prior to any cross-over or open label extension. However, 
data on secondary outcomes and adverse drug reactions were taken from the same trial end-
point as the BMI data, using the highest quality data reported in each trial; whether the ITT 
population, a subset of the ITT population, or completers (patients who completed the 
treatment during the clinical trial period). Where standard deviations were not reported, these 
were calculated from standard errors, t values or p values that related to the differences between 
means in the two groups.  
 
The DerSimonian and Laird Q test (the random effect) was performed to assess the degree of 
heterogeneity between studies, and the I2 statistic was used to describe the percentage of total 
variation across studies due to heterogeneity. Due to the small number of studies included, we 
were unable to assess publication bias by inspection of funnel plot asymmetry. Secondary 
outcomes (e.g. fasting lipids, glucose or insulin) were included in the meta-analysis if each 
outcome was reported in ≥2 studies for each drug.  All analyses in this review were performed 
using RevMan 5.0.16 (Review Manager 2011). RevMan is a software programme that can be 
used to prepare study protocols and summarise findings in tables and/or graphs. It can also 
perform meta-analysis of included studies and present the results graphically. This software 
can be downloaded free of charge for preparing a Cochrane review or for academic purposes.  
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3.7.Results 
3.7.1.Studies identified from searching and screening  
The extensive search identified 101 studies (Figure 3.3). The titles and abstracts of these 101 
studies were screened to ascertain if the studies were relevant; 85 studies did not meet the 
inclusion criteria. The most common reasons for exclusion of studies were the participants’ 
age, >20 years, it was a review article or it had a different primary outcome. The full articles 
of the remaining 16 studies were retrieved (Table 3.5). Two of the 16 studies were identified 
as sub-group analyses and excluded (Budd et al., 2007; Daniels et al., 2007) the remaining 14 
studies met the criteria for inclusion (Table 3.6).  
 
3.7.2.Appraisal of the clinical trial studies 
Details of the remaining 14 studies are shown in Table 3.6. Of the 6 studies of orlistat; 4 were 
excluded,3 were open-label uncontrolled studies (McDuffie et al., 2002; Norgen et al., 2003; 
McDuffie et al., 2004), and one (Ozkan et al., 2004) was an open-label non-blinded randomised 
controlled trial. Eight of the appraised studies were for sibutramine; 4 of which were excluded 
from the meta-analysis, 2 were open-label studies without a control (placebo) group (Reisler 
et al., 2006; Violante-Ortiz et al., 2005), 1 randomised controlled trial had a study duration of 
only 3 months (Van Mil et al., 2007), and 1 randomised controlled trial excluded subjects with 
primary or nutritional obesity (Danielsson et al., 2007). Two studies of orlistat, 4 studies of 
sibutramine, and no study of rimonabant were identified as eligible for meta-analysis.   
 
3.7.3.Study subjects and co-interventions 
Subjects across all the trials included in the meta-analysis had similar demographic profiles; 
the majority of the participants were aged 12-18 years, their mean BMI was between 30kg/m2 
and 40kg/m2, and they were predominantly white or Hispanic. In each trial, subjects with 
secondary causes of obesity were excluded, as were those with diabetes mellitus. All trials 
included a standardised low fat low energy diet and encouragement to exercise, with a variable 
element of behavioural modification in some trials. 
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Figure 3.3: QUOROM statement flowchart for the randomised controlled trials of anti-
obesity drug use in children and adolescents: from January 1996 to January 2008 
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Studies excluded on initial review (total 85): 
  Primary outcome different      n= 13 
  Wrong topic        n=   9 
  Study participants aged >20 years   n= 29 
  Literature review     n= 22 
  Lifestyle modification trial      n=   1 
  Observational study       n=   1    
  Duplicate articles     n=   9 
  Trial in progress     n=   1 
Potential relevant studies identified for inclusion in systematic review 
 
 
  Orlistat (n=6)          Rimonabant (n= 0)              Sibutramine (n=10) 
   
 
Studies included for meta-analysis         
Sibutramine (4 studies) 
Studies excluded from meta-analysis: 
Open label design (3 studies)  
Open un-blinded controlled trial (1 study) 
 
   
 
Excluded 4 studies on sibutramine for 
meta-analysis: 
 
Open label design (2 studies)  
Duration < 6 months (1 study) 
Secondary obesity (1 study) 
  
 
 To identify potentially relevant articles from: MEDLINE, 
EMBASE, CENTRAL and website searches  
Studies included for meta-analysis   
Orlistat (2 studies) 
2 studies excluded as they 
were subgroup analyses of a 
study already included (n=2) 
 
101 abstracts were identified and initial 
review of these abstract was carried out   
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Table 3.5: Studies included for full text review 
Orlistat studies 
 
Author  Study title 
 
 
McDuffie et al. (2002) 
 
Norgren et al. (2003) 
Three-month tolerability of orlistat in adolescents with obesity-related comorbid 
conditions 
Orlistat treatment in obese prepubertal children: a pilot study 
 Ozkan et al. (2004) Addition of orlistat to conventional treatment in adolescents with severe obesity. 
 McDuffie et al. (2004) 
 
Chanoine et al. (2005) 
 
Maahs et al. (2006)  
Efficacy of orlistat as an adjunct to behavioural treatment in overweight African 
American and Caucasian adolescents with obesity-related co-morbid conditions 
Effect of orlistat on weight and body composition in obese adolescents: a 
randomized controlled trial 
Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in 
adolescents 
Sibutramine studies  
 
Author  Study title 
 Berkowitz et al. (2003) Behaviour therapy and sibutramine for the treatment of adolescent obesity: a 
randomized controlled trial. 
 Godoy-Matos et al. (2005) 
 
Violante-Ortiz et al., (2005)  
Garcia-Morales et al. (2006) 
 
Berkowitz et al. (2006) 
Treatment of obese adolescents with sibutramine: a randomized, double-blind, 
controlled study 
Use of sibutramine in obese Hispanic adolescents 
Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, 
double-blind, placebo-controlled, parallel-group trial 
Effects of sibutramine treatment in obese adolescents: a randomized trial 
 Reisler et al. (2006) Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity 
 Budd et al. (2007) Weight loss in obese African American and Caucasian adolescents: secondary 
analysis of a randomized clinical trial of behavioural therapy plus sibutramine 
 Van Mil et al. (2007) The effect of sibutramine on energy expenditure and body composition in obese 
adolescents. 
 Daniels et al. (2007) 
 
Danielsson et al. (2007) 
Cardiovascular effects of sibutramine in the treatment of obese adolescents: 
results of a randomized, double-blind, placebo-controlled study 
Impact sibutramine therapy in children with hypothalamic obesity or obesity with 
aggravating syndromes 
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Table 3.6: Appraised trials of sibutramine and orlistat for weight reduction in children and adolescents 
Study  Location Design Duration 
 
Age 
(yrs) 
Sample 
case: placebo 
BMI (SD) before 
treatment 
Co-intervention Dose Ethnic group Meta-analysis 
Orlistat RCT           
Chanoine et al. 2005 US, Canada RCT 54 wk 12-16 357: 182 Case: 35.74.2 
Placebo: 35.44.1 
Diet; behavioural modification; 
exercise counselling 
Orlistat 120 mg t.i.d White: 141 
Black: 25 
Other: 15 
 
Yes 
Maahs et al. 2006 US RCT 6 mo 14-18 20: 20 Case: 39.21.2 
Placebo: 41.72.6 
Dietary counselling; exercise 
counselling 
Orlistat 120 mg t.i.d White 
 
Yes 
Orlistat Open-label trial           
McDuffie et al. 2002 US OL 3 mo 12-17 20 44.112.6 Diet; behavioural programme Orlistat 120 mg t.i.d White: 10 
African American: 10 
 
No 
Norgen et al. 2003  
 
Sweden OL 12 mo 7-12 11 33.3 Diet Orlistat 120 mg t.i.d 
or q.i.d 
 
Scandinavian No 
McDuffie et al. 2004 US OL 6 mo 12-17 20 White: 36.21.2 
African American: 
50.31.3 
 
Diet; behavioural programme Orlistat 120 mg t.i.d  Caucasian: 10 
African American: 10 
No 
Ozkan et al. 2004 Turkey OC 5-15 mo 10-16 22:20 Case: 32.5 
Placebo: 31.2 
20% reduction in daily calories 
based on age and gender; 
increased activity level 
Orlistat 120 mg t.i.d White No 
Sibutramine RCT           
Berkowitz et al. 2003 US RCT 
followed 
by OL 
Phase 1:6 
mo RCT 
Phase 2: 6 
mo OL 
13-17 43:39 37.83.8 Behavioural protocol; dietary 
counselling, encouraged 
exercise 
Phase 1 
15 mg sibutramine 
daily 
Phase 2 
All received 
sibutramine 
White: 54.9 % 
Black: 41.5% 
Others: 3.6% 
Yes 
 
Godoy-Matos et al.2005  
 
 
 
 
 
 
 
Brazil 
 
RCT 
 
6 mo 
 
14-17 
 
30:30 
 
Case 
Female: 37.53.8 
Male: 37.64.3 
Placebo  
Female:35.84.2 
Male:37.41.9 
 
 
500 kcal/d deficit diet; dietary 
counselling; encouraged 
exercise 
 
 
 
 
 
Sibutramine 10mg 
q.d 
 
 
 
 
 
 
Brazilian 
 
Yes 
Berkowitz et al. 2006 US RCT 12 mo 12-16 368:130 Case: 36.13.8 
Placebo: 35.94.1 
500 kcal/d deficit diet; 
behaviour protocol; encouraged 
exercise 
mo 1-5: sibutramine 
10 mg q.d.mo 6: 
increased to 15mg 
in participants who 
did not lose ≥ 10% 
BMI from baseline  
White 57% 
Black  21% 
Hispanic 16% 
Yes 
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Continue. 
Study  Location Design Duration 
 
Age 
(yrs) 
Sample 
case: placebo 
BMI (SD) before 
treatment 
Co-intervention Dose Ethnic group Meta-analysis 
Sibutramine RCT 
Garcia-Morales et al. 2006              Mexico 
 
 
 
Danielsson et al., 2007                    Sweden     
 
 
 
 
 
 
Sibutramine Open-label trial 
Van Mil et al. 2007                         NL 
 
 
 
 
 
RCT 
 
 
RCT 
followed 
by OL 
 
 
 
 
 
 
RCT 
 
6 mo 
 
 
20wk+20
wk RCT, 
followed 
by 6 mo 
OL 
 
 
 
 
3 mo 
 
 
 
14-18 
 
 
7-20 
 
 
 
 
 
 
 
 
12-18 
 
23:23 
 
 
50 
 
 
 
 
 
 
 
 
12:12 
 
Case: 35.15.3 
Placebo: 36.65.2 
 
Range: 2.9-9.7 
 
 
 
 
 
 
 
 
Case: 30.14.5 
Placebo: 33.35.0 
 
Dietary 
recommendations 
 
Lifestyle modification 
 
 
 
 
 
 
 
 
Dietary and exercise 
advice 
 
Sibutramine 10 mg 
q.d. 
 
Phase 1:sibutramine 
10mg q.d.; dose was 
tailored up to 15mg, 
if bw reduction 
<4kg within 8 wk 
Phase 2: sibutramine 
10mg or 15 mg 
 
 
Sibutramine 5 mg 
q.d.; after 2 wk the 
dose was increased 
to 10 mg q.d. 
 
 
 
Mexican 
 
 
Scandinavian 
 
 
 
 
 
 
 
 
White 
 
                    Yes 
 
 
                     No 
 
 
 
 
 
 
 
 
                   No 
Reisler et al. 2006    Israel OL 12 mo 13-18 20 405.6 Calorie-restricted diet; 
encouraged exercise 
Sibutramine 10 mg 
q.d 
 
 
White                     No 
Violante-Ortiz et al. 2005    Mexico OL 6 mo 12-18 67 34.26.0 Diet, aerobic physical 
activity 
Sibutramine 10 mg Mexican                     No 
 
Abbreviations: NL, the Netherlands; BMI, body mass index; RCT, randomized controlled trial; OL, open-label; OC, open (un-blinded) control trial; SDS, standard deviation score; bw, body weight; t.i.d, three times a day; 
q.d, once a   day; q.i.d, four times a day; mo – months; wk: week. 
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3.7.4.Methodological quality 
Studies were all of similar quality based on the QUOROM checklist.  All studies included an 
intention to treat analysis, reported eligibility criteria, and co-interventions were similar in 
intervention and control groups. Most studies did not describe the randomisation process nor 
were there comments on allocation concealment or blinding of outcome assessors. Since there 
was little variation in quality, a sensitivity analysis according to study quality was not 
performed. Secondary end points of interest were reported inconsistently, and frequently in a 
sub-group of patients or not in an extractable fashion.  
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3.8.Studies included in meta-analysis 
3.8.1.Orlistat 
Two studies fulfilled the criteria to be included in the meta-analysis, with a total sample size 
for BMI outcomes of 573 adolescents. One ran for 6 months and one for 12 months. Each used 
the recommended dose of orlistat, 120 mg three times daily, and participants also received 
behavioural, dietary and exercise counselling. Participants in both studies also received multi-
vitamin supplements. Figure 3.4 shows that the pooled estimate of mean BMI change with 
orlistat was a reduction of 0.83 kg/m2 (95% CI 0.47 to 1.19) compared with placebo. There 
was no evidence of heterogeneity.  An analysis of proportions achieving 5 and 10% BMI or 
weight loss was not undertaken as this was reported in only 1 study.   
 
Secondary outcomes for orlistat compared with placebo are shown in Table 3.7. There were 
no significant differences in fasting lipids, glucose or insulin between orlistat and placebo. As 
waist circumference, body fat and blood pressure were each only reported in a single study, 
these outcomes were not included in the meta-analysis. The effect of orlistat and placebo on 
changes in vitamin A, D and E levels were not included in the meta-analysis as the dose of 
multi-vitamin used in each trial was not specified; however, both studies reported no significant 
difference in levels of each vitamin between groups during the trial. Sensitivity analyses for 
orlistat were not undertaken due to the low study numbers. Adverse reactions for orlistat 
compared with placebo are shown in Table 3.7. Those taking orlistat were significantly more 
likely to experience a range of gastrointestinal adverse reactions. It was not possible to assess 
the risk of specific gastrointestinal event, or study discontinuation due to gastrointestinal 
adverse reactions, as studies only provided the overall number of patients reported with 
gastrointestinal adverse reactions. The reasons for discontinuation of treatment were not clearly 
reported in the studies.  
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Figure 3.3: Mean reduction in body mass index (kg/m2) with orlistat 
 
Heterogeneity statistics: a test for differences across studies using Tau2 (tau-squared), the chi-square test, and I2 statistic to express  
the among-study variance. Percent weights were given to each study.     
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Table 3.7: Secondary outcomes and adverse drug reactions with orlistat 
 
 
Secondary outcomes No. of Patients* Weighted mean difference (95%CI) 
 Orlistat Placebo Total  
Fasting 
Triglycerides (mmol/L) 
 
368 
 
199 
 
567 
 
  0.00 (-0.17, 0.18) 
Cholesterol Total (mmol/L)            339 181 520   0.03 (-0.17, 0.23) 
HDL (mmol/L)    339 181 520   0.00 (-0.02, 0.03) 
LDL (mmol/L)    338 180 518  -0.05 (-0.11, 0.01) 
Glucose (mmol/L) 298 154 452   0.02 (-0.25, 0.28) 
Insulin  (mU/L) 287 150 437   -0.41 (-4.83, 4.01) 
GI Adverse drug reactions     
Fatty /oily stool    368            199               467                0.53 (0.27, 0.79) 
Oily spotting    368            199               467                0.49 (0.00, 0.99) 
Oily evacuation    368            199               467                0.51 (-0.08, 1.10) 
Faecal urgency    368            199               467                0.10 (0.04, 0.16) 
Flatus with discharge    368            199               467                0.17 (0.12, 0.21) 
Flatulence    368            199               467                0.05 (0.01, 0.09) 
Faecal incontinence    368            199               467                0.08 (0.05, 0.11) 
*Number of patients in each group for whom secondary outcomes and/or adverse drug reactions were reported. Two studies 
were included in this analysis: Maahs et al. (2006) and Chanoine et al. (2005).  
 
 
 92 
 
3.8.2.Sibutramine 
Data from 4 RCTs were included in the meta-analysis, with a total sample size for BMI 
outcomes of 464 adolescents. Three studies ran for 6 months and one study for 12 months. 
Two studies used a dose of 10mg of sibutramine per day, 1 study used 10 mg per day for the 
first 6 months, increasing the dose to 15mg per day for the second 6 months if subjects had 
failed to lose ≥10% of initial BMI (Berkowitz et al., 2006), and 1 study used a dose which 
increased from 5mg to 15mg over the first 7 weeks (Berkowitz et al., 2003)  
 
Figure 3.5 shows that the pooled estimate of mean change in BMI was a reduction of 2.20 
kg/m2 (95% CI: 1.57 to 2.83). The heterogeneity statistic showed a moderate heterogeneity 
(I2:47%) between studies but there was no significant heterogeneity (p=0.13). Secondary 
outcomes for sibutramine compared with placebo are shown in Table 3.8. For sibutramine 
treatment, the loss of ≥5% of initial BMI was 45% and 39% for the loss of ≥10% initial BMI, 
and decreased waist circumference by nearly 6cm on average, compared with placebo. 
Sibutramine was associated with significant improvements in triglycerides and HDL-
cholesterol compared with placebo (2 studies each).  Data were unavailable on the effect of 
sibutramine on body composition e.g. fat mass loss.  
 
3.8.3.Sensitivity analyses  
Sensitivity analyses were conducted for study duration (6 or 12 months) and the use of a 
behaviour therapy programme (BT) as a co-intervention. A BT co-intervention was used for 
all study participants in two (Berkowitz et al., 2003; Berkowitz et al., 2006) of the four 
sibutramine studies. Sibutramine plus BT co-intervention produced a mean BMI reduction of 
2.23 (95% CI -3.12 to -1.34) kg/m2 compared with placebo and BT. Sibutramine without BT 
produced a mean BMI reduction of 2.04 (95% CI -3.50 to -0.58) kg/m2. The intention to treat 
analysis (ITT) was undertaken at 6 months in 3 studies and 12 months in 1 study. Sibutramine 
produced a mean BMI reduction of 2.60 (95% CI -3.16 to -2.04) in the single 12 month study 
(Berkowitz et al., 2006) and 1.95 kg/m2 (95% CI -2.81 to -1.08) in the three 6 month studies.  
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The 6 month analyses were repeated with the addition of an intermediate non-intention to treat 
data from the 6 month assessments in the single 12 month study. Mean BMI reduction across 
the 4 studies at 6 months was largely unchanged: -2.02kg/m2 (95% CI -2.49 to -1.55). It was 
not possible to undertake a sensitivity analysis with respect to sibutramine dose.  
 
Adverse drug reactions to sibutramine compared with placebo are shown in Table 3.8. Those 
receiving sibutramine had higher systolic (1.4 mmHg) and diastolic (1.7 mmHg) blood 
pressure and heart rate (4.7 beats per minute) (4 studies each). As hypertension was not an 
exclusion condition in all studies, and because of variable data reports, we were unable to 
assess trial withdrawal due to hypertension across the studies. Those taking sibutramine were 
also significantly more likely to experience a dry mouth but there were no other adverse 
reactions. 
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Figure 3.4: Mean reduction in body mass index (kg/m2) with sibutramine 
 
 
 Heterogeneity statistics: a test for differences across studies using Tau2 (tau-squared), the chi-square test, and I2 statistic to express the among-study variance.  
 Percentage weights were given to each study.     
Study or Subgroup
García 2006
Berkowitz 2003
Godoy 2005
Berkowitz 2006
Total (95% CI)
Heterogeneity: Tau² = 0.19; Chi² = 5.70, df = 3 (P = 0.13); I² = 47%
Test for overall effect: Z = 6.84 (P < 0.00001)
Mean
-3.2
-3.19
-3.6
-2.9
SD
2.2
2.55
2.5
2.88
Total
23
43
30
368
464
Mean
-2
-1.52
-0.9
-0.3
SD
2.6
2.05
0.9
2.74
Total
23
39
30
130
222
Weight
14.9%
22.9%
24.2%
38.0%
100.0%
IV, Random, 95% CI
-1.20 [-2.59, 0.19]
-1.67 [-2.67, -0.67]
-2.70 [-3.65, -1.75]
-2.60 [-3.16, -2.04]
-2.20 [-2.83, -1.57]
sibutramine placebo Mean Difference Mean Difference
IV, Random, 95% CI
-2 -1 0 1 2
Favours sibutramine Favours placebo
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Table 3.8: Secondary outcomes and adverse drug reactions with sibutramine 
 
Secondary outcomes No. of Study No. of Patients* Weighted mean difference 
(95% CI) 
 
  Sibutramine Placebo Total  
Fasting      
Waist circumference (cm) 4 375 167 542 -5.78 (-7.03, -4.52) 
Triglycerides (mmol/L) 2 299 96 395 -0.31 (-0.39, -0.23) 
Cholesterol Total (mmol/L) 2 46 38 84 -0.02 (-0.72, 0.69) 
HDL 2 299 96 395 0.09 (0.05, 0.13) 
LDL 2 46 38 84 -0.18 (-0.62, 0.25) 
Glucose (mmol/L) 2 46 38 84 -0.04 (-0.08, 0.00) 
Insulin  (mU/L) 2 300 95 395 -4.21 (-9.79, 1.38) 
Systolic blood pressure (mmHg) 4 453 205 658 1.38 (0.13, 2.63) 
Diastolic blood pressure (mmHg) 4 453 205 658 1.73 (1.01, 2.46) 
Heart rate (beats per minute) 4 453 205 658 4.70 (1.65, 7.76) 
Adverse drug reactions      
Headache 3 419 179 589 -0.08 (-0.24, 0.08) 
Dry mouth 3 419 179 589 0.06 (0.01, 0.11) 
Dizziness 2 398 160 558 0.02 (-0.02, 0.06) 
Abdominal pain 2 398 160 558 0.00 (-0.05, 0.06) 
Constipation 2 398 160 558 0.14 (-0.12, 0.40) 
Flu-like symptoms 2 398 160 558 0.01 (-0.04, 0.05) 
Weight loss 
Loss of ≥5% of initial BMI 
 
4 
 
377 
 
171 
 
548 
Risk difference (95% CI) 
0.45 (0.32, 0.59) 
Loss of ≥10% of initial BMI 4 377 171 548 0.39 (0.31, 0.65) 
Number of patients in each group for whom secondary outcomes and/or adverse drug reactions were reported.  
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3.9.Updated systematic review 
It is common practice for researchers to update systematic reviews after a certain period of 
time following completion of the original review (Moher & Tsertsvadze, 2006). As discussed, 
one of the advantages of systematic reviews is that it is easy to replicate the search. On 7th 
August 2014, an updated search was carried out using the same search strategies. The updated 
search results from February 2008 to August 2014, are summarised in the QUORUM flow 
diagram given in Figure 3.6.   
 
The updated search identified 48 studies. Of these, 47 studies were excluded after reviewing 
abstracts. One study was included after the abstract had been screened (Chanoine & Richard, 
2011). The full article of this study was obtained for inclusion in the final review. This included 
study was an additional analysis from a previous one which had already been included in our 
original review (Chanoine et al., 2005). This additional analysis was to compare the 
relationship between weight changes in the orlistat treated group and control group at baseline 
and 12 weeks after treatment, as well as metabolic markers change. As this secondary analysis 
of orlistat use did not meet the inclusion criteria, this study was excluded after reviewing the 
full article.  
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Figure 3.5: Flowchart for the randomised controlled trials of anti-obesity drug in 
children and adolescents: an updated from February 2008 to August 2014 
 
 
 
 
 
 
 
 
 
 
 
 
      
      
      
     
      
 
 
         
 
 
 
       
 
                                                                       
 
 
 
 
 
 
 
   
Studies excluded on review (total 47):  
Primary outcome different      n= 12 
Wrong topic      n= 17 
Study participants aged >20 years   n= 2 
Literature review studies              n=16 
    
Potential relevant studies identified and 
screened to be included from updated search  
Orlistat = 1 
Sibutramine = 0 
Rimonabant = 0              
   
 
 48 abstracts were identified and initial 
review of these abstracts was carried out 
+ 
Studies from previous iteration of this 
review from Jan 2008 to Nov 2011: 
Orlistat= 6 
Sibutramine= 10 
Rimonabant= 0 
Total studies of original review and updated review:  
Orlistat= 7 
Sibutramine= 10 
Rimonabant= 0 
 To identify potentially relevant articles from: MEDLINE, 
EMBASE, CENTRAL and website searches  
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3.10.Discussion 
Meta-analysis of randomised controlled trials of anti-obesity drugs in children and adolescents 
with primary obesity showed that treatment with either orlistat or sibutramine resulted in a 
significant BMI reduction compared with placebo: 0.83 kg/m2 for orlistat and 2.20 kg/m2 for 
sibutramine. The clinical significance of such reductions will vary with the BMI distribution 
in different populations: the standard deviation (SD) for BMI in mid adolescence is 
approximately 2.7 kg/m2 in the UK and approximately 3.5 kg/m2 in the USA (Cole et al., 1995; 
CDC, 2009).  
 
The effect size for orlistat was smaller and of borderline clinical significance at 0.24-0.3 SD. 
While orlistat had no beneficial or adverse effects on metabolic outcomes, it was associated 
with an approximately 50% increase in minor gastrointestinal adverse events such as oily 
spotting and an 8-17% increase in the absolute incidence of more major gastrointestinal events 
such as flatus with discharge and faecal incontinence. 
 
For sibutramine, this is a clinically meaningful mean effect size (0.6-0.8 SD) for BMI 
reduction. Sibutramine also increased the absolute percentage of those achieving a ≥10% BMI 
loss by approximately 40%, it also reduced waist circumference by a mean of 5.8 cm compared 
with placebo, an effect size of approximately 1.0 SD (McCarthy et al., 2003) and improved 
HDL-cholesterol minimally.  Sensitivity analyses suggested that the addition of behaviour 
therapy programmes to sibutramine use, minimally increased mean BMI loss (0.2 kg/m2), and 
also that a longer duration of sibutramine use may increase BMI loss by approximately 0.6 
kg/m2. Adverse drug reactions with sibutramine included significant but small increases in 
systolic and diastolic blood pressure, heart rate, dry mouth. There was no increase in the risk 
of other adverse reactions.  
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3.11.Comparison with the literature 
The findings of this review are similar to those of a recent meta-analysis of anti-obesity drug 
use in children and adolescents by McGovern et al. (2008), which reviewed drug trials as part 
of a wider systematic review of childhood obesity treatment. They reported a mean BMI 
reduction for sibutramine from 3 RCTs of 2.4 kg/m2, similar to our finding of 2.2 kg/m2, and 
a mean BMI reduction for orlistat of 0.7 kg/m2, again similar to our finding of 0.83 kg/m2 
(McGovern et al., 2008). However, McGovem et al. this review included un-blinded studies 
therefore the inclusion criteria differ from our review. In addition, they also included 
sibutramine and orlistat as subcategories within a larger random-effects meta-analysis and did 
not undertake sensitivity analyses or examine secondary outcomes in detail. A recent 
systematic review by Oude et al. (2009) reported similar findings for orlistat (mean reduction 
of 0.76 kg/m2). This review included only two small studies in a meta-analysis for sibutramine, 
reporting a mean reduction of 1.66 kg/m2, considerably lower than our estimate. Neither of 
these published systematic reviews undertook a meta-analysis of adverse reactions with orlistat 
or sibutramine.   
 
This review did not compare findings directly with results from adult studies as BMI loss is 
not directly comparable to weight loss, either in terms of absolute loss or proportions of people 
who lose ≥5% or ≥10% of initial weight. Weight loss was not included in this review, as BMI 
reduction is the goal of treatment of obesity in childhood and adolescence, growing children 
may lose BMI while gaining weight and BMI centiles continue to shift in later adolescence 
even after height growth has ceased (Viner et al., 2000). However, approximate comparisons 
can be made for older adolescents who are at or near final height.  
 
Meta-analyses in adults have shown that weight loss from sibutramine and orlistat are limited 
to 3kg to 4 kg over 12 months (Rucker et al., 2007). In contrast, the weight loss corresponding 
to a loss of 2.2 kg/m2 related to sibutramine use in 14- and 15-year old adolescents with a 
height on the 50th centile for their sex is approximately equivalent to a 6 kg loss for boys and 
girls, a relationship that holds true across the obese BMI range. The corresponding weight loss 
for orlistat is approximately 2.3 kg. The reasons for this are unclear. This may be an artefact 
of the paucity of data on adolescents and also the lack of long-term data. Alternatively, this 
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may suggest sibutramine is more potent in suppressing appetite in adolescents, possibly due to 
developmental immaturity in their hypothalamic appetite control systems.  
 
Sibutramine was found to have modest beneficial effects on triglycerides and HDL-cholesterol, 
similar to findings in adults (Rucker et al., 2007). However, we found no evidence of beneficial 
metabolic effects associated with orlistat use, in contrast to a meta-analysis in adults which 
suggested that orlistat has a small beneficial effect on LDL and total cholesterol (Rucker et al., 
2007). The reasons for this difference are unclear but may relate to the modest BMI loss seen 
with orlistat in adolescents and the small number of studies included in the meta-analysis. In 
addition, if patient’s the levels of cholesterol are not abnormal at baseline, it would not 
necessarily expect a reduction of weight loss. The effect of orlistat had been studied and related 
to the reduced absorption of triglyceride from the gut and lower portal delivery of fat to the 
liver. This may be a weight-independent effect such as atherosclerosis.  (Suter et al., 2005).   
 
Study quality was relatively high; attrition rates (25% for orlistat and 19% for sibutramine) 
were moderately high, but lower than those reported in a meta-analysis of adult trials of these 
drugs (30% for orlistat; 0% for sibutramine) (Rucker et al., 2007). However, the number of 
studies of each drug in adolescents is limited, and the trials had all been undertaken in 
secondary care settings, limiting the generalisability of the findings (see Table 3.6). We were 
unable to identify any published studies with a duration ≥ 12 months, so we could not examine 
long-term maintenance of BMI loss. Our findings apply to young people with simple or 
primary obesity. However, we note that our BMI effect size for sibutramine is similar to that 
of 0.7 SD BMI reduction reported by Danielsson et al. (2007) in a randomised controlled trial 
of sibutramine for 20 weeks in adolescents with secondary or monogenic obesity (Danielsson 
et al., 2007) which was not eligible for inclusion in our meta-analysis.  
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3.12. Safety  
The safety profile of orlistat was similar to that noted in adults i.e. a marked increase in 
unpleasant and anti-social gastrointestinal experiences but there was little evidence of 
significant health risks. Theoretical concerns about fat-soluble vitamin deficiencies were not 
supported although subjects in both trials were given multi-vitamins. In contrast, sibutramine 
was generally well tolerated by subjects but was associated with small rises in systolic and 
diastolic blood pressure and resting heart rate. The magnitude of these changes is very similar 
to that seen in adult studies; a recent meta-analysis found that sibutramine increased adults’ 
systolic blood pressure by 1.7 mmHg, diastolic blood pressure by 2.4 mmHg and heart rate by 
4.5 beats/min (Rucker et al., 2007). Even small increments in blood pressure can have an 
adverse impact on cardiovascular risk in the long-term, particularly in at-risk groups such as 
obese adolescents, who often have higher blood pressure compared with peers. Authorities 
note that the long-term safety of anorectic agents has not been established in children and 
adolescents (Freemark et al., 2007). However, the clinical significance of small blood pressure 
increments over a short treatment period remains unclear, particularly when balanced against 
the beneficial cardiovascular effects of successful weight reduction. 
3.13. Strengths and Limitations  
A rigorous systematic review and meta-analysis was undertaken using independent reviewers 
adhering to the established Cochrane Collaboration methodology. In contrast to adult studies 
(Ruckner et al., 2007), studies in the review included a range of non-white ethnic groups. 
However, the findings have several limitations which need to be noted. Firstly, all published 
studies have demonstrated efficacy of orlistat and sibutramine in BMI and body weight 
reduction. This suggests the possibility of publication bias; however there were too few studies 
for either drug to warrant the generation of funnel plots to assess publication bias. Secondly, 
there was a moderate but non-significant statistical heterogeneity between the studies for 
sibutramine BMI outcomes. This was addressed by using a random effects meta-analysis. It is 
likely that this heterogeneity was the result of differences in co-interventions, study duration 
and study population. The review included studies of differing length in the meta-analysis, as 
it was not possible to standardise duration due to the differing timings of the ITT analysis. The 
reviewers did not have access to individual patient data to investigate the cause of this 
heterogeneity.  
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Thirdly, for sibutramine, one trial was excluded from the meta-analysis as study duration was 
only 3 months and an ITT analysis was not performed (Van Mil et al., 2007). Repeating the 
meta-analysis for BMI, including this study, reduced the estimate of BMI reduction to -1.8 
kg/m2 (95% CI: -2.65 to -0.95). Fourthly, all included studies were conducted in specialist 
environments, and the generalisability of these findings to more general populations of obese 
adolescents is unclear. Finally, the analyses only included data that were extractable from 
studies, which may be a source of bias as studies may only publish secondary outcomes that 
differed significantly from placebo. This was the case for the largest included trial of 
sibutramine, Berkowitz et al., (2006), which only published metabolic outcomes that differed 
significantly between sibutramine and placebo, and the reviewers were unable to include in the 
analyses this study’s data on secondary outcomes that were not significantly different. 
However, the analyses found no significant mean difference for any of these secondary 
outcomes in the studies that were included in the meta-analyses for these outcomes.  
3.14.Conclusion 
Evidence from this systematic review has shown that sibutramine together with behavioural 
support in obese adolescents produces a clinically meaningful reduction in BMI of 0.6-0.8 SD 
with raised blood pressure. In contrast, orlistat with behavioural support produces a minimal 
effect (0.24-0.3 SD) with frequent gastrointestinal adverse reactions which has limited utility 
as a weight reduction treatment in adolescents. As sibutramine was withdrawn from the EU 
market in 2010, a further study to assess long-term maintenance of effectiveness of orlistat 
treatment in young people is needed. 
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Chapter 4  Anti-obesity drug prescribing patterns to young people in 
primary care in the UK 
4.1.Introduction 
In the UK, patients are primarily registered with a general practitioner (GP). Although there is 
no accurate official figure for the population registered with a GP, it has been estimated that 
approximately 95% of the UK population is registered with a GP (Lawrenson et al., 1999). A 
small proportion of patients due to their circumstances, may not be registered with a GP; these 
include the homeless, those who choose not to register, prisoners, and members of the armed 
forces (Lawrenson et al., 1999). In the UK, the general practitioners (GPs) act as the gatekeeper 
for patient healthcare through the National Health System (NHS). GPs are responsible for 
providing primary care and for organising referrals to specialist care for their patients. When 
patients are seen in secondary care (e.g. hospitals), consultants or specialists will make the 
diagnosis and initiate treatment, and GPs will usually continue to monitor patients with chronic 
conditions and issue prescriptions. In recent years, most GPs have used computers to assist 
with the management of their clinical practices. The official survey figure has shown that over 
90% of practices are computerised in the UK (Lawrenson et al., 1999). There are many 
computer software systems available which have the facility to generate prescriptions and 
maintain records of diagnoses, symptoms, consultations, referral letters, test results and 
demographic data. All data which can be abstracted from general practice databases are 
anonymised to ensure patient confidentiality.  
 
4.1.1.Description of GP databases in UK 
In the UK, computerised databases derived from general practice medical records have been 
extensively used for research. The most widely used are the General Practice Research 
Database (GPRD), the Health Improvement Network (THIN), IMS Disease Analyzer (IMS 
DA), QRESEARCH, and Doctor’s Independent Network (DIN). Another database the Tayside 
Medicines Monitoring Unit (MEMO) has also been used for epidemiological research, but this 
database is relatively small and contains anonymised patient data only from one region in 
Scotland. The Fourth Survey of Morbidity in General Practice (MSGP4) is another relatively 
small general practice database which contains data on approximately 502,000 patients from 
60 practices in England and Wales. The MSGP4 provides individual level demographic, socio-
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economic, ethnicity, and a complete record of consultations with GPs, however there is no 
prescribing information in this database (McCormick et al., 1995).  
 
There are other routinely collected data that could be used for research and other purposes such 
as the Yellow Card Scheme (collects spontaneous reports of adverse drug reactions), 
Prescribing Analysis and Cost (PACT) data, and NHS Prescription Services (formally known 
as Prescription Pricing Authority)  (http://www.nhsbsa.nhs.uk/). Hospital episode statistics 
(HES) is another data source which has been frequently used by researchers; HES only 
provides hospital admission data in England. Analyses and summarised tables are published 
annually on their website (http:www.doh.gov.uk/hes/). The data structure of HES is based on 
admission episodes not patient-level. It needs to be noted that one patient may have more than 
one episode of illness in HES data, therefore it is not possible to identify whether individual 
patients have a single or multiple hospital episodes. Despite being valuable sources of data for 
research, data sources such as the Yellow Card Scheme and PACT are not useful for 
epidemiological research such as disease prevalence or drug prescribing patterns.   
 
It is beyond the scope of this thesis to cover all these computerised databases in detail, the next 
section is restricted to an overview of longitudinal patient-level databases from general practice 
in the UK: General Practice Research Database (GPRD), the Health Improvement Network 
(THIN), IMS Disease Analyzer (IMS DA), QRSEARCH, Doctors’ Independent Network 
(DIN), and Tayside Medicines Monitoring Unit (MEMO). A summary of these databases is 
presented in Table 4.1., which describes individual databases in more detail as well as their 
strengths and limitations. A brief description of each of these databases is given below.   
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Table 4.1: Clinical database from primary care in the UK 
  
Database  Year Started Population covered No. of 
Practice 
Area covered  Website  
General Practice Research Database 
(GPRD) (also known as FF-GPRD) 
1987 Approx. 9 million 
patients (5.2 million 
active patients) 
630 England, Scotland,  
Wales and Northern 
Ireland 
www.gprd.com 
 
The Health Improvement Network 
(THIN) 
2003 Approx. 9 million 
patients (3.4 million 
active patients) 
479 England, Scotland, 
Wales, and 
Northern Ireland 
www.epic-uk.org 
 
QRESEARCH 1990 Over 13 million 
patients  
660 England, Scotland, 
Wales, and 
Northern Ireland  
www.qresearch.org 
IMS Disease Analyzer (IMS DA) 
(formerly MediPlus) 
1992 3 million patients 125 England, Scotland, 
Wales, and 
Northern Ireland 
www.imshealth.com 
Doctors’ Independent Network  
(DIN) 
1989 Over 3 million 
patients 
Over 300 England and Wales NA 
Tayside Medicines Monitoring Unit 
(MEMO) 
NA Over 400,000 patients 320 Tayside region of 
Scotland  
http://www.dundee.ac.uk
/memo/ 
Abbreviation: FF-GPRD, Full Feature General Practice Research Database; NA, not available.  
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4.1.2.The General Practice Research Database (GPRD) 
The General Practice Research Database (GPRD) was initially developed by Dr Alan Dean in 
1987. Data were provided from contributing practices and the amount and quality of the data 
have increased over the years. Most data are considered to have reached research standard (‘up-
to-standard’). Data for the GPRD are collected from GPs using the practice management 
software, the Value Added Medical Products (VAMP) software, which was designed by the 
VAMP Ltd software company. GPs enter data using VAMP software which enables them to 
contribute anonymised data to a central database. Therefore, it was previously known as the 
VAMP General Practice Research Database (VAMP-GPRD) (Lis & Mann, 1995). There are 
currently two versions of the GPRD operating in parallel: the original VAMP software GPRD, 
and newly developed Full Feature GPRD (FF-GPRD). However, the VAMP-GPRD is 
gradually being phased out since the FF-GPRD currently provides external linkage with other 
national databases (e.g. disease registry, Hospital Episode Statistics). The GPRD group is 
updating the FF-GPRD data from the VAMP GPRD in order to include complete historical 
data in the current database.  
 
The participating GPs submit records at regular intervals, following the agreed guidelines for 
recording clinical and prescribing data. In 1993, Reuters Health Information acquired VAMP 
Ltd, and subsequently donated the database to the Department of Health (DoH) for health 
research purposes on a non-profit making basis and the database were renamed the GPRD. 
Since then, the database has been managed by the UK DoH. At present it is maintained by the 
Medicines and Healthcare products Regulatory Agency (MHRA). All research proposals that 
request data from the GPRD need to be approved by the GPRD’s Scientific and Ethical 
Advisory Group (SEAG) which was set up in 1995. This has subsequently been replaced by 
the Independent Scientific Advisory Committee for MHRA database research (ISAC), which 
was set up in 2006. The purpose of this committee is to review protocols of GPRD research 
and ensure that the study methodologies are well-defined and patient confidentiality is 
protected.  In March 2012, the GPRD was renamed the Clinical Practice Research Datalink 
(http://www.cprd.com/intro.asp) but at the time of writing this thesis it was known as the 
GPRD which is used throughout the thesis.  
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The GPRD is a large consolidated database of general practice clinical records in the UK. The 
GPRD contains anonymised computerised information entered by GPs in their clinical 
practices. This database comprises anonymised patient and practice-level data; thus individual 
patients are not named and cannot be identified from the computer system. All patients in the 
database are given a unique anonymised identifier, which can only be decoded by the practice. 
The computerised information includes demographics, diagnoses from specialist referrals, 
prescriptions, hospital admissions, consultations, and the results of laboratory tests. The 
database contains information on over 4.5 million active patients, equivalent to approximately 
7.4% of the UK population. The age and sex distribution of the patient population in the 
database at any point in time is broadly representative of the population in England and Wales 
(Figure 4.1).  
 
Figure 4.1: A comparison of the GPRD population with the England and Wales 
population in 1998 (data source: Office for National Statistics 1998) 
 
 
 
 
 
 
 
 
 
 
 
 
0
2
4
6
8
10
12
14
16
18
0-4 5-15 16-24 25-34 35-44 45-54 55-64 65-74 75-84 85 +
age
p
e
rc
e
n
ta
g
e
 o
f 
p
o
p
u
la
ti
o
n
 (
%
)
GPRD
UK
 108 
 
The demographic distribution of the GPRD is broadly representative of that of the UK; thus 
analysis of GPRD prescribing data will provide information on GP prescribing trends that are 
generally representative of national GP prescribing trends. The database is also able to provide 
a denominator to estimate prevalence and incidence. Studies on mortality, hospital admissions, 
cancer registration and prescribing have yielded similarities to the population in terms of age 
and sex distribution from other sources such as Office for National Statistics (ONS), and the 
Prescription Pricing Authority (PPA) (Hansell et al., 1999; Hollowell, 1997).  
The following information is available from the GPRD:  
 Demographic records: year of birth, gender, date of registration 
 Clinical records: these contain medical diagnoses which are coded using the Oxford 
Medical Information System codes (OXMIS) and Read codes. 
 Therapy records: these contain all prescriptions issued by GPs. Prescribed drugs are 
coded using Multilex®2. Information on drug name, prescribing date, duration, dose, 
route of administration, number of pacts dispensed, and daily quantity are all recorded.  
 Referral records: these contain information on secondary or tertiary referrals.  
 Test records: these include results from laboratories.  
 Immunisation records: all vaccines are listed.  
 Miscellaneous information, including smoking status, height, weight, BMI, and other 
lifestyle factors such as alcohol consumption, may also be listed.  
 
Two systems, both hierarchical, are used for coding clinical symptoms and diagnoses known 
as OXMIS disease classification and Read clinical terms (Perry, 1978; Chisholm, 1990). Read 
is a comprehensive clinical coding system and was specifically devised for GPs to use in UK 
practice. It also has procedural and administrative terms therefore it allows more accuracy in 
recording than OXMIS. In 1995, Read was introduced to the Vision software (a practice 
management software) and OXMIS were gradually phased out. Table 4.2 shows the main 
branch of Read code classification (Dave & Petersen, 2009).  
 
 
                                                 
2 Multilex® is a dictionary which classifies products using unique codes and is maintained by First DataBank.   
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Table 4.2: The main branch of Read code classification 
1 History & symptoms 
2 Examination and signs 
3 Diagnostic procedures 
4 Laboratory procedures 
5 Radiology & physics in medicine 
6 Preventative procedures 
7 Operations, procedures & sites 
8 Other therapeutic procedures 
9 Administration 
A Infectious and parasitic diseases 
B Neoplasms 
C Endocrine, nutrition, metabolic and immunity disorders 
D Disease of blood and blood forming organs 
E Mental disorders 
F Nervous system and sense organ diseases 
G Circulatory system diseases 
H Respiratory system diseases 
J Digestive system diseases 
K Genitourinary system diseases 
L Complications of pregnancy, childbirth and the puerperium 
M Skin & subcutaneous tissue disease 
N Musculoskeletal and connective tissue diseases 
P Congenital anomalies 
Q Perinatal conditions 
R Symptoms, signs and ill-defined conditions 
S Injury & poisoning 
T Causes of injury and poisoning 
U External causes of morbidity and mortality 
Z Unspecified conditions 
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As for data quality control, the internal check is continually assessed by an automated audit 
before being uploaded into a central database. A quality measure referred to as the “Up To 
Standard (UTS)” is applied. This warrants that the data meets quality standards at patient and 
practice level. The criteria for assessment are listed below (MHRA, 2010):  
 
 An empty or invalid first registration date. 
 Absence of a record for a year of birth. 
 A first registration date prior to their birth year. 
 A transferred out reason with no transferred out date. 
 A transferred out date with no transferred out reason. 
 A transferred out date prior to their first registration date.  
 A transferred out date prior to their current registration date. 
 A current registration date prior to their birth year. 
 A gender other than female/male/indeterminate. 
 An age of greater than 115 at end of follow up. 
 Recorded health care episodes in years prior to birth year 
 Registration status of temporary patients.  
 
If any of the above applies, the patient is considered ‘unacceptable’ and is not recommended 
for inclusion in a research dataset. Validation studies have shown that the quality and 
completeness of the data is high (Hollowell, 1997; Walley &Mantgani, 1997).  
 
The GPRD also provides a verification service for researchers to obtain more information on 
patients. Researchers can request copies of hospital letters, discharge summaries, death 
certificates and post-mortem reports through GPRD. Questionnaires can also be sent to GPs to 
obtain detailed information regarding patients’ conditions. In order to protect patient 
confidentiality, all data returned to researchers from the GPRD are anonymised.  GPRD is a 
population-based database of primary care in the UK. It provides a rich source of longitudinal 
data from general practices, and it has the advantage of data collected at the time of the event, 
including demographic information, clinical event and prescriptions. Data from over 4.4 
million patients are held on the database; the findings from the GPRD can be generalised to 
represent UK practices. In addition, this large computerised database can be used broadly and 
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efficiently to investigate rare conditions. As the GPRD contains data only from primary care 
practices, there are certain limitations. There is no coded information on hospital admissions 
such as reason for admission, length of stay, or drug use during inpatient episodes. In addition, 
there are no over-the-counter (OTC) prescriptions recorded in the database. The GPRD does 
not have a direct link of prescriptions to clinical diagnoses, which is a recognised limitation in 
many computerised databases (Wong & Murray, 2005). Although the GPRD has limitations, 
the database is of high quality with a large sample size, and has therefore been extensively used 
for research worldwide. 
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4.1.3.IMS Disease Analyzer (IMS DA) 
The IMS (previously known as Intercontinental Medical Statistics), is an international 
healthcare information company, collecting anonymised health information within the UK and 
across the world. The database IMS Disease Analyzer (formally known as Mediplus) is one of 
the largest longitudinal clinical databases in the world and was first established in 1992. The 
purpose of setting up this database was for research (De Lusignan et al., 2002). In the UK, IMS 
DA contains approximately 2 million anonymous patient records and over 95 million 
prescriptions from about 125 general practices with more than 500 general practitioners (Strom 
et al., 2006). Patient data in IMS DA are anonymised at practice-level and consist of patient 
demographics, indications for treatment and prescription details. Prescribed drugs are coded 
based on the Anatomical Therapeutic Chemical (ATC) classification issued by the European 
Pharmaceutical Market Research Association (EpMRA), and medical diagnoses are coded to 
Read code (a UK medical diagnostic code) which can be linked to the International 
Classification of Disease (ICD) version 10 Codes (WHO, 2010). 
 
The following information is also collected in the UK IMS DA:  
 Practice data:  
1. Regional Health Authority 
2. Town Size 
3. Patients per practice in the current quarter 
4. Patients per practice in the last quarter 
5. Drug-dispensing flag 
6. Number of doctors 
 Doctor data: 
1. Active status 
2. Age 
3. Sex 
4. Date of birth  
5. Doctor registration year 
6. Trainer status 
 
 Patient data: 
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1. Age, sex, height, weight and BMI 
2. Marital status 
3. Registration status 
4. Regional Health Authority  
 Consultation day: date of visit 
 Clinical records: medical diagnoses are coded using Read code and ICD 10 codes: 
1. Read codes and text (level 1 to 5) 
2. ICD-10 codes and text (level 1 to 4) 
3. Referral records 
4. Sick notes 
5. Tests 
6. Further diagnosis and symptoms  
7. History of or family history  
 Therapy records:  
1. Medication 
2. Manufacturer 
3. ATC (levels 1 to 4) 
4. Product (brand and generic name) 
5. Pack form 
6. Therapy text (Read code) 
7. Price 
8. Pack size, form and strength  
9.  Recommended dosages 
10. Therapy stop 
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Figure 4.2 shows a typical medical record for a patient in the IMS DA database. The IMS DA 
has a direct link between prescriptions and the medical diagnosis which is different from other 
primary care databases. However, there is no information on hospital outcomes and OTC 
prescriptions in IMS DA. This database has a similar potential to the GPRD in drug utilisation 
studies and risk assessment studies (e.g. case-control studies) (Clayton et al., 2008). The IMS 
DA is subject to internal validation and quality checks and is consistent with other UK 
prescription counts (Langman et al., 2001). In order to improve data recording quality, data 
quality markers are used to ensure that only data that reaches specific quality standards are 
included in IMS DA. The data quality markers are based on ten different assessment criteria, 
as outlined in Table 4.3. GPs will receive payment as incentive for their time in providing 
quality data for IMS DA. As the quality of data recorded in IMS DA is high, it has been widely 
used in paediatric medication research in Europe in recent years (Sturkenboom et al., 2008; 
Hsia et al., 2009; Neubert et al., 2010; Neubert et al., 2011; Sen et al., 2011; Hsia et al., 2012).  
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Figure 4.2: Example of medical record for a patient in UK IMS DA (reproduced with permission from UK IMS) 
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Table 4.3: The ten data quality markers used by IMS DA database (modified from De 
Lusignan et al., 2002) 
Quality Marker Reasons for its inclusion 
1. Percentage of registered patients for whom there 
has been a change in the record over the previous 
12 months  
An indication that the system is being 
used routinely  
2. Percentage of patients with year of birth and sex 
recorded 
Ensures that researchers can analyse 
disease by age and sex of patient 
3. Percentage of problems or diagnoses with Read 
Code of level 3 or lower 
Lower-order codes represent more 
specific diagnoses. Some high-order 
contain negatives within the lower orders 
4. Percentage of notes linked to problem or 
diagnosis 
Linkage of notes increasingly important 
for analysis of test results 
5. Percentage of notes in which Read Code is level 
3 or lower 
As marker 3 
6. Number of prescriptions issued per week per 
1000 registered patients 
This is a crude measure of how much 
prescribing is not being recorded in 
database. Also looking for abnormalities 
in trends over time that would allow 
detection of missing data 
7. Complete dose and regimen details related to 
dose-effect or adverse drug reactions (ADR) 
Important for prescribing analyses 
8. Proportion of acute prescriptions issued linked to 
a problem title or diagnosis 
A key function of the database is to show 
what the prescribing  
9. Proportion of repeat prescriptions linked to a 
problem title or diagnosis 
A key function of the database is to show 
the prescribing behaviour of general 
practitioners  
10. Ratio of acute prescriptions issued to chronic 
prescriptions 
Checks for consistent usage 
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4.1.4.EPIC The Health Information Network (THIN) 
EPIC (Epidemiology Pharmacology Information Core) is a commercial research company 
established in 1994, specialising in the collection of patient data from general practice within 
and outside UK. The Health Improvement Network (THIN) has been collecting patient records 
in the UK continuously since 2003. The latest dataset contains information on over 7.7 million 
patients from 546 general practices (October 2011) in the UK which use the Vision software 
system to record their consultations. This amounts to over 41 million patient years of 
computerised data. As both GPRD and THIN use the same computer management software 
(Vision), there is approximately 50% overlap of the general practices between the two 
databases (personal communication); therefore the THIN database structure is similar to the 
GPRD. Patient data in THIN are anonymised at practice-level and include demographics, 
details from general practitioner’s visits, diagnoses from specialist referrals and hospital 
admissions, prescriptions and the results of laboratory tests. The Read classification is used to 
code specific diagnoses, and a drug dictionary based on data from the MULTILEX 
classification is used to code drugs.  
 
The THIN database also contains anonymised comments and other information such as 
Townsend deprivation scores (used for social deprivation). Currently, EPIC is working with a 
specialist data privacy company to develop a methodology which will enable THIN to link 
with secondary care such as Hospital Episode Statistics (HES), cancer data, cause of death data 
and dispensed prescription information.  
 
THIN contains clinical primary care data, covering approximately 5.7% of the UK population. 
Similar to GPRD, the demographic distribution of THIN is broadly representative of that of 
the UK. All data are held anonymously, with patient identifiers removed. Similar to GPRD, 
EPIC also offers a facility on follow up questionnaire research. This service is subject to a fee 
paid by researchers via EPIC to GPs. Researchers can also obtain further clarification and 
validation of patient medical records such as copies of death certificates, discharge details, 
hospital letters, and free text information through EPIC. All data sent to the researchers from 
the EPIC verification service is anonymised to protect patient confidentiality.  
The data collected in THIN are audited regularly and participating general practices are 
subjected to a number of quality checks. One unique indicator in this database is “acceptable 
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mortality reporting (AMR)”. The AMR is used to indicate the year from which a practice’s 
mortality records are deemed complete, this indicator can be used to avoid biases related to 
“immortal period” (Maguire et al., 2008). This immortal period is defined as no observed 
deaths in the practice although deaths were expected during this period. An example is that in 
a practice, no deaths were observed prior to data conversion to the new computer software. 
Apparently the practice only kept the medical records of patients who were alive at the time 
data conversion took place. Currently, over a hundred papers have been published in peer-
reviewed journals using the THIN database.  
 
4.1.5.QRESEARCH  
QRESEARCH is another medical record database composed of anonymous data collected 
from general practitioners. It is owned by the University of Nottingham and EMIS (Egton 
Medical Information Systems; a supplier of software management for primary care). It contains 
data from 660 practices and includes information on over 13 million patients in the UK, 
equivalent to approximately 21% of the UK population. Historical data are recorded in the 
database from as early as the 1990s. The QRESEARCH database also has a well-defined 
population with longitudinal data and is representative of the UK population in age, gender and 
geography (www.qresearch.org). This database has been set up on a not-for-profit basis with 
no intention of being in a commercial relationship with pharmaceutical companies and other 
industry. The QRESEARCH database is currently the largest computerised database of 
anonymised patient data from general practices in the UK.  
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4.1.6.The Doctors’ Independent Network (DIN)  
The Doctor’s Independent Network (DIN), an anonymised computerised database in the UK 
was established in 1989. Of the national computerised primary care databases, DIN is less well 
known. The DIN database collects practice records from over 300 general practices in the UK, 
equating to over 3 million patients using Torex (formerly known as MEDITEL) software 
(Carey et al., 2004). Data available from DIN include patient demographics, prescription 
details and indications for treatment. Prescribed drugs and diagnoses are coded using Read 
codes. DIN also contains a socio-economic indicator based on individual patient postcodes, 
which differs from that used by the GPRD where a patient’s socio-economic status is recorded 
only at the practice-level, not the individual patient level. A validation study showed that age 
and sex structure of DIN is similar to that of England and Wales (Carey et al., 2004), but most 
of the practices contributing to the DIN database are from southern England. Although DIN 
provides a unique source of population-based clinical information, it is used mainly by 
pharmaceutical companies to investigate trends of drug prescribing (Carey et al., 2004).   
 
4.1.7.The Medicines Monitoring Unit (MEMO)  
The Medicines Monitoring Unit (MEMO) is a university-based organisation that uses record-
linkage techniques to undertake pharmacoepidemiologic and pharmacovigilance research in 
Tayside, Scotland (Evans et al., 1995; Evans et al., 1999). The population of Tayside is 
approximately 400,000 people (Evans et al., 1995). The patient population contained within 
MEMO is demographically similar to that of the rest of Scotland (Evans et al., 1999). This 
database contains data generated within the National Health Service in Scotland (NHSiS) and 
all prescriptions dispensed in Tayside. Morbidity data include inpatient hospital admissions, 
biochemical tests, cancer registration, death certificates, and diagnostic procedures 
(MacDonald et al., 1995). This database provides useful data although it only covers one region 
in Scotland and is smaller than its other computerised counterparts. However, the data in 
MEMO may not be representative of the UK population as a whole.  
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4.1.8.Summary of primary care databases  
Table 4.4 summarises the detailed information recorded in these databases as well as their 
strengths and limitations. In general, the computerised GP databases have the advantages of 
longitudinal records and detailed prescribing data. In recent years, those databases have been 
broadly and intensively used for epidemiological research. As these databases provide 
historical data, it can also shorten the time to conduct a study compared to a prospective study 
design, which may require up to several years to recruit enough patients to obtain robust 
estimates. Also, the large size of the databases permits the study of rare diseases. Despite the 
strengths of computerised GP databases, there are general limitations that need to be addressed. 
Most databases contain referral and hospital admission information. However, it is unclear 
which specialist confirmed the diagnoses and/or symptoms at the time of onset of the condition. 
It has been estimated that 95% of prescriptions issued by GPs are recorded in both GPRD and 
IMS DA databases (formally known as MediPlus) (Lawrenson et al., 1999). As medical 
records and prescriptions are entered by GPs in primary care, medications prescribed by 
specialists in hospitals (e.g. secondary care, tertiary care), or by GPs at home visits and 
controlled drugs such as methadone, may be incomplete (Lawrenson et al., 1999). In addition, 
there is no information on treatment compliance as with all observational data and over-the-
counter (OTC) prescriptions are not recorded in the databases. A general limitation of primary 
care databases is that prescriptions and indications data are not directly linked, except in the 
IMS DA database.  
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Table 4.4: Summary table of primary care databases in UK:  
 
Database  Computer 
system used 
Data collected Strengths  Limitations  
General Practice Research 
Database (GPRD) (also 
known as FF-GPRD and 
Clinical Practice Research 
Datalink) 
VAMP 
system  
-Demographic information* 
-Symptoms and diagnoses 
-Prescriptions issued 
-Referral records 
-Laboratory tests and results 
-Immunisation records 
-Miscellaneous information: 
smoking, height, weight, BMI, 
alcohol consumption 
1. Data are broadly representative of national 
population (covers about 7.4% of UK 
population).  
2. The quality and completeness of recording 
are high and validity have been reported to 
be high (Walley & Mantgani, 1997; 
Nazareth et al., 1993a,b; Jick et al., 1991). 
3. Additional services are provided by the 
GPRD group such as questionnaires to GPs 
to obtain further information.  
4. Data have been widely used by 
researchers and over 890 articles published 
in peer-review journals. 
1. Data are primarily collected for clinical 
management not for research purposes.  
2. It requires intensive training to use data and also 
knowledge of relational databases.  
3. License for accessing data is expensive. 
4. There is no information on hospital data, length of 
stay and prescriptions.  
5. Over-the-counter (OTC) prescriptions are not 
recorded.  
6. Prescription records are not directly linked with 
diagnoses.  
7. Information on individual socioeconomic status 
and ethnicity are not recorded.  
 
The Health Improvement 
Network (THIN) 
 
 
 
 
 
 
 
 
 
 
 
In practice 
systems 
(INPS)  
 
 
 
 
 
 
 
 
 
 
 
-Demographic information 
-Symptoms and diagnoses 
-Prescriptions issued 
-Referral records 
-Laboratory tests and results 
-Immunisation records 
-Miscellaneous information: 
smoking, height, weight, BMI, 
alcohol consumption 
-Socioeconomic data: postcode, 
Townsend score quintile 
 
 
1. Data are broadly representative of national 
population (covers 5.7% of UK population).  
2. The database contains useful ‘Acceptable 
Mortality Reporting’ filter to avoid the 
danger of “immortal period” bias (Maguire 
et al., 2009) 
3. Anonymised comments and Townsend 
deprivation scores are available.  
4. Additional service are offered such as 
questionnaires to GPs to obtain further 
information. 
 
 
 
1. Data are primarily collected for clinical 
management not for research purpose. 
2. There is no information on hospital tests, length of 
stay and prescriptions.  
3. Cost of using the data is high. 
4. Over-the counter (OTC) prescriptions are not 
recorded.  
5. Ethnicity is not recorded.  
6. No direct link between prescriptions and 
diagnoses.  
7. The database was newly available so little 
validation work had been conducted at the time.  
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Continued. 
    
QRESEARCH 
 
EMIS clinical 
computer 
system 
-Demographic information 
-Symptoms and diagnoses 
-Prescriptions issued 
- smoking, height, weight, BMI 
It is operated on a not-for-profit basis 
and the main interest is “supporting non-
commercial research which will 
improve patient care” 
(www.qdscore.org) 
 
1. There is no information on hospital tests, length of stay 
and prescriptions.  
2. Over-the-counter (OTC) prescriptions are not recorded. 
3. There is no information on ethnicity 
 
 
UK IMS Disease Analyzer 
(IMS DA)  
Meditel 
system 
-Demographic information 
-Symptoms and diagnoses 
-Prescriptions issued 
-Referral records 
-Immunisation records 
-Laboratory tests and results 
1. Data are broadly representative of the 
UK population (covers 3% of UK 
population). 
2. There is a direct link between 
prescriptions and diagnoses.  
3. The validity and completeness of data 
reported to be high (Lawrenson et al., 
1998) 
4. Symptoms and diagnoses are cross-
mapped to ICD codes.  
 
1. Information on socioeconomic status and ethnicity are 
not recorded. 
2. There is no information on hospital tests, length of stay 
and prescriptions.  
3. Over-the-counter (OTC) prescriptions are not recorded.  
Doctors’ Independent 
Network  
(DIN) 
iSOFT 
software 
(formerly 
Torex) 
-Demographic information 
-Diagnostic information  
-Prescriptions issued 
-Referral records 
-Immunisation records 
-Socioeconomic indicator (the 
ACORN index) 
1. Data are broadly representative of 
England and Wales’ population.  
2. Socioeconomic measure is based on 
individual level not practice level.   
 
1. There is no information on hospital tests, length of stay 
and prescriptions.  
2. Over-the-counter (OCT) prescriptions are not recorded. 
3. It only contains data from England and Wales.  
4. Most of the practices in DIN are in the South of 
England.  
 
Tayside Medicines 
Monitoring Unit (MEMO) 
NA -Demographic information 
-Diagnostic information 
-Prescriptions issued (from 
both GP practice and hospitals) 
 
1. It contains prescriptions issued during 
hospital admissions and prescriptions 
dispensed in Tayside primary care.  
2. It contains cancer registration and 
death certificate information.  
1. It contains data from only one Scottish region, so it 
may not be representative of the UK population as a 
whole.  
 
                    *Demographic information: age, gender, registration date, de-registration date. NA: not available.  
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4.1.9.Utility of GP databases in research 
Data from large computerised clinical databases such as claims databases and automated 
medical record databases have been extensively used for epidemiological studies in the USA 
and Canada since the late 1970s (Strand et al., 1994; Hershel, 1997). An example on the 
process of using computers to automate information is presented in Figure 4.3.  
 
Figure 4.3: An example of the process of generating computerised data for research 
(adopted from De Lusignan & Weel, 2006) 
 
In order to derive data from a computer system to answer a specific question, researchers 
should be able to use data extraction tools which extract data based on their research questions. 
Furthermore, researchers should have strong programming skills to manipulate large datasets 
in an appropriate statistical package in order to model longitudinal data (Lawrenson et al., 
1999). Once data have been extracted, data cleaning should be performed which should include 
cross checking to identify unexpected patterns, recording errors or duplication. The acquisition 
of data extraction is shown in Fig 4.4.  
Implement computerised 
medical records with:  
1. A reliable denominator 
2. The capability to be    
searched 
The system provides:  
1. Data about the quality of 
care and clinical practice 
2. Information about the 
epidemiology of the 
condition  
Using informatics for:  
1. Clinical audit 
2. Health service 
planning 
3. Research 
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Figure 4.4: The general technical process of data extraction from a computerised 
database (adopted from De Lusignan & Weel, 2006) 
 
A crucial concern for the user of computerised database is validity, which includes 
completeness and accuracy of recording. This key attribute for recorded diagnoses and 
prescriptions in general practice databases needs to be addressed before carrying out a study. 
One example is to verify that patients with a certain recorded diagnosis in the database actually 
have that condition. Further confirmation to verify that patients have that diagnosis can be 
obtained by going back to their GPs or by requesting a hospital summary. This approach is 
time-consuming and it can also be expensive. Several validation studies have been carried out 
using GPRD and IMS DA for various conditions. Furthermore, to improve the quality of data 
contained in GPRD and IMS DA, GPs receive reimbursement for their time (Lawrenson et al., 
1999; De Lusignan et al., 2002). GPs receive approximately £400 per year as an incentive to 
meet the data quality score for ten assessment criteria in IMS DA (De Lusignan et al., 2002).    
 
In April 2004, a new General Medical Service (GMS) contract was introduced into general 
practice: the Quality and Outcomes Framework (QOF). This new pay-for-performance scheme 
was expected to have profound implications to improve the quality of care in primary care.  It 
was a voluntary incentive scheme for GP practices. To measure achievement, GPs have to enter 
and maintain high quality information from their clinical practice system. The scheme started 
in 2004 and included 136 quality indicators (DoH, 2004b). The QOF has four domains, also 
known as indicators, to measure the achievement: clinical, organisational, patient experience, 
and additional services. The overall achievement of a practice would be measured through a 
points system, and payment would be based on points achieved. In order to qualify for 
Define system architecture:  
1. Unique patient identifiers  
2. Problem orientated 
records  
3. Linkage: conditions to 
treatment 
4. Coding system 
5. Develop any prompting 
or decision support 
1. Develop technical means 
of data extraction 
2. Ensure information 
security/data protection 
3. Extracted data can be 
mapped to existing data 
about condition in question 
 
Defined processes for 
data:  
1. Aggregation ensuring 
referential integrity 
2. Cleaning processing 
3. Analyses 
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payment, information entered has to be recordable, reliable, consistent and auditable (Roland, 
2004). Therefore, data recording by GPs was expected to improve. However, there is currently 
insufficient evidence to demonstrate whether the QOF improves patient care and data recording 
in GP practices.  
 
Despite the concerns about data validity, computerised databases have been extensively used 
in North America for pharmacoepidemiological research since the 1970s. These have routinely 
collected data and have also been used in research such as incidence and/or prevalence of 
disease in community (disease epidemiology), pharmacoeconomics, and health service 
research (Strom et al., 2006). This information will enable researchers, clinicians, and policy 
makers to identify the gap between practice and evidence. In the past, the lack of resources 
available for pharmacoepidemiologic research in the UK was highlighted (Hall, 1992). A study 
by Black et al. (2004) showed that most electronic databases were not being utilised for 
research and it concluded that more support was needed in the UK, because routinely collected 
data from general practice should be used beyond clinical management. In recent years, there 
has been a surge in the use of computerised databases for pharmacoepidemiologic studies in 
the UK (Wong & Macey 2005).  
 
Pharmacoepidemiology is a relatively new field and it is defined as: ‘the study of the use and 
the effects of drugs in a large population’ (Strom et al., 2006). It applies epidemiological 
methods in the area of clinical use of drugs in populations. Pharmacoepidemiologic studies can 
be broadly divided into drug utilisation studies, post-marketing surveillance, hypothesis-testing 
studies (e.g. case-control study) (Hall, 1992; Hennessy, 2006; Smeeth et al., 2006). The 
advantage of using computerised databases is that they enable medical research to be carried 
out in a large sample of a particular population that would normally be excluded from clinical 
trials, such as children and pregnant women. For instance, a report by the Medical Research 
Council, the UK Department of Health and the Association of the British Pharmaceutical 
Industry recommended that clinical databases should be used for paediatric medication 
research (Royal College of Paediatrics & Child Health, 2004).  
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Drug utilisation studies are increasingly being used in pharmacoepidemiology. A drug 
utilisation study is defined by the WHO as “the marketing, distribution, prescription, and use 
of drugs in a society, with special emphasis on the resulting medical, social and economic 
consequences” (WHO, 2000). This study design can be used to monitor the patterns of drug 
prescribing during the post-marketing phase as it is impossible to predict this at the pre-
marketing clinical trial phase. Drug utilisation studies can be divided into two types: 
quantitative or qualitative. Quantitative drug utilisation studies are used to quantify the present 
state, developmental trends, and time course of drug usage in a large population. Qualitative 
drug utilisation studies are used to assess the appropriateness of drug use by linking 
prescription data to the reasons for prescribing (e.g. diagnosis) (Lee et al., 2006).  The 
pharmacoepidemiologic studies described in this thesis are mainly drug utilisation studies.  
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4.1.10.Summary 
Prior to the development of computerised databases, it was a complex and expensive process 
to identify and follow-up a large cohort of patients to measure disease prevalence and examine 
prescribing trends. Currently, computerised databases from general practice allow researchers 
to conduct studies with a large sample size and more complete medical and prescription data, 
as well as historical records. In addition, it is considered to be a more cost-effective and less 
time consuming approach compared to traditional field study. Although the primary intention 
for developing GP databases was to manage patient care in the clinical setting, it is also an 
invaluable source of data for research.  
 
The clinical computerised databases from general practice used for the studies described in this 
thesis have provided us with large cohorts of patients receiving anti-obesity drugs and have 
enabled us to investigate trends in drug utilisation in the UK. Although there are several GP 
databases in the UK and all have their own advantages and limitations for conducting 
pharmacoepidemiological research, the work conducted in this thesis primarily utilised data 
retrieved from the GPRD and IMS DA. Various methods of data manipulation and statistical 
analysis were used to analyse the data for these drug prescribing studies conducted in primary 
care; they are described in detail in each of the sections.  
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4.2.Drug utilisation of orlistat, sibutramine and rimonabant in general practice 
 
4.2.1.Introduction 
As discussed previously, there were three drugs approved for obesity treatment in adults in the 
UK between 1999 and 2006: orlistat (licensed in 1999), sibutramine (licensed in 2001) and 
rimonabant (licensed in 2006). The NICE guidelines (2006) recommended that orlistat and 
sibutramine should be considered as useful adjuncts to lifestyle modification in adolescents 
≥12 years old with physical co-morbidities, but use in <12 years old should be reserved for 
those with life-threatening co-morbidities. The NICE guidelines do not recommend 
rimonabant for obese young people. This may be due to limited data on rimonabant use in 
young people at the time NICE guideline was released, as rimonabant was licensed for obesity 
treatment in adults in 2006. Prior to 2007, there was no information on anti-obesity drug 
prescribing patterns (orlistat, sibutramine, rimonabant) in children and adolescents in the UK. 
Although rimonabant and sibutramine were withdrawn from the EU market after the start of 
this project in 2008 and 2010, respectively, the experience of their prescribing patterns and use 
could be useful for future anti-obesity drug prescribing in this population. Therefore, data on 
the prescribing patterns of these drugs were also included in our study. A drug utilisation study 
was conducted to investigate the prescribing patterns of orlistat,  sibutramine, and rimonabant, 
in chidlren and adolescents, in primary care in the UK between 1999 and 2006.  
 
4.2.2.Aim and objectives  
The aim of this study was to investigate the prescribing patterns of orlistat, sibutramine and 
rimonabant in young people in primary care. This was achieved by investigating annual, sex- 
and age-specific prevalence of anti-obesity drug prescribing in children and adolescents aged 
0-18 years between January 1999 and December 2006.  
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4.2.3.Methods 
4.2.3.1.Data Source 
As described in section 4.1.2, the GPRD is a longitudinal primary care database maintained by 
the MHRA. At the time of our study in 2007, the database contained anonymised patient 
records for approximately 5% of the UK population. Detailed information on the database 
structure is described in section 4.1.2.  The study population comprised all children and 
adolescents with at least 6 months’ data, who received at least one prescription for an anti-
obesity drug in the study period, between January and December 2006.   
 
4.2.3.2.Data extraction  
The GPRD is a relational database, it is necessary to link all datasets to produce a complete 
patient dataset for data analyses (Appendix 4). An online GPRD (FF-GPRD) enables 
researchers to access the full range of raw data in the GPRD. An online medical browser 
extraction tool, Business Objects and Business Objects Information Systems (BORIS), is 
provided by the GPRD which acts as an interface between researchers and the database. This 
medical browser allows researchers to create queries for specific questions in their research 
area. Figure 4.5 illustrates an overview of how data are obtained and processed from the central 
database to create a master dataset for analysis. All the databases were imported onto the local 
server at the School of Pharmacy, where data cleaning and merging of these databases were 
carried out. In order to create appropriate queries to retrieve information, criteria were defined 
based on the aim and objectives of this project. In this study, a number of steps were undertaken 
to extract data on the use of anti-obesity drugs in the UK.  
 
The study cohort was comprised of patients who had received orlistat, sibutramine, or 
rimonabant. The first step of data extraction was to compile a comprehensive list of study drug 
codes. Once the list of drug codes was collated, the second step was to enter these codes into 
Business Objects (BO) query to retrieve information on patients who had received these drugs 
during the study period. Appendix 5 illustrates the details of the BO query to retrieve all 
patients under 19 years old who had ever been issued anti-obesity drug prescriptions during 
the study period. The third step was to carry out data cleaning. Once the data had been retrieved 
from the GPRD, the process of data cleaning was performed which involved crosschecking 
 130 
 
duplicates and unexpected recording patterns in the database. The statistical software 
(Stata/MP version 10) was used to clean the dataset.  
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Figure 4.5: Flowchart of data extraction from the GPRD 
 
 
 
 
Log in to FF-GPRD  
(Full feature GPRD) 
A unique number from fob key to access the database 
Extract data 
BORIS interface is used 
to extract additional 
clinical data 
Import dataset to local server 
Data will be stored at School of 
Pharmacy server for analysis. 
Create query 
Business Objects (BO) 
interface software is used 
to identify study cohort. 
GPRD website 
www.gprd.com 
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4.2.3.3.Calculation of Prevalence 
In an epidemiology study, prevalence is defined as the proportion of patients in a population 
who have the disease at a specific time (Hennekens & Buring, 1987). To use this concept in a  
pharmacoepidemiological study the number of patients who were receiving a certain drug(s) 
during a particular time period is calculated. In these analyses, annual prevalence was defined 
as the number of patients with at least one anti-obesity drug prescription during the year of 
investigation divided by the total number of patient-years (aged 0-18 years) in the same year. 
Patient-years are defined as the sum of the number of years contributed by each patient at risk 
of being prescribed an anti-obesity drug during the study period in the study population 
(children and adolescents aged 0-18 years). The sex- and age-specific prevalence was 
calculated as the number of patients receiving at least one anti-obesity prescription during the 
year of investigation divided by the total number of patient-years in the same year stratified by 
age and gender. 
 
In order to calculate patient-years, the censoring date for each individual patient needs to be 
determined. Patients may enter or leave the study at various points in time and are only eligible 
for inclusion in the study between their respective ‘left-censoring’ and ‘right-censoring’ dates 
in the database. This means that not all patients will be included in the study throughout the 
whole study period. The left-censoring and right-censoring dates can be used to calculate the 
length of time that each patient was contributing data to the database. Figure 4.6 illustrates the 
process of data censoring in the GPRD primary care database. The date of left-censoring date 
is referred to as: 1) study start date, or 2) patient date of registration, or 3) practice up-to-
standard date (e.g. GPRD). The right-censoring date is defined as the date data cease to be 
contributed to the database, this may be when patients left or transferred out of the practice or 
died. 
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Figure 4.6: Schematic of censoring dates in database  
 
 
  
 
 
A Chi-squared test (Cochran–Armitage test for trend) was used to examine if changes in 
prevalence of prescribing were significant. Ninety-five percentage Confidence Intervals (95% 
CI) were generated using Poisson approximation. P-values of <0.05 were considered 
statistically significant.  
 
  
Right-censoring date 
Study period 
Patient A 
Patient B 
Patient C 
Patient D 
Left censoring date 
Transferred out 
from practice 
Patient died 
             Patients and conditions of interest not eligible for inclusion 
 
  Right-censoring date: end of study period 
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4.2.3.4.Treatment duration of anti-obesity drugs  
The duration of anti-obesity drug treatment was analysed using the Kaplan–Meier survival 
method and Log-rank test. Kaplan-Meier survival analysis is widely used for cancer studies to 
measure the time to an event of interest (i.e. death), and the term for the time to event of interest 
is survival time (Altman, 1990). This statistical analysis can also be applied to other medical 
studies to analyse ‘time-to-event’ data, meaning that the data have an end point time when the 
event occurs (Jager et al., 2008). Figure 4.7 illustrates survival times for patients from the study 
cohort who received anti-obesity drugs.  
 
Figure 4.7: Schematic of duration of anti-obesity drug treatment 
 
 
 
The distinctive feature of survival analysis is that the event of interest will probably not occur 
at the end of study period. In the above illustration (Figure 4.7), Patient 1 will be censored as 
this person referred out from practice during the study period. The survival time of Patient 2 
would also need to be censored at the end of study period as we don’t know when this person 
will stop anti-obesity drug treatment. The censoring can also happen for other reasons such as 
lost to follow-up during the study period. Survival time of Patient 3 will not be censored as this 
Patient 1 
Patient 2 
Patient 3 
Status 
Transferred out 
from practice 
Stopped treatment 
Event occurs 
Censored 
Censored 
Time from start of anti-obesity drug treatment (months) 
0     2     4     6      8     10   12 
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patient stopped treatment (event of interest) during the study period.  
In this study, treatment was considered to have stopped if there were no further anti-obesity 
prescriptions issued within 90 consecutive days (3 months) after the date of the last anti-obesity 
prescription. Study subjects were censored either if the end of the study period was within 90 
consecutive days after their last anti-obesity prescription or if they had left the practice without 
stopping treatment. 
 
The logrank test was performed in this study to compare treatment duration between anti-
obesity drugs. The Logrank test is used to compare survival time between groups. This test can 
detect whether the event of interest is consistently greater in one group than another (Altman, 
1990; Jager et al., 2008). It should be noted that the Logrank test is mainly one of significance 
and it cannot estimate the difference in size between the groups (Altman, 1990).  
 
4.2.3.5.Obesity related co-morbidities 
Information on obesity related co-morbidities was also examined in the dataset for study 
subjects prescribed one of the anti-obesity drugs. Given the range of conditions potentially 
associated with obesity, the search for obesity related co-morbidities was restricted to 
hypertension, dyslipidaemia, insulin resistance syndrome (metabolic syndrome) and 
depression.  Data were manipulated and analysed using Stata version 11.0 (College Station, 
TX, USA).  
 
4.2.3.6.Ethical Approval  
The GPRD study protocol presents in Appendix 6 and approval for this study was granted by 
the GPRD’s Scientific and Ethnical Advisory Group (Appendix 7).  
 136 
 
4.2.4.Results 
A total of 452 children and adolescents received 1,334 prescriptions for anti-obesity drugs 
between January 1999 and December 2006. As there was only one prescription for rimonabant 
(in a patient aged 18 years in 2006), further analyses refer only to orlistat and sibutramine. 
Orlistat made up 78.4% (n=1,045; 1,045/1,334) of all prescriptions.  The majority of 
prescriptions were issued to female patients (82.3%; 372/452). The mean age at which patients 
were first prescribed an anti-obesity drug was 17.0 years (SD 1.33; range 10-18 years). For 
female patients, the mean age at first prescription was 17.1 years (SD 1.27); for male patients, 
the mean age was 16.7 years (SD 1.53). The median number of anti-obesity drug prescriptions 
per subject was 2.0 (inter-quartile range 3.0), and 40.5% (n=183) of patients received only one 
anti-obesity prescription during the study period.  
 
The number of patients who received an anti-obesity drug steadily increased between 1999 and 
2006, particularly for female patients (Table 4.5). Figure 4.8 shows the number of prescriptions 
by calendar year. The use of both orlistat and sibutramine increased rapidly after each drug 
was introduced into the UK clinical practice. The number of orlistat prescriptions rose from 10 
to 282 per year between 1999 and 2006, a 28-fold increase. From 2001 to 2006, the number of 
sibutramine prescriptions rose from 8 to 128, a 16-fold increase.  
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Table 4.5: Description of study subjects between 1999 and 2006 by gender and calendar year 
 Number of patients Person-years for total study population* 
Year Boys Girls Total Boys Girls Total 
1999 1 4 5 421,126.3 
 
403,384.2 
 
 
824,510.4 
 
2000 5 12 17 477,904.7 
 
458,427.2 
 
 
936,331.9 
 
2001 12 32 44 532,525.5 
 
510,634.9 
 
 
1,043,160.3 
 
2002 14 44 58 569,844.4 
 
546,502.5 
 
 
1,116,346.9 
 
2003 8 43 51 595,658.5 
 
571,827.6 
 
 
1,167,486.2 
 
2004 11 53 64 634,025.4 
 
609,673.3 
 
 
1,243,698.7 
 
2005 12 80 92 666,092.6 
 
643,415.1 
 
 
1,309,507.8 
 
 
2006 
 
18 103 121 681,887.7 
 
660,069.4 
 
 
1,341,957.1 
 
*Person-years: the sum of the number of years contributed by the total population in the database aged 0-18 years, during each year of the study 
period (1999-2006).  
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Figure 4.8: Number of anti-obesity prescriptions to children and adolescents aged 0-18 
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Figure 4.9 shows the prevalence of overall anti-obesity prescribing by calendar year and gender 
for children and adolescents aged 0-18. Overall use of anti-obesity drugs significantly 
increased from 0.006 per 1000 person-years (95%CI 0.0007 to 0.0113) in 1999 to 0.091 
(95%CI 0.07 to 0.11) in 2006 (p< 0.0001), a 15-fold increase. Similar increases were seen in 
both genders over the study period, increasing in girls from 0.009 (95%CI 0.0001 to 0.019) to 
0.156 (95%CI 0.126 to 0.186) (p<0.0001), and in boys from 0.002 (95%CI 0.0019 to 0.004) to 
0.027 (95%CI 0.012 to 0.04) (p<0.02).  
 
Figure 4.10 shows the age-specific prevalence of anti-obesity prescribing by gender. No anti-
obesity drugs were prescribed to children aged <10 years, although 25 prescriptions were 
issued to children aged < 11 years old. Prescribing rose with increasing age, particularly from 
14 years onwards in both boys and girls.  
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Figure 4.9: Sex-specific annual prevalence of anti-obesity drug prescribing in children and adolescents aged 0-18 
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Figure 4.10: Age-specific prevalence of anti-obesity drug prescribing in children and adolescents 
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Figure 4.11 shows Kaplan-Meier survival curves for treatment duration for orlistat and 
sibutramine. The mean duration of orlistat use was significantly shorter (3.0 months; 95%CI 
2.72-3.47) compared with sibutramine (4.2 months; 95%CI 3.4-5.0) (p<0.003). Approximately 
45% of patients who received orlistat were discontinued within the first month, with about 10% 
remaining on treatment after 6 months. Approximately 25% of patients who received 
sibutramine were discontinued within the first month, with less than 20% remaining on drug 
use at 6 months.   
 
Figure 4.11: Kaplan-Meier survival curves for children and adolescents who received 
anti-obesity drug treatment 
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Thirty-nine patients were prescribed both orlistat and sibutramine; 34 patients were initially 
prescribed orlistat and subsequently switched to sibutramine, and five patients initially 
received sibutramine and then switched to orlistat. Reasons for changing between anti-obesity 
drugs were not available in the database.  
 
Table 4.6 shows specific obesity-related co-morbidities in those prescribed anti-obesity drugs. 
We identified 22 patients with diabetes in the study population. Those patients all received 
anti-diabetic drug treatment (either insulin or oral hypoglycaemic drugs).  
 
 
Table 4.6: Selected obesity-related comorbidities within the population treated with 
anti-obesity drugs 
Co-morbidity diagnosis % (n) 
Diabetes mellitus 4.9 (22) 
Hypertension  2.2 (10) 
Depression  28.5 (129) 
Polycystic ovarian syndrome* 7.5 (28/372 female study subjects) 
*Polycystic ovarian syndrome: only for girls in study population.  
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4.2.5.Discussion 
This study has demonstrated that prescribing of anti-obesity drugs in children and adolescents 
has increased dramatically between 1999 and 2006.  The results showed that in 2006 
approximately 0.1 per 1000 of those aged ≤18 years were being prescribed anti-obesity drugs. 
Generalising across the UK population of 13,928,000 persons aged ≤18 years, this would 
suggest that approximately 1300 young people were prescribed anti-obesity drugs annually. 
However, persistence with these drugs past the first month was strikingly poor, and only 25% 
of those prescribed orlistat and 35% of those prescribed sibutramine remained on the drug for 
longer than 3 months, generally regarded as an adequate time to ascertain whether significant 
weight loss has occurred. 
 
Orlistat and sibutramine were not licensed for obesity treatment in children and adolescents in 
the UK. A rapid increase in prescribing for children and adolescents of off-label anti-obesity 
drugs was demonstrated, which in most cases are discontinued before patients can reasonably 
expect to see a clinical benefit. Furthermore, this pattern of drug use is likely to be significantly 
wasteful of resources, as anti-obesity medications are relatively expensive 
(Shrishanmnganathan et al., 2007). Although orlistat and sibutramine have shown significant 
but limited benefits for weight reduction and have reported good tolerability in a small number 
of randomised placebo-controlled trials in young people, evidence for their effectiveness in 
large populations of young people is largely lacking (Molnar, 2005). The 2006 NICE guidance 
on the use of sibutramine and orlistat was based on very limited effectiveness data. Further 
research into effective and safe use of anti-obesity drugs in children and adolescents outside of 
efficacy trials is needed. Investigation of the reasons for discontinuation of anti-obesity drugs 
may allow the development of support strategies that minimise the occurrence of adverse drug 
reactions and maximise drug continuation when used in young people. 
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4.2.6.Strengths and limitations 
The GPRD contains robust data on prescriptions issued in primary care, and given the universal 
nature of the NHS in the UK, our estimates of population prescribing prevalence in primary 
care are highly likely to be sound and generalizable to UK primary care. However, several 
limitations need to be highlighted. Firstly, the GPRD records prescriptions issued in primary 
care only, excluding drugs issued from hospitals. However, the vast majority of anti-obesity 
drugs are prescribed from primary care in the UK in both adults and children 
(Shrishanmuganathan et al., 2007), although often under the advice of hospital specialists. In 
children and young people, the NICE guidance (2006) suggests that anti-obesity drugs should 
be initiated by specialist paediatric services but that continuation of prescribing is appropriate 
in primary care. It is thus possible that our data do not include a very small number of initial 
hospital prescriptions; unfortunately, there are no data to investigate the extent of hospital 
prescribing. Secondly, the GPRD does not contain data on socioeconomic status and ethnicity, 
thus precluding analysis of their impact on prescribing patterns. Thirdly, we had no access to 
data regarding reasons for discontinuation of anti-obesity drug treatment. However, given that 
the commonest causes of drug discontinuation are lack of efficacy and adverse effects, we 
believe that it is reasonable to speculate that discontinuation occurred due to either of these 
factors. A further limitation is the lack of data on BMI. Whereas weight was recorded 
frequently in the database, there were relatively few recordings of height for most patients. As 
a result, we were unable to calculate accurate BMI data in relation to prescription dates and 
thus could not assess either the mean BMI of patients received anti-obesity drugs, or the change 
in BMI in those who received treatment. 
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4.2.7.Comparison with the literature 
This is the first known published study using population-based data on prescriptions to 
investigate the trends and patterns use of orlistat and sibutramine in children and adolescents 
in the UK. The only comparable data on prescription prevalence is from a report of total 
national prescription counts in England from 1998 to 2005, which were not broken down by 
age but are almost certain to be mainly for adults for whom the use of anti-obesity drugs is 
licensed. This study found a 25-fold increase in orlistat prescriptions and a 4-fold increase in 
sibutramine prescriptions between 1998 and 2001 (Shrishanmuganathan et al., 2007). A similar 
increase in orlistat prescriptions in children and adolescents was also identified (28-fold 
increase from 1999) with a much larger increase (16-fold increase from 2001) in sibutramine 
prescriptions. The orlistat prescriptions outnumbered those for sibutramine by approximately 
four to one over our study period; however, this was likely to be an artefact of the earlier 
introduction of orlistat. In 2006, there were approximately twice as many prescriptions for 
orlistat as sibutramine, similar to the ratio described for adults (Shrishanmuganathan et al., 
2007). 
 
The only comparable data on tolerability and persistence with orlistat and sibutramine in 
children and young people comes from a small number of efficacy studies. For orlistat, 
published reports conclude repeatedly that it is ‘well tolerated’ (McDuffie et al., 2002; 
Chanoine et al., 2005; Henness & Perry 2006) in children and adults. However, published trial 
data show that although persistence with orlistat for ≥3 months in clinical trials was markedly 
greater than in our data, gastrointestinal side-effects were reported in >50% (Chanoine et al., 
2005). The largest study of orlistat in adolescents, a randomized placebo-controlled study of 
539 subjects over 12 months, reported that 65% (232/357) of those randomised to orlistat 
completed 12 months’ treatment, and that only 2% (2/357) in the orlistat arm dropped out due 
to adverse reactions. However, gastrointestinal adverse events were reported by 50% of those 
taking orlistat (Chanoine et al., 2005). A detailed study of the tolerability of taking orlistat 
together with a comprehensive behavioural and dietetic programme in 20 adolescents over 3 
months found that 85% completed 3 months on orlistat, but that 50–60% reported a 
combination of unpleasant gastrointestinal side-effects (McDuffie et al., 2002). In a small 
open-label randomized controlled trial, gastrointestinal side-effects were reported in all 22 
adolescents receiving orlistat, of whom seven (32%) dropped out of the trial during the first 
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month due to side-effects attributable to orlistat (Ozkan et al., 2004). 
 
Similarly, for sibutramine, published studies report that this drug is generally well tolerated in 
adolescents (Berkowitz et al., 2003; Berkowitz et al., 2006; Godoy-Matos et al., 2005). The 
largest trial, a randomised placebo-controlled trial in 498 obese adolescents over 12 months, 
reported that 76% of those in the sibutramine arm continued the drug for the full 12-month trial 
period, with only 6% of subjects withdrawing because of adverse events (Berkowitz et al., 
2006). In a smaller randomised controlled trial of 60 obese adolescents over 6 months, 93% 
completed the 6-month trial and no subjects withdrew due to sibutramine side-effects (Godoy-
Matos et al., 2005). In a further small randomised trial of 46 obese adolescents, 81% (21/26) 
in the sibutramine arm completed the 6-month trial, and none withdrew because of adverse 
events (Garcia-Morales et al., 2006). 
 
Findings in our analysis do not support the above reports on tolerability of and persistence with 
orlistat and sibutramine. In contrast, our results showed that in general clinical use, only one-
third of patients continued treatment past 3 months. Although we do not have data on reasons 
for discontinuation, this is likely to reflect either poor therapeutic efficacy of the drug in the 
young people, and/or lower level of parental education, and high frequency of side-effects due 
to excessive intake of dietary fat (Molnar, 2005) or, alternatively, unrealistic expectations of 
rapid major weight loss, leading to discontinuation when this is not achieved. Although we 
have no data on reasons for discontinuation in our study, evidence suggests that both orlistat 
and sibutramine are less well tolerated and more rapidly discontinued in children and 
adolescents than in highly selected, motivated and supported clinical trial populations. These 
differences may reflect the routine weight management support programmes that were an 
integral part of many of the clinical trials of orlistat and sibutramine (McDuffie et al., 2002; 
Chanoine et al., 2005; Berkowitz et al., 2006; Godoy-Matos et al., 2005).  
 
A further reason for early discontinuation in patients in our study may have been the relatively 
high proportion (approximately 29%) with a comorbid diagnosis of depression, as feelings of 
hopelessness and negativity may contribute to early discontinuation of the drug. Although we 
have no further information about the validity of recorded diagnoses of depression, this figure 
is higher than the 13% reported from population-based estimates of psychological distress in 
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obese UK adolescents (Viner et al., 2006). This suggests that in clinical practice, obese 
adolescents with significant psychological distress may be over-represented in those prescribed 
anti-obesity drugs. Children <12 years old were found to be prescribed anti-obesity drugs, 
contravening the Summary of Product Characteristics (SPC), and very few patients in our 
analysis continued their anti-obesity drug for a 6- to 12-month trial suggested by NICE. We 
also found that the number of girls received anti-obesity drugs was higher than boys in our 
study. This sex ratio is similar to that seen in a population-based study of anti-obesity drug use 
in Taiwanese adults (Liou et al., 2007), and reflects well-described higher proportions of body-
weight concerns in adolescent girls (Taylor et al., 2005). 
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4.2.8.Conclusion  
This study shows that prescriptions of off-label anti-obesity drugs in children and adolescents 
have dramatically increased between 1999 and 2006. However, the majority of these drugs 
were rapidly discontinued before patients could see a clinical benefit, suggesting they are 
poorly tolerated or less efficacious when used in young people, in contrast to findings from 
clinical trials. The early discontinuation of treatment in this study is unclear. Further research 
into the long-term efficacy and safety of anti-obesity drugs in children and adolescents is 
needed. In addition, a further study should investigate the reasons for early discontinuation of 
these drugs in this population.  
 
4.2.9.Issues leading to investigation of metformin prescribing in children and adolescents 
As discussed previously (Chapter 1), due to the withdrawal of rimonabant in 2008 and 
sibutramine in 2010, there are several drugs that have been considered for potential obesity 
treatment. Of these drugs, metformin has been recommended as the best choice of drug for the 
treatment of obesity as these patients are more likely to have metabolic syndromes (e.g. 
diabetes) (Viner et al., 2005). Therefore, the popularity of metformin for obesity therapy in 
clinical practice may have increased. In addition, there is no evidence on its use in children and 
adolescents from general practices in the UK. Therefore, the prescribing trend for metformin 
and the indications for its use in the primary care setting were examined and are reported in 
the next section.  
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4.3.Metformin prescribing patterns to young people in primary care in the UK 
4.3.1.Introduction  
Metformin is the most commonly prescribed oral anti-diabetic drug for diabetes mellitus (DM) 
in children and adolescents in the UK (Hsia et al., 2009). As metformin has been shown to be 
effective in reducing testosterone levels and improving irregular menstrual cycles (Harwood 
et al., 2007), it has also been prescribed for the treatment of polycystic ovarian syndrome 
(PCOS) in women of reproductive age (Ehrmann, 2005; Mastorakos et al., 2006).  In two large 
randomised controlled trials (RCTs) metformin was shown not to be more efficacious than 
placebo in adult women with PCOS (Moll et al., 2006; Legro et al., 2007), whereas its 
effectiveness in treating PCOS in adolescent girls has been shown in several RCTs (Ibáñez et 
al, 2004; Bridger et al., 2006; De Leo et al., 2006). However, in contrast to these findings, a 
recent RCT did not show benefit from metformin treatment along with lifestyle modification 
in adolescents with PCOS (Hoeger et al., 2008). For both women and adolescent girls there is 
still controversy regarding metformin use in the treatment of PCOS. However, despite the 
controversy, metformin is still recommended as one of the therapeutic options for PCOS in 
teenage girls (Harwood et al., 2007).  
 
In addition to its use in treating PCOS, studies have shown that metformin is associated with 
moderate BMI reduction in obese non-diabetic adolescents (Rogovik et al., 2010; Park et al., 
2009). In the UK, metformin is licensed only for children aged over 10 years with type 2 
diabetes who have failed strict dieting (BNFC, 2011). At present, metformin is not licensed for 
the treatment of PCOS or obesity in adults or children in the UK (BNFC, 2011; BNF, 2011; 
SPC). Little is known about the extent to which this drug has been used in young people in UK 
primary care. Therefore, this study was conducted to examine metformin prescribing patterns 
in children and adolescents in the UK primary care setting.  
 
 
 
 
 
 151 
 
4.3.2.Methods 
A retrospective cohort study was conducted using the IMS Disease Analyzer (IMS DA) 
database which was described earlier in this thesis (Chapter 4.3.1). This cohort study consisted 
of children and adolescents aged <19 years registered with a GP who contributed data to the 
IMS DA between January 2000 and December 2010. All subjects needed to have a minimum 
of six months’ valid data in the database; this is to ensure that patients were not temporarily 
registered with a practice in the database. Age bands were based on a modification of the 
International Conference of Harmonization (ICH) classification as follows: < 2, 2-11, 12-15 
and 16-18 years (Rose & Stotter, 2007).  
 
Annual prevalence of metformin prescribing was calculated as the total number of subjects 
with at least one prescription of metformin during each year of investigation divided by the 
total number of person-years in the same year, using Poisson distribution with a 95% 
confidence interval and stratified by age and gender. A Chi-square test (Cochran-Armitage test 
for trend) was used to examine the yearly trend of metformin prescribing. As IMS DA directly 
links prescriptions to medical indications, the following were examined for metformin 
prescriptions: diabetes (ICD10 E10-E14), PCOS (E282), and obesity (E66). Analyses were 
carried out using Stata/MP version 11.0 (College Station, TX, USA).  
 
4.3.3.Ethical Approval  
The IMS study protocol presents in Appendix 8 and approval for this study was granted by the 
IMS Independent Scientific and Ethical Advisory Committee (see Appendix 9).  
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4.3.4.Results 
A total of 2,674 metformin prescriptions were issued to 337 children and adolescents for all 
indications, between January 2000 and December 2010. The majority of patients who received 
metformin were female (80%; 270/337).  There were no metformin prescriptions issued to 
children aged less than 2 years. More female adolescents aged 12-18 years received metformin 
than other age groups (Table 4.7). The overall annual prevalence of metformin prescribing 
increased from 0.03 per 1000 person-years (95% CI 0.02 to 0.05) in 2000 to 0.16 per 1000 
person-years (95% CI 0.12 to 0.20) (p=0.001) in 2010 (Figure 4.12).  
 
There were 290 patients with at least one diagnosis of DM, PCOS and/or obesity in their 
medical records, of which 235 patients were female (81%) (Table 4.8). Of these 290 patients, 
120 female patients were prescribed metformin for the treatment of PCOS and obesity. Also 
there were 23 female patients with diagnoses of DM, PCOS and obesity who received 
metformin treatment during the study period. There were 22 patients (7.6%; 22/290) who were 
prescribed metformin for obesity treatment alone. A total of 47 patients were prescribed 
metformin without either a specific diagnosis or relevant diagnosis; after scrutinising their 
medical records, the most common diagnosis for prescribing was “unknown and unspecified 
causes of morbidity”. As the IMS DA only contains data from GPs, there are no hospital 
records in the database to verify diagnoses for these prescriptions. 
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Table 4.7: Age and gender of patients in cohort by calendar year, 2000 to 2010 
 
 Aged <2 Aged 2-11 Aged 12-15 Aged 16-18  Person-years for total study population*  
Year Boys Girls Boys Girls Boys Girls Boys Girls Total Boys Girls Total 
2000 0 0 2 4 0 3 1 10 20 266,537.2 257,100.8 523,638.0 
2001 0 0 1 9 1 3 5 18 38 265,419.0 256,182.8 521,601.7 
2002 0 0 4 5 2 7 1 18 37 263,778.0 254,243.0 518,020.9 
2003 0 0 7 5 7 10 3 29 61 258,312.5 248,746.9 507,059.4 
2004 0 0 5 7 6 15 2 38 73 244,468.2 235,088.5 479,556.7 
2005 0 0 5 6 5 9 5 34 64 233,251.9 223,886.7 457,138.6 
2006 0 0 7 8 5 9 5 41 75 226,924.2 218,008.5 444,932.7 
2007 0 0 1 6 4 11 3 41 66 219,137.0 210,379.6 429,516.6 
2008 0 0 4 6 1 15 10 29 65 211,939.1 203,246.9 415,186.0 
2009 0 0 2 4 3 14 7 28 58 201,208.5 192,740.3 393,948.8 
2010 0 0 3 3 3 13 5 34 61 191,773.4 183,644.6 375,418.0 
  *Person-years: the sum of the number of years contributed by the total population in the database aged 0-18 years, during each year of the study period (1999-2006).  
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Figure 4.12: Annual prevalence of metformin prescribing in children and adolescents aged 0-18 years by calendar year 
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Table 4.8: Total number of patients prescribed metformin for diabetes, polycystic 
ovarian syndrome (PCOS) and obesity between 2000 and 2010 
 
Diagnosis Number of patients 
 
 Boys Girls Total 
Diabetes only  
 
48 66 114 
Obesity only  
 
4 18 22 
PCOS and obesity 
 
NA 120 120 
Diabetes and obesity  
 
3 8 11 
Diabetes, PCOS and obesity 
 
NA 23 23 
NA: not applicable 
 
4.3.5.Discussion  
This study shows that the overall use of metformin in the paediatric population has steadily 
increased in primary care, with prescribing prevalence increasing from 0.03 per 1000 
person-years in 2000 to 0.16 per 1000 person-years in 2010. This increase was particularly 
marked amongst girls aged 12-18 years.  
 
There is limited data on paediatric metformin prescribing patterns in the UK. As some 
prescribing databases do not have links with indications for prescribing, an added strength 
of this study is that we were able to identify the disease indication for metformin therapy 
for the majority of patients. However, these findings are subject to some limitations. Firstly, 
the IMS DA only records prescriptions which issued in primary care and excludes 
prescriptions issued from hospitals so our data did not include the small number of 
prescriptions initiated by hospitals. Although the great majority of these would have been 
continued in primary care and so have been included in our study, unfortunately there are 
no data to investigate the extent of metformin prescribing in hospitals. Secondly, this study 
was unable to identify whether subjects were treated with lifestyle modification along with 
metformin, as healthy diet and exercise are mainstays of treatment for obesity, PCOS and 
type 2 diabetes (Mastorakos et al., 2006; Harwood et al., 2007). Thirdly, there was no 
information on the diagnostic criteria used for any of the conditions we investigated in this 
study. Diagnoses are often made in secondary care and the IMS DA does not record which 
criteria have been used to confirm diagnoses in primary care.   While diagnostic criteria for 
type 2 diabetes are internationally accepted, a number of different definitions exist for 
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obesity and PCOS. Fourthly, the IMS DA does not contain data on ethnicity and 
socioeconomic status, thus their impact on prescribing patterns could not be studied. 
 
The finding that PCOS with obesity was the main indication for metformin prescribing in 
female adolescents was unexpected. It has been well-documented that adolescent obesity 
is increasing in population-based studies in the US (Ogden et al., 2002) and also in the UK 
(Viner et al., 2009). In addition, a previous study has shown an increased prevalence of 
type 2 diabetes in adolescents aged 12-18 years in the UK (Hsia et al., 2009). Therefore, it 
is possible that the prevalence of PCOS in adolescents may also have increased. Although 
metformin has been shown to be of benefit in teenage girls with PCOS in a number of 
studies (Ibáñez et al., 2004; Bridger et al., 2006; De Leo et al., 2006), a recent RCT did not 
show benefit of metformin treatment in adolescents (Hoeger et al., 2008).  Therefore, its 
efficacy in treating PCOS remains controversial.   
 
There were a small number of patients who received metformin for the treatment of obesity 
only in this study. In October 2006, in Europe rimonabant was withdrawn due to serious 
psychiatric adverse reactions. And in January 2010, sibutramine was withdrawn from all 
markets in the EU due to the risk of adverse cardiovascular events in adults (EMEA 2011). 
Consequently orlistat is the only licensed anti-obesity drug for use in patients aged over 18 
years in the UK (BNF 2011; BNFC 2011; SPC). As there is currently a limited choice of 
drugs for obesity treatment, metformin may gain in popularity for obesity treatment. A 
current on-going clinical trial (ClinicalTrials.gov identifier: NCT01487993) has been 
carried out in the Netherlands to investigate short-term (18 months) and long term (36 
months) metformin treatment in obese children and adolescents aged ≥ 10 and ≤ 16. This 
study is expected to be completed by 2016 
(http://clinicaltrials.gov/ct2/show/NCT01487993). Furthermore, a UK-based clinical trial 
study (ClinicalTrials.gov identifier: NCT01273584) set up to investigate metformin use in 
obese non-diabetic pregnant women aged 19-50 years (MOP study) is currently recruiting 
patients. This clinical trial is expected to recruit 850 patients and be completed by 2014. 
The recruitment of MOP study was completed in July 2015 and there is no result being 
published at the time of writing this thesis. 
(http://clinicaltrials.gov/ct2/show/NCT01273584).   
 
After the withdrawal of sibutramine, orlistat is the only drug recommended for obesity 
treatment in children and adolescents with life-threatening co-morbidities in the NICE 
 157 
 
guideline (2006). However, gastrointestinal adverse reactions often limit its use. Compared 
with orlistat, metformin may be an alternative option for obesity treatment as it can improve 
hyperglycaemia, dyslipidaemia, and weight reduction (Charles et al., 2000; Glueck et al., 
2001). These beneficial effects will consequently reduce the risk of developing diabetes 
and cardiovascular conditions for obese children and adolescents in adulthood.  
 
4.3.6.Conclusion  
Metformin prescribing in children and adolescents for obesity, PCOS or diabetes treatment 
has increased substantially in the past decade. During this period, the number of teenage 
girls receiving metformin for PCOS treatment in general practice has increased, although 
it is not approved for use in this condition. Metformin is only approved for the treatment of 
type 2 diabetes in children aged over 10 years and in adults. However, its beneficial effects 
in improving insulin sensitivity and weight loss may increase metformin use for obesity 
treatment in clinical practice. Currently, the NICE guideline only recommends orlistat for 
obese children and adolescents (aged ≥ 12 years) with severe co-morbidities. As choice of 
drug for obesity treatment is limited, metformin use for weight reduction in this population 
requires further investigation.   
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Chapter 5 Anti-obesity drug prescribing patterns to obese young people 
in secondary care in the UK 
5.1.The efficacy of metformin on weight reduction in children and adolescents: a 
systematic review and meta-analysis from randomised controlled trials 
 
5.1.1.Introduction 
As discussed earlier (Chapter 1.5.4), a systematic review (Park et al., 2009) investigated 5 
RCTs on metformin treatment effect in children and adolescents without diabetes aged ≤ 
19 years (Freemark et al., 2001; Srinivasan et al., 2006; Atabek et al., 2008; Love-Osbome 
et al., 2008; Yanovski et al., 2008). This review showed that metformin reduced BMI by 
1.41 kg/m2 over 6 month’s treatment. Since this review was published, new RCTs 
investigating metformin use in obese children and adolescents have been published in 
recent years. Therefore, we undertook a systematic review of randomised controlled trials 
(RCTs) investigating the efficacy of metformin for reducing BMI in obese young people 
without diabetes.   
 
5.1.2.Aim and objective 
Aim: To investigate efficacy of metformin treatment on weight loss in obese young people 
from RCTs. 
Objective: To conduct a systematic review and meta-analysis to investigate metformin 
efficacy from published RCTs in non-diabetic children and adolescents aged 0-18 years 
 
5.1.3.Methods 
5.1.3.1.Literature search 
The following databases were searched for RCTs published from January 1996 to February 
2014: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials 
(CENTRAL). We also searched clinical trial registers: the metaRegister of Controlled 
Trials (www.controlled-trials.com), WHO clinical trials registry platform 
(http://www.who.int/ctrp/en) and the US Clinical trials registry 
(http://www.clinicaltrials.gov/). Hand searching was also carried out to examine the 
reference lists of the studies identified. Search strategies are presented in Table 5.1.  
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Table 5.1: Search strategy and search terms in each database 
 
Ovid MEDLINE 
1. Metformin or Glucophage or Riomet or Fortamet or Glumetza or Obimet or Dianben or Diabex or 
Diaformin  
2. exp Metformin/ 
3. 1 or 2 
4. obes$ or obesity 
5. Overweight or loss of overweight 
6. BMI or Body mass index or Body-mass-index or Weight for height or Weight-for-height or Weight to 
height ratio or Weight-to-height ratio or Weight height ratio or Weight-height ratio 
7. Weight gain or Weight loss or Weight management or Weight maintenance or Weight reduction or 
Weight decrease or Weight control 
8. Waist circumference or Waist measurement 
9. Body fat or Body fat percent$ or Percent$ body fat or Fat mass or Adiposity or Body composition 
10. Skinfold thickness or skin fold thickness or skin-fold thickness 
11. Hyperinsulin or Insulin resistance or metabolic risk or metabolic syndrome 
12. Dyslipid?emia or Hyperlipid?emia or Hypercholesterol?emia or Cholesterol or Total cholesterol or 
Low density lipoprotein cholesterol or LDL cholesterol or High density lipoprotein cholesterol or HDL 
cholesterol or Triglyceride$ 
13. Satiety or Hunger or Appetite or Binge eating 
14. ponderal index 
15. (adverse effect$ or adverse reaction$ or side effect$).tw. 
16. exp Obesity/ 
17. body weight changes/ or overweight/ 
18. Adipose Tissue/ 
19. exp "Body Weights and Measures"/ 
20. exp Hyperinsulinism/ 
21. exp Dyslipidemias/ 
22. exp Appetite/ 
23. or/4-22 
24. exp Child/ 
25. exp Adolescent/ 
26. juvenile 
27. exp Infant/ 
28. child$ 
30. infan$ 
31. teen$ 
32. P?ediatric$ 
33. Pediatrics/ 
34. or/24-33 
35. Randomi#ed controlled trial.pt. 
36. exp Randomized Controlled Trial/ 
37. exp Random Allocation/ 
38. exp Double-Blind Method/ 
39. exp Single-Blind Method/ 
40. Clinical trial.pt. 
41. exp Clinical Trial/ 
42. (clinical$ adj5 trial$).tw. 
43. (single or double or treble or triple) adj5 (blind$ or mask$)  
44. Placebos/ 
45. (placebo$ or random$).tw. 
46. research design/ 
47. Comparative study/ 
48. exp evaluation studies/ 
49. Follow-up studies/ 
50. Prospective studies/ 
51. Intention-to-treat.tw. 
 
52. Randomi#ed controlled trial 
53. Randomi#ed adj5 controlled 
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54. or/35-53 
55. 34 and 3 and 23 and 54 
56. limit 55 to humans 
Abbreviations: exp=exploded MeSH term; tw=textword; pt=publication type; adj=adjacency; dollar sign ($), asterisk (*) 
and percentage sign (%) =unlimited truncation; question mark (?)=optional wildcard. 
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EMBASE 
1. Metformin or Glucophage or Riomet or Fortamet or Glumetza or Obimet or Dianben or Diabex or 
Diaformin 
2. Metformin/ 
3. 1 or 2 
4. obese or obesity or overweight or adiposity or overeating 
5. BMI or Body mass index or Body-mass-index or Weight for height or Weight-for-height or Weight to 
height ratio or Weight-to-height ratio or Weight height ratio or Weight-height ratio 
7. Weight gain or Weight loss or Weight management or Weight maintenance or Weight reduction or 
Weight decrease or Weight control 
8. Waist circumference or Waist measurement 
9. (Body adj5 fat) or (Body adj5 fat adj5 percent$) or Percent$ body fat or Fat mass or Adiposity or 
Body composition 
10. Skinfold thickness or (skin adj5 fold adj5 thickness) or skin-fold thickness) 
11. waist adj5 hip adj5 ratio 
12. Hyperinsulin?emia or insulin resistance or metabolic risk 
13. Dyslipid?emia or Hyperlipid?emia or Hypercholesterol?emia or Cholesterol or Total cholesterol or 
Low density lipoprotein cholesterol or LDL cholesterol or High density lipoprotein cholesterol or HDL 
cholesterol or Triglyceride$ 
14. Satiety or Hunger or Appetite or (Binge adj5 eat$) 
15. appetite/ 
16. adverse effect$ or adverse reaction$ or side effect$ 
17. obesity/ 
18. body mass/ 
19. body weight/ 
20. or/4-19 
21. Clinical trial/ 
22. Randomized controlled trial/ 
23. Randomization/ 
24. Single blind procedure/ 
25. Double blind procedure/ 
26. Crossover procedure/ 
27. Placebo/ 
28. Randomi?ed controlled trial$.tw. 
29. Rct.tw. 
30. Random allocation.tw. 
31. Randomly allocated.tw. 
32. Allocated randomly.tw. 
33. (allocated adj2 random).tw. 
34. Single blind$.tw. 
35. Double blind$.tw. 
36. ((treble or triple) adj blind$).tw. 
37. Placebo$.tw. 
38. Prospective study/ 
39. or/21-38 
40. child/ 
41. adolescent/ 
42. pediatrics/ 
43. child$ 
44. adolescen$ 
45. infan$ 
46. teen$ 
47. p?ediatric$ 
48. juvenile 
49. or/40-48 
50. 39 and 49 and 3 and 20 
51. limit 50 to human 
Abbreviations: exp=exploded MeSH term; tw=textword; pt=publication type; adj=adjacency; dollar sign ($), asterisk (*) 
and percentage sign (%) =unlimited truncation; question mark (?)=optional wildcard. 
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Database 
Cochrane Central Register of Controlled 
Trials 
metaRegister of Controlled Trials 
“metformin”,  
AND  
“child*, adolescen*, teen*”  
AND  
“obes*, overweight”  
in Title, Abstract or Keywords 
Metformin 
AND  
(child% OR adolescen%)  
AND  
(obes% OR overweight) 
Abbreviations: exp=exploded MeSH term; tw=textword; pt=publication type; adj=adjacency; dollar sign ($), asterisk (*) 
and percentage sign (%) =unlimited truncation; question mark (?)=optional wildcard. 
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5.1.3.2.Eligibility and exclusion criteria 
The inclusion criteria for the systematic review were published double-blind randomised 
RCTs investigating the efficacy of metformin for BMI reduction in young people aged ≤19 
years without diabetes, with treatment duration ≥6 months. We excluded quasi-randomised 
open-label crossover trials and studies those published only in abstract form. There was no 
restriction on language. Primary outcomes of interest were BMI (kg/m2) reduction. 
Secondary outcomes included insulin sensitivity, fasting insulin (µU/mL), homeostatic 
model assessment insulin resistance (HOMA-IR), fat mass, blood pressure, fasting lipids, 
and adverse effects.  
 
5.1.3.3.Data extraction and quality assessment 
Two reviewers performed the electronic searches and screened the articles independently: 
YF Hsia and MH Park, a research fellow from London School of Hygiene and Tropical 
Medicine. Articles that clearly did not meet the eligibility criteria were rejected on initial 
review. Articles marked for potential inclusion were then obtained electronically or in paper 
copy, and assessed again for inclusion. Disagreements were resolved by discussion until a 
consensus was reached. The studies that deemed to meet inclusion criteria by both 
reviewers were included and appraised. The standard form included study design, blinding 
status, trial duration, mean age of participants, gender, number of participants in treatment 
and placebo group, interventions and the assessment of intention-to-treat (ITT) analysis. 
The QUOROM (Quality of Reporting of Meta-analysis) guideline was used for reporting 
our review.   
 
5.1.3.4.Measures of treatment efficacy and heterogeneity 
The primary outcome was expressed as change in BMI (kg/m2). The weighted mean 
differences for continuous outcome and risk difference for dichotomous outcomes at the 
end of study follow-up were calculated. The secondary outcomes of interest included body 
weight, fat mass, blood pressure, fasting lipids, and adverse effects. Where five or more 
studies reported a common secondary outcome, treatment effect was assessed in a meta-
analysis. To identify the potential causes of the statistical heterogeneity, sensitivity analysis 
was additionally performed based on the studies’ methodological quality. The meta-
analysis used a random effects model with RevMan 5.0.16 (Oxford, UK: The Cochrane 
Collaboration, 2007). The primary outcome analysis was based upon ITT data from the 
completion of the randomised trial, prior to any cross-over or open-label extension. Where 
standard deviations (SD) were not reported, these were obtained from standard errors, 
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confidence intervals, t values or P values that related to the differences between the means 
in two groups. The DerSimonian and Laird Q test was performed to assess the degree of 
heterogeneity between studies, and the I2 statistic was used to determine the percentage of 
total variation across studies due to heterogeneity.  
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Figure 5.1: Flow chart of selection and inclusion of papers for systematic review and  
meta-analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 166 
 
5.1.4.Results 
The extensive searching identified 738 studies between 1996 and 2013, of which 151 
studies were duplicated. A total studies were excluded after the title screening. We went 
through the abstracts of remaining 38 studies; 26 studies did not meet the inclusion criteria. 
The most common reasons for exclusion of studies were that the participants’ were aged>20 
years, or there was a different primary outcome. The full articles of the remaining 12 studies 
were retrieved (Figure 5.1). All 12 studies met the inclusion criteria (Freemark et al., 2001; 
Srinivasan et al., 2006; Love-Osborne et al., 2008; Atabek et al., 2008; Clarson et al., 2009; 
Wiegand et al., 2010; Yanovski et al., 2011; Rynders et al., 2011; Wilson et al., 2012; 
Mauras et al., 2012; Bernadette et al., 2012; Kendall et al., 2013). Six studies were 
conducted in the U.S. (Freemark et al., 2001; Love-Osborne et al., 2008; Rynders et al., 
2011; Yanovski et al., 2011; Wilson et al., 2012; Mauras et al., 2012;), and one each in 
Australia (Srinivasan et al., 2006), Germany (Wiegand et al., 2010), Chile (Bernadette et 
al., 2012), Canada (Clarson et al., 2009), and UK (Kendall et al., 2013).   
 
Details of the included studies are shown in Table 5.2. Sample size ranged from 16-120 
participants at randomisation. All trials lasted ≥6 months with metformin doses from 1,000-
2000 mg/day. Most studies included adolescents; though one US study (Yanovski et al., 
2011) looked only at younger children (aged 6-12years). Different lifestyle intervention 
programmes were undertaken such as diet, exercise, goal setting, or motivational support. 
Two studies did not undertake the lifestyle intervention in either trial arms (Freemark et al., 
2001; Srinivasan et al., 2006). Dosage of metformin varied in the different trials ranging 
from 1000mg to 2000mg per day. Some studies recruited participants of different ethnicity; 
in the U.S trials and Australia, most ethnic minorities were African American, Hispanic, or 
Asian (Freemark et al., 2001; Srinivasan et al., 2006; Love-Osborne et al., 2008; Yanovski 
et al., 2011). Wheras in the UK trial (Kendall et al., 2013), the majorityof the participants 
were white British although 24% wereethnic minorities from British Asian or Afro-
Caribbean backgrounds. 
 
The pooled analysis based on 12 studies, there is a statistically significant BMI reduction 
with metformin treatment compared to placebo of 0.64 kg/m2; (95% CI: -0.90 to -0.37; 
n=719) after 6 months use (Figure 5.2). Sensitivity analysis was conducted by removing 2 
studies with poorly rated qualities (Rynders et al., 2011; Bernadette et al., 2012), and the 
overall estimated effect was -1.25 mg/m2 (95%CI: -1.90 to -0.61), which remains 
statistically significant (p<0.0001).  
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Pooled metformin effect on the homeostasis model assessment of insulin resistance 
(HOMA-IR) was -0.84 (95% CI: -1.91 to 0.22) (I2 = 63%; n=592) in 9 studies, but the 
difference did not reach statistical significance (Figure 5.3). Reduction in fasting insulin 
was greater in metformin than placebo group in 9 studies, with a reduction of -4.15 µU/mL 
(95% CI: -7.96 to -0.34) (I2 = 57%; n=604) (Figure 5.4). Analyses did not provide strong 
evidence for a treatment effect on weight reduction, fasting glucose, cholesterol, or 
triglyceride level (Figure 5.5-5.8). Pooled metformin effect on HDL was 0.15 (95% CI: -
0.07 to 0.38) (I2 = 97%; n=640), and -0.03 (95% CI: -0.08 to 0.02) (I2 = 33%; n=526) if the 
US study by Freemark (2001) (outlier result) was excluded (Figure 5.9). 
 
Gastrointestinal problems (diarrhoea, nausea, and abdominal pain) were the most 
commonly reported adverse events and were more frequently reported in the metformin 
than in the placebo group. Two studies reported gastrointestinal problems as the reason for 
participants leaving studies (Love-Osborne et al., 2008; Wiegand et al., 2010). In addition 
to gastrointestinal adverse events, the German study also reported unspecific events such 
as weakness or fatigue for a short time though with spontaneous remission in both the 
metformin (n=3) and placebo (n=4) groups (Wiegand et al., 2010).  
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Table 5.2: Summary of randomised controlled trials (RCT) of metformin use for obese non-diabetic young people aged ≤19 
 
Study Country No of patients† Age 
(years) 
Length of 
treatment 
Daily dose 
(mg)   
Outcomes 
 
Lifestyle intervention 
Atabek et al. 2008 Turkey 120  (metformin: 
90; placebo: 30) 
9-17 6 months 500mg x 2 Reduction in BMI of 2.7kg/m2 in metformin 
group. 
Diet, exercise, behavioural therapy 
tailored  for individual patients 
Clarson et al. 2009  Canada 25 (metformin: 
11; placebo: 14) 
10-16 6 months 500mg x 3  Reduction in BMI of 1.8kg/m2 in metformin with 
lifestyle intervention group.  
Increased in BMI of 0.5 kg/m2 in lifestyle 
intervention only group.  
Lifestyle intervention (nutritional and 
exercise education and motivational 
support)   
Freemark et al. 2001 US 29 (metformin: 
14: placebo: 15) 
12-19 6 months 500mg x 2 Reduction in BMI of 0.5 kg/m2 with metformin 
treatment. 
BMI was increased of 0.9 kg/m2 in placebo 
group.  
No lifestyle intervention  
Love-Osborne et al. 
2008 
US 85 (metformin: 
60; placebo: 25) 
12-19 6 months 850mg x 2  Overall, there was no difference in BMI change; 
girls who have better adherence on metformin 
treatment with significant different  
Lifestyle intervention (personal goal 
setting). 
Srinivasan et al. 2006 Australia 22 (Metformin: 
10; placebo: 12) 
9-18 6 months 1000mg x 2 Reduction in BMI of 1.26kg/m2 and weight by 
4.35kg in metformin group.  
No lifestyle intervention 
Yanovski et al. 2011 US 100 (Metformin: 
45; placebo: 40) 
6-12 open-label 
metformin treatment 
(months 7-12) 
1000mg x 2 Reduction in weight of 3.38kg, and a reduction in 
BMI of 1.09kg/m2 in metformin group. 
Lifestyle intervention,  
Abbreviation: BMI: body mass index; BMI SDS: BMI Standard Deviation Score. . HOMA-IR: homeostatic model assessment insulin resistance. *Studies not included in Park et al. review paper. †No. of patients were those 
patients included in the final analysis in each study.  
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Continued  
Study Country No of patients† Age  
(years) 
Length of 
treatment 
Daily dose  Outcomes 
 
Lifestyle intervention 
Wiegand et al. 2010  Germany 70 (metformin:36; placebo: 34) 12-18 6 months 500mg x 2 No significant reduction in BMI in 
metformin group 
Lifestyle intervention  
Rynders et al. 2011 US 16 (metformin:9; placebo:7) 14.3±2.4 6 months 500mg x 2 (<12 years) 
 
1000mg x 2 (≥12 years) 
Reduction in BMI of 1.7kg/m2 with 
metformin and lifestyle intervention 
Lifestyle intervention (diet or 
exercise) 
Wilson et al. 2012 
(Glaser Pediatric 
Research Network) 
US 77 (metformin: 39; placebo:38) 13-18 48 weeks 2000mg Reduction in BMI of 0.9 kg/m2 with 
metformin and lifestyle intervention  
Reduction in BMI  of 0.2 kg/m2 with 
lifestyle intervention only 
Lifestyle intervention 
Mauras et al. 2012 US 42 (metformin: 23; placebo:19) 8-17  500mg x 2 (<12 years) 
 
1000mg x 2 (≥12 years) 
Reduction in BMI of 2.4 kg/m2 with 
metformin and lifestyle intervention  
Reduction in BMI  of 1.1 kg/m2 with 
lifestyle intervention only 
Lifestyle intervention (diet or 
exercise) 
Bernadette et al. 2012 Chile 19 (metformin: 10; placebo:9) 13-19 6 months 500 mg extended release 
daily 
Reduction in BMI of 1.85 kg/m2 with 
metformin and lifestyle intervention  
Reduction in BMI  of 1.5 kg/m2 with 
lifestyle intervention only 
Lifestyle intervention 
Kendall et al. 2013 
(MOCA trial) 
UK 151 (Metformin :74; Placebo: 77) 8-18 6  months 1500mg Reduction in BMI of 0.25kg/m2 with 
metformin and lifestyle intervention 
Increased in BMI of 0.21 in placebo group 
Lifestyle intervention (diet and 
exercise advice) 
Abbreviations: BMI, body mass index; BMI SDS, BMI Standard Deviation Score; HOMA-IR, homeostatic model assessment insulin resistance; MOCA, Metformin in Obese Children and Adolescents.†No. of patients were those 
patients included in the final analysis in each study.  
 170 
 
 
Figure 5.2: Forest plot comparing change in BMI (kg/m2) in metformin and placebo groups 
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Figure 5.3: Forest plot comparing change in homeostasis model assessment of insulin resistance (HOMA-IR) 
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Figure 5.4: Forest plot comparing change in fasting insulin (µU/mL) in metformin and placebo groups 
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Figure 5.5: Forest plot comparing body weight (kg) change in metformin and placebo groups 
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Figure 5.6: Forest plot comparing fasting glucose (mmol/litre) change in metformin and placebo groups 
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Figure 5.7: Forest plot comparing cholesterol (mmol/litre) change in metformin and placebo groups 
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Figure 5.8: Forest plot comparing triglycerides (mmol/litre) change in metformin and placebo groups 
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Figure 5.9: Forest plot comparing HDL (mmol/liter) change in metformin and placebo groups 
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5.1.5.Discussion  
In this updated systematic review and meta-analysis, 12 RCTs on metformin treatment in 
non-diabetic obese children and adolescents were included in the analysis. Compared with 
placebo, metformin reduced BMI by 0.64 kg/m2 (95% CI: -0.90 to -0.37) in this population. 
Fasting insulin was improved in the metformin-treated obese young people compared to 
those treated with placebo, with a reduction of 4.15 µU/ml (95% CI: -7.96 to -0.34), and 
no statistically significant heterogeneity amongst individual studies. Also there was a 
reduction of HOMA-IR in metformin treated obese young people [-0.84 (95% CI: -1.91 to 
0.22)] compared with the placebo group. There were no serious adverse reactions reported 
in any of the included studies. The most commonly reported adverse events were 
gastrointestinal problems.   
 
Comparison with other reviews 
This review included more trials and is current as of February 2014; the findings were 
consistent with previously published review that demonstrated a short-term metformin 
treatment effects on BMI reduction in non-diabetic obese young people. Whereas a 
previous meta-analysis of three studies reported no statistically significant change in BMI 
reduction in patients receiving metformin after 6 months [-0.17 kg/m2 (95% CI: -0.62 to -
0.28)] (McGovern et al., 2008). It needs to be addressed that the trials included in 
McGovern and colleagues systematic review ranging from 8-week trial (Kay et al., 2001) 
to 6-month trial (Freemark et al., 2001; Srinivasan et al., 2006). Another meta-analysis of 
five studies reported that metformin reduced BMI by 1.42 kg/m2 (95% CI: 0.83 to 2.02) 
after 6 months of treatment (Park et al., 2009). The most recent systematic review and meta-
analysis study which included 8 trials, which show a statistically significant BMI reduction 
by 1.40 mg/m2 (95% CI: -1.98 to -0.81) in the metformin-treated group  after 6 months 
treatment (McDonagh et al., 2014). However, this recent review study only included studies 
published from 1996 to December 2012, so it was not included in the MOCA trial in  UK 
(Kendall et al., 2013) and a RCT trial in Chile (Bernadette et al., 2012). When compared 
with orlistat a drug that is currently licensed for obesity, metformin has a smaller effect: 
meta-analysis of RCTs of orlistat reported an effect of -0.83 kg/m2 (95%CI: -0.47 to -1.9) 
after 6 months of treatment (Viner et al., 2009).  Also metformin may not be as effective 
as behaviour interventions in reducing BMI in obese young people as a Cochrane review 
which included 64 RCTs (5,230 participants) reported a BMI reduction of 3.04 kg/m2 (95% 
CI: -3.14 to -2.94) at 6 months with behavioural interventions alone in obese adolescents 
and this was maintained at 12 months follow-up (Oude et al., 2009).   
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Strengths and limitations 
A rigorous systematic review and meta-analysis was undertaken using 2 independent 
reviewers adhering to the established Cochrane Collaboration methodology. In addition, 
we included more recent trials in our review compared to a previous study which analysed 
only 5 RCTs in the review (Park et al., 2009).  However, our findings have several 
limitations which should be noted.  Firstly, there was moderate and significant statistical 
heterogeneity between studies for several of the metabolic parameters (e.g. HOMA-IR, 
fasting insulin, fasting glucose, HDL, triglycerides). It is likely that this heterogeneity is 
the result of differences in co-interventions and participants from different ethnic 
backgrounds (e.g. African American, Hispanic, Asian, Afro-Caribbean). The issue of 
heterogeneity between studies has been addressed in previous reviews (Bouza et al., 2012; 
McDonagh et al., 2014). Several sensitive analyses were performed in these two review 
studies but the cause of the heterogeneity remains unclear (Bouza et al., 2012). However, 
the reviewers did not have access to individual patient data to investigate the cause of this 
heterogeneity. Secondly, all trials that were included were conducted in s specialist care 
setting, so the generalisability of these findings to the general population remains unclear. 
Also, the participants included in the trials were very carefully selected obese young people, 
the results of which   are difficult to extrapolate to other populations. Thirdly, we only 
analysed data that were extractable from the publications of the studies and this may be a 
source of bias as studies may have only published secondary outcomes that differed 
significantly from the placebo. Fourthly, there was an absence of specific results such as 
sex, ethnic group, or socioeconomic level in individual studies. Therefore, we were unable 
to conduct stratified analyses based on these variables, which may have affected metformin 
treatment outcomes.  
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5.1.6.Conclusion 
Compared to placebo, metformin caused a decrease in BMI by 0.64 mg/m2 in non-diabetic 
obese young people from short-term RCTs after 6 months of treatment. Metformin may be 
efficacious in reducing BMI amongst obese children and adolescents in short-term RCT. 
However, this treatment effect may not be clinically relevant in terms of improving 
cardiovascular risk for obese young people. Further, RCTs with longer treatment periods 
and larger sample sizes are needed. In addition, it is difficult to extrapolate findings from 
RCTs to real-life clinical practice. Therefore, we conducted a prospective cohort study in a 
regional paediatric clinic to investigate the effect of metformin on weight loss in obese 
young people.  
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5.2.Drug prescribing patterns for obesity treatment in young people: experience in a 
regional paediatric weight management clinic 
 
5.2.1.Introduction 
As discussed in Chapter 1, the 2006 NICE guidelines recommended that drug treatment for 
obesity should be initiated by a specialist at a secondary care clinic, for children and 
adolescents aged ≥12 years, with life-threatening co-morbidities or severe psychological 
co-morbidities. However, there is currently no published evidence on drug use for obesity 
treatment initiated in secondary care in the UK. Therefore, a cohort study was conducted 
to investigate drug prescribing patterns for obesity treatment at a regional paediatric weight 
management clinic.  
 
5.2.2.Aim and objectives  
A retrospective cohort study to determine the effect of metformin treatment on weight 
status in obese young people aged 10-18 years treated in a paediatric weight management 
clinic in the UK National Health Service (NHS). The specific objective was to compare 
BMI, BMI standard deviation score (SDS), and weight change for obese patients who 
received metformin  with lifestyle intervention (exercise advice and healthy eating) to 
patients who received lifestyle intervention alone after 6 months of treatment.  
 
5.2.3.Methods 
5.2.3.1.Data collection and handling  
Data were retrospectively collected at a paediatric weight management clinic at UCLH 
between January 2007 and December 2010. Data collection was conducted by two final 
year pharmacy students, Reema Patel and Iao Choe Lei, from the Centre for Paediatric 
Pharmacy Research (CPPR), UCL School of Pharmacy (previously known as the School 
of Pharmacy, University of London). As this study involved accessing patients’ clinical 
records which could be considered a violation of patient confidentiality, if undertaken by 
non-UCLH staff, both pharmacy students had an honorary contract approved from UCLH 
before commencing data collection. Patients’ data were only accessed within UCLH 
premises under the supervision of Dr Billy White3 and the investigator.   
 
Information was mainly obtained from the Clinical Data Repository (CDR) which is a form 
of electronic medical records consisting of information that includes a patient identifier, the 
                                                 
3 Dr.Billy White-Clinical Research Fellow at University College London Hospital.  
  182 
patient’s date of birth, postcode, demographic information (e.g. sex, ethnicity), medical 
treatment, out-patient appointments, and clinical correspondence related to all patients 
under the care of UCLH. At each clinic appointment, patients attending the paediatric 
weight management clinic had their weight and height measured by nurses and these 
measurements were recorded in paper-based medical records. All obese patients who 
attended the paediatric weight management clinic at UCLH were given lifestyle 
intervention, including advice on exercise and on healthy eating from a dietician (lifestyle 
intervention). In addition to lifestyle intervention for managing obesity, other treatment 
options would also be discussed with patients and their families based on each patient’s 
medical and psychological conditions. For those patients with significant morbidities, drug 
treatment (e.g. orlistat, sibutramine) would be prescribed together with lifestyle 
intervention. Insulin resistance was measured using oral glucose tolerance test (OGTT) at 
the clinic. For patients with insulin resistance syndrome, metformin was prescribed together 
with lifestyle intervention (Viner & Nicholls, 2005). However, data on insulin resistance 
were not available in this analysis. After the completion of each clinic visit, medical doctors 
summarised the consultation and wrote a letter to each patient’s GP (which included the 
patients’ height and weight). These letters were also available on the CDR. In the CDR 
database, ethnicity was grouped into six categories: White British, Black, Asian, mixed, 
other ethnic group, and not stated.  
 
Each patient’s postcode was mapped to the Index of Multiple Deprivation 2007 (IMD) 
(http://www.communities.gov.uk/documents/communities/pdf/576659.pdf) using the 
Geographical Information System (GIS) methods for individual patients 
(http://geoconvert.mimas.ac.uk/index.htm). Detailed information on the IMD domain 
indicators are provided in Appendix 11. The steps to obtaining IMD are presented in 
Appendix 12. The IMD is the UK Government’s official measure of deprivation on a small 
area level, which is widely used as the current standard measure of deprivation (Jordan et 
al., 2004). The IMD is based on information from seven domain indicators: income, 
employment, health and disability, education, skills and training, barriers to housing and 
services, crime, and living environment (http://www.communities.gov.uk). The IMD 
assigns a score of overall deprivation based on the characteristics of a geographical unit 
called Super Output Area (SOA) (http://www.communities.gov.uk).  
 
There are three layers of SOA: lower layer, middle layer and upper layer. The middle 
Supper Output Area (SOA) and the upper SOA tend to have diverse populations as the data 
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analysed are from larger areas. The Office for National Statistic (ONS) has decided that 
there was not enough interest to generate the upper SOA data 
(http://www.ons.gov.uk/ons/index.html). In this study, the Lower SOA (LSOA) was used. 
The advantage of using the LSOA is that population data and deprivation scores are 
obtained from the smallest area, and populations will be more homogeneous in small areas 
and have similar levels of deprivation. LSOA can then be grouped into deprivation deciles 
(10 groups) or quintiles (5 groups). Compared to quintiles the deciles give a more precise 
picture of deprivation and are more useful for further inequalities analysis as the larger 
number of groupings provides a more accurate indication of deprivation. The ten deciles of 
the IMD are given below: 
 
1. Most deprived (Decile 1) : IMD rank between 1 and 3248 
2. Second most deprived (Decile 2): IMD rank between 3249 and 6496 
3. Third most deprived (Decile 3): IMD rank between 6497 and 9745 
4. Fourth most deprived (Decile 4): IMD rank between 9746 and 12993 
5. Fifth most deprived (Decile 5): IMD rank between 12994 and 16241 
6. Sixth most deprived (Decile 6): IMD rank between 16242 and 19489 
7. Seventh most deprived (Decile 7): IMD rank between 19490 and 22737 
8. Eighth most deprived (Decile 8): IMD rank between 22738 and 25986 
9. Ninth most deprived (Decile 9): IMD rank between 25987 and 29234 
10. Least deprived (Decile 10): IMD rank between 29235 and 32482 
 
BMI was calculated using the formula: weight in kilograms divided by the square of height 
in meters (kg/m2). The BMI Standard Deviation Score (SDS) was calculated from weight 
and height by adjusting for age and gender by using British 1990 reference data (Cole et 
al., 1995). The ImsGrowth programme was used for BMI SDS calculation 
(http://homepage.mac.com/tjcole). The ImsGrowth programme is a Microsoft Excel “add-
in programme” using Excel 2000 with Visual Basic for Application (VBA). This 
programme was designed to analyse the growth data according to age and sex, and it was 
developed by Professor Tim Cole at UCL Institute Child Health.4  
 
For each individual patient, a unique identification code was allocated to provide 
anonymity. Data were inputted into a Microsoft Excel spread sheet (Microsoft Corporation, 
Washington, US) during data collection. The excel spread sheet was then imported into 
Stata/MP 11 (StataCorp, College Station, Texas, US) for data cleaning purposes. The 
                                                 
4ImsGrowth is available to be downloaded from http://www.healthforallchildren.co.uk/. 
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dataset for analysis was stored on a secure sever at CPPR and it was only made available 
to the main researcher-Yingfen Hsia, who analysed the data.  
 
5.2.3.2.Statistical analysis 
The results were analysed using descriptive statistics, by use of Stata/MP software. 
Frequency of results was analysed using cross tabulation.  
 
5.2.4.Ethical considerations 
This study was a service evaluation to investigate drug prescribing to young people at the 
UCLH paediatric weight management clinic. Ethical approval was granted by UCL School 
of Pharmacy Ethics Research Committee (Appendix 10).  Approval for the study was 
sought and received from, Professor Russell Viner at the UCLH paediatric weight 
management clinic. 
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5.2.5.Results 
A total of 1,231 clinic appointments were captured for 301 patients (57% girls; n=173) aged 
10-18 years during the 4-year study period, with a median number of clinic appointments 
per patient of 3 (interquartile range 4). Table 5.3 shows the baseline characteristics of the 
whole study population by gender. The overall mean age of the study population was 
14.2±2.2 years at baseline (14.3±2.1 years for boys and 14.1±2.2 years for girls). Ethnicity 
had been recorded for 272 patients but for 29 patients their ethnicity was recorded as “not 
stated”. One hundred and eighty patients (180/301; 59.8%) were White British, 36 patients 
(36/301; 11.2%) were Black (e.g. African, Caribbean, other Black), 27 (27/301; 8.9%) 
patients were Asian (e.g. Pakistani, Indian, Bangladeshi, other Asian), 22 (22/301; 7.3%) 
were mixed race, and 7 (7/301; 2.3%) were from other ethnicities. The overall mean BMI 
(with standard deviation; SD) at baseline was 36.9±8.2 kg/m2 and the overall mean BMI 
SDS was 3.3±0.8. In boys, the mean BMI at baseline was 37.7±8.5 and 36.5±7.9 in girls. 
The mean BMI SDS at baseline was 3.4±0.6 and 3.2±0.8 in boys and girls, respectively.   
 
Metformin was the drug most frequently prescribed for obesity treatment in both sexes. A 
total of 183 (60.7%; 183/301) patients in the study population had received a drug for 
obesity treatment during the study period. Of these, 166 (90.7%; 166/183) patients had 
received metformin. The number of patients who received orlistat and/or sibutramine for 
treatment was relatively low (Table 5.1). Based on the IMD score of LSOA, most patients 
were living in the most deprived areas (decile 1 and decile 2) compared to living in the least 
deprived area (decile 10).  
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Table 5.3: Baseline characteristics of study cohort (aged 10-18 years) between 2007 
and 2010 at the UCLH paediatric weight management clinic 
 Boys  Girls   Total   
Number of patients (%) 128 173 301 
Age (year) 14.3±2.1 14.1±2.2 14.2±2.2 
Ethnicity % (n)      
British White  60.2 (77) 59.5 (103) 59.8 (180) 
Black  11.7 (15) 12.1 (21) 11.9 (36) 
Asian† 7.0 (9) 10.4 (18) 8.9 (27)  
Mixed 7.0 (9)  7.5 (13) 7.3 (22) 
Other ethnic group 0.8 (4)  1.7 (3) 2.3 (7) 
Not stated 10.9 (14) 8.7 (15) 9.6 (29) 
Weight (kg) (n=285) 106.1±29.9 96.4±25.7 100.5±27.9 
Height (cm) (n=285) 167.0±12.5 161.8±9.5 164.0±11.2 
BMI (kg/m2) (n=285) 37.7±8.5 36.5±7.9 36.9±8.2 
BMI SDS (n=285) 3.4±0.6 3.2±0.8 3.3±0.8 
BP (n=202)    
Systolic BP (mmHg)  129.1±13.9 125.7±16.2 127.0±15.4 
Diastolic BP (mmHg) 73.3±9.0 71.1±9.5 72.0±9.4 
Anti-obesity drug treatment‡ % (n) 
(n=183; 112 girls and 71 boys)     
Orlistat   7.0 (5) 13.4 (15)  10.9 (20)  
Sibutramine  11.3 (8)  14.3 (16)  13.1 (24) 
Metformin  93.0 (66)  89.3 (100)  90.7 (166)  
IMD 2007 decile % (n) 
(n=273)     
Decile 1(Most deprived) 19.3 (23) 11.0 (17) 14.7 (40) 
Decile 2 28.6 (34) 20.8 (32) 24.2 (66) 
Decile 3 10.9 (13) 21.4 (33) 16.9 (46) 
Decile4 12.6 (15) 11.0 (17) 11.7 (32) 
Decile 5 5.0 (6) 8.4 (13) 7.0 (19) 
Decile6 7.6 (9) 6.5 (10) 7.0 (19) 
Decile 7 3.4 (4) 7.8 (12) 5.9 (16) 
Decile 8 4.2 (5) 4.6 (7) 4.4 (12) 
Decile 9 3.4 (4) 3.3 (5) 3.3 (9) 
Decile 10 ( Least deprived) 5.0 (6) 5.2 (8) 5.1 (14) 
Data are presented as mean ±standard deviation. Abbreviations: BMI, body mass index; SDS, standard deviation score; 
BP, blood pressure; IMD, Index Multiple Deprivation. Black included: African, Caribbean, and other Black. †Asian 
included: Pakistani, Indian, Bangladeshi, and other Asian. ‡Total number of patients who received a drug for obesity 
treatment; patients may have received more than one anti-obesity drug during the study period.  
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Figure 5.10 shows that between 2007 and 2010, more patients received drugs (orlistat, 
sibutramine, metformin) together with lifestyle intervention than the number of patients 
who received lifestyle intervention alone. A total of 50 girls received drug treatment 
together with lifestyle intervention in 2007 and this increased to 65 girls in 2010. Similarly, 
23 boys received drugs together with lifestyle intervention for obesity treatment in 2007 
and this increased to 43 boys in 2010.  
 
Figure 5.10: Number of patients who received obesity treatment at paediatric  
weight management clinic 
 
 
*Drug treatment included: orlistat, sibutramine, or metformin. Lifestyle intervention included exercise advice 
and healthy eating advice from a dietician. Patients in lifestyle intervention group did not receive any drug  
for obesity treatment during study period. 
 
 
0
10
20
30
40
50
60
70
80
90
100
2007 2008 2009 2010
n
u
m
b
er
 o
f 
p
at
ie
n
ts
Girls:Drug+ lifestyle intervention* Girls: Lifestyle intervention
Boys:Drug+lifestyle intervention* Boys:Lifestyle intervention
  188 
Figure 5.11 demonstrates the increase in prescribing of metformin during 2007 and 2010. 
The number of patients who received metformin increased from 63 in 2007 to 105 in 2010. 
This increase in metformin prescribing was observed in both girls and boys. It indicates 
that the majority of patients in this study population may have metabolic syndromes. The 
number of patients who received orlistat and/or sibutramine was low during this period.       
 
Figure 5.11: Overall Number of patients who received anti-obesity drug  
treatment by year 
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Figure 5.12 shows the percentage of patients who received anti-obesity drugs by sex and 
age. There was a trend of rising anti-obesity drug prescribing with increasing age 
particularly in girls. The use of metformin in boys (n=66) was relatively low compared to 
girls (n=100) during the study period. As a high number of obese girls received metformin 
in this study population, there is a possibility that these obese girls may also have PCOS 
and/or diabetes.    
 
 
Figure 5.12: Percentage of patients who received an anti-obesity drug,  
by age and sex, 2007-2010 
 
 
Percentage was calculated by dividing the number of patients who received an anti-obesity drug (orlistat, 
sibutramine, metformin) for each age and sex by the total number of patients in the study population of the 
same age and gender multiplied by 100.  
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5.2.6.Discussion  
This is a large cohort study from a regional paediatric weight management clinic 
investigating drug prescribing patterns for obesity treatment in the UK from 2007-2010. 
The patients in this study population were mainly girls from a White British background. 
The study subjects were obese with an overall mean BMI of 36.9 kg/m2 and a mean BMI 
SDS of 3.3 at baseline. In addition, boys were observed to have a greater BMI and BMI 
SDS than girls. From the IMD decile, it was shown that most study subjects were living in 
the most deprived areas. The association between obesity and deprivation has long been 
recognised in adults and in children (National Institutes of Health, 1985; Sanjay et al., 
2000). A recent national study has demonstrated again the strong association between 
prevalence of childhood obesity and deprivation in England (Conrad & Capewell, 2012).  
 
Between 2007 and 2010, there were more patients who received drugs (e.g. orlistat, 
sibutramine, metformin) together with lifestyle intervention (e.g. exercise, diet) for obesity 
treatment compared to those patients who received lifestyle intervention only and had never 
received drug treatment for obesity. The release of the NICE guidelines in 2006 may have 
changed the prescribing behaviour of specialists in the secondary care setting in the UK 
during this study. However, this explanation should be further examined as we only 
investigated the drug prescribing practice from one regional specialist clinic so it is not 
possible to generalise to other clinical centres across the UK.   
 
Metformin was the most frequently prescribed drug for obesity treatment especially in 
teenage girls at this regional specialist clinic. It is problematic to compare this prescribing 
pattern with the results in primary care (Section 4.3.4). The data in secondary care were 
collected from 2007 to 2010 and the study investigating metformin prescribing in primary 
care was between 2000 and 2010. Further investigation into metformin prescribing in both 
primary care and secondary care at the same period of time is needed, as this will determine 
whether metformin use for obesity treatment in young people will continue increase in 
clinical practice. At present, metformin is only licensed for treatment of type 2 Diabetes 
Mellitus (DM) in children over 10 years old and also adults. The high number of patients 
who received metformin may indicate that most patients may have metabolic syndromes 
such as DM and/or PCOS in girls.  Due to the absence of co-morbidity data, it is not known 
what types of metabolic syndrome coexisted with obesity or how many patients had 
metabolic syndrome in this study population. 
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5.2.7.Conclusion 
This study provides an insight into the current practice of anti-obesity drug use in young 
people at the UCLH paediatric weight management clinic. Between 2007 and 2010, more 
patients received a drug(s) together with lifestyle intervention (exercise and healthy eating 
advice) for obesity treatment compared to the number of patients who received lifestyle 
intervention only. This prescribing practice at this specialist care clinic may be attributed 
to the release of the NICE guideline on weight management in children in 2006.  Metformin 
was the most frequently prescribed drug for obesity treatment and its use increased with 
age especially in adolescent girls.  
 
5.2.8.Issues leading to additional analyses of the effect of metformin treatment on 
weight loss  
As a high number of patients received metformin for obesity treatment in this study, this 
raises a question about the effect of metformin treatment on weight loss. As discussed in 
Chapter 1, due to the limited choice of drugs, several potential drugs have been used for 
obesity treatment. Of these potential drugs, metformin has been considered the best choice 
of drug for obesity treatment (Hundal & Inzucchi, 2003). Although metformin has not been 
licensed for weight reduction in either adults or children to date, it is important to gain a 
firm understanding of its treatment effect in weight loss in young people, as our study has 
shown that it is widely used to treat obesity in this population. Therefore, the aim of the 
next section of this chapter was to investigate the effectiveness of metformin treatment in 
obese young people in real-life practice. An observational study was conducted to 
determine the effect of metformin treatment on weight loss in this population. The 
additional analyses carried out are presented in the next section.  
 
 
  192 
5.3.The effect of metformin treatment on weight reduction in young people 
5.3.1.Introduction 
As described in 5.1, there have been several RCTs of metformin treatment in obese children 
and adolescents without diabetes. However, it is not possible to extrapolate findings from 
RCTs to real-life clinical practice as study participants are highly selected in clinical trials. 
From the previous analysis in Section 5.2, it was shown that a high number of obese 
paediatric patients received metformin for obesity treatment. Therefore, an observational 
study was subsequently conducted to determine the effect of 6 months of treatment with 
metformin on weight loss in young people.  
 
5.3.2.Aim and objectives 
The aim of this study was to determine the treatment effect of metformin on weight 
reduction in young people aged 10-18 years in a real-life practice. The specific objective 
was to compare BMI, BMI SDS, and weight change for obese patients who received 
metformin together with lifestyle intervention (exercise advice and healthy eating) with 
patients who received lifestyle intervention but who did not receive drug treatment, after 6 
months of treatment.   
 
5.3.3.Study population  
The study population in this additional analysis was derived from the previous cohort study 
population (n=301). Figure 5.13 shows the number of patients throughout the study. There 
were 18 patients who received orlistat and/or sibutramine for obesity treatment, these 
patients were excluded from the final analyses as we did not intend to investigate the 
treatment effects of these drugs in these analyses. Of the remaining 283 patients, 3 patients 
with less than 6-months of follow-up, 98 patients who had only one clinic appointment, and 
3 patients without baseline measurements were excluded. The remaining 179 patients 
formed the sub-cohort for the final analyses. These patients were classified into two groups: 
metformin and lifestyle group (n=127) and the lifestyle only group (n=52). 
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Figure 5.13: Patient flow: patients with six months follow up during study period 
(2007-2010) 
 
 
 
301 patients were included in the cohort population (aged 10-18) 
Lifestyle group 
(n=52) 
127 patients included in the 
six month analysis; based on 
intention to treat (ITT) 
52 patients included in the six 
month analysis; based on 
intention to treat (ITT) 
283 patients were included in sub-cohort for additional analysis 
Patient excluded:  
-18 patients received orlistat 
and/or sibutramine 
Patients excluded: 
-3 patients with less than six months of 
follow up data 98 patients with only one 
clinic visit  
-3 patients without baseline 
measurements  
179 patients in sub-cohort for 
final analysis 
Analysis 
Stratification  Metformin and lifestyle group 
(n=127) 
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5.3.4.Statistical Analyses 
The demographics and baseline characteristics of the subgroup cohort were described for 
the metformin and lifestyle intervention group and the lifestyle intervention group. 
Differences in baseline variables in the two groups were tested by using the independent t-
test for continuous variables and the χ2-test for categorical variables. Data were analysed 
on an Intention-To-Treat (ITT) approach regardless of compliance (Hollis & Campbell, 
1999). Outcomes of BMI, BMI SDS, and weight were post-treatment at 6-month follow-
up. These outcomes were tested for normality by using Kolmogorov-Smirnov tests. 
 
Analyses incorporated corrections for missing data on BMI, BMI SDS, and weight, using 
Multiple Imputation (MI). The MI model was under a “missing at random” (MAR) 
assumption. The detailed discussion of imputing missing data is presented in the following 
section. All available baseline and 6 months follow-up measurements were included in the 
imputation models. The final model was fitted on the basis of multiple imputed datasets 
using Rubin’s rules to combine effect estimates and estimate standard error (Rubin, 1987).  
 
The adjusted mean values on outcomes were adjusted for baseline values using linear 
regression. The mean differences in BMI, BMI SDS, and weight between groups were 
analysed using paired t-test at the end of the 6-month follow-up. All analyses used a 2-
tailed test with P value <0.05 for statistical significance. Stata/MP 11 (StataCorp, College 
Station, Texas, US) was used for all analyses.  
 
5.3.4.1.Missing data handling 
Missing data are a major concern in epidemiological studies, particularly when data need 
to be collected from individual patients. Inadequately handling missing data in statistical 
analysis will lead to biased estimates for the outcome of interest. The first step for handling 
missing data is to understand what and why variables are missing in the dataset. Little and 
Rubin’s framework (2002) has been commonly used to classify the type of missing data. 
There are three types of missing data mechanism (‘missingness’ mechanism): missing 
completely at random (MCAR), missing at random (MAR) and missing not at random 
(MNAR). The definitions of MCAR, MAR and MNAR are defined below (Little & Rubin, 
2002; White et al., 2009; Sterne et al., 2009):  
 
 Missing completely at random (MCAR): There are no systematic differences 
between the missing values and the observed values.  
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 Missing at random (MAR): Any systematic difference between the missing values 
and the observed values can be explained by differences in observed data.  
 Missing not at random (MNAR): Even after the observed data are taken into 
account, systematic differences remain between missing values and observed 
values.  
 
The ‘missingness’ mechanism is only an assumption based on observed data in the database 
needs to be addressed, and this assumption can then provide guidance on data analysis.  
 
The traditional statistical approach for missing data is to remove individuals with 
incomplete values (e.g. complete case analysis) by using “listwise deletion” or “casewise 
deletion” (Fitzmaurice, 2008). The last observation carried forward (LOCF) is another 
common approach to deal with missing data, especially in obesity studies (Gadbury et al., 
2003). The LOCF is used to impute the missing value with the individual’s last observation. 
It is based on the assumptions that the missing value has not changed from the previous 
measurement (Wood et al., 2004). All these traditional approaches may lead to a reduction 
of precision estimates in statistical analysis. 
 
In recent years, several advanced statistical techniques such as maximum likelihood- 
Expectation–Maximization (EM) algorithm, single random imputation, and multiple 
imputation (MI) have become increasingly popular in medical research due to software 
development (Mackinnon, 2010). In general, these statistical techniques replace missing 
data with estimates from observed values which overcome the limitations of the traditional 
approaches. Each of these techniques has their advantages and disadvantages. However, as 
detailed information for individual statistical techniques is beyond the scope of this thesis, 
the following discussion is restricted to multiple imputations which was used in this study.   
 
 
 
 
 
MI is used to impute (or fill in) missing values by using a regression model based on the 
individual’s data (Wood et al., 2004). The advantage of using MI is that it takes all 
variances into account to generate more reliable estimates compared to the traditional 
methods (Wood et al., 2004; Sterne et al., 2009). Figure 5.14 shows the process of MI. The 
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MI works by imputing the missing values, with predications from observed data, multiple 
times. This step will create a set of complete datasets with no missing values. The analysis 
is then run individually on each dataset and the final results are combined across the entire 
data set using Rubin’s combination rule (Rubin, 1987).  
 
Figure 5.14: Multiple imputation process 
 
In this study, as the dataset contained missing values, it warranted comprehensive data 
cleaning prior to final analysis. The data cleaning process for this study was broken down 
into the following steps:  
 
Step 1: To describe missing variables and assess the ‘missingness’ mechanism.  
There were 1152 records for the variables (BMI, BMI SDS, blood pressure) captured in 
this sub-cohort population (n=283).  The percentage of missing values for each variable 
ranged from 15.9% to 48.3% (Table 5.4). For blood pressure measurements, values were 
not recorded for approximately half of the patients in the dataset.   
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Results 2 
Analysis/ 
Results X 
Combination of results 
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Table 5.4: Percentage of missing records in study cohort 
Variable name Description  No. of missing 
records 
% missing 
Weight  Weight measured at each clinic visit 183 15.9 
Height  Height measured at each clinic visit 183 15.9 
BMI  Calculated from weight and height 183 15.9 
BMI SDS Calculated from ImsGrowth programme 183 15.9 
Systolic blood pressure Blood pressure measured at each clinic visit  556 48.3 
Diastolic blood pressure Blood pressure measured at each clinic visit 556 48.3 
Abbreviations: BMI, body mass index; SDS, standard deviation score.  
 
The ‘missingness’ mechanisms of BMI, BMI SDS, and weight were examined between 
patients without missing records and patients with missing records. As blood pressure was 
not the main outcome of interest in this study, those missing blood pressure records were 
not included in the multiple imputations. As the ‘Missing At Random’ (MAR) is defined 
as ‘any systematic difference between the missing values and the observed values can be 
explained by difference in observed data’ (Sterne et al., 2009). The missing pattern in our 
study population appears to be MAR as patients without missing records have lower BMI, 
BMI SDS, and weight compared to patients with missing values in both sexes (Table 5.5). 
This may be due to extremely obese patients being more reluctant to be measured than 
patients with a lower BMI.  
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Table 5.5: Description of the ‘missingness’ mechanisms in study cohort 
 
Patients with missing records Patient without missing records 
 Mean (s.e.)  Mean (s.e.) 
Boys  Boys  
BMI  39.87±0.66 BMI 37.63±0.59 
BMI SDS 3.47±0.04 BMI SDS 3.33±0.04 
Weight  120.88±2.40 Weight 106.11±1.99 
    
Girls   Girls  
BMI  37.12±0.59 BMI 35.67±0.38 
BMI SDS 3.18±0.07 BMI SDS 3.19±0.04 
Weight 97.09±1.45 Weight 94.62±1.22 
      Abbreviations: BMI, body mass index; SDS, standard deviation score. s.e., standard error.  
 
The best approach for dealing with the MAR pattern of missing values is the Multiple 
Imputation by Chained Equation (MICE) procedure (Schafer & Graham, 2002). The MICE 
procedure is also known as the “fully conditional specification” or “sequential regression 
multiple imputation” (Azur et al., 2011). This is a flexible approach as it can handle 
variables of varying types such as continuous or binary (Raghunathan et al., 2001; Azur et 
al., 2011). The MICE approach is particularly useful for handling missing data in a large 
dataset as missing data may occur in different types of variables. Therefore, the MICE 
procedure has become a popular approach in recent years, for handling multiple 
imputations (Royston and White 2011). The MICE package is implemented in Stata 
software. In this study, the MICE procedure was used for imputing missing values on BMI, 
BMI SDS, and weight. 
 
 
Step 2: To examine the normality of the data distribution between the metformin-treated 
group and the non-pharmacologically treated group, before carrying out the MI procedure. 
The two-sample Kolmogorov-Smirnov test was used to examine whether there were 
differences in the distributions of BMI, BMI SDS, and weight between the two groups.  
Figure 5.15 shows that there were no significant differences in the distribution of BMI, 
BMI SDS, and weight values, between the two groups.    
 
  
  199 
Figure 5.15: Distribution of recorded BMI, BMI SDS, and weight between the 
metformin and lifestyle group and the lifestyle group before multiple imputation 
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Smaller group        D             P-value               Corrected 
 ---------------------------------------------------------------------------------- 
 1:                   0.0318      0.938 
 2:                  -0.1636    0.186 
 Combined K-S:      0.1636      0.369                      0.297 
 
Two-sample Kolmogorov-Smirnov test for equality of distribution: BMI SDS 
Smaller group         D             P-value               Corrected 
 ----------------------------------------------------------------------------------- 
 1:                   0.0091     0.995 
 2:                  -0.1955     0.091 
 Combined K-S:      0.1955      0.181       0.134 
 
Two-sample Kolmogorov-Smirnov test for equality of distribution: Weight 
Smaller group         D         P-value    Corrected 
 ------------------------------------------------------------------------------------ 
 1:                          0.0864      0.626 
 2:                         -0.1591     0.204 
 Combined K-S:    0.1591      0.404       0.330 
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Step 3: To impute missing values for BMI, BMI SDS, and weight using the MICE 
approach. The Stata command for the MICE approach is ‘ice’. In the imputed dataset, it 
includes incomplete variables (e.g. BMI, BMI SDS, weight, height) as well as complete 
variables (e.g. sex, age, treatment condition). In general, 5 to 10 imputed datasets are 
considered to be enough to achieve high efficiency (Rubin, 1987). In recent years, it has 
been recommended that more imputation such as 20 imputations (m=20) or 100 imputations 
(m=100), will be beneficial (Graham et al, 2007). However, more imputations will increase 
the computational effort. In this study, twenty copies of imputed datasets (m=20) were 
created. The imputation procedure in the Stata programme is given below: 
 
 
 
 
  
. ice gender met weight1 weight2 bmi2 sds_bmi2, gen(m_) 
saving("mi_20", replace) m(20) seed(29390) 
 
   #missing | 
     values |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          0 |        112       87.50       87.50 
          3 |         16       12.50      100.00 
------------+----------------------------------- 
      Total |        128      100.00 
 
   Variable | Command | Prediction equation 
------------+---------+-------------------------------------------
------------ 
     gender |         | [No missing data in estimation sample] 
        met |         | [No missing data in estimation sample] 
    weight1 |         | [No missing data in estimation sample] 
    weight2 | regress | gender met weight1 bmi2 sds_bmi2 
       bmi2 | regress | gender met weight1 weight2 sds_bmi2 
   sds_bmi2 | regress | gender met weight1 weight2 bmi2 
------------------------------------------------------------------ 
Imputing 
..........1..........2..........3..........4..........5..........6 
......7..........8..........9..........10..........11..........12.
.........13..........14..........15..........16..........17.......
...18..........19.....> .....20 
file mi_20.dta saved 
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Step 4: To examine the imputed data and observed data to ensure that the imputed data are 
reasonable. The graphs are presented for the imputed data and the observed data for BMI, 
BMIS SDS, and weight (see Appendix 13). The Two-sample Kolmogorov-Smirnov test 
was used to examine whether the imputed data and the observed data were normally 
distributed. The summary statistics of mean, median and inter-quartile range (IQR) are 
presented for BMI, BMI SDS, and weight in Table 5.6. This shows that the imputed data 
were very similar to those from observed data. The imputed data in the final dataset appear 
reasonable for final analysis.  
 
Step 5: To analyse the multiple imputed data. After the imputations were created and the 
examined imputed data were reasonable, the 20 imputed datasets were used for the final 
analyses. As mentioned earlier, the analysis was run individually within each complete 
dataset then the results were combined using Rubin’s rules.     
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Table 5.6: Summary statistics for BMI, BMI SDS and weight, from recorded data and imputed data at 6 month follow-up period 
 
 Recorded data at 6 months Imputed data at 6 months 
Metformin and lifestyle group Mean (s.e.)  Median  IQR (IQR range) Mean (s.e.) Median  IQR (IQR range) 
  BMI 37.77±0.48 36.06 7.56 (32.92-40.48) 37.77±0.46 36.21  7.69 (32.92-40.61) 
  BMI SDS 3.41±0.04 3.38 0.66 (3.10-3.76) 3.41±0.03 3.38 0.67 (3.09-3.76) 
  Weight  102.52±1.63 99.20 29.4 (86.30-115.70) 102.51±1.58 99.27 29.7 (86.30-115.98) 
Lifestyle group       
   BMI 35.67±0.72 34.82 9.51 (31.39-40.90) 35.69±0.69 34.87 9.59 (31.34-40.93) 
   BMI SDS 3.19±0.08 3.22 0.80 (2.90-3.70) 3.19±0.08 3.21 0.80 (2.89-3.69) 
   Weight  98.62±2.83 98.00 43.90 (77.10-121.0) 98.56±2.73 97.88 40.71 (78.03-118.74) 
               Abbreviation: BMI, body mass index; SDS, standard deviation score; IQR, inter-quartile range; s.e, standard error. IQR is the difference between first quartile (Q1) and third quartile (Q3).IQR is 
calculated as Q3minus Q1.  
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5.3.5.Results  
5.3.5.1.Baseline characteristics of sub-cohort subjects 
Table 5.7 shows the baseline characteristics of the sub-cohort (n=179) and the two 
treatment groups. There were more girls than boys in both groups. Over half of the patients 
were White British in the metformin and lifestyle group (63.8%) and the lifestyle group 
(63.5%). Mean BMI SDS was 3.4 in metformin group which indicates that these patients 
were extremely obese, and it was significantly higher than that of the lifestyle group. There 
were no other significant differences between the groups for baseline demographic, weight, 
height, BMI, or blood pressure (systolic and diastolic).  
 
In this sub-cohort study, the IMD distribution showed that more patients were living in the 
more deprived areas (decile 1=14.5%; decile 2=24%) than in the less deprived deciles 
(decile 9 =2.2%; decile 10=3.9%). This was similar in both groups and there was no 
significant difference between the groups (p=0.51).   
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Table 5.7: Comparison of baseline characteristics of patients (aged 10-18 years) 
between treatment groups 
 
 Sub-cohort  
(n=179) 
Metformin and lifestyle  
(n=127) 
Lifestyle  
(n=52) 
Statistic P-value 
Age (year) 13.9 (2.11) 13.9 (2.12) 13.8 (2.09) t=0.2 0.86 
Gender % (n)    χ2=1.0 0.31 
Girls  55.9 (100) 58.3 (74) 50.0 (26)   
Boys  44.1 (79) 41.7 (53) 50.0 (26)   
Ethnicity % (n)    χ2=7.5 0.18 
British White  63.7 (114)  63.8 (81) 63.5 (33)   
Black  11.2 (20) 10.2 (13) 13.5 (7)   
Asian 7.3 (13) 8.7 (11) 3.8 (2)   
Mixed 7.3 (13) 9.4 (12 ) 1.9 (1)   
Other ethnic group 2.2 (4) 1.6 (2) 3.8 (2)   
Not stated  8.4 (15) 6.3 (8) 13.5 (7)   
Weight (kg) (n=154) 100.6 (26.0) 101.6 (25.2) 97.9 (28.01) t=0.85 0.40 
Height (cm) (n=154) 163.9 (11.7) 163.6 (11.6) 164.8 (12.0) t=-0.61 0.54 
BMI (kg/m2) (n=154) 37.0 (7.3) 37.6 (7.2) 35.5 (7.4) t=1.76 0.08 
BMI SDS (n=154) 3.3 (0.7) 3.4 (0.5) 3.2 (0.9) t=2.27 0.02* 
BP (n=128)      
Systolic BP (mmHg)  127.7 (16.6) 127.9 (18.2) 127.1 (11.6) t=0.23 0.81 
Diastolic BP (mmHg) 72.7 (9.7) 73.8 (9.9) 70.2 (8.7) t=1.89 0.06 
IMD 2007 decile % (n) 
(n=163)    
χ2=8.3 0.51 
Decile 1 (Most deprived) 14.5 (26 ) 14.2 (18 ) 15.4 (8)   
Decile 2 24.0 (43) 23.6 (30) 25.0 (13)   
Decile 3 15.1 (27) 14.9 (19) 15.4 (8)   
Decile 4  9.5 (17) 7.9 (10) 13.5 (7)   
Decile 5 6.1 (11) 5.5 (7) 7.7 (4)   
Decile 6 5.6 (10) 5.5 (7) 5.8 (3)   
Decile 7 6.1 (11) 7.9 (10) 1.9 (1)   
Decile 8 3.9 (7) 5.5 (7) 0.0 (0)   
Decile 9 2.2 (4) 3.1 (4) 0.0 (0)   
Decile 10 (Least deprived) 3.9 (7) 3.9 (5) 3.8 (2)   
Abbreviation: BMI, body mass index; SDS, standard deviation score; BP, blood pressure; IMD, Index Multiple 
Deprivation. Patients in each group all received lifestyle intervention (e.g. dietician for healthy eating advice and medical 
advice).The figures are presented as means±s.d (standard deviation), or number % (n) percentage of total. Significant 
differences of values are indicated as *P<0.05. 
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5.3.5.2.Within-group change 
The effects of metformin treatment together with lifestyle intervention and those of lifestyle 
intervention alone are shown in Table 5.8. In the metformin and lifestyle group, both boys 
and girls experienced a significant reduction in BMI SDS at the end of the 6 month period 
of treatment. However, whereas the girls had a significant reduction in BMI with metformin 
treatment and lifestyle intervention (p=0.001) the boys (p=0.38) did not. The patients’ body 
weights were slightly increased in both the metformin and lifestyle intervention group and 
the lifestyle group. After adjustment for baseline weight, there was significant increase in 
weight for both boys and girls in the metformin and lifestyle group. In the lifestyle group, 
there were no significant changes in either BMI or in weight for both boys and girls. 
However there was a significant reduction in BMI SDS for boys (p<0.0001) but a 
significant increase of BMI SDS for girls (p<0.0001) in the lifestyle group.  
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Table 5.8: Within-group changes at 6 months of treatment 
 
 Baseline mean  Adjusted Mean  Mean change P value 
Metformin and lifestyle group     
All (n=127)     
  BMI (kg/m2) 37.65 ± 0.45 37.55 ± 0.26 -0.10 (0.05)    0.03* 
  BMI SDS 3.42 ± 0.03 3.38 ± 0.02 -0.04 (0.03)    <0.0001** 
  Weight (kg) 101.64 ± 1.58 102.79 ± 0.61 +1.15 (0.15)    <0.0001** 
  Height (cm) 163.64 ± 0.72 164.76 ± 1.04 +1.12 (1.26)    0.37 
Boys (n=53)     
  BMI (kg/m2) 38.17 ± 0.74 38.29±0.66 +0.12 (0.14)    0.38 
  BMI SDS 3.45 ± 0.05 3.42 ± 0.07 -0.03 (0.01)    0.01* 
  Weight (kg) 108.24 ± 2.66 109.76 ± 1.47 +1.52 (0.42)    0.0004** 
  Height (cm) 167.75 ± 1.28 169.5±1.79 +1.75 (2.19)    0.42 
Girls (n=74)     
  BMI (kg/m2) 37.28 ± 0.57 36.99 ± 0.43 -0.29 (0.08)    0.001** 
  BMI SDS 3.40 ± 0.05 3.33 ± 0.04 -0.07 (0.01)   <0.0001** 
  Weight (kg) 96.91 ± 1.84 98.16 ± 0.99 +1.25 (0.24)   <0.0001** 
  Height (cm) 160.70 ± 0.76 161.33 ± 1.08 +0.63 (1.32)    0.63 
Lifestyle group      
All (n=52)     
  BMI (kg/m2) 35.55 ± 0.72 35.52 ± 0.72 -0.03 (0.14)    0.83 
  BMI SDS 3.17 ± 0.09 3.22 ± 0.05 +0.05 (0.01)    0.001** 
  Weight (kg) 97.98 ± 2.73 98.61 ± 1.49 +0.63 (0.43)    0.15 
   Height (cm) 164.82 ± 1.17 165.89 ± 1.62 +1.07(1.99)    0.59 
Boys (n=26)     
  BMI (kg/m2) 36.78 ± 0.88 36.90 ± 0.89 +0.12 (0.25)    0.63 
  BMI SDS 3.36±0.08 3.27 ± 0.07 -0.09 (0.02)    <0.0001** 
  Weight (kg) 104.22 ± 3.74 103.45 ± 2.14 -0.77 (0.84)    0.36 
  Height (cm)  167.22 ± 1.82 168.49 ± 2.55 +1.27 (3.13)    0.68 
Girls (n=26)     
  BMI (kg/m2) 34.30 ± 1.12 34.47 ± 1.42 +0.17 (0.35)    0.63 
  BMI SDS 2.97 ± 0.16 3.13 ± 0.08 +0.16 (0.03)    <0.0001** 
  Weight (kg) 91.74 ± 3.82 92.01 ± 2.58 +0.27 (0.90)    0.76 
  Height (cm) 162.43 ± 1.42 163.28 ± 1.92 +0.85 (2.38)    0.72 
Abbreviation: BMI, body mass index; SDS, standard deviation score. Figures represent means± standard error. Patients in each 
group all received lifestyle intervention (e.g. dietician for healthy eating advice and medical advice). The 6-month follow up 
data were calculated based on the intention-to-treat (ITT) with imputed datasets. Adjusted mean was adjusted from baseline 
value using linear regression for multiple imputation data. Significant differences of values are indicated as *P<0.05 or **P<0.01. 
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5.3.5.3.Between-group changes  
Table 5.9 shows the between-group changes. Overall, there were no significant between-
group differences for BMI, BMI SDS, weight, and height. The height was increased in both 
the metformin and lifestyle group and also in the lifestyle group, as well as in both sexes, 
but this increase was not significantly different between the two groups. However, there 
was a significant effect of metformin treatment with lifestyle intervention on BMI SDS in 
girls compared to only lifestyle intervention [difference between metformin and lifestyle 
group and lifestyle group: -0.23; 95% CI -0.28 to -0.18, p<0.0001].  There was a significant 
increase of BMI by 0.12 mg/m2 and of weight by 1.52 mg/m2 in boys after 6 months of 
metformin treatment.  
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Table 5.9: Between-group changes at 6 months treatment 
 
 Metformin and lifestyle  
(n=127)  
Lifestyle  
(n=52) 
Mean difference 
  (95% CI) 
P value*  
All      
  BMI (kg/m2) -0.10 (0.05) -0.03 (0.14) -0.07 (-0.38 to 0.16) 0.55 
  BMI SDS -0.04 (0.03) +0.05 (0.01) -0.09 (-0.18 to 0.003) 0.06 
  Weight (kg) +1.15 (0.15) +0.63 (0.43) +0.52 (-0.19 to 1.23) 0.15 
  Height (cm) +1.12 (1.26) +1.07 (1.99) +0.05 (-4.57 to 4.67) 0.98 
 Metformin and lifestyle 
(n=53)  
Lifestyle  
(n=26) 
Mean difference 
(95% CI) 
P value   
Boys     
  BMI (kg/m2) +0.12 (0.14) +0.12 (0.25) 0.0 (-0.53 to 0.53) 1.0 
  BMI SDS -0.03 (0.01) -0.09 (0.02) +0.06 (0.02 to 0.09) 0.003** 
  Weight (kg) +1.52 (0.42) -0.77 (0.84) +2.29 (1.07 to 3.51) 0.0004** 
  Height (cm) +1.75 (2.19) +1.27 (3.13) +0.48 (-7.12 to 8.08) 0.90 
 Metformin and lifestyle 
(n=74)  
Lifestyle 
(n=26) 
Mean difference 
(95% CI) 
P value   
Girls     
  BMI (kg/m2) -0.29 (0.08) +0.17 (0.35) -0.46 (-0.95 to 0.03) 0.06 
  BMI SDS -0.07 (0.01) +0.16 (0.03) -0.23 (-0.28 to -0.18) <0.0001** 
  Weight (kg) +1.25 (0.24) +0.27 (0.90) +0.98 (-0.34 to 2.30) 0.14 
  Height (cm)  +0.63 (1.32) +0.85 (2.38) -0.22 (-5.44 to 5.00) 0.93 
Abbreviations: BMI, body mass index; SDS, standard deviation score; CI, confidence interval. The figures are presented as means and s.e (standard error). The 6-month  
follow up data were calculated based on the intention-to-treat (ITT) with imputed datasets. Mean difference: metformin and lifestyle group minus lifestyle group.  
Significant differences of values are indicated as *P<0.05 or **P<0.01. 
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5.3.6.Discussion 
This cohort study sought to determine the effect of metformin treatment combined with 
lifestyle intervention on weight loss in obese young people treated in the NHS. In this non-
randomised controlled clinic-based sample, we found that metformin treatment together 
with standard care lifestyle advice resulted in a statistically significant decrease of BMI 
SDS in both boys and girls and a reduction of BMI in girls compared to baseline. When 
compared with standard care alone, the metformin group had a small but significant 
increase in BMI and BMI SDS loss at 6 months in girls, but a very slightly statistically 
significant increase in BMI SDS amongst boys.  
 
Strength and limitations 
This is the first known observational study to investigate metformin treatment in obese 
young people at a regional specialist clinic in the UK or elsewhere. However, this study is 
subject to several methodological limitations.  Firstly, as the data were collected from one 
paediatric weight management clinic, our findings cannot necessarily be generalised. 
However, given that the clinic used is one of the largest in the UK, findings are likely to be 
similar in other specialist paediatric weight management services seeing young people of 
comparable BMI. Secondly, our estimated metformin treatment effect may be biased by the 
differences in baseline risk for other underlying factors and/or other treatment 
interventions. This limitation is due to the absence of information on co-morbidities, co-
prescribing medication, and other interventions (e.g. psychological intervention) that 
patients may also have received for obesity treatment. An observational study is widely 
used to investigate drug treatment effects in routine clinical practice, as this type of study 
design allows a broader population of patients to be included which may sometimes be 
excluded from RCTs (e.g. young children, patients with severe co-morbidities) (Klungel et 
al., 2004). The main concern in assessing the effect of drug treatment in observational 
studies is confounding factors. It has been suggested that sufficient baseline information 
should be collected to analyse confounding by pre-existing differences, when comparing 
treated and untreated groups in an observational study (Jepsen et al., 2004; Stürmer et al., 
2007). A variety of individual or group therapies (e.g. psychological intervention, 
behavioural therapies) have been recommended for weight management (NICE 2006). 
Young people are also likely to be undertaking a range of self-initiated actions such as self-
directed diets, exercise programmes or involvement in commercial weight management 
programmes. However, we do not have information on other weight management activities 
young people in the clinical cohort had self-initiated. Thirdly, the data on waist 
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circumference were not available from the records as this is not measured routinely in the 
clinic. Thus, the impact of metformin on change in visceral adiposity could not be assessed. 
The study did not have access to adequate data on cardiometabolic risk for this study cohort. 
The data obtained in the study were not of sufficient quality to be used in these analyses 
due to very high levels of missing data. Therefore, we were unable to investigate whether 
metformin improved cardiometabolic risk in these obese young people, nor whether those 
with insulin insensitivity responded better to metformin than those with normal insulin 
sensitivity.  
 
A further limitation is missing data for the BMI outcomes. All patients should have had 
their weight and height recorded before each consultation. However, there was a relatively 
high proportion of missing measurements for weight and height in the current database. 
There are two possible reasons for missing measurements in the present study: (i) clinical 
procedures; (ii) patient refusal. Weight and height are normally measured by nurses at the 
clinic, and these measurements may sometimes not be recorded in patient’s medical notes. 
It was observed that patients with higher BMI have more missing measurements compared 
to patients with lower BMI. This suggests that some patients may refuse to be weighted at 
clinic, resulting in missing measurements in their medical notes. Finally, the study did not 
assess adherence or adverse effects as these data were not routinely collected in a usable 
form. Metformin dose in the present study was not examined. The data in the study were 
collected from a paediatric management clinic and we do not know the reasons patients 
changed metformin dosage during the 4-year study period. Data from real-life clinic 
practice are different from RCT data, as clinicians are required to follow a standardised 
protocol to adjust dosage use.  
  
Comparison with previous studies 
No comparable data on metformin treatment in routine NHS practice has been published in 
the UK. The only comparable data on metformin treatment effect come from RCTs, 
although patients in the RCT are usually highly selected and generally more motivated in 
terms of adherence. The reduction in BMI SDS of -0.23SD identified in girls at 6 months, 
equivalent to 0.46kg/m2 reduction in BMI, is less than the 1.4kg/m2 estimate of BMI 
reduction reported by the systematic review by Park et al (2009). It is however similar to 
the effect size reported in the only UK RCT, which reported that metformin resulted in a -
0.1SD (-0.18, -0.02) reduction in BMI SDS compared with placebo at 6 months (Kendall 
et al., 2013). We found an effect for metformin in girls but not boys in our study. This is 
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consistent with a US study by Love-Osborne and colleagues (2008). They reported a 
statistically significant reduction of BMI by 0.40 kg/m2 in girls with metformin (n=33) 
treatment compared with 1.04 kg/m2 in placebo group (n=9). This treatment effect was not 
seen in boys with metformin treatment. The authors gave several explanations: 1) this may 
represent true sex differences in the action of metformin; 2) the underlying differences in 
mechanism or degree of insulin resistance; 3) girls were more likely to report a decrease in 
portion size than boys when they were taking metformin or placebo (Love-Osborne et al. 
2008). However, the reasons for a sex difference in metformin response remain unclear to 
date. Further investigation is warranted on the metformin treatment effect on the gender 
difference in this population.  
 
5.3.7.Conclusion  
The data from this study suggests that metformin can be effective in reducing BMI in obese 
adolescent females over 6 months in routine clinical practice, although the benefits are less 
than those seen in RCTs. There was no evidence of benefit in obese young men. The effect 
size seen in clinical practice is small and of borderline clinical significance. However, any 
benefits no matter how small can be important in the difficult field of weight management, 
as they may presage gradual weight loss over time. Metformin is currently only licensed 
for the treatment of type 2 diabetes in adolescents and not specifically indicated for the 
treatment of obesity. The current evidence on metformin use for weight loss is based on 
small and short-term RCTs in young people. There is a clear need for longer larger scale 
RCTs in obese children and adolescents to meaningfully assess the place of metformin and 
identify subgroups most likely to benefit.  
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Chapter 6 Anti-obesity drug prescribing to young people in primary 
care and secondary care: a national questionnaire survey  
 
6.1.Introduction  
Clinical guidelines for prevention and treatment of obesity (Scottish Intercollegiate 
Guidelines Network, NICE) recommend a multicomponent approach for obesity treatment 
in obese young people in primary care. The recommendations for treating obese and 
overweight children in primary care include: 1) to measure height and weight and assess 
co-morbidities; 2) discuss weight issues and give advice to parents and/or guardian or 
carers; 3) treatment approaches include: lifestyle intervention, behavioural intervention, 
physical activity, and dietary advice; 4) pharmacological intervention should only be 
considered after above-mentioned approaches have been started and evaluated; 4) referral 
to appropriate specialist in secondary care. Pharmacological intervention used in childhood 
obesity management is described in Chapter 1, section 5. Pharmacological intervention is 
recommended for childhood obesity in the NICE guidelines for certain circumstances. 
Since the withdrawal of sibutramine, the more recent NICE guidelines suggest that orlistat 
should be considered a useful adjunct to lifestyle intervention in adolescents ≥12 years old 
with physical co-morbidities and that use in <12 years should be reserved for those with 
life-threatening co-morbidities (NICE 2006). The recently revised NICE recommendation 
on pharmacological intervention for obesity treatment in young people is presented in Table 
6.1.   
 
Sometimes lifestyle intervention change alone fails to achieve weight loss in young people, 
so the combination of lifestyle intervention and medication should be considered (August 
et al., 2008). However, lifestyle change remains the most appropriate intervention for 
childhood obesity management, but anti-obesity drugs together with lifestyle intervention 
may offer additional benefits for weight loss. A Cochrane review included 64 RCTs (5,230 
study participants) to investigate the efficacy of lifestyle intervention, anti-obesity drug and 
surgical interventions for childhood obesity treatment (Oude et al., 2009). The results of 
the Cochrane review support the consideration of pharmacological therapy as adjunct to 
lifestyle interventions in obese adolescents; however, the authors state that this approach 
needs to be carefully weighed against the potential adverse effects of drug treatment.  
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Table 6.1: Revised NICE guideline* recommendations for pharmacological 
intervention in children 
 
General: indications and initiation  
1. Pharmacological treatment should be considered only after dietary, exercise and behavioural approaches 
have been started and evaluated 
2. Drug treatment is not generally recommended for children younger than 12 years 
3. If children younger than 12 years, drug treatment may be used only in exceptional circumstances, if 
severe life-threatening comorbidities (such as sleep apnoea or raised intracranial pressure) are present. 
Prescribing should be started and monitored only in specialist paediatric settings.  
4. In children are aged 12 years and older, treatment with orlistat is recommended only if physical 
comorbidities (such as orthopaedic problems or sleep apnoea) or severe psychological comorbidities are 
present. Treatment should be started in a specialist paediatric setting, by a multidisciplinary team with 
experience of prescribing in this age group. 
5. Orlistat should be prescribed for obesity in children only by a multidisciplinary team with expertise in:  
 Drug monitoring 
 Psychological support 
 Behavioural interventions 
 Interventions to increase physical activity  
 Interventions to improve diet    
6. Orlistat should be prescribed only if the prescriber is willing to submit data to the proposed national 
registry on the use of these drugs in young people. 
7. After drug treatment started by specialist care, it may be continued in primary care if local circumstances 
and/or licensing allow. 
Continued prescribing and withdrawal  
1. Pharmacological treatment may be used to maintain weight loss, rather than for continued weight loss. 
2. If there is concern about the adequacy of micronutrient intake, a supplement providing the reference 
nutrient intake for all vitamins and minerals should be considered, particularly for vulnerable groups such 
as young people (who need vitamins and minerals for growth and development). 
3. Where drug treatment is being withdrawn, support should be offered on maintaining weight loss, as their 
self-esteem and belief in their ability to make changes may be low if target weight was not achieved.  
4. If orlistat is prescribed for children, a 6-12-month trial is recommended, with regular reviews to assess 
effectiveness, adverse effects and adherence.  
*Sibutramine was previously included in the NICE guideline. After the withdrawal of sibutramine in UK in 2010, the 
current NICE guidelines only recommend orlistat for obesity treatment in young people.  
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Childhood obesity is one of the highest health priorities in the UK. It is routine practice for 
general practitioners (GPs) to continue obesity management after recommendation from 
specialists in secondary care in the UK. Primary care has the potential to play a pivotal role 
in obesity management in the UK primary care setting (Epstein & Ogden 2005). In 2002, 
the National Service Frameworks issued by the Department of Health stated that primary 
care should “use every opportunity to promote healthy lifestyle, and should provide advice 
on diet, weight reduction, and exercise” (Department of Health 2002). Doctors regularly 
miss opportunities to discuss weight with their patients but there is good evidence that 
physician acknowledgement can trigger lifestyle changes (Post et al., 2011). In 2006, 
measurement of obesity using body mass index (BMI) for adults but not for children was 
included in the National Quality and Outcome Framework (QOF) scheme, as a pay-for-
performance scheme offering financial rewards to GPs for achieving targets in managing 
and measuring chronic disease (Roland 2004). The Department of Health published a care 
pathway for the assessment and management of overweight and obese young people and 
children in primary care, in order to assist practitioners tackling obesity in young people 
(Department of Health, 2006). The NICE guidelines on obesity management in adults and 
young people were first published in 2006 and had a strong focus on obesity management 
in primary care advocating dietary advice and increased physical activity as first line 
management. However, lifestyle interventions need to be intensive to achieve weight 
reduction and sustained to continue to be effective. This can pose particular challenges for 
managing obesity in children and adolescents and GPs who need to interact with the family 
as a whole (Matson & Fallon, 2012; King et al., 2007). In recent years, a number of studies 
have been conducted to examine practitioners’ views in managing childhood obesity in 
primary care (Jelalian et al., 2003; Goldman et al., 2004; Gerner et al., 2006; Spurrier et 
al., 2006; Walker et al., 2007; King et al., 2007; Turner et al., 2009; Gage et al., 2010). 
The majority of these studies were carried out in other countries (e.g. US, Australia); there 
is little published research on childhood obesity management in UK primary care (Walker 
et al., 2007; Turner et al., 2009; Gage et al., 2010).  
 
In the UK, an interview study of 12 GPs and 6 nurses working in a GP practice, contracted 
to Rotherham Primary Care Trust (PCT), has shown that GPs and practice nurses felt 
childhood obesity was sometimes a problem, which was difficult to address (Walker et al., 
2007). The authors expressed the difficulties in treating childhood obesity: they do not want 
to upset the child and parents by bringing attention to the child’s weight and concerns about 
breakdown in family relationships if the problem of a child’s weight is mentioned. Another 
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qualitative UK-based study was conducted after the publication of the childhood obesity 
care pathway and the NICE guidelines. In this study which was carried out in Bristol 30 
practitioners (12 GPs, 10 practice nurses, 4 school nurses, and 4 health visitors) from 7 
general practices were interviewed (Turner et al., 2009). All practitioners felt that they were 
concerned about the current childhood obesity epidemic, but none had seen the Department 
of Health’s obesity care pathway for young people. Only 2 GPs and 1 practice nurse had 
looked at the NICE obesity guideline.  A questionnaire survey of GPs and parents was 
conducted to explore their opinions on childhood obesity management in southern England. 
There was a clear difference between GPs and parents’ attitudes towards obesity 
management in children. Approximately one-third of responders (GPs and parents) agreed 
that GPs did not have the necessary expertise, or the lack of financial incentive was an 
inhibiting factor in child weight management (Gage et al., 2010). None of the UK-based 
studies investigated the role of pharmacological intervention for obesity treatment in their 
studies in children and young people.  
 
A previous report showed that in the primary care, the majority of anti-obesity drugs were 
discontinued within 3 months of initiation, even before reasonable weight loss would be 
expected (Viner et al., 2009). The reasons for this early discontinuation of anti-obesity 
drugs in young obese patients were unclear. Metformin has gained in popularity for obesity 
treatment in children and adolescents (Rogovik et al., 2010). The current evidence suggests 
that orlistat and metformin are the two most commonly prescribed drugs for obesity 
treatment in children and adolescents (Matson & Fallon 2012; Petkar & Wright, 2013). 
Several studies have been carried out to explore health practitioners’ views on childhood 
obesity management however most of the studies were conducted outside the UK. It is 
difficult to ascertain how generalizable the results from other countries are to the UK 
population. In addition, the research undertaken so far in this area has been limited to 
assessing the views of practitioners in general, and their experiences in prescribing anti-
obesity drug to young people have not been explored in detail. As a result, orlistat and/or 
metformin prescribing to treat young people with obesity across primary care and 
secondary care were examined through a questionnaire survey.  
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6.2.Aims and objectives:  
The aim of this chapter was to evaluate clinicians’ experiences and attitudes toward 
prescribing anti-obesity drug to obese young people in their clinical practice through 
questionnaires to patients’ GPs. There were four specific objectives:  
 
1) To gain better understanding of GP experiences on prescribing anti-obesity drug 
treatments to young people 
2) To gain better understanding of GP knowledge and skills on prescribing anti-obesity 
drugs 
3) To gain understanding of reasons for anti-obesity drug discontinuation. 
4) To identify key elements for future prescribing guide or intervention to support anti-
obesity drug prescribing in clinical practice 
6.3.Method: 
6.3.1.Data source 
Data from The Health Improvement Network (THIN) database were used to identify 
patients who received anti-obesity drug treatment. THIN covers approximately 5.7% of the 
UK population with 3.6 million active patients from 464 general practices (Cogedim 
Strategic Data Medical Research UK 2009). The practices included in the database are 
broadly representative of practices in the UK in respect of patients’ demographics and 
characteristics (Murray et al., 2013). GP surgeries participating in THIN are trained to use 
and enter medical records using the Vision general practice system (In Practice Systems; 
London, UK) (McCarthy et al., 2013).  Drugs are coded in the database using MULTILEX® 
codes (First DataBank; THIN). Diagnoses and symptoms are coded using READ code, a 
comprehensive hierarchical system (Chisholm 1990). Previous studies have confirmed the 
representativeness of the THIN population and the validity of diagnoses recorded in THIN 
(Lewis et al., 2007; Ruigómez et al., 2010). Prescription records within THIN are 
considered to be complete and accurate (Langley et al., 2010; McCarthy et al., 2012a,b; 
Murray et al., 2013). The questionnaire study is an additional validation service provided 
by THIN’s Additional Information Service (AIS) to assist researchers who require more 
detailed information that was not available from information recorded in the medical 
records.  
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6.3.2.Patient identification 
Patients who had a prescription record of either orlistat or metformin on the THIN database 
during the study period 31st May 2010 to 31st May 2012 were identified. This sampling 
timeframe provided the most recent data available at the time the study was initiated in 
April 2012. As the purpose of this study was to explore GPs’ experiences and opinions on 
medication used in obese young people, of those patients identified above, only those aged 
18 years or under during the study period were included.  
 
6.3.3.Questionnaire design and distribution  
The investigator YingFen Hsia in conjunction with Dr Billy White (a clinical research 
fellow), Dr Russell Viner (a consultant paediatrician), Dr Sonia Saxena (a general 
practitioner) and Prof Ian Wong (a pharmacoepidemiologist) design the questionnaires. 
YingFen Hsia entered and analysed the returned questionnaires. The questionnaire was 
designed to cover the following outcome of interests:  
 
1) Patients’ demographic details such as gender, year of birth, type of anti-obesity drug 
received, ethnicity, co-morbidities. 
2) Whether GP received advice from secondary/tertiary care team before the drug was 
initiated for obesity treatment; which assessment had been carried out before drug 
was initiated. 
3) GP’s experiences and opinion towards anti-obesity drug use for their patients.  
4) One question asked specifically how competent GPs felt towards prescribing 
orlistat or metformin in both adults and children. This question was scored on 10-
point Likert scale (one being not confident and 10 being very confident). 
5) There was one open-ended question asking GPs’ opinions on developing a guide to 
support anti-obesity drug prescribing in clinical practice.  
 
The final 14-item questionnaire was designed in a check box format. Respondents (GPs) 
were also given a choice to provide additional information using free text. For most 
questions, respondents were able to provide more than one answer.  
 
The questionnaire was sent to GPs by THIN’s AIS, a research company licensed to contact 
GPs for research purposes. The questionnaires were only administered to GPs in practices 
that were willing to participate in THIN research studies. The THIN staff contacted GPs up 
to three times over a 3 month period.  Investigators did not contact patients or GPs directly 
to maintain confidentiality. The THIN staff printed out the questionnaires and sent them 
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directly to GPs. All selected patients in the database had a unique patient identifier (patient 
ID code and encrypted practice ID code). The unique patient ID enabled the GP to identify 
the patient(s). Each GP was requested to complete the questionnaire for their patient(s) and 
send questionnaires back to THIN. The THIN staff ensured that full confidentiality of the 
GP practices and patients were maintained throughout the questionnaire data collection and 
return of results to the research group. Any personal information that could disclose doctor’ 
or patient’s identity was removed before forwarding a copy of the questionnaire to 
researchers. The original questionnaires were retained in the THIN. GPs received a 
payment for each questionnaire completed (£100).  
 
6.3.4.Data handling  
Returned questionnaires were anonymised and inputted into two Microsoft Access 
(Microsoft Corporation, Washington, US) databases for first and second entry by YingFen 
Hsia. Double entry was for data cleaning purposes and also checked for internal 
consistency. The two Access databases were then imported into Stata/SE version 11.0 
(Stata Corp, College Station, Texas, United States) to check any discrepancies. Each 
discrepancy identified was examined using the original questionnaire as a reference. 
YingFen Hsia conducted all the analyses of the returned questionnaires.  
 
6.3.5.Data analyses 
The overall aim of this study was to provide descriptive information on the current practices 
in childhood obesity treatment in primary care so descriptive statistics were used for each 
question in this survey study. Categorical variables were described as frequencies and 
percentages. Outcomes were tested for normality by using Kolmogorov-Smirnov tests. 
Continuous variables were reported using means and standard deviations (SD) for normally 
distributed variables and median and inter-quartile range (IQR) for non-parametric 
distributions. The drug treatment duration was calculated from the reported “date of first 
prescription” and “date of last prescription” in the questionnaires. Likert item scores were 
examined using Wilcoxon rank-sum test to investigate the confidence between prescribing 
medication to adults and children.  Responses to the one open-ended question which asked 
about development of a guide to support drug prescribing in clinical practice were explored 
for common themes. Thematic analysis, a qualitative research technique, was used to 
identify the recurring terms, statements or comments in the responses and organised into 
prospective categories (Braun & Clarke 2006). Results were also presented by individual 
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drug. For each question, the responses were analysed in respect of the numbers of 
questionnaires where the information for that question were completed by the GP.   
 
6.3.6.Ethical approval 
The National Health Service NRES Committee London- Surrey Borders Research Ethics 
Committee (REC reference: 11/LO/1020) granted ethnical approval for this study.  
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6.4.Results 
A total of 151 patients were identified to receive orlistat or metformin between 31st May 
2010 and 31st May 2012 (study period) in the database. One hundred and fifty-one 
questionnaires were sent to those patients’ GPs across the UK (England, Wales, Northern 
Ireland, and Scotland); 121 GP-completed questionnaires were returned. Of the 121 
patients, GPs returned 2 questionnaires for 6 of the patients as they had been receiving both 
orlistat and metformin during the study period. The response rate was high, with 80.1% 
(121/151) of the questionnaires returned. Only questionnaires in which the GPs confirmed 
their patient(s) received orlistat and/or metformin were considered valid for the study and 
were included in the final analyses. A flow chart of the process of identifying valid 
questionnaires is presented in Figure 1. A total of 114 GP-completed questionnaires were 
included in the final analyses in this study, though not all of the questions were answered 
on all of the questionnaires.  
 
The demographics of the patients are presented in Table 6.2. Of the 114 patients, 98 were 
female patients (86.0%) and 16 were male patients (14.0%). There were marginally more 
patients receiving orlistat (53.5%; n=61) than metformin (51.8%; n=59). The median age 
at first drug prescription was 17 years (IQR: 16-18) for female patients and 16 years (IQR: 
14-17) for male patients. Five patients received both orlistat and metformin at different time 
periods during our study period. The majority of respondents lived in England, of which 20 
(17.5%) were from the West Midlands and 17 from London (14.9%; 17/114). Thirteen 
patients were from Wales (11.4%; 13/114), 9 patients (7.9%; 9/114) were from Scotland, 
and 5 patients from Northern Ireland (4.8%; 5/114). The majority of patients were reported 
as White (78/114; 68.4%), although for nearly 20% of the patients (22/114; 19.3%) 
ethnicity was not specified.    
 
From GP reported duration, the mean duration of orlistat use was 1.7 months (IQR 0.5-8.5 
months) and 13.9 months (IQR 4.0-24.1 months) of metformin use. Of these 114 patients, 
only 68 patients (59.6%) had more than one weight and height measurement in the returned 
questionnaires. The summaries of GPs’ opinions and experiences on prescribing orlistat or 
metformin to their patients are presented in Table 6.3. Approximately 79% (48/61) of 
patients who received orlistat prescribed by their GPs without advice from 
secondary/tertiary care, whereas only 29% (17/59) of patients received metformin 
prescribed by GPs without advice from secondary or tertiary care. This indicates that 
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specialists from secondary/tertiary care initiated the majority of metformin prescriptions 
for obese young people.  
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Figure 6.1: Flow diagram to identify valid questionnaires 
 
 
 
 
 
 
 
 
 
 
 
 
  
121 patients’ questionnaires were returned (6 of these 
patients 2 questionnaires were returned) 
Excluded questionnaires:  
-GPs answered that patients did not receive 
orlistat or metformin but patients have 
prescription records in THIN database (n=5) 
-GPs responded patients were not eligible for 
this study and no information was provided 
(n=1) 
-GP returned 2 questionnaires for one patient 
received orlistat with different responses (n=1) 
114 patients’ questionnaires were included 
in the final analysis 
 
151 patients identified received orlistat or 
metformin in THIN database between 
31/05/2010 and 31/05/2012 
 
151 questionnaires sent to 82 GPs across the UK 
(England, Wales, Scotland, and Northern Ireland) 
Number of patients 
received metformin: 59 
Number of patients 
received orlistat: 61 
Number of patients 
received metformin and 
orlistat: 4  
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Table 6.2: Patient demographics in returned questionnaires 
 
Patient demographics Total number of patients 
(n=114) 
Gender   
   Female  98 (86.0%) 
   Male  16 (14.0%) 
Medication use  
   Median age (years) at 1st anti-obesity drug for female  17 (IQR: 16-18) 
   Median age (years) at 1st anti-obesity drug for male  16 (IQR: 14-17) 
   Number of patients received 1 anti-obesity drug 109 (95.6%) 
   Number of patients received more than 1 anti-obesity drug 4 (3.5%) 
   Number of patients received orlistat 61 (53.5%) 
   Number of patients received metformin  59 (51.8%) 
Country   
   England (by old NHS Strategic Health Authorities)   
    East of England  7 (6.1%) 
    North East 3 (2.6%) 
    North West 13 (11.4%) 
    South Central 15 (13.5%) 
    South East Coast 7 (6.1%) 
    South West 3 (2.6%) 
    West Midlands 20 (17.5%) 
    Yorkshire & Humber 2 (1.8%) 
    London  17 (14.9%) 
   Wales 13 (11.4%) 
   Scotland 9 (7.9%) 
   Northern Ireland 5 (4.8%) 
Reported ethnicity   
White  78 (68.4%) 
Non-White  
   Asian  2 (1.8%) 
   British African 1 (0.9%) 
   British Pakistani 3 (2.6%) 
   Caribbean 1 (0.9%) 
   Greek 1 (0.9%) 
   Indian 2 (1.8%) 
   Iranian  1 (0.9%) 
   Turkish 1 (0.9%) 
   Mixed 2 (1.8%) 
   Unknown  22 (19.3%) 
Abbreviations: IQR, inter-quartile range; NHS, National Health Service. *Strategic Health Authorities (SHAs): SHAs 
were organisations within the NHS in England that were responsible for developing and improving health services in their 
local areas (http://www.mstrust.org.uk/atoz/sha.jsp).  
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Table 6.3: GPs’ responses to each question on obesity treatment in young people 
Questions Orlistat Metformin  Total  
1. Question: What co-morbidities has this patient had?*  Number of respondents: 41 Number of respondents:43 Number of respondents: 84 
Hypertension  0 (0%) 1 (2.3%) 1 (1.2%) 
Hyperinsulinemia  0 (0%) 0 (0%) 0 (0%) 
Dyslipidaemia 2 (4.9%) 1 (2.3%) 3 (3.6%) 
Type 2 diabetes 3 (7.3%) 0 (0%) 3 (3.6%) 
Psycho-social distress (e.g. low self-esteem, teasing and bullying)  12 (29.3%) 4 (9.3%) 16 (19.0%) 
Mental and behavioural disorders† 13 (31.7%) 10 (23.3%) 23 (27.4%) 
Weight-related exacerbations of conditions such as asthma 7 (17.1%) 3 (7.0%) 10 (11.9%) 
Polycystic ovarian syndrome 7 (17.1%) 32 (74.4) 39 (46.4%) 
Metabolic syndromes‡  0 (0%) 4 (9.3%) 4 (4.8%) 
Orthopaedic/mobility issues related to weight  3 (7.3%) 2 (4.7%) 5 (6.0%) 
Others 7 (17.1%) 2 (4.7%)  9 (10.7%) 
2. Question: How was this medication initiated?     
 Q2.1: GP issued this medication without secondary/tertiary care advice Number of respondents: 48 Number of respondents: 17 Number of respondents: 65 
Which of the following did the patient receive before initiation of medication?     
A. General assessment*:    
1) Dietetic review  22 (45.8%) 6 (35.3%) 28 (43.1%) 
2) Lifestyle review 36 (75.0%) 8 (47.1%) 44 (67.7%) 
3) Medical causes of obesity  16 (33.3%) 4 (23.5%) 20 (30.8%) 
4) Growth and pubertal status 7 (14.6%) 4 (23.5%) 11 (16.9%) 
5) Family history of obesity and co-morbidities  11 (22.9%) 3 (17.6%) 14 (21.5%) 
6) Records inadequate to answer  8 (16.7%) 6 (35.3%) 14 (21.5%) 
B. Assessment of any co-morbidities*:     
1) Hypertension  12 (25%) 2 (11.8%) 14 (21.5%) 
2) Hyperinsulinemia 4 (8.3%) 0 (0%) 4 (6.2%) 
3) Dyslipidaemia  6 (12.5%) 0 (0%) 6 (9.2%) 
4) Type 2 diabetes 8 (16.7%) 3 (17.6%) 11 (16.9%) 
5) Sleep apnoea 0 (0%) 0 (0%) 0 (0%) 
6) Exacerbations of conditions such as asthma 5 (10.4%) 2 (11.8%) 7 (10.8%) 
7) Psycho-social distress (e.g. low self-esteem, teasing, bullying) 12 (25.0%) 4 (23.5%) 16 (24.6%) 
8) Mental health (e.g. depression, eating disorder)  9 (18.8%) 3 (17.6%) 12 (18.5%) 
9) Records inadequate to answer  13 (27.1%) 4 (23.5%) 17 (26.2%) 
C. Motivation review:     
1) Review of willingness and motivation to change 31 (64.6%) 13 (76.5%) 44 (67.7%) 
2) Records inadequate to answer  14 (29.2%) 2 (11.8%) 16 (24.6%) 
D. Other treatment options attempted*:     
1) Mental/emotional health support  11 (22.9%) 5 (29.4%) 16 (24.6%) 
2) Exercise prescription  9 (18.8%) 5 (29.4%) 14 (21.5%) 
3) Structured community intervention (e.g. MEND) 3 (6.3%) 0 (0%) 3 (4.6%) 
4) Records inadequate to answer  12 (25%) 1 (5.9%) 13 (20.0%) 
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Table 6.3 Continued  
Questions Orlistat  Metformin  Total  
Question: How was this medication initiated?  Number of respondents: 6 Number of respondents: 34 Number of respondents: 40 
Q2.2: GP issued this medication after advice from secondary/tertiary care team    
A. Who recommended starting this medication?     
1) Paediatrician  3 (50.0%) 18 (52.9%) 21 (52.5%) 
2) Adult physician  1 (16.7%)  4 (11.8%) 5 (12.5%) 
3) Other (please specify)  2 (33.3%) 12 (35.3%) 14 (35.0%) 
B. Was this practitioner part of a multi-disciplinary team with expertise in 
managing obesity in this age group?  
   
1) Yes 1 (16.7%) 7 (20.6%) 8 (20.0%) 
2) No 3 (50.0%) 19 (55.9%) 22 (55.0%) 
3) Don’t know  2 (33.3%) 8 (23.5%) 10 (25.0%) 
C. Did patient require support from primary care with this medication?*     
1) Yes: side effect 0 (0%) 1 (2.9%) 1 (2.5%) 
2) Yes: efficacy 2 (33.3%) 4 (11.8%) 6 (15.0%) 
3) Yes: other (please specify)  2 (33.3%)  4 (11.8%) 6 (15.0%) 
4) No 1 (16.7%) 19 (55.9%) 20 (50.0%) 
5) Don’t know  0 (0%) 6 (17.6%) 6 (15.0%) 
3. Question: What is the current status of this medication?  Number of respondents: 57 Number of respondents: 48 Number of respondents: 105 
1) New prescription issued within last 3 months 4 (7.0%) 25 (52.1%) 29 (27.6%) 
2) Patient stopped taking/ not requested prescription for more than 3 months. 
Please specify reasons if known 
51 (89.5%) 21 (43.8%) 72 (68.6%) 
3) Medication stopped by doctor. Why? 2 (3.5%) 2 (4.2%) 4 (3.8%) 
a) Lack of efficacy  2  0  2  
b) Non-concordance  0  1  1  
c) Adverse effects  0  0  0  
4. Question: Were any nutritional/vitamin supplement prescribed? *  Number of respondents: 58 Number of respondents: 47 Number of respondents: 105 
1) No 56 (96.6%) 45 (95.7%) 101 (96.2%) 
2) Yes, please specify 2 (3.4%) 2 (4.3%) 4 (3.8%) 
5. Question: Who reviewed the patient to assess effectiveness, adverse effects and 
adherence? *  
Number of respondents: 57 Number of respondents: 47 Number of respondents: 104 
1) GP 36 (63.2%) 21 (44.7%) 57 (54.8%) 
2) Paediatrician  2 (3.5%) 16 (34.0%) 18 (17.3%) 
3) Adult physician  1 (1.8%) 3 (6.4%) 4 (3.8%) 
4) Other (please specify)  13 (22.8%) 10 (21.3%) 23 (22.1%) 
5) Don’t know  11 (19.3%) 6 (12.8%) 17 (16.3%) 
6. Question: Were there any adverse effects of this drug?  Number of respondents: 57 Number of respondents: 47 Number of respondents: 104 
1) No 36 (63.2%) 35 (74.5%) 71 (68.3%) 
2) Yes (please specify) 0 (0.0%) 2 (4.3%) 2 (1.9%) 
3) Don’t know 21 (36.8%) 10 (21.3%) 31 (29.8%) 
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Table 6.3 Continued 
Question Orlistat  Metformin  Total  
7. Question: Did the patient’s weight change while on the medication?  Number of respondents: 57 Number of respondents: 46 Number of respondents: 103 
1) Loss 23 (40.4%) 12 (26.1%) 35 (34.0%) 
2) Neutral  6 (10.5%) 11 (23.9%) 17 (16.5%) 
3) Gain 5 (8.8%) 8 (17.4%) 13 (12.6%) 
4) Don’t know 23 (40.4%) 15 (32.6%) 38 (36.9%) 
8. Question: Do you think this medication benefitted the patient?  Number of respondents: 56 Number of respondents: 47 Number of respondents: 103  
1) Yes 9 (16.1%) 13 (27.7%) 22 (21.4%) 
2) No 20 (35.7%) 10 (21.3%) 30 (29.1%) 
3) Unsure  27 (48.2%) 25 (53.2%) 52 (50.5%) 
9. Question: Metformin only: what was the indication for prescribing metformin?  *  Number of respondents: 0 Number of respondents: 46 Number of respondents: 46 
1) Diabetes NA 0 (0%) 0 (0%) 
2) Polycystic ovarian syndrome NA 35 (76.1%) 35 (76.1%) 
3) Insulin resistance/hyperinsulinemia NA 9 (19.6%) 9 (19.6%) 
4) Impaired glucose tolerance/impaired fasting glucose NA 4 (8.7%) 4 (8.7%) 
5) Obesity with none of the above NA 2 (4.3%) 2 (4.3%) 
6) Other: please specify NA 0 (0%) 0 (0%) 
10. Question: What tools were used to support the prescribing of this medication? *  Number of respondents: 43 Number of respondents: 34 Number of respondents: 77 
1) NICE guidance 20 (46.5%) 7 (20.6%) 27 (35.1%) 
2) MIMS** 1 (2.3%) 0 (0%) 1 (1.3%) 
3) BNF 19 (44.2%) 7 (20.6%) 26 (33.8%) 
4) GP notebook  5 (11.6%) 5 (14.7%) 10 (13.0%) 
5) Local prescribing recommendations   9 (20.9%) 11 (32.4%) 20 (26.0%) 
6) Others  3 (7.0%) 14 (41.2%) 17 (22.1%) 
11. Question: How confident do you feel about prescribing anti-obesity medications using 
a scale 1-10 (10= very confident)  
   
To adults:  Number of respondents: 51 Number of respondents: 44 Number of respondents: 95 
Score range  2-10 4-10 2-10  
Mean score (SD) 7.9 (1.8) 8.1 (1.4) 8.0 (1.6) 
Median score (IQR)  8 (7-9) 8 (8-9) 8 (8-9) 
To children:  Number of respondents: 48 Number of respondents: 45 Number of respondents: 93 
Score range 0-8 0-10 0-10 
Mean score (SD) 3.3 (2.5) 3.8 (2.8) 3.6 (2.6) 
Median score (IQR)  3.5 (1-5) 3 (2-6) 3 (2-5) 
Other comments (GP did not score the scale)  1 GP: on advice of specialist  2 GPs : would not prescribe 3 GPs did not give score 
Abbreviations: *Respondents could choose more than one answer NICE, National Institute for Health and Clinical Excellence; MIMS, the Monthly Index of Medical Specialities; BNF, British National Formulary; GP, general 
practitioner; NA: not applicable; SD, standard deviation; IQR, interquartile range. MEND: Mind, Exercise, Nutrition, Do it. MEND is an obesity prevention and treatment programme in the UK. ** MIMS is a national medical 
resource to provide healthcare professional with information on prescription medicines every month. † Mental and behavioural disorders include: depression, eating disorder, learning difficulty, speech and language disorder, 
autism,  attention deficit hyperactivity disorder (ADHD). ‡Metabolic syndromes include: insulin resistance, impaired glucose tolerance.     
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Co-morbidities  
A total of 50 patients (43.8%; 50/114) reported 1co-morbidity and 29 (25.4%) with ≥2 co-
morbidities. The two most frequently reported co-morbidities in the orlistat treated group were: 
mental and behavioural disorders (31.7%; 13/41) and psycho-social distress (29.3%; 12/41). 
PCOS was the most frequently reported co-morbidity in the metformin treated group (74.4%; 
32/43) followed by mental and behavioural disorders (23.3%; 10/43).  
 
Prescribing medication for obesity treatment  
GPs were asked whether they received advice from a secondary or tertiary care team before 
issuing a prescription for orlistat and/or metformin to their patients. A total of 74.5% (105/141) 
GPs responded. More GPs (61.9%; 65/105) replied that they did not receive advice from a 
specialist team compared to those GPs (38.1%; 40/105) who did.  
 
1) GP issued medication without secondary/tertiary care team advice 
Over half of GPs (61.9%; 65/105) responded that they issued medication to their patients 
without secondary or tertiary care team advice. Of these 65 GPs, 48 GPs prescribed orlistat and 
17 prescribed metformin to their patients.  This shows that more GPs initiated orlistat 
prescriptions without specialist advice, whereas more GPs prescribed metformin with advice 
from secondary or tertiary care. Overall, the most frequently reported general assessments 
made before patients received medication for treatment of obesity were: lifestyle review 
(67.7%; 44/65), dietetic review (43.1%; 28/65), and medical causes of obesity (30.8%; 20/65. 
Seventeen GPs (26.2%; 17/65) responded to the “Records inadequate to answer” for co-
morbidity assessment. The most commonly reported co-morbidities GPs assessed were: 
psycho-social distress (24.6%; 16/65), hypertension (21.5%; 14/65), mental health (18.5%; 
12/65), and type 2 diabetes (16.9%; 11/65). For the motivation review, the majority of GPs 
(67.7%; 44/65) responded that they would review patients’ willingness and motivation to 
change before prescribing orlistat/metformin. “Mental/emotional health support” (24.6%; 
16/65) and “Exercise prescription” (21.5%; 14/65) were the most frequently reported other 
treatment options that had been offered. However, nearly one quarter of GPs (20.0%; 13/65) 
responded “Records inadequate to answer”.    
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2) GP issued medication with secondary/tertiary care team advice 
Forty GPs (38.1%; 40/105) responded they received advice from a secondary or tertiary care 
team before prescribing medication to their patients. The majority (85.0%; 34/40) answered 
that they prescribed metformin after receiving advice from specialists in secondary/tertiary 
care team. GPs were asked who recommended starting the medication. The frequently reported 
specialist was paediatrician (21/40; 52.5%). Fourteen GPs responded “Other (please specify)” 
but only 10 of them provided additional information; 5 gynaecologists and 2 endocrinologists 
who recommended metformin while 1 gynaecologist and 1 dietician recommended orlistat. 
One GP responded that the recommendation to prescribe orlistat came from the lipid clinic. 
 
GPs were asked if prescribers were part of a multi-disciplinary team with expertise in managing 
obesity in young people. Over more than half of GPs (55.0%; 22/40) answered they were not 
part of a multi-disciplinary team that managed obesity in this age group. Half of the GPs 
(50.0%; 20/40) responded that patients did not require support from primary care with their 
medication treatment while only 13/14 reported that the patients needed support. 1 GP 
responded “Yes: side effect” for metformin treatment. Four GPs responded “Yes: efficacy” for 
metformin treatment and 2 ‘efficacy’ for orlistat treatment. Six GPs responded “Other (please 
specify)” and 4 GPs provided additional information. Of these 4 GPs, one responded that 
supervision for metformin treatment was required. There were three responses that patients 
required support from primary care for: weight (n=1), psychological (n=1), and medication 
(n=1) in the orlistat treated group.      
 
Current status of medication treatment  
GPs were asked the current status of medication treatment for their patients at the time of 
questionnaire completion. There was a clear difference between the orlistat and the metformin 
treated patients.  For the orlistat treated group, the majority of GPs (89.5%; 51/57) responded 
that patient had stopped taking orlistat or had not requested a prescription for more than 3 
months in the orlistat treated group. Over half of GPs (52.1%; 25/48) responded that a new 
prescription was issued within the last 3 months in the metformin treated group. GPs were 
further asked if medication was stopped by a doctor and the reason for treatment 
discontinuation. Two GPs responded that medication was stopped by a doctor because of “Lack 
of efficacy” in the orlistat treated group. Two GPs responded that metformin was stopped by a 
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doctor but only one GP answered “Non-concordance”. None of the GPs responded that 
medication stopped by a doctor was due to “Adverse effects” for this question.  
 
Nutritional or vitamin supplement prescribing  
The vast majority of GPs (96.2%; 101/105) stated that patients did not receive any nutritional 
or vitamin supplement at the time they received orlistat or metformin treatment. One GP stated 
that the patient received orlistat along with multivitamin OTC (Over The Counter) and another 
answered that the patient received vitamin D with orlistat treatment. In the metformin treated 
group, 2 GPs answered, “Yes” but details were provided.   
 
Who reviewed the patient to assess effectiveness, adverse effects and adherence?  
In general, GPs (54.8%; 57/104) were the most common healthcare professional to review 
patients’ medication treatment. In the metformin treated group, 16 GPs (34.0%; 16/34) stated 
that paediatricians reviewed patients’ medication treatment while only 2 GPs (3.5%; 2/57) 
responded that a paediatrician reviewed treatment in orlistat group. A total of 23 GPs (22.1%; 
23/104) answered “Other, please specify”. Of these 23 GPs, 17 (22.1%; 17/23) provided 
information regarding treatment review and the remaining 2 GPs did not give additional 
information. In the metformin treated group, 3 GPs responded gynaecologist, 1 responded 
dietician, 1 responded endocrinologist, and 1 responded patient did not attend for review. Three 
GPs responded that the practice nurse reviewed orlistat treatment, one responded that patient 
was not seen again for 9 months, one responded that patient stopped attending and only had 
one prescription, and 4 responded that patients did not attend follow-up.  
 
Adverse effects of drug treatment  
GPs were asked whether there were any adverse effects of drug treatment. Overall, more than 
half of GPs (68.3%; 71/104) responded “No” to this question. Approximately 30% of GPs 
(31/104) answered, “Don’t know”. Two GPs reported adverse effects of nausea (n=1) and 
diarrhoea (n=1) to metformin treatment.   
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Weight change during orlistat or metformin treatment  
GPs were asked about weight loss in patients who received medication. Overall, approximately 
36.9% (38/103) of GPs stated they did not know whether their patients’ weight changed while 
on medication. In the orlistat treated group, approximately 40% of GPs (n=23; 23/57) 
responded they did not know if their patients’ experienced weight change. Twenty-three GPs 
(40.4%; 23/57) answered that their patients lost weight while on orlistat; of these, 17 provided 
weight loss information. Eleven patients experienced weight reduction from 2kg to 5kg, 5 
patients lost between 7 kg and 10kg, and 1 patient had a weight loss of 22kg. One GP responded 
that a patient “lost one stone on WW (Weight Watchers)”. Two GPs responded that their 
patients gained 2kg whilst on orlistat for obesity treatment.  
 
In the metformin group, 12 GPs (26.1%; 12/46) stated that their patients lost weight while on 
treatment. Of these, only 6 GPs provided detailed weight loss data. Two GPs stated that their 
patients lost 4kg and 6kg body weight. Four GPs responded that their patients lost weight range 
from 6kg to 12kg. Eight GPs stated that their patients gained weight when they received 
metformin treatment but only 5 GPs gave details about the weight gain. Of these 3 responses: 
1 patient gained 1.5 kg, and 2 patients gained 9kg and 10kg when they received metformin 
treatment. The remaining 2 GPs’ responses were: 1 patient “gained weight but was not 
compliant” and 1 patient’s “BMI increased”.  
 
The benefit of medication treatment  
In response to the question about whether their patients benefited from medication treatment, 
overall half of GPs (50.5%; 52/103) were “Unsure”. According to the responses, 35.7% (20/56) 
of patients on orlistat and 21.3% (10/47) on metformin did not benefit from treatment. 
Approximately 27% (13/47) of patients experienced the benefits of metformin. Only 16% 
(9/56) of patients experienced the benefit of orlistat treatment on weight loss.  
 
Tools to support the prescribing of medication in primary care 
GPs were asked which tools they used to support medication prescribing. Twenty GPs (46.5%; 
20/43) used NICE guidelines and BNF (44.2%; 19/43) to support orlistat prescribing. 
Compared to orlistat, less GPs used NICE and BNF when prescribing metformin. For the 
metformin group, most GPs responded “Others” (41.2%; 14/34) and “Local prescribing 
recommendation” (32.4%; 11/34). Of the 14 GPs who responded with “Others”, 4 answered, 
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“Don’t know”. The remaining 10 GPs provided additional information including: 
“recommended by consultant” (n=3), “endocrinologist” (n=1), “gynaecologist” (n=1), “ask 
paediatrician” (n=1), “specialist advice” (n=1), “given by locum” (n=1), “previous knowledge” 
(n=1), and “not recorded, too long ago” (n=1).   
 
Indications for prescribing metformin 
GPs were asked the indications for which metformin was prescribed to their patients. The two 
main indications for prescribing metformin were “Polycystic ovarian syndrome” (76 %; 35/46) 
and “Insulin resistance/hyperinsulinemia” (19.6%; 9/46).  Only 2 GPs (4.3%; 2/46) answered 
“Obesity with none of the above”.  
 
GP’s confidence regarding prescribing medication for obesity treatment in adults and 
children  
GPs were asked to rank how confident they felt about prescribing anti-obesity medication using 
the scale from 1-10 (10= very confident). Overall, GPs felt more confident prescribing orlistat 
or metformin to adults than to children.  Twelve GPs (12.5%; 12/96) stated “0” (not confident) 
in prescribing orlistat or metformin to children for obesity treatment. Although we asked GPs 
to score their confidence from 1 to 10, approximately 12% of GPs had scored 0 when scoring 
their confidence on prescribing medication to children in this question.  Three GPs provided 
additional comments about their level of confidence in prescribing medication to children: 1 
GP stated, “on advice of specialist” in the orlistat group, and 2 GPs “would not prescribe” in 
the metformin group.  
 
Additional comments regarding prescribing drug for obesity treatment  
GP were asked to give comments regarding prescribing drugs for obesity treatment. Thirty-
two respondents in total supplied additional comments regarding their experiences and 
opinions on orlistat or metformin use for obesity treatment.  
 
Comments on orlistat use for obesity treatment  
Four GPs had no comments to this question. Fourteen GPs provided additional comments on 
prescribing orlistat for obesity treatment. We report here the general themes of these additional 
comments including: patients were not willing to continue drug treatment, patients did not 
attend clinic for follow-up assessment, and uncertainty about treatment effect.  
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“He was not keen to take it and probably did not take any since has defaulted from 
endocrinology follow up.” (Questionnaire 23) 
 
“Clearly patient was not keen to comply; more support needed?” (Questionnaire 42) 
 
“Drug was initiated by FY2 (Foundation Doctor Year 2) or who no longer works here. Patient 
never returned” (Questionnaire 26) 
 
“Inadequate counselling, no weight taken on day of prescription; did not attend follow up” 
(Questionnaire 131) 
 
“Not sure value of lifestyle, drug” (Questionnaire 22) 
 
“Only given one month unsure if used; told to avoid fatty foods and other measures trials 
beforehand.” (Questionnaire 114) 
 
“Not very effective from past experience; bloatedness and diarrhoea as side effect” 
(Questionnaire 39) 
 
“I try to avoid whenever possible” (Questionnaire 129) 
“Not good outcome and poor results.” (Questionnaire 145) 
 
“In this case, patient had already lost 1 stone in weight but struggling to lose more” 
(Questionnaire 111) 
 
Other reported comments were not relevant to drug treatment in obesity management.  
 
“Patient had gastric band” (Questionnaire 128) 
 
“Mother had used” (Questionnaire 149) 
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Comments on metformin use for obesity treatment 
The 16 responses about metformin use for obesity treatment were reviewed, of which 4 had no 
comment on metformin use for obesity treatment. There were some recurring themes: 
metformin was for PCOS treatment, prescribed by specialists, and not prescribed for weight 
loss. The following comments from respondents illustrate these points:  
 
“Poor record keeping reply height/weight although was more for PCOS, patient had gone and 
read up on it. Had already joined weight watchers herself” (Questionnaire 10) 
 
“Only for secondary care initiation” (Questionnaire 18) 
 
“This drug was for PCOS, hair loss, insulin resistance recommended by paediatric 
endocrinologist” (Questionnaire 19) 
 
“Not prescribed as anti-obesity” (Questionnaire 55) 
 
“Prescribed by consultant” (Questionnaire 69) 
 
“Probably prescribed on valid recommendation since after registration” (Questionnaire 75) 
 
“This was prescribed for PCO. Wouldn’t normally prescribe this just for weight loss” 
(Questionnaire 104) 
 
“Metformin was used not just to help with weight but to help with amenorrhea and polycystic 
ovaries” (Questionnaire 151) 
 
“Metformin for PCOS” (Questionnaire 155) 
 
Few other responses on metformin treatment in obese young people as below:  
 
“Is working well” (Questionnaire 78) 
 
“Needs to know has weight loss is the prime effect of metformin” (Questionnaire 104) 
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“Unusual to prescribe metformin in this age group” (Questionnaire 155) 
 
To develop guidelines to support clinicians in prescribing for obesity  
A total of 65 responses to the open-ended question about developing guidelines to support 
clinicians in prescribing drugs to obese young people were reviewed. The majority of responses 
are positive comments on developing a guideline to assist with prescribing medication for 
obesity treatment in young people. In addition, respondents expressed what they would like 
included in the guideline. There were only 7 responses (10.8%; 7/65) that expressed no interest 
in developing a guideline. A number of themes emerge from these supporting comments 
including: drug information (e.g. indication, dose, side effect) in children, a clear and simple 
guide to follow, advice on other non-pharmacological interventions. Examples of responders’ 
comments representing the aforementioned themes are given as below:  
 
Drug information:  
“Prescribing indications criteria.” (Questionnaire 23) 
 
“Indications, dose, regimen, side effects, outcomes.” (Questionnaire 36) 
“Paediatric indication.” (Questionnaire 65) 
 
“Indications, follow up, other investigations to consider.” (Questionnaire 35) 
 
“Exclusion/contraindications. Safety advice. When to stop if not working.” (Questionnaire 59) 
 
“Yes; age group and advice anti-obesity.” (Questionnaire 79) 
 
“Age related prescribing.” (Questionnaire 82)  
 
“Exclusion/contraindications. Safety advice. When to stop if not working.” (Questionnaire 59) 
 
“Paediatrics advice.” (Questionnaire 91)  
 
“Prescribing in <18 years.” (Questionnaire 92) 
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“Guidance for drug use, duration of use, monitoring, when to stop.” (Questionnaire 120) 
 
“Indications” (Questionnaire 129) 
 
 “As OTC medication not sure an intensive team involvement is needed.” (Questionnaire 149) 
 
“Side effects and risk.” (Questionnaire 150) 
 
“Role of medication use.” (Questionnaire 151) 
 
A clear and simple guide to follow:  
“Clear stepwise instructions, criteria, and thresholds. Advice on continuing treatment when to 
stop etc.”(Questionnaire 34) 
 
“Clear protocols on assessment before initiating anti-obesity drugs.” (Questionnaire 58) 
“Protocol to follow easily.” (Questionnaire 116) 
 
“Simple guideline. Frequency of follow up.” (Questionnaire 131) 
 
“Clear advice please.” (Questionnaire 134) 
 
“Clear concise guideline.” (Questionnaire 135) 
 
“A flow diagram patients can have too” (Questionnaire 137; Questionnaire 139) 
 
“Easy flow chart.” (Questionnaire 154) 
 
“Clear guidance of when to start monitoring and when to stop it.” (Questionnaire 155) 
 
Although we asked for opinions on developing a guideline for drug prescribing, some GPs 
expressed the need for non-pharmacological interventions to be included.  
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Advice on other non-pharmacological interventions:  
“Emphasis on lifestyle advice as well as side effects on medication” (Questionnaire 18) 
 
“What screening support and intervention should be used before treatment advice, monitoring 
and when to stop.” (Questionnaire 74) 
 
“Emphasis on non-drug treatment that is very important (diet/exercise/lifestyle) when to stop 
treatment.” (Questionnaire 104) 
 
“Advice on other measures to take beforehand or references/leaflet to give out.” 
(Questionnaire 114) 
 
“Others interventions to be used in conjunction with medication.” (Questionnaire 124) 
 
“Information about targets and investigation.” (Questionnaire 127) 
 
“Working with a group together and special clinic for monitoring and support for patients.” 
(Questionnaire 145)  
 
“Provide advice about lifestyle, eating and long term change.” (Questionnaire 159) 
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6.5.Discussion  
Summary of main findings 
In the UK, GPs play an important role in managing childhood obesity in primary care. This 
study adds to the current understanding of the role of GPs in the treatment of this condition, 
including their prescribing of anti-obesity drugs, also their attitudes, and opinions regarding 
medication use in obesity management in young patients. We used data from a computerised 
UK primary care medical records database to identify patients under 19 years who had received 
orlistat or metformin. Questionnaires were sent to GPs of the patients identified, to explore 
GPs’ experiences and elicit comments on prescribing orlistat and metformin. A high 
questionnaire response rate (80%; 121/151) was achieved in this study, which has also been 
reported (>95%) in previous studies using data from the THIN database (Lo Re V 3rd et al., 
2009; Ruigomez et al., 2010; McCarthy et al., 2013). The high response rate may in part be 
due to the financial incentive given for return of a completed questionnaire. In addition, to 
contributing data to the THIN database, the GPs who participated in our study had also given 
consent to provide additional anonymised patient information for research purposes.  
 
Details of different interventions (lifestyle, behavioural, physical activity, and also 
pharmacological) for obesity management in children are fully described in the NICE 
guidelines. Despite clear guidance that anti-obesity drugs should be started in a specialist 
paediatric setting before they can be continued in primary care (NICE 2006), our survey 
findings  suggest that over half of GPs (61.9%; 65/105) did not receive specialist advice before 
initiating medication (orlistat or metformin). This prescribing practice is not in accordance with 
the NICE guidance. The questionnaire for the current study was administered in 2012; the data 
obtained related to the study period 2010 to 2012, a time when the NICE guidelines were 
already in place. The NICE guidelines provide comprehensive evidence that are quite lengthy, 
which may make it difficult for GPs or other healthcare professionals to read or implement in 
practice. A previous study found GPs and practice nurses in Glasgow did not routinely use 
weight management guidelines (the Scottish Intercollegiate Guidelines Network; SIGN), 
mainly due to lack of time (Mercer et al., 2001). Similarly, a study in Bristol found that most 
GPs and practice nurses did not look at the NICE or the Department of Health guidance on 
childhood obesity management (Turner et al., 2009). This may explain why, in our study, most 
GPs did not consult specialists’ before initiating anti-obesity drug treatment.  
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It is interesting to note that most GPs initiated an orlistat prescription without seeking advice 
from specialists, whereas the majority of GPs consulted specialists before initiating a 
prescription for metformin. At present, metformin is not recommended for obesity treatment 
in national guidelines such as NICE or authoritative drug prescribing documents widely used 
in the UK (BNF; BNF Children; Summary of Product Characteristics). Few GPs reported that 
they prescribed metformin on the recommendation of specialists (e.g. paediatric 
endocrinologist).  Possible reasons that GPs consult specialist’ advice prior to starting 
treatment with metformin may be a lack of an authoritative guideline, and current limited 
evidence that supports use for obesity treatment in both adults and children. Over half of GPs 
in our study also expressed uncertainty about metformin efficacy on weight loss, especially for 
young people. This may also explain why most GPs felt incompetent to prescribe metformin 
for obesity treatment, especially in children. In addition to obesity treatment, metformin is 
commonly used for PCOS treatment in clinical practice. In contrast to metformin, several 
studies have shown the efficacy of orlistat along with lifestyle interventions in weight loss in 
adults and children in the past few years. Therefore, GPs may feel more confident about 
initiating orlistat for treatment of obesity in young people without advice from specialists.  
 
Obesity is associated with a range of co-morbidities such as hypertension, diabetes, depression, 
and low self-esteem in young people (Viner et al., 2006; Kimm et al., 1997; Goodman et al., 
2002). Due to these obesity-related conditions, a range of healthcare professionals such as 
dieticians, endocrinologists, and psychologists will also be involved in obesity treatment for 
paediatric patients (Ogden & Flanagan 2008). In our study, of those GPs who reported that 
they contacted a specialist, the majority consulted a paediatrician for advice before initiating 
prescribing but some contacted other specialists such as gynaecologists, adult physicians, and 
endocrinologists have also been contacted for advice. However, over half of the specialist 
practitioners (52%) who provided GPs with advice were not part of a multi-disciplinary team 
with expertise in managing obesity in young people. The NICE guidelines state that an anti-
obesity drug should only be prescribed to children by a multidisciplinary team with expertise 
in obesity management in this age range.  
 
Orlistat inhibits pancreatic and gastric lipase by decreasing ingested triglyceride hydrolysis; 
consequently, it may impair absorption of fat-soluble vitamins (e.g. A, D, E, K). It is 
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recommended that a multivitamin supplement (especially Vitamin D) be taken while patients 
are taking orlistat if there is concern about deficiency of fat-soluble vitamins (Summary of 
Product Characteristic Orlistat 2012; BNF Children). However, the data from our study 
showed that the vast majority of patients (96%) who received orlistat for treatment of obesity 
did not take a multivitamin supplement. This may be due to the lack of experience in 
prescribing medication to young people for obesity treatment. Many GPs felt more confident 
prescribing a drug for obesity treatment to adults compared to young people. GPs reported that 
nearly 90% of patients stopped taking or had not requested an orlistat prescription for more 
than 3 months. We have previously reported that only one-quarter of patients remained on 
orlistat treatment for longer than 3 months and the majority of patients discontinued treatment 
within the first 3 months (Viner et al., 2009). Orlistat was approved in the UK to treat obesity 
and it has recognised and well established adverse event profile including (but not limited to) 
faecal urgency, liquid or oily stools, faecal incontinence, though gastro-intestinal effects can 
be minimised by reduced fat intake. According to GPs, 63% of patients did not experience 
adverse events and the remaining GPs did not know if patients had an adverse event associated 
with orlistat treatment. Only 1 GP provided information about adverse events (bloatedness and 
diarrhoea) that the patient experienced while on orlistat treatment. As for drug treatment effect, 
approximately 40% of GPs did not know their patients’ weight change while on orlistat 
treatment. Approximately 48% of GPs were unsure whether their patients benefitted from 
orlistat treatment.   
 
Approximately 74% of patients did not experience adverse events while receiving metformin 
treatment and more than half of the GPs (53.2%) were unsure about the effect of metformin 
treatment effect on weight loss in their patients, a higher proportion than for orlistat. In contrast 
to orlistat, more patients (52%) had new metformin prescription issued within last 3 months. 
Our study was not designed to estimate drug treatment adherence, but according to the patients’ 
GP, the mean treatment duration of metformin was longer than that of orlistat. It may be that 
the majority of patients were issued metformin primarily for the treatment of PCOS and not 
for the treatment of obesity. Several GPs had commented that metformin was issued for PCOS 
for obesity treatment. This is consistent with a previous study in the UK, which used a 
longitudinal primary care database and demonstrated that PCOS was the main indication for 
metformin prescribing to female adolescents (Hsia et al., 2012).  
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Most GPs in our study reported that they did not have adequate documentation on treatment 
outcome. For a number of the questions the GPs did not know the answers. This was 
particularly the case when GPs were asked their opinion on the benefits of medication 
treatment. Also, details of orlistat and metformin adverse events were not reported by the GPs. 
This could be because patients did not return for follow-up assessment or inadequate 
documentation in GPs’ clinical records. Another study found that none of the practitioners 
(GPs, practice nurses, health visitors) were in regular contact with the obese children. The 
authors commented that even when practitioners offered follow-up appointments most patients 
did not return. One GP further expressed that they only saw a small proportion of obese young 
people who sought help from their GP (Turner et al., 2009). In 2003, in order to reinforce good 
prescribing practice in all clinical settings, the Royal College of Physician of London published 
guidance on appropriate prescribing and management on anti-obesity drugs (Royal College of 
Physician of London 2003). It suggested that clear documentation is required when patients 
receive anti-obesity drugs for treatment. Also, the guidance recommended that there should be 
written notification to the patient’s GP, if another physician initiated prescriptions. The 
information that should be documented included the reason for treatment, the dose and 
intended treatment duration, and possible untoward effects. The fact that GPs did not know the 
treatment outcome in many cases indicates that management practices for childhood obesity 
could be further improved.   
 
To develop a new guide supporting anti-obesity drug treatment     
Since the release of the NICE guideline on obesity management in young people in 2006, 
practitioners have been given specific guidance in assessing, treating, and preventing obesity 
in these patients. However, our data indicated that the current guideline does not fulfil its main 
objectives. A range of views was expressed by the GPs in our study on developing new 
guidance to support clinicians on drug prescribing for obesity treatment. Despite 
comprehensive guidance provided in the NICE guideline, in our study, GPs expressed their 
support for the development of a new guide for prescribing anti-obesity drug to young people. 
Some GPs also commented that recommendations on non-pharmacological interventions 
should be included in the new guideline. The current NICE guideline contains evidence-based 
literature on diet, exercise, and behavioural change approaches, and also drug treatment for 
management of obesity in childhood. The comments from GPs in our study again raised the 
question of how practical NICE guidelines are for practitioners to follow in their day-to-day 
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practice. Previous studies have shown that practitioners rarely use NICE guidelines in their 
clinical practice (Mercer et al., 2001; Turner et al., 2009; Owen-Smith et al., 2010). The study 
by Turner and colleagues (2009) found that only 3 practitioners had looked at the NICE obesity 
guideline (10%; 3/30) and that the remaining practitioners had never seen the guideline. 
Another recent study reported that some healthcare professionals did not trust the reliability of 
NICE guidance and so were less likely to implement these in practice. The comment from one 
GP was “I think where we [GPs] perceive that NICE guidance has come up with politically 
correct statements. I think we are pretty sceptical and probably ignore it. For 
instance…prescribing of obesity medications….I don’t think that’s the right solution to those 
problems.” (Owen-Smith et al., 2010). Similarly, the Glasgow study reported that the SIGN 
guidelines were clearly not used much amongst practitioners (GPs and practice nurses); who 
felt that the SIGN guidelines overly promoted the use of anti-obesity drugs (Mercer et al., 
2001). Several GPs in our study expressed the need to develop an easy and simple new guide 
to follow. Both NICE and SIGN guidelines are lengthy and detailed and it is not easy to 
implement these guidelines into clinical practice.      
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Strengths and limitations 
To our knowledge, this is the first questionnaire survey used to assess GP’s experiences in 
prescribing orlistat and metformin to young people for obesity treatment in UK primary care. 
The main strength of this study was that we utilised a large primary care health record database 
(THIN) that covers 5.7% of the UK population to examine GP’s views on prescribing 
medication for obesity treatment to their young patients. Additionally, the questionnaires were 
sent to GPs across the UK so the results from the current study should be generalizable. GPs’ 
experiences in prescribing orlistat and also metformin to young people for obesity treatment 
were examined, as no research in this area had been previously undertaken.  Further, a high 
response rate was achieved in this study. There are a number of reasons that are likely to 
contribute to this high response rate; the GPs who contribute data to THIN database are a self-
selected group, and those who completed and returned questionnaires were compensated.  
However, there are a number of limitations to this study.  
 
Firstly, this study was conducted to understand GP’s experiences of prescribing medication for 
obesity treatment in young people and so we did not examine which non-pharmacological 
interventions had been used in prior to or in addition to drug treatment. Secondly, we could not 
assess prescriptions initiated at secondary care because THIN only records prescriptions issued 
in primary care, excluding prescriptions dispensed in hospitals. Thus prescriptions that were 
prescribed in secondary care were not included in the present study. Thirdly, there were a high 
number of missing records in returned questionnaires. There was the varying response rate for 
individual questions. For a number of questions asked, the answers were not known by the 
GPs. We did not know whether the missing information/data were due to inadequate 
documentation in the practice. Fourthly, the assessment of the open comments in the 
questionnaire to ascertain common themes is subjective, as this open-ended question was 
included for exploratory purposes. The study was not intended to be a qualitative study. Finally, 
a limitation of most postal surveys is that of response bias and our study is not exempt although 
the response rate was high (about 80%). It may be that those who responded to the 
questionnaires were more interested in childhood obesity. A further limitation is that some GPs 
provided the weight and height measurements in the return questionnaire, but we did not intend 
to investigate treatment effect on orlistat or metformin. We primarily used this information to 
indicate the completeness of the recording of these measurements in primary care setting. 
There were many measurements (height, weight) that were not recorded in the returned 
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questionnaires. We do not know whether these missing measurements were not documented 
or patients’ weight and height were not measured at the GP practice.  
 
Implication for practice and future research  
Childhood obesity continues to be a problem in the UK. It is important to examine how 
practitioners are addressing this critical issue in order to identify the need for further training 
and services in clinical practice.  The present study provides a timely and useful update of GPs’ 
practice on prescribing medication for obesity treatment in young people. Results of this study 
will generate recommendations for clinical practice in childhood obesity management, which 
may further inform policy guidelines. Despite the current NICE guidelines, we have seen that 
clinical practitioners support the development of a prescribing guide on childhood obesity 
treatment. At present, the obesity indicator in the QOF scheme does not apply to young people 
aged under 16.  To target successful childhood obesity management, children and adolescents 
should also be included in the QOF scheme. In addition, GPs should be offered further training 
and support on the appropriate anti-obesity drug to prescribe. A useful area for future research 
would be to explore patients’ views on medication use for obesity management and the reasons 
for them to stop treatment.  
 
6.6.Conclusion 
The findings of this study show that GP’s prescribing practices seem not to be in accordance 
with NICE guidance on the management of obesity in children and adolescents. More than half 
of GPs initiating medication did not receive advice from specialists in secondary care. Results 
in the study reveal that the majority of GPs have a lower level of confidence in prescribing 
anti-obesity drugs to young people compared to adults especially for prescribing metformin. 
About 89% of GPs supported and suggested there was a need to develop simple and easy 
guidance to assist them with prescribing anti-obesity drugs, and several of them also suggested 
that non-pharmacological interventions should be included in the guide. Over one-quarter of 
GPs did not know whether their patients had experienced any adverse drug reaction. In 
addition, more than one-third of GPs did not know their patients’ treatment outcome while on 
drug treatment. This study highlights an urgent need to improve current practice in childhood 
obesity management in primary care.     
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Chapter 7  Overall Discussion and Conclusion  
Prior to the commencement of this thesis, a number of gaps in the knowledge of anti-obesity 
drug use in children and adolescents were identified, gaps which this thesis sought to address. 
This thesis has increased the current knowledge of anti-obesity drug use in children and 
adolescents in primary care and secondary care in the UK. This thesis has systematically 
evaluated the efficacy and adverse drug reactions of anti-obesity drugs used in children and 
adolescents from published RCTs by utilising a systematic review and meta-analysis (Chapter 
3). Pharmacoepidemiological studies utilising large health care databases (General Practice 
Research Database, IMS Disease Analyzer) have been performed to investigate anti-obesity 
drug prescribing patterns in children and adolescents in the primary care setting (Chapter 4). 
Also, a prospective cohort study was conducted to investigate drug prescribing patterns for 
obesity treatment in young people in secondary care. Further analysis of this study was 
performed to determine the effect of metformin treatment together with lifestyle intervention 
compared to lifestyle intervention alone, after 6 months of treatment (Chapter 5). To date, there 
is no research to assess GP’s experiences in prescribing anti-obesity drugs to obese children 
and adolescents in the UK primary care. Thus, a GP questionnaire survey study was conducted 
to evaluate GP’s experiences and attitudes in prescribing medication to young people for 
obesity treatment across the UK (England, Scotland, Wales, North Ireland) (Chapter 6). This 
final chapter summarises the main findings of these studies, including an overall discussion of 
the results of the studies, and recommendations for future research are given.   
 
7.1.Summary of main findings 
7.1.1.Systematic Review and meta-analysis of RCTs of anti-obesity drugs used in children 
and adolescents 
A systematic review and meta-analysis of RCTs published between January 1996 and January 
2008, was conducted to investigate the efficacy of licensed anti-obesity drugs (orlistat, 
sibutramine, rimonabant) and the reported ADRs in children and adolescents (aged ≤ 18 years).  
A total of 16 RCTs were appraised and assessed for inclusion in the meta-analysis: 6 RCTs for 
orlistat and 10 RCTs for sibutramine. Of these 16 RCTs, 2 studies of orlistat and 4 studies of 
sibutramine were included in the meta-analysis. No RCTs for rimonabant in this population 
were identified. The results from the 2 RCTs for orlistat showed that 6 months of treatment 
with orlistat together with behavioural support reduced BMI by 0.83 kg/m2. The meta-analysis 
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of the 4 RCTs for sibutramine demonstrated that with behavioural support, BMI was reduced 
by 2.20 kg/m2. From a search of papers published from February 2008 to November 2011, 
conducted to update the systematic review, only one RCT of orlistat was identified, after the 
initial screening of the abstracts (Chanoine & Richard, 2011). As this study was an additional 
analysis from a previous study which had been included in our original review (Chanoine et 
al., 2005), we did not include it in the meta-analysis.     
 
The results of the review are consistent with the results of previous systematic reviews 
(McGovern et al. 2008; Oude Luttikhuis et al. 2009). Each of the RCTs included in these 
reviews, demonstrated a statistically significant effective on weight loss of anti-obesity drug 
treatment in young people however, this benefit was not always of clinical significance. These 
two systematic reviews by McGovern et al., (2008) and Oude Luttikhuis et al. (2009) did not 
undertake a meta-analysis of ADRs on orlistat and sibutramine. In reviewing the ADRs 
reported in the RCTs, the most frequently reported ADRs are those that are included in the 
SPCs. In this review, the frequency of reported gastrointestinal ADRs to orlistat was high 
compared to the placebo groups. Sibutramine was found to increase systolic and diastolic blood 
pressure.  
 
Evidence from the short-term (6 months) RCTs in children and adolescents, support the benefit 
of anti-obesity drugs as an adjunct to lifestyle interventions (e.g. behavioral support, exercise, 
diet). At present, the long-term (e.g. over 1 year treatment) effectiveness and risk of these drugs 
in young people is lacking as no long-term RCTs have been published in this population. In 
contrast, the benefits of long-term use of orlistat and sibutramine in adults have been well-
documented. Li et al., (2005) and Rucker et al., (2007) reported the efficacy of long-term (over 
1 and/or 2 years) treatment with orlistat or sibutramine in adults, from RCTs. A systematic 
review of 4 RCTs has shown a significant effect of rimonabant on weight loss in adults (Curioni 
& André, 2006). However, this drug was not recommended in NICE guideline (2006) on the 
treatment of obesity in young people. In January 2010, the NICE revised the 2006 obesity 
management guideline after the withdrawal of sibutramine. Orlistat is currently the only drug 
recommended for obesity treatment in young people with certain caveats (e.g. severely life-
threating co-morbidities). Further research is required to determine the long-term effects of 
orlistat for the treatment of obesity in this population.  
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7.1.2.Prescribing patterns of anti-obesity drugs in children and adolescents in primary 
care 
The use of the GPRD database (a primary care database) enabled us to study a large cohort of 
young people who had received orlistat, rimonabant, or sibutramine, and to follow them over 
a period of several years. In terms of prescribing patterns, orlistat was the most frequently 
prescribed drug for the treatment of obesity in young people between January 1999 and 
December 2006 (study period). In contrast, there was only one prescription for rimonabant 
issued during the study period.  After the introduction of orlistat and sibutramine to the UK 
market in 1999 and 2001, respectively, the overall annual prevalence of prescribing of these 
drugs to children and adolescents increased 15-fold from 0.006 per 1000 patient-years in 1999 
to 0.091 per 1000 patient-years in 2006.  
 
In this study if no further prescription was issued within 90 days (3 months) of the end of the 
previous prescription, treatment was considered to be discontinued. An unexpected finding 
from this study was that approximately 45% of orlistat prescriptions and 25% of sibutramine 
were discontinued after only one month. The majority of prescriptions were rapidly 
discontinued within a month before patients could see any clinical benefit. Although there was 
no information on treatment discontinuation, a few possible reasons that may have contributed 
to treatment cessation were postulated. Rapid discontinuation of the drug may indicate poor 
therapeutic efficacy or that these drugs were poorly tolerated by this population.  In addition, 
approximately 29% (n=129; 129/452) of the patients in this study population had been 
diagnosed with depression. Their feelings of hopelessness and negativity may have contributed 
to the treatment being prematurely stopped. The preliminary data from a recent conference 
abstract has shown early discontinuation of orlistat treatment in Scottish young people.  Eighty 
two children aged <19 years (81.7% female), who were newly prescribed orlistat between 2006 
and 2009 were identified from the Primary Care Clinical Information Unit (PCCIU) database. 
Approximately 54% of these children discontinued orlistat within one month of starting 
treatment and 74% discontinued treatment within 3 months (Sun et al., 2011). The authors 
concluded that discontinuation of orlistat treatment could be a potential signal for ADRs. 
However, there is no detailed information in the abstract to further explain their conclusion.     
 
At present, there is only one drug (orlistat) approved for obesity treatment in adults in the UK.  
Several marketed drugs have been considered for the treatment of obesity (Chapter 1, section 
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1.5). Of these, metformin has been suggested as the best choice of drug for obesity treatment 
as obese patients are more likely to have metabolic syndromes. A study from the Diabetes 
Prevention Program has reported that both metformin and lifestyle change reduced the 
incidence of type 2 DM in adults (Knowleret et al., 2002). As obesity in children is a major 
predictor of developing type 2 DM later in life (Kahn et al., 2000; Franks et al., 2007), it is 
expected that in clinical practice metformin will gain in popularity for treating obesity in young 
people. A drug utilisation study of metformin prescribing in young people was conducted to 
investigate its prescribing trend and the indications for prescribing it in primary care to children 
and adolescents in the UK. Increased prescribing of metformin over the past decade was 
observed in this study, especially in teenage girls aged 16-18 years. Polycystic ovary syndrome 
(PCOS) was the most common indication for metformin prescribing in girls followed by 
diabetes. Approximately 7.6% (n=22; 22/290) of the patients received metformin, only for the 
treatment of obesity between January 2000 and December 2010. As sibutramine was 
withdrawn in February 2010, more data should be collected in future to determine whether 
prescribing continues to increase in young people in general practice. 
 
7.1.3.Systematic review and meta-analysis of RCTs of metformin effect on weight loss in 
non-diabetic children and adolescents  
A systematic review and meta-analysis of RCTs was conducted to investigate the efficacy of 
metformin on obesity treatment in obese non-diabetic children and adolescents. A pooled 
analysis of 12 RCTs showed that metformin reduced BMI by 0.64 kg/m2 over 6-months of 
treatment in this population. There was also an improvement of fasting insulin by 4.15 µU/ml 
in patients who received metformin treatment. Analyses did not provide strong evidence for a 
treatment effect on HOMA-IR, cholesterol, HDL, or triglycerides. However the findings of our 
review must be interpreted with caution, as these studies were short-term and the study 
populations were small. Currently, there is only one licensed anti-obesity drug for obesity 
treatment. Metformin has been increasingly used off-label for obesity treatment in recent years. 
As discussed in Chapter 1.5, several drugs (e.g. diethylpropion, fluoxetine, topiramate) have 
been recommended as potential anti-obesity drugs in clinical practice. Compared to these, 
metformin has a good safety profile. However, evidence to support metformin in children and 
young people remain deficient to date. Large, long-term studies on metformin across different 
populations are needed in order to establish its role on childhood obesity management.  
 
 248 
 
7.1.4.Drug prescribing for obesity treatment in a regional paediatric weight management 
clinic 
As suggested in the NICE guidelines (2006), treatment with anti-obesity drugs in children and 
adolescents should be initiated by a specialist in secondary care. However currently there is no 
published evidence on drug use for obesity management in young people from the secondary 
care sector in the UK. A large cohort study was conducted at University College London 
Hospital (UCLH) paediatric weight management clinic between 2007 and 2010. This study 
represented a cohort of extremely obese young people and was dominated by girls with a White 
British background. As the individual patient’s postcode was captured, we were able to obtain 
the Indices of Multiple Deprivation (IMD) 2007 score to assess the deprivation in this study 
population. The majority of patients in this population were living in deprived areas.  The 
percentage of obese patients was almost four times higher in the most deprived decile (decile 
1=19%) compared to the least deprived decile (decile 10=5%) in our study. Our finding is 
similar to the National Child Measurement Programme in Worcestershire. Their report has also 
shown that the prevalence of obese children in the most deprived decile (IMD decile 1) is 
double that in the least deprived decile (IMD decile 10) during 2007-2008 and also 2009-2010 
(National Child Measurement Programme, 2011). The association of deprivation with 
childhood obesity has long been recognised. Two studies have demonstrated a strong 
association between childhood obesity and deprivation in the UK (Kinra et al., 2000; Conrad 
& Capewell, 2012).  
 
In the secondary care study, more patients received a drug together with lifestyle intervention 
(advice on healthy diet and exercise) for obesity treatment than patients who received only 
lifestyle intervention.  This indicates that the national guideline (NICE 2006) may have had an 
effect on prescribing practice in secondary care for obesity management in young people.  
Metformin was the drug most commonly prescribed to obese young people whereas the use of 
orlistat or sibutramine was low. Although we were unable to obtain data on co-morbidities for 
this study population, it is believed that the majority of obese patients who received metformin 
may have metabolic syndromes (Viner & Nicholls, 2005). Although this was a large cohort 
study from a regional secondary care setting, it is not appropriate to extrapolate these 
prescribing patters to other specialist care across the UK.  
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As this study population was relatively large, subsequently we were able to conduct an 
observational study to determine the effect of metformin treatment in this population. There 
were significant reductions for BMI SDS in both girls and boys treated with metformin together 
with lifestyle intervention at 6 months (within group comparison). BMI was only significantly 
reduced in girls treated with metformin and lifestyle intervention treatment but not in boys 
(within group comparison). Overall, the reduction of BMI and BMI SDS were not significant 
(between group differences).  When comparing by gender, there was a small but significant 
effect of metformin and lifestyle intervention treatment on BMI SDS in girls compared to the 
girls who only received lifestyle intervention only. 
 
7.1.5.Anti-obesity drug prescribing to young people: a national GP questionnaire survey 
study 
In the UK, no study has been conducted specifically to evaluate clinicians’ experiences on 
prescribing drugs to obese young people as treatment. By utilising a primary care, an electronic 
healthcare database (THIN), we were able to demonstrate clinicians’ views towards prescribing 
drugs to young people for obesity treatment. Furthermore, we were able to demonstrate 
prescribing attitudes across different healthcare settings (primary care and secondary care). 
Our findings have shown that more than half of GPs initiating medication did not seek advice 
from specialists in secondary care. Most GPs reported that metformin was prescribed for the 
treatment of PCOS (76.1%; 35/46) not for obesity treatment (4.3%; 2/46). This is consistent 
with our findings using another primary care database (IMS DA) (Chapter 4.3) which showed 
that majority of metformin prescriptions were issued for PCOS treatment not for obesity 
treatment. The majority of GPs have low levels of confidence in prescribing drugs to young 
people compared to adults, especially metformin. Despite comprehensive NICE guidance on 
childhood obesity management, nearly 90% of GPs supported and suggested a need to develop 
simple and easy guidance to assist them with prescribing medication to obese children and 
adolescents. They also suggested that the new guidance should also include guidance on the 
use of non-pharmacological interventions. Approximately one-quarter of GPs did not know 
whether their patients had experienced any adverse drug events, and one-third of GPs did not 
know the treatment outcome. This survey study highlights a need to improve current practice 
in childhood obesity management in the UK.  
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7.2.Strengths and Limitations  
In this thesis, different epidemiological study designs were applied to investigate anti-obesity 
drug use in children and adolescents which enable us to demonstrate anti-obesity drug 
prescribing trends and patterns in both primary care and secondary care as well as the efficacy 
and ADRs of their use from published RCTs. However, there are methodological issues that 
need to be addressed.   
 
Systematic reviews and the statistical technique of meta-analysis are important ‘tools’ to 
synthesise data from several RCTs to ascertain the efficacy and the commonly reported ADRs 
for a particular drug used to treat  a particular condition. One potentially serious limitation of 
systematic reviews and meta-analysis is publication bias. Studies that have significant findings 
are more likely to be published than the studies without significant and/or negative findings 
(Hopewell et al., 2009). A practical solution to deal with publication bias is the “funnel plot”. 
This is a statistical method to detect publication bias in systematic reviews and meta-analysis, 
by plotting intervention effect estimates from individual studies against the measure of each 
study’s size (Cochrane, 2006).  Due to the small number of included RCTs in our meta-
analysis, we were unable to assess publication bias in our review using this method. In our 
review, all studies included for meta-analysis had demonstrated the effectiveness of orlistat 
and sibutramine on weight loss. Two RCTs were included in the meta-analysis to estimate 
efficacy and adverse drug reactions of orlistat (Chanoine et al., 2005; Maahs et al., 2006). The 
study by Chanoine et al. (2005) was industry-funded (Hoffmann-La Roche Ltd). The 4 RCTs 
of sibutramine included were all industry-funded (Abbott Laboratories Ltd). It appears that 
these published fully or partly industry-funded RCTs of anti-obesity drugs treatment all 
reported positive outcomes. In our systematic review and meta-analysis, we found that adverse 
reactions of orlistat and sibutramine treatment patients experienced from RCT data were 
tolerated. Although the RCT design is considered the “gold standard” for investigating drug 
efficacy, some severe ADRs are unlikely to be detected during the trial period due to e.g. short 
length of follow up, the limited numbers of patients, and exclusion/inclusion criteria for 
patients. In addition, ADRs may have been under-reported in the clinical trials. A review study 
which investigated 192 published pharmaceutical trials, found that less than one third of the 
trials had adequate reporting of the ADRs or laboratory toxicological findings (Rothwell, 
2005). Therefore, we cannot completely rule out publication bias in our review. Furthermore, 
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we unexpectedly observed a rapid discontinuation of anti-obesity drug treatment in our 
population-based study. This early discontinuation of treatment may indicate poor efficacy of 
the treatment or intolerance to the ADRs.  
 
An issue that also needs to be addressed is the validity of assessing the effect of drug treatment 
in observational studies. This has long been debated and remains controversial (McKee et al., 
1999; Concato et al., 2000). Despite this, observational studies are an important study design 
for determining the effectiveness of drug treatment in routine clinical practice (Faries et al., 
2007; Nallamothu et al., 2008), as RCTs can only provide evidence of treatment effect under 
controlled conditions in a selected group of patients, for a defined period of treatment (Klungel 
et al., 2004). Stratification may be carried out in observational studies to divide patients into 
subgroups or strata on the basis of characteristics that are potentially confounding factors the 
analysis (Lu, 2009). It is suggested that sufficient baseline information should be collected to 
overcome any confounding by pre-existing differences, when comparing treated and untreated 
groups in an observational study (Jepsen et al., 2004; Stürmer et al., 2007). Due to the absence 
of information on co-morbidities and co-prescribing medication (potential confounding 
factors), in our study, the estimated metformin treatment effect may be biased by differences 
in baseline risk for other factors and/or other treatment interventions (e.g. psychological 
intervention). In recent years, several methods have been proposed to overcome the criticisms 
of assessing treatment effects in observational studies. The main objective of these methods is 
to overcome the potential bias and selection bias caused by the non-randomised assignment of 
treatment (Klungel et al., 2004). Table 7.1 summarises the strengths and limitations of the 
epidemiological study designs used in this thesis to investigate the drug treatment effect 
(Hannan, 2008; Nallamothu et al., 2008). A systematic review and meta-analysis is a 
systematic and quantitative approach to synthesise existing data to answer important 
therapeutic questions. This method has been widely used to assess drug treatment and identify 
commonly occurring ADRs by combining evidence from diverse study designs and study 
populations from published RCTs. The meta-analysis is a powerful statistical method in which 
studies can be weighted according to their sample size and provides an overall estimate of the 
treatment effect. However, the main limitations of systematic reviews and meta-analyses are 
publication bias and flaws in the included studies (Sutton et al., 2000). If systematic reviews 
and meta-analyses are done and interpreted carefully this type of study is extremely helpful in 
assessing the effect of drug treatment and identifying frequently occurring ADRs.          
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As discussed, due to the absence of randomisation procedure in observational studies, this type 
of study design is always limited by confounding or selection bias for determining drug 
treatment effect (Nallamothu et al., 2008). In contrast, the randomisation procedure conducted 
in a RCT design ensures that certain kinds of potential selection bias (e.g. inclusion and 
exclusion criteria) will be removed, such as clinician preference for giving certain treatment to 
selected patients and also that unobserved differences in patient characteristics are randomly 
distributed between treatment groups (Klungel et al., 2004). Several statistical approaches have 
been implemented to overcome the absence of randomisation in observational study for 
assessing therapeutic effect such as asymmetric stratification, propensity score adjustment, and 
multivariate confounder scores (Klungel et al., 2004). With appropriate statistical techniques, 
an observational study is an invaluable source for informing clinical practice.  
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Table 7.1: Strengths and limitations of study designs used to investigate drug treatment 
effect in this thesis (adapted from Hannan, 2008; Silverman, 2009) 
 
Study design Strengths  Limitations  
Systematic review and 
Meta-analysis  
1.Systematic review can provide 
helpful information in clinical decision 
making 
2. Pooling of data allows for 
evaluations of small but important 
subgroups of patients  
3. Provides insights into heterogeneity 
of treatment effects across studies 
4. Systematically assess concurrent 
ADRs for specific drugs 
5. Studies can be weighted according to 
their sample size 
6. Meta-analysis can save considerable 
time and resources between a research 
finding and the clinical implementation 
of a new therapy, by accumulating 
evidence as it becomes available 
1.Susceptible to study design limitations 
within individual studies 
2.Suffers from potential publication and 
reporting bias of large treatment effects 
3.Heterogeneity may be inadequately 
addressed in study selection or analysis  
4.Difficult to obtain patient-level data 
from investigators  
5. ADRs data can only be obtained from 
published results.  
Observational study  1.Involves a large and diverse 
population of patients in treated in  
‘real world’ clinical practice 
2. It can investigate multiple outcomes 
3. It can provide insight into the 
clinical context in which multiple 
therapies are delivered 
4. It can be relatively inexpensive and 
can be performed relatively rapidly 
5. Results can be generalized to general 
population  
1.If conducted prospectively, it may take 
years to complete 
2. Confounding or selection bias of 
patients-or the two combined-make it 
difficult to compare treated and untreated 
patients 
3. Several statistical approaches are 
available to investigate treatment effect 
but may be inconsistently applied or 
reported 
Abbreviation: ADR, adverse drug reaction; RCT, randomised controlled trial. 
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7.3.Areas for recommended future research  
This thesis examined the efficacy and safety of anti-obesity drugs from RCTs, and also the 
prescribing patterns of these drugs in both primary and secondary care settings, in the UK. 
Below are suggestions for future research.  
 
The first area of future research identified from the drug utilisation studies would be to 
investigate the reasons for discontinuation of anti-obesity drug treatment and what approaches 
could be used by young people to lose weight after drug treatment failure. In this thesis, it was 
not possible to investigate the reasons for the rapid discontinuation of the drug therapy, due to 
the limited coded information available from the primary care database. Qualitative research 
is needed to examine the reasons and possible factors affecting the cessation of anti-obesity 
drug treatment. Qualitative research is currently carried out by other team members of 
PROMSE programme. A GP questionnaire study could be conducted to investigate whether 
anti-obesity drugs are being prescribed in accordance with the 2006 NICE guideline on obesity 
management. Also, an interview study could be carried out to investigate reasons for anti-
obesity drug discontinuation and the experience of these drugs used in children and 
adolescents.  
 
A second area of future research would be to investigate to what extent other factors affected 
the treatment outcomes in the observational cohort study conducted at the UCLH paediatric 
weight management clinic. Additional information such as psychological interventions, co-
morbidities, and co-prescribing medications, anthropometric (e.g. fasting glucose, insulin, 
fasting glucose) and lipid (e.g. high-density lipoprotein cholesterol) levels could be obtained 
from other sources. This additional information could be used to identify potential factors that 
may affect treatment outcome.   
 
The third area of further research should be to develop a collaborative, prospective, obesity 
management surveillance network for children and adolescents across other specialist centres 
in the UK. This could examine drug prescribing patterns along with other interventions (e.g. 
psychological intervention, bariatric surgery) for weight management, and it could also 
monitor the clinical effectiveness and any complications of different interventions in a much 
larger population. As the findings on drug prescribing patterns for obesity treatment reported 
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in this thesis came from only one specialist centre and they cannot be generalised to other 
specialist centres across the UK.  
 
The fourth area of further work would be to investigate drug prescribing trends (orlistat and 
metformin) over the same period of time in both primary care and secondary care. This could 
provide us with a clear picture of whether metformin use for obesity treatment in young people 
continues to increase in clinical practice.  
 
The final area of work identified for further research is the long-term efficacy and safety of 
metformin for weight loss. To date, the long-term (over 1 year) efficacy and identification of 
adverse drug reactions after long term treatment with metformin in obese young people remains 
unknown. There are a few on-going RCTs investigating efficacy of metformin for obesity 
treatment in adults. However, it is not appropriate to extrapolate adult data to children and 
adolescents due to different physiological responses. A large-scale long-term RCT to 
investigate metformin efficacy and safety in young people is needed. Although a RCT is a gold 
standard to investigate therapeutic effect, this type of study design can sometimes add 
complexity with regard to cost and time. Also, the RCT study is normally limited to a selected 
targeted population so it is difficult to generalise to routine clinical practice. With appropriate 
statistical techniques applied, an observational study should also be considered, as it can assess 
the effect of metformin treatment at a population level. Propensity score matching is a 
relatively new statistical method, which has been extensively used in observational studies to 
determine treatment effects. Using a primary care database and a propensity score matching 
technique, the effect of metformin treatment on weight loss in a real-life clinical practice, could 
be investigated. Furthermore, this study design could minimise the cost and time compared to 
a RCT.  
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7.4.Conclusions  
The findings from this thesis advanced our understanding of the efficacy, effectiveness, safety 
and prescribing patterns of anti-obesity drug treatments in children and adolescents in different 
clinical settings. The efficacy of anti-obesity drugs from published short-term RCTs (6 months) 
has shown that both orlistat and sibutramine together with behavioural support reduced BMI 
in children and adolescents but a high frequency of gastrointestinal adverse reactions was 
reported amongst those patients who received orlistat. Patients who received sibutramine were 
reported to have higher systolic and diastolic blood pressure and heart rate compared with those 
treated with placebo. In primary care, the prescribing of anti-obesity drugs (orlistat, 
sibutramine) to young people aged 0-18 years increased between 1999 and 2006 but a high 
proportion discontinued drug treatment within a month.  This may indicate that these drugs 
were poorly tolerated or not effective.  
 
As the limited drug of choice, metformin has been recommended for obesity treatment. There 
was a steady increase in metformin prescribing in particular to teenage girls aged 16-18 years 
between 2000 and 2010, in primary care; the main indication for it being prescribed was PCOS. 
Our updated meta-analysis of 12 RCTs showed a small effect of metformin on BMI reduction 
over 6 months of treatment in obese young people without diabetes. Frequently reported 
adverse events were gastrointestinal problems and no serious ADR was reported in any of these 
trials. At a specialist care weight management clinic more patients received metformin for 
obesity treatment between 2007 and 2010 than received orlistat or sibutramine.  Metformin 
treatment together with lifestyle intervention produced a small but statistically significant 
reduction of BMI SDS compared to lifestyle intervention alone in girls after 6 months of 
treatment.  
 
Despite clear NICE guidance that recommended anti-obesity drugs should be started in a 
specialist paediatric setting before they can be continued in primary care (2006), our 
questionnaire survey study suggested that over half of GPs did not receive specialists’ advice 
before they initiated medication (orlistat or metformin) treatment to obese young people. Also, 
GPs expressed a need to develop a simple and easy to follow guidance for pharmacological 
intervention as well as for non-pharmacological interventions. Most GPs does not know the 
treatment outcome and whether their patient had had an adverse drug event of the drug their 
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patients were taking for obesity treatment. In addition, some GPs have expressed lower level 
of confidence to prescribing drug to children compared to adults. There is an urgent need to 
improve childhood obesity management in the UK practices. 
 
To date, research on the long-term efficacy of metformin as a treatment for obesity is required, 
as currently it is not licensed for obesity treatment in either children or adults nor has it been 
recommended as a pharmacological treatment in the current NICE guidance on obesity 
management in adults and children. As there is increased use of metformin for obesity 
treatment, in both primary and secondary care, clinicians should use the most up-to-date 
evidence when prescribing metformin for obesity treatment in young people. The findings from 
this thesis have increased our knowledge of anti-obesity drug use in both primary and 
secondary care, for children and adolescents. This knowledge should enable clinicians and 
healthcare providers to offer more effective pharmacological interventions for obesity 
management in young people in clinical practice, as drug treatment has been an important 
adjunct to lifestyle intervention for obesity management in young people.  
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Appendices 
Appendix 1: MEDLINE (through PubMed) search strategy for randomised controlled 
trials of anti-obesity drugs 
 
Searched date from January 1996 to January 2008 
Step  Search terms 
1 orlistat [Title/abstract] 
2 xenical [Title/abstract] 
3 sibutramine [Title/abstract] 
4 reductil [Title/abstract] 
5 rimonabant [Title/abstract] 
6 acomplia [Title/abstract] 
7 or/#1-#6 
8 obes* [Title/abstract] 
9 obesity[MeSH Terms] 
10 weight gain* [Title/abstract] 
11 weight gain [MeSH terms] 
12 weight loss [MeSH terms] 
13 body mass index [MeSH terms] 
14 adipos* [Title/abstract] 
15 overweight [Title/abstract] 
16 over weight [Title/abstract] 
17 binge eating disorder* [Title/abstract] 
18 fat overload syndrome*[Title/abstract] 
19 overeat* [Title/abstract] 
20 overfeed* [Title/abstract] 
21 over eat* [Title/abstract] 
22 over feed* [Title/abstract] 
23 weight loss* [Title/abstract] 
24 weight cycling [Title/abstract] 
25 weight reduce* [Title/abstract] 
26 weight losing [Title/abstract] 
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27 weight maint* [Title/abstract] 
28 weight decreas* [Title/abstract] 
29 weight watch* [Title/abstract] 
30 weight control* [Title/abstract] 
31 or/#8-#30 
32 randomized controlled trial [Publication type] 
33 randomized controlled trials [MeSH terms] 
34 random allocation [MeSH terms] 
35 random* [Title/abstract] 
36 alloc* [Title/abstract] 
37 assign* [Title/abstract] 
38 controlled clinical trial [Publication type] 
39 clinical trial [Publication type] 
40 clinical trials [MeSH terms] 
41 clinical trial* [Title/abstract] 
42 cross over studies [MeSH terms] 
43 cross over stud* [Title/abstract] 
44 crossover stud* [Title/abstract] 
45 cross over trial* [Title/abstract] 
46 crossover trial* [Title/abstract] 
47 cross over design* [Title/abstract] 
48 crossover design* [Title/abstract] 
49 double blind method [MeSH terms] 
50 single blind method [MeSH terms] 
51 singl* blind* [Title/abstract] 
52 singl* mask* [Title/abstract] 
53 double* blind* [Title/abstract] 
54 double* mask* [Title/abstract] 
55 trebl* blind* [Title/abstract] 
56 trebl* mask* [Title/abstract] 
57 tripl* blind* [Title/abstract] 
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58 tripl* mask* [Title/abstract] 
59 placebo [MeSH terms] 
60 placebo* [Title/abstract] 
61 research design [MeSH terms] 
62 evaluation studies [MeSH terms] 
63 follow up studies [MeSH terms] 
64 prospective studies [MeSH terms] 
65 prospective* [MeSH Terms] 
67 prospective* [Title/abstract] 
68 or/#32-#67 
69 child* [Title/abstract] 
70 children [Title/abstract] 
71 child [MeSH terms] 
72 paediatr* [Title/abstract] 
73 pediatr* [Title/abstract] 
74 pediatrics [MeSH terms] 
75 adolescent [Title/abstract] 
76 adolescent [MeSH terms] 
77 or/#69-#76 
78 #7 AND #31 AND #68 AND #77 
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Appendix 2: EMBASE search strategy for randomised controlled trials in anti-obesity 
drugs 
 
Searched Date from January 1996 to January 2008 
Step Search terms 
1 body weight/ or weight gain/ or weight reduction/ or birth weight/ 
2 obesity 
3 or/ #1-#2 
4 antiobesity agent 
5 sibutramine 
6 orlistat 
7 xenical 
8 reductil 
9 rimonabant 
10 acomplia 
11 or/ #4-#10 
12 3 AND 11 
13 randomised controlled trial 
14 meta analysis 
15 clinical trial 
16 double blind 
17 double dummy 
18 random 
19 or/#13-#18 
20 12 AND 19 
21 child or adolescent 
22 20 AND 21 
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Appendix 3: CENTRAL (on the Cochrane Library) search strategy for randomised 
controlled trials in anti-obesity drugs 
 
Searched Date from January 1996 to January 2008 
Step Search terms 
1 body weight/ or weight gain/ or weight reduction/ or birth weight/ 
2 obesity 
3 or/ #1-#2 
4 antiobesity agent 
5 sibutramine 
6 orlistat 
7 xenical 
8 reductil 
9 rimonabant 
10 acomplia 
11 or/ #4-#10 
12 3 AND 11 
13 randomised controlled trial 
14 meta analysis 
15 clinical trial 
16 double blind 
17 or/#13-#16 
18 12 AND 17 
19 child or adolescent 
20 18 AND 19 
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Appendix 4: Schematic diagram to illustrate the relational linking of data files in FF-GPRD 
 
 
Practice File 
Demographic 
data 
Registration 
data 
Patient File 
Registration data 
Demographic data 
 
Transfer out 
 
Death 
Consultation 
Clinical 
Test 
Immunisation 
Treatment 
Referral 
Clinical 
details 
Symptoms 
Diagnoses 
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 Appendix 5: Business Objectives Report for retrieving records from FF-GPRD for anti-obesity drugs 
 
 
Business Objects report File name/location: R:\userdocs\antiobesity_patients.rep 
Date created: 11/09/2007  
Objects 
Practice EID (Current), Patient EID (Current), Birth Year (Current), Birth Month (Current), Current Gender (Current),  
GPRD Product Code (Event), Age at event, Event date* 
Conditions 
EventType = ‘Therapy’ 
AND Age at Event Year < 19 
AND (GPRD Product Code (Events) in list (given below) 
AND Event date *Between 01/01/1992 and 31/08/2007 
AND Patient Record Deleted Flag Equal to “N” 
AND Standard Patient Criteria 
AND Event Deleted Flag = ‘N’ 
 
GPRD Product Codes 
4070960, 4084882, 4095773, M02501001, M02501002, M10585001 
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Appendix 6: Anti-obesity drug prescribing in children and adolescents study protocol 
for GPRD  
ISAC APPLICATION FORM:   
PROTOCOLS FOR RESEARCH USING THE GPRD DATA 
 
ISAC use only: 
Protocol Number 
Date submitted 
 
................................ 
................................ 
IMPORTANT 
If you have any queries, please contact ISAC Secretariat: 
ISAC@gprd.com 
 
1. Study Title  
Anti-obesity drugs prescribing in children and adolescents 
 
2. Does this protocol describe a purely observational study using GPRD data (this may include the review of 
anonymised free text or access to anonymised data via the GPRD data linkage scheme)? 
 
 Yes    No   
 
3. Does this protocol involve requesting any additional information from GPs?  
 
 Yes   No  
 
 If yes, please indicate what will be required:  
   
 Completion of questionnaires by the GP*     Yes      No   
 Provision of anonymised records (e.g.  hospital discharge summaries)  Yes      No   
 Other (please describe)          
 
*any questionnaire for completion by GPs needs to be approved by ISAC before being sent out for completion.   
 
GUIDANCE ON ANSWERING QUESTIONS 4-6: 
These questions must be completed by all applicants.  You should note the following:   
(i) if you have answered NO to question 2, you will have to seek separate ethics approval from an NHS 
Research Ethics Committee for this study 
 (ii) if you have answered YES answered to question 2 above and you will be using data obtained from the 
GPRD Group at the MHRA, this study does not require separate ethics approval from an NHS 
Research Ethics Committee.  
If you will be using data obtained from EPIC, you will need to consult the data provider regarding 
their arrangements for obtaining ethics approval for the study.  
NB: Answering YES to question 2 means that the answers to questions 4-6 should all be NO. If any of the 
answers below are YES please review your answer to question 2 as it should be NO. 
 
4. Does the study involve linking to patient identifiable data from other sources?    Yes       No   
 
5. Does this study require contact with patients in order for them to  
 complete a questionnaire?       Yes        No   
 
6. Does this study require contact with patients in order to collect a sample?  Yes       No   
 If yes, please state what will be collected            
 
7. Type of Study (please tick one box below) 
 
Adverse Drug Reaction  Drug Use          Disease Epidemiology                   
Pharmacoeconomic           Drug Effectiveness                     Other    
 
8. Data source  (please tick one box below) 
 
GPRD Division at MHRA     Other         
       (please specify)                                             
Full Feature on-line access              
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Ad hoc dataset      
MRC dataset      
Other commissioned study    
 
 
9. Financial Sponsor of study 
 
MRC*                      Pharmaceutical Industry (please specify)         
Government / NHS (please specify)         Other (please specify)  European Commission via the 
Taskforce European Drug Development for the Young (TEDDY) network of Excellence European Commission 
Framework 6 Programme 2005-2010.   
None        
 
* Tick this box if you wish to access GPRD data under the MRC licence with GPRD.  It is expected that if you 
use the MRC licence, no other direct commercial/public sector funding for this study will be sought/has been 
applied for or is in place. If funding is in place, but does not cover the use or extraction of GPRD data, please tick 
the boxes for relevant funding sources (including MRC) and provide details in the protocol of why funding under 
the MRC licence is required. 
 
10. Is the study intended for 
Publication in peer reviewed journals                             Presentation at scientific conference               
Presentation at company/institutional meetings            Other                
 
11. Principal Investigator (full name, job title, organisation & e-mail address for correspondence regarding this 
protocol) 
Professor Ian Wong, DH National Public Health Career Scientist & Professor of Paediatric Medicines Research, 
Centre for Paediatric Pharmacy Research, The School of Pharmacy, University of London. E-mail: 
ian.wong@pharmacy.ac.uk 
 
12. Affiliation (full address) 
Centre for Paediatric Pharmacy Research, The School of Pharmacy, University of London, 29-39 Brunswick 
Square, London, WC1N 1AX 
 
13. Type of Institution (please tick one box below) 
 
Academia  Research Service Provider                     Pharmaceutical Industry    
NHS            Government Departments       Others     
 
14. Experience/expertise available  
 
Please complete the following questions to indicate the experience/expertise available within the team of 
researchers actively involved in the proposed research, including  analysis of data and interpretation of results 
                                   Previous GPRD                                                          Publications                   
                                         Studies                                                             using GPRD data 
 
None                                                                                              
1-3                                                                                               
> 3                                                                                               
                                                                                                                             Yes                             No 
Is statistical expertise available within the research team?                                                                 
                           If yes, please outline level of experience                                        
 
Is experience of handling large data sets (>1 million records)                                                     
 available within the research team?                            
                           If yes, please outline level of experience                                        
 
Is UK primary care experience available within the research team?                                                 
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                           If yes, please outline level of experience                                        
 
15. Other collaborators (if applicable: please list names and affiliations of all collaborators) 
Dr. Russell Viner-Adolescent Medicine UCL Institute of Child Health & Honorary consultant in Adolescent 
Medicine & Endocrinology UCL Hospitals & Gt. Ormond St. Hospital London.  
Dr. Antje Neubert- Centre for Paediatric Pharmacy Research 
Miss Yingfen Hsia- Centre for Paediatric Pharmacy Research 
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PROTOCOL CONTENT CHECKLIST 
 
In order to help ensure that protocols submitted for review contain adequate information for protocol 
evaluation, ISAC have produced instructions on the content of protocols for research using GPRD data. 
These instructions are available on the GPRD website (www.gprd.com/ISAC). All protocols using 
GPRD data which are submitted for review by ISAC must contain information on the areas detailed in 
the instructions.  IF you do not feel that a specific area required by ISAC is relevant for your protocol, 
you will need to justify this decision to ISAC.  
Applicants must complete the checklist below to confirm that the protocol being submitted includes all 
the areas required by ISAC, or to provide justification where a required area is not considered to be 
relevant for a specific protocol.  Protocols will not be circulated to ISAC for review until the checklist 
has been completed by the applicant.  
Please note, your protocol will be returned to you if you do not complete this checklist, or if you 
answer ‘no’ and fail to include justification for the omission of any required area. 
 Included in 
protocol? 
 
Required area Yes No If no, reason for omission 
Objective, specific aims and rationale         
Background         
Study design         
Study population, including estimate 
of expected number of relevant 
patients in the GPRD 
        
Sample size/ power calculation   This is a cohort study. The sample 
size in the GPRD paediatric 
population is large enough to 
investigate prevalence and 
incidence of overweight/obesity 
and prescribing patterns.  
Selection of comparison group(s) or 
controls 
  The study is not a case-control or 
comparative cohort study. 
Exposures, outcomes and covariates         
Data Analysis         
Patient/ user group involvement †  
 
 This study does not have 
involvement of patients or user 
groups.    
Limitations of the study design, data 
sources and analytic methods 
        
Plans for disseminating and 
communicating study results 
        
† It is expected that many studies will benefit from the involvement of patient or user groups in their planning and 
refinement, and/or in the interpretation of the results and plans for further work. This is particularly, but not exclusively 
true of studies with interests in the impact on quality of life.   Please indicate whether or not you intend to engage 
patients in any of the ways mentioned above.   
ISAC strongly recommends that researchers using GPRD consider registering as a NRR data provider in order that others 
engaged in research within the UK can be made aware of current works. The National Research Register (NRR) is a register 
of ongoing and recently completed research projects funded by, or of interest to, the United Kingdom's National Health 
Service. Information on the NRR is available on www.nrr.nhs.uk . 
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Study title: obesity and overweight in children and adolescents  
 
Aim 
To investigate the prevalence of obesity, overweight in children and adolescents aged 0-18, and to 
estimate prevalence and incidence rate of anti-obesity treatment.  
 
Objectives 
 To identify patients who were overweight and obesity in the GPRD paediatric population (0-
18 years). 
 To estimate the prevalence and incidence of anti-obesity drugs prescribing in this study 
population.   
  
Background  
Obesity in childhood has caused global concern in recent years. Evidence has shown a continued 
increase of obesity and overweight in youths. The US study (the National Health and Nutrition 
Examination Survey) reported that 10% of children aged 2-5 was overweight and 15% amongst children 
aged 6-19 in 1999-2000 [1].  Similarly, studies from continental Europe have shown an increased 
prevalence of obesity and overweight in children and adolescents [2-4].  
 
In the UK, data from the Health Survey for England (HSE) reported the prevalence of overweight and 
obesity increased from 22.7% in 1995 to 27.7% in 2003 amongst children aged 2-10 [5]. Previous 
national studies also demonstrated an increased prevalence of obesity and overweight in children [6-9]. 
Although theses studied had been carried out to investigate obesity and overweight in youths, it should 
be addressed that data from most studies were collected during the mid 1990s which can not reflect the 
current situation. Also, these studies did not examine anti-obesity drugs prescribing patterns.  
 
Obesity in children and adolescents is a serious public health as this condition can persist into 
adulthood. Consequently, it will lead to several complications such as diabetes, cardiovascular diseases 
[10]. Information on obesity prevalence and anti-obesity drug prescribing in paediatric population are 
particularly important as this is directly related to health care plans and management. Therefore, we 
would like to propose to investigate the prevalence, incidence of obesity, overweight and anti-obesity 
prescribing pattern in children and adolescents using the General Practice Research Database (GPRD).  
 
1. Ogden CL, Flegal KM, Carroll MD, and Johnson CL. Prevalence and trends in overweight 
among US children and adolescents, 1999-2000. JAMA 2002, 288: 1728-1732.  
2. Kautiainen S, Rimpela A, Vikat A, and Virtanen SM. Secular trends in overweight and obesity 
among Finnish adolescents in 1977-1999. International Journal of Obesity 2002, 26: 544-552. 
3. Schober E, Rami B, Kirchengast S, Waldhor T and Sefranek R. Recent trend in overweight and 
obesity in male adolescents in Austria: a population-based study. European Journal of 
Pediatrics 2007, 166: 709-714.  
4. Papadimitrious A, Kounadi D, Konstantinidou M, Xepapadaki P, and Nicolaidou P. Prevalence 
of Obesity in elementary schoolchildren living in northeast Attica, Greece. Obesity 2006, 14: 
1113-1117. 
5. Jotangia D, Moody A, Stamatakis E, and Wardle H. Obesity among children under 11. 
Department of Health. Available from: 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_41
09245 [accessed on 06/09/2007]. 
6. Reilly JJ, and Dorosty AR. Epidemic of obesity in UK children. Lancet 1999, 354: 1874-1875. 
7. Chinn S, and Rona RJ. Prevalence and trends in overweight and obesity in three cross sectional 
studies of British children, 1979-1994. British Medical Journal 2001, 322: 24-26. 
8. Kinra S, Nelder RP, and Lewendon GJ. Deprivation and childhood obesity: a cross sectional 
study of 20973 children in Plymouth, United Kingdom. Journal of Epidemiology and 
Community Health 2000; 54: 456-460.  
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9. Jebb SA, Rennie KL, Cole TJ. Prevalence of overweight and obesity among young people in 
Great Britain. Public Health Nutrition 2003, 7: 461-465. 
10.  Freedman DS, Dietz WH, Srinivasan SR, and Berenson GS. The relation of overweight to 
cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. 
Pediatrics 1999, 103: 1175-1182. 
11.  Cole TJ, Freeman JV, Preece MA. Body mass index reference curves for the UK, 1990. 
Archives of Disease in Childhood 1995, 73: 25-29.  
 
Study Design 
Descriptive cohort study 
Study Population 
The study population will comprise all patients in GPRD who are: 
 18 years or younger 
 Have at least 1 year up-to-standard data available, except children < 1 year-old. 
 Have a known gender. 
 Have an acceptable patient registration status (permanent, transferred out) 
Inclusion Criteria for cases 
Patients aged 0-18 years between 1 January 1992 to 31 August 2007 who had a diagnosis of obesity 
and/or obesity-related complications (Annex 1) and/or received at least one prescription for anti-obesity 
drug(s) (Annex 2).  
Definition of obesity and overweight for cases 
The value of BMI (Body Mass Index) will be used as a mean to define overweight and obese. 
Overweight is defined as BMI above the 85th percentile. Obesity is defined as BMI ≥95th percentile 
[11]. 
Diagnosis and Exposure of Interest 
Obesity and obesity-related complications diagnosis  
Anti-obesity drugs  
Body mass index (BMI) 
Selection of Controls 
None  
Clinical Outcome of Interest 
This is a descriptive epidemiological study; therefore there are no specific clinical outcomes of interest. 
However, medical codes and clinical events such as body mass index (BMI) will be examined for 
diagnosis of obesity, overweight and prescription of anti-obesity drugs.  
Data Collection 
Data will be extracted using standard GPRD data tools. Stata/SE version 9.1 (StataCorp, College 
Station, Texas, United States) will be used for data management and statistical analysis. 
Outcome 
Cases will be identified from the cohort described above. Patients in the cohort will be followed from 
the date of entry into the database. Cases will be defined as patients who received prescriptions for anti-
obesity drug, and/or a medical code related to obesity.  
Data analysis 
Prevalence will be defined as the number of patients with a record of obesity, overweight, obesity-
related complications and/or prescription of anti-obesity drug during each year of investigation. The 
calculation for prevalence is given below:  
 
 
 
Prevalence =  
Number of patients with a diagnosis of obesity or prescription of anti-obesity drug x 1000 
 
       Total number of patient in GPRD population aged 18 years and younger 
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Prevalence will be presented as number of patients per 1000 for each year of the study. 
 
Incidence cases will be defined as patients who had no record of obesity, overweight, obesity-related 
complications and/or prescription of anti-obesity drugs in the previous year but thereafter. Patients who 
received their first prescription of anti-obesity drug and/or first obesity medical code under 1 year-old, 
they will also be considered as incident cases. The incidence will be calculated as the number of new 
cases divided by the person years at risk in the GPRD paediatric population (aged 0-18 years).The 
calculation for incidence is given below: 
 
Incidence = 
       Number of patients with a diagnosis of obesity or prescription of anti-obesity drug x 1000 
 
              Total number of patient years in GPRD population aged 18 years and younger 
 
Incidence will be presented as number of patients per 1000 patient years for each year of the study. 
 
The prevalence and incidence will be presented with 95% confidence intervals and stratified by age, 
gender, type of drug, and year of study. A 2 test (Cochran-Armitage test for trend) will be used to 
examine the yearly trend in anti-obesity drug prescribing. Boy-girl prevalence ratio for anti-obesity 
prescribing will be calculated using the Taylor series method with 95% confidence intervals.  
 
Limitations 
The GPRD does not provide data on dispensing of medication or patients’ compliance. The absense of 
dispensing and compliance data is an acknowledged limitation of automated databases. The GPRD does 
not contain ethnicity information, so it is not possible to investage whether this factor is associated with 
obesity and overweight.  
 
Methods of disseminating the research 
Results of the study will be presented in conferences and submitted to scientific journals.  
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Appendix 7: GPRD ethics approval letter for obesity study 
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Appendix 8: Study protocol for IMS DA  
 
Confidential - not for publication     No:  2010/ISEAC/001 
 
 
INDEPENDENT SCIENTIFIC AND ETHICAL ADVISORY 
COMMITTEE 
 
 
APPLICATION FOR APPROVAL FOR 
INVESTIGATION INVOLVING THE UK DISEASE 
ANALYZER DATABASE 
 
1. BRIEF TITLE OF PROJECT 
 
Drug utilisation study in paediatric patients in 1992-2010 
 
2. PRINCIPAL RESEARCHERS 
 
 (Include qualifications, position and role in study)  
 
 Name     Post    
 
Prof Ian Chi Kei Wong   Director 
Dr Macey Murray   Teaching and Research Fellow 
Ms Yingfen Hsia   Research Fellow 
 
Official Address    
 
Centre for Paediatric Pharmacy Research 
The School of Pharmacy, University of London 
The Institute of Child Health, University College London 
Great Ormond Street Hospital for Children 
 
Correspondence: 
The School of Pharmacy , University of London 
Level 1, BMA House 
Tavistock Square 
London WC1H 9JP 
United Kingdom 
Tel:  0207 874 1544 
Fax:  0207 387 5693 
Email: ian.wong@pharmacy.ac.uk 
 macey.murray@pharmacy.ac.uk 
 yingfen.hsia@pharmacy.ac.uk 
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3. SPONSOR OF STUDY 
 (If any - please state any commercial or financial interests) 
 
Centre for Paediatric Pharmacy Research, University of London. 
No other commercial or financial interests. 
4. ABSTRACT OF THE PROPOSED STUDY 
 
Briefly describe the study and what you intend to determine from the data available 
on the Disease Analyzer - Mediplus Database.  The scientific case, and the potential 
importance and implications of any findings and conclusions should be summarised 
here.   
 
The main objective of this project is to promote research on the safe and effective use of 
medicines for children, and to expand and integrate knowledge of, and to build research 
capacity in drug development for male and female children. To achieve these goals, one of the 
activities is to conduct drug utilisation studies in children whilst using existing clinical 
databases from different European countries. Data from IMS Disease Analyzer (IMS DA) will 
be analysed to describe prescribing patterns, prevalence, and incidence of conditions in UK 
primary care. The results will equip us to identify priorities for further research in the area of 
medicines for children within Europe. 
 
5. AIMS AND OBJECTIVES OF THE STUDY 
 
Indicate what questions are to be answered from the study and what information 
you hope to obtain (approximately 250 words) 
 
This drug utilisation study aims to investigate the prescribing patterns, to young people aged 
0-18 years, in UK primary care, based on the Anatomical Therapeutic Chemical (ATC) 
Classification System with respect to number of prescriptions, prevalence, incidence, 
indication, formulation and dosage, consultations, and specialist referrals. The study period 
will be between 1 January 1992 and 31 December 2010. Data will be compared with other 
European countries, e.g. The Netherlands, Italy and the results will be used to prioritise further 
research in paediatric medicine.   
 
 
6. SCIENTIFIC BACKGROUND TO STUDY 
 
Complete this section in approximately 250 words including any references to 
previous work. 
 
Pharmacoepidemiological and prospective cohort studies could provide vital safety and 
efficacy data on paediatric medicines; however, resources need to be invested into 
methodological research.[1] Recently, the Department of Health Standing Medical Advisory 
Committee in England recommended that children's medication prescribing data should be 
collected for evaluation.[2] Moreover, the need for drug utilisation studies and 
pharmacovigilance systems for children was specifically proposed in the draft regulations on 
medicinal products for paediatric use.[3] Undoubtedly, research capabilities using clinical 
databases will have to be further developed in order to support the rapidly expanding agenda 
of paediatric medication research. 
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Several publications have been published used IMS DA database to investigate medication use 
in paediatric population. [4-10] We consider IMS DA to be a valuable resource for 
pharmacoepidemiological research, and it provides us with a unique opportunity to study the 
use of drugs prescribed to children.  We believe that so far this database has been underused 
for paediatric drug research and therefore, this proposed study could further demonstrate the 
value of IMS DA databases in this area of research.  
 
References:  
1. Wong ICK, Sweis D, Cope J, Florence A. Children Medicines Research in the UK – How to move 
forward? Drug Safety 2003;26(11):529-37.  
2. Standing Medical Advisory Committee Advice. Licensing and Prescribing of Drugs in Children 
(SMAC Advice 5/2001). http://www.advisorybodies.doh.gov.uk/smacdrugschildren.htm (accessed 
10/06/2004). 
3. Commission Consultation on a Draft Proposal for a European Parliament and Council Regulation 
(EC) on Medicinal Products for Paediatric Use. Brussels: European Commission 2004. 
4. Wong IC, Murray ML, Camilleri-Novak D, Stephens P. Increased prescribing trends of paediatric 
psychotropic medications. Archives of Disease in Childhood 2004;89(12):1131-2. 
5. Murray ML, Thompson M, Santosh PJ, Wong IC. Effects of the Committee on Safety of Medicines 
advice on antidepressant prescribing to children and adolescents in the UK. Drug Safety 
2005;28(12):1151-7. 
6. Hsia Y, Neubert A.C., Rani F, Viner RM, Hindmarsh PC, Wong ICK, An increase in the prevalence 
of type 1 and 2 diabetes in children and adolescents: results from prescription data from a UK general 
practice database. British Journal of Clinical Pharmacology. 2009: 67(2): 242-249. 
7. Hsia Y, Neubert A, Sturkenboom M, Verhamme KMC, Sen EF, Giaquinto C.,Ceci A., Murray ML., 
Wong ICK on behalf of the TEDDY Network of Excellence. Antiepileptic drug prescribing 
comparison in three European countries. Epilepsia. 2010;51(5):789-96. 
8. Antje Neubert, Katia Verhamme, Macey Murray, Gino Picelli, Y Hsia, Fatma Sen, Carlo Giaquinto, 
Adriana Ceci, Miriam Sturkenboom, and Ian Wong. The prescribing of analgesics and non-steroidal 
anti-inflammatory drugs in paediatric primary care in the UK, Italy and the Netherlands. Pharmacol 
Res. 2010;62(3):243-8. 
9. Neubert  A, Hsia Y, TW de Jong-van den Berg L, Janhsen K, Glaeske G,  Furu K, Kieler H, 
Nørgaard M, Clavenna A, Wong ICK. Comparison of anti-diabetic drug prescribing in children 
and adolescents in seven European countries. British Journal of Clinical Pharmacology 2011 (in 
press).  
10. Hsia Y, Dawoud D, Sutcliffe AG, Viner R, Kinra S, Wong ICK.  Unlicensed use of metformin in 
children and adolescents in UK. British Journal of Clinical Pharmacology. 2011 (in press) 
 
7. OUTCOME MEASURES 
 
 Indicate the specific primary end point(s) and any secondary end points of the study. 
 
This is descriptive study and therefore there is no end point measure as such. However, we will 
analyse the data on the following parameters: 
1. age and gender of patients 
2. prescriptions by ATC High-level (see Annex 1), ATC Therapeutic-level (see 
Annex 2) and ATC Chemical (molecule)-level. 
3. prevalence by calendar year, age & gender 
4. formulation and dosages by age 
5. indication for which the drugs have been prescribed by age 
6. incidence and duration of treatment 
7. clinical problems and diagnoses related to treatment 
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8. consultations and specialist referrals  
8 DESIGN 
 
a) STUDY TYPE  
E.g. cohort study, case-control study, secular trends in prescribing. 
 
Retrospective cohort study of young people aged 0-18 years, investigating trends in prescribing 
and drug utilisation. 
b) NUMBERS NEEDED 
 
Cases, controls, number of years over which data are needed etc.  Assumptions 
regarding indications of significance level and power likely to be achieved.  Please 
note that IMS can provide top line numbers for potential patients to be included if 
necessary.  All applications should include statistical justification for the numbers to 
required in a study. This should demonstrate that the results are likely to be 
interpretable with reasonable confidence. This requirement applies to "descriptive" 
studies as well as to those involving comparisons of any sort. 
This is a descriptive and quantitative study and all patients aged between 0-18 will be included 
during the study period. The study period will between 1 January 1992 and 31 December 2010. 
For time-trend analysis, this entire period is possible to detect any significant prescribing 
change.   
 
c) ELIGIBILITY 
 
Indicate the criteria for both inclusion in, and exclusion from, the study.  
Inclusion Criteria 
Patients must: 
 be aged between 0 and 18 years 
 have at least 6 months of data available unless newborn. Newborns will be included in 
the study cohort regardless of the amount of data available. 
 have a known gender 
Exclusion Criteria 
Patients must: 
 not be temporarily registered to their general practice 
 
d) DATA ITEMS TO BE COLLECTED  
 
Data to be used for stratification, etc. 
Indicate data items relating to both patients and practices if relevant, including Read 
Codes (see appendix), age, sex, co-morbidity, prescriptions, tests and 
investigations. 
The following information will be required for the analyses: 
 age and gender of all young people in the database 
 dates of registration & de-registration (transferred out date) of all young people in the 
database 
 all drug prescriptions including ATC Classification Code and date of prescription  
 indication, dosage and formulation (for the five most frequently prescribed drugs (by 
prevalence) in each ATC Therapeutic Level). 
 Problems and diagnoses 
 Consultations, specialist referrals related to treatment or conditions  
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9. ANALYSIS OF THE STUDY  
 
Describe the approaches to be taken in analysis, including the statistical techniques 
to be applied. 
 
Descriptive analysis will be conducted for patient demographics and prescription data. To 
describe the study cohort, the age and gender distribution and total person years of patients will 
be calculated. Time-trend analyses, age-specific and gender-specific drug measure estimates, 
consultations and specialist referrals will be assessed.  
 
Prevalence will be defined as the number of youths who received one or more prescriptions for 
the drug classes divided by the person time of young people who are present in the database. 
As the prevalence varies depending on the duration of follow-up for each individual, 
prevalence will be calculated for each calendar year (annual prevalence). Ninety-five percent 
confidence intervals of prevalences will be calculated based on the Poisson distribution. 
Overall prevalence will be calculated for the entire study period by adding the numbers of 
youths who received one or more prescriptions of the drug classes and dividing by the total 
person time of the study population.  
In addition to prescription data, information on problems, diagnoses, consultations and 
specialist referrals will also be investigated. These data can provide in-depth understanding on 
GP practice patterns and disease management in primary care. 
ATC Anatomical & Therapeutic level prescriptions  
Annual prevalences and overall prevalence by drug classes based on the ATC Anatomical and 
Therapeutic levels will be presented by age and gender. 
ATC C level (molecule) prescriptions: 
For the ATC Therapeutic levels A, D, H, J, P, C, N, M, R and L, overall prevalence will be 
estimated for each generic drug (ATC Chemical level) and presented by age and gender. On 
the basis of these prevalences, the five most frequently prescribed drugs per ATC Therapeutic 
Level will be retrieved and the following analysis applied: 
1. Dosage and formulation 
Mean dosage, Standard Deviation and 25th, 50th and 75th percentiles will be calculated 
and presented by ATC Chemical level, formulation and age.  
2. Indications 
To obtain insight into the medical conditions of the children and how they are treated, 
the indications for drug prescriptions will be derived from the linked indication and 
presented by ATC Chemical level, age and gender. 
3. Incidence 
A child will qualify as incident user if he/she has not received a prescription for the 
drug under study in the previous year. The incidence rate will be the number of children 
with a first prescription of a drug during follow-up divided by the number of person-
years or the number of children attributing to the study cohort during follow-up. 
Incidence rates will be given by calendar year, age and gender.  
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4. Number of prescriptions and treatment duration 
For each prevalent and each incident user, the number of prescriptions will be 
calculated. For incident users, the treatment duration will be calculated from the 
prescribed quantity and prescribed daily dosage. Prescriptions will be combined with a 
maximum gap of  90 days.  
Problems, consultations and referrals  
The problems, consultations and referrals are coded using the Read code and ICD 10 
classification. A treatment or condition which is linked to problems, consultations or specialist 
referrals will be investigated.  
Data manipulation and analysis will be conducted using STATA/SE 11.0 for Windows 
(StataCorp LP, Texas, USA). 
 
10. DISSEMINATION STRATEGY 
 
 List the journals and presentations in which it is intended that the results of the 
study will be published, and indicate whether and how the results of the study are 
likely to be used commercially.  
 
It is planned that a number of papers will be published from this study, primarily in the 
following journals, reports and conferences: 
 British Medical Journal 
 Pediatrics 
 British Journal of Clinical Pharmacology 
 Archives of Disease in Childhood 
 Pharmacoepidemiology and Drug Safety 
The results will be used solely for research purposes. 
 
 
11. INDICATE ANY ETHICAL PROBLEMS THAT YOU ENVISAGE 
 
 List those ethical issues not raised so far that might be important or present 
particular difficulties with the proposed study.   Please also list any other information 
which you consider would be helpful to ISEAC. 
 
None known 
 
 
 
 
 
 Signature of Applicant(s) 
 
 ................................................      Date 16/03/2011.................................. 
 
 
 ................................................................... Date  .................................. 
ISEAC DECISION 
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Signed ................................................................... Date  …………………………………… 
 
   (Chairman) 
 
 
COMMENTS 
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Appendix 9: IMS ethics approval letter  
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Appendix 10:  Ethics approval from UCL School of Pharmacy Ethics Research 
Committee  
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Appendix 11: Index of Multiple Deprivation Domain Indicators (IMD) (taken 
from English Indices of Deprivation Technical Report: 
http://www.communities.gov.uk/publications/corporate/statistics/indices2010technicalr
eport) [last accessed 01/09/2012] 
1. Income Deprivation Domain indicators:  
 Adults and children in income support families  
 Adults and children in income-based Jobseeker’s Allowance families 
 Adults and children in Pension Credit (Guarantee) families 
 Adults and children in Child Tax Credit families (who are not claiming income) 
 Support, income-based Jobseeker’s Allowance or Pension Credit) whose 
equivalised income (excluding housing benefits) is below 60% of the median before 
housing costs 
 Asylum seekers in England in receipt of subsistence support, accommodation 
support, or both 
2. Employment Deprivation Domain indicators:  
 Claimants of Jobseeker’s Allowance (both contribution-based and income based), 
women aged 18-59 and men aged 18-64 
 Claimants of incapacity benefit aged 18-59/64 
 Claimants of Severe Disablement Allowance aged 18-59/64 
 Claimants of Employment and Support Allowance aged 18-59/64 (those with a 
contribution-based element) 
 Participants in New Deal for 18-24s who are not claiming Jobseeker’s Allowance 
 Participants in New Deal for 25+ who are not claiming Jobseeker’s Allowance 
 Participants in New Deal for Lone Parents aged 18 and over (after initial interview) 
3. Health Deprivation and Disability Domain indicators:  
 Years of Potential Life Lost: An age and sex standardised measure of premature 
death 
 Comparative Illness and Disability Ratio: An age and sex standardised 
morbidity/disability ratio 
 Acute morbidity: An age and sex standardised rate of emergency admission to 
hospital  
 Mood and anxiety disorders: The rate of adults suffering from mood and anxiety 
disorders 
4. Education, Skills and Training Deprivation Domain indicators:  
 Key Stage 2 attainment: The average points score of pupils taking English, maths 
and science Key Stage 2 exams 
 Key Stage 3 attainment: The average points score of pupils taking English, maths 
and science Key Stage 3 exams 
 Key Stage 4 attainment: The average capped points score of pupils taking Key Stage 
4 (GCSE or equivalent) exams 
 Secondary School absence: The proportion of authorised and unauthorised absences 
from secondary school 
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 Staying on in education post 16: The proportion of young people not staying 
on in school or non-advanced education above aged 16 
 Entry to higher education: The proportion of young people aged under 21 not 
entering higher education 
 Adult skills: The proportion of working age adults aged 25-54 with no or low 
qualifications  
5. Barriers to Housing and Services Domain indicators:  
 Household overcrowding: The proportion of all households in an LSOA 
which are judged to have insufficient space to meet the household’s need 
 Homelessness: The rate of acceptances for housing assistance under the 
homelessness provisions of housing legislation 
 Housing affordability: The difficulty of access to owner-occupation, 
expressed as a proportion of households aged under 35 whose income means 
that they are unable to afford to enter owner occupation 
 Road distance to a GP surgery: A measure of the mean distance to the closest 
GP surgery for people living in the LSOA 
 Road distance to a food shop: A measure of the mean distance to the closest 
supermarket or general store for people living in the LSOA 
 Road distance to a primary school: A measure of the mean distance to the 
closest primary school for people living in the LSOA 
 Road distance to a Post Office: A measure of the mean distance to the closest 
post office or sub post office for people living in the LSOA 
6. Crime Domain indicators: 
 Violence: The rate of violence (19 recorded crime types) per 1000 at-risk 
population 
 Burglary: The rate of burglary (4 recorded crime types) per 1000 at-risk 
properties 
 Theft: The rate of theft (5 recorded crime types) per 1000 at-risk population 
 Criminal damage: The rate of criminal damage (11 recorded crime types) per 
1000 at-risk population 
7. Living Environment Deprivation Domain indicators:  
 Housing in poor condition: The proportion of social and private homes that 
fail to meet the decent homes standard 
 Houses without central heating: The proportion of houses that do not have 
central heating 
 Air quality: A measure of air quality based on emissions rates for four 
pollutants 
 Road traffic accidents: A measure of road traffic accidents involving injury 
to pedestrians and cyclists among the resident and workplace population 
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Appendix 12: Steps of obtaining the IMD 2007 of Lower Super Output Area ranking and score 
 
Step 1: Compile a list of all patients’ postcodes 
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Step 2: Access to GeoConvert website 
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Step 3: Select the function to obtain IMD ranking and score 
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Step 4: Select IMD 2007 Rank and Score classification 
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Step 5: To upload the list of postcode 
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Step 6: The completion of file uploading 
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Step 7: Download the results 
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Step 8: Results of IMD 2007 ranking and score for included patients 
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Appendix 13:  Distribution of observed and imputed BMI, BMI SDS, and weight at 6 
months follow up data 
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Two-sample Kolmogorov-Smirnov test for equality of distribution functions: BMI 
Smaller group       D        P-value     Corrected 
 ----------------------------------------------------------------- 
 0:                        0.0797            0.761 
 1:                       -0.1584           0.340 
 Combined K-S:  0.1584           0.653      0.562 
 
Two-sample Kolmogorov-Smirnov test for equality of distribution functions: BMI SDS 
 Smaller group       D                P-value    Corrected 
 ----------------------------------------------------------------- 
 0:                        0.0325            0.956 
 1:                       -0.2029            0.170 
 Combined K-S:  0.2029            0.339      0.257 
 
Two-sample Kolmogorov-Smirnov test for equality of distribution functions: weight 
Smaller group       D           P-value    Corrected 
 ----------------------------------------------------------------- 
 0:                      0.0649    0.822 
 1:                      -0.1187   0.519 
 Combined K-S:   0.1187    0.899             0.851 
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Appendix 14: Publications from this thesis 
